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Abstract	  
Fruit	   and	   vegetable-­‐rich	   diets	   reduce	   blood	   pressure	   and	   risk	   of	   ischaemic	   stroke	  
and	   ischaemic	   heart	   disease.	   Whilst	   the	   cardioprotective	   effects	   of	   a	   fruit	   and	  
vegetable-­‐rich	   diet	   are	   unequivocal,	   the	   exact	   mechanisms	   of	   this	   effect	   remain	  
uncertain.	   Recent	   evidence	   has	   highlighted	   the	   possibility	   that	   dietary	   nitrate,	   an	  
inorganic	   anion	   found	   in	   large	   quantities	   in	   vegetables	   (particularly	   green	   leafy	  
vegetables),	  might	  have	  a	  role	  to	  play.	  This	  beneficial	  activity	  lies	  in	  the	  processing	  
in	   vivo	   of	   nitrate	   to	   nitrite	   (a	   process	   that	   has	   been	   traditionally	   viewed	   as	  
detrimental)	   and	   thence	   to	   the	   pleiotropic	   molecule	   nitric	   oxide.	   Ingestion	   of	  
dietary	   (inorganic)	   nitrate	   elevates	   circulating	   and	   tissue	   levels	   of	   nitrite	   via	  
bioconversion	   in	   the	   entero-­‐salivary	   circulation.	   In	   addition,	   nitrite	   is	   a	   potent	  
vasodilator	   in	  humans;	   an	  effect	   thought	   to	  underlie	   the	  blood	  pressure	   lowering	  
effects	  of	  dietary	  nitrate	  ingestion.	  	  
	  
In	   a	   series	   of	   randomized,	   cross-­‐over,	   placebo	   controlled	   studies	   in	   healthy	   and	  
hypertensive	  subjects	  (n=6-­‐20),	  I	  show	  that	  single-­‐dose	  supplementation	  with	  either	  
inorganic	   nitrate	   capsules	   (4-­‐24	  mmol	   KNO3)	   or	   dietary	  nitrate	   (as	   beetroot	   juice,	  
3.3-­‐5.5	  mmol	  nitrate)	  elevated	  plasma	  nitrite	  levels	  and	  reduced	  blood	  pressure	  in	  a	  
dose-­‐dependent	   manner.	   In	   a	   separate	   study,	   interruption	   of	   the	   entero-­‐salivary	  
circulation	  with	  antiseptic	  mouthwash	  use	  for	  7	  days	  reduced	  plasma	  nitrite	  levels	  
and	   elevated	   blood	   pressure	   significantly.	   Stratification	   of	   results	   by	   sex	   revealed	  
important	  differences	  in	  the	  entero-­‐salivary	  circulation	  of	  nitrate	  to	  nitrite	  that	  had	  
consequences	  on	  resting	  blood	  pressure	  and	  response	  to	  nitrate	  supplementation.	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In	   conclusion,	   these	   studies	   challenge	   the	   current	   dogma	   that	   inorganic	   nitrate	   is	  
only	  detrimental,	  and	  on	  the	  contrary	  suggests	  that	  dietary	  nitrate	  is	  important	  for	  
cardiovascular	   health.	   It	  may	   be	   that	   sufficient	   supply	   of	   nitrate	   through	   the	   diet	  
together	   with	   functioning,	   oral	   microflora	   is	   essential	   for	   normal	   cardiovascular	  
homeostasis	   and	   may	   be	   a	   contributing	   factor	   to	   the	   lower	   blood	   pressure	   and	  
vasoprotective	  phenotype	  of	  pre-­‐menopausal	  women.	  Lastly,	  the	  importance	  of	  the	  
oral	   microflora	   to	   maintain	   plasma	   nitrite	   levels	   intimates	   that	   oral	   hygiene	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Despite	   major	   advances	   over	   the	   past	   two	   decades	   in	   the	   pharmacotherapy	   of	  
cardiovascular	  diseases	  (CVDs),	  CVDs	  have	  still	  become	  the	  biggest	  killer	  worldwide	  
with	  incidence	  likely	  to	  increase	  further	  as	  the	  non-­‐western	  world	  adopts	  a	  western	  
lifestyle	   (World	   Health	   Organization,	   2011).	   This	   rise	   in	   the	   incidence	   of	   CVDs	   is	  
associated	  with	  a	  huge	  economic	  cost	  with	  direct	  and	  indirect	  health	  costs	  in	  2006	  
estimated	   to	   total	   €192	   billion	   within	   the	   EU	   and	   £31	   billion	   in	   the	   UK	   alone	  
(Allender	  et	  al.,	  2008).	  Such	  figures	  clearly	  support	  an	  urgent	  need	  to	  develop	  novel	  
and	   cost-­‐effective	   strategies	   to	   combat	   these	   diseases.	   This	   imperative,	   in	   part,	  
underlies	   the	   major	   emphasis	   in	   the	   western	   world,	   over	   the	   last	   decade,	   to	  
increase	   the	   public	   consumption	   of	   fruit	   and	   vegetables	   (World	   Health	  
Organization,	  2003;	  Lichtenstein	  et	  al.,	  2006).	  In	  the	  UK,	  this	  has	  taken	  the	  form	  of	  a	  
large-­‐scale	  multimedia	  ‘5-­‐a-­‐day’	  campaign	  (Department	  of	  Health,	  2003)	  run	  by	  the	  
Department	   of	  Health.	   This	   approach	   has	   been	   initiated	   as	   a	   consequence	   of	   the	  
substantial	   body	   of	   evidence	   accumulated	   over	   the	   last	   century	   that	   fruit	   and	  
vegetable-­‐rich	  diets	   reduce	   the	   incidence	  of	  many	  modern-­‐day	  diseases,	  not	   least	  
the	  broad	  spectrum	  of	  CVDs.	  	  
	  
1.1	  Beneficial	  effects	  of	  a	  fruit	  and	  vegetable-­‐rich	  diet	  
In	  the	  early	  20th	  century,	  nutritionists	  noted	  that	  vegetarian	  diets	  were	  associated	  
with	  lower	  blood	  pressure	  (BP)	  (Donaldson,	  1926),	  a	  finding	  corroborated	  by	  further	  
observational	   studies	   in	   different	   populations	   including	   American	   macrobiotists	  
(Sacks	  et	  al.,	  1974),	  Australian	  7th	  day	  Adventists	  (Armstrong	  et	  al.,	  1977,	  1979)	  and	  
Sephardic	  Israelis	  (Ophir	  et	  al.,	  1983).	  This	  finding	  was	  tested	  in	  a	  number	  of	  small-­‐
scale	   controlled	   studies	   (Rouse	   et	   al.,	   1983;	   Lindahl	   et	   al.,	   1984;	  Margetts	   et	   al.,	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1986;	   John	   et	   al.,	   2002),	   including	   the	   landmark	   Dietary	   Approaches	   to	   Stop	  
Hypertension	   (DASH)	   study	   (Appel	   et	   al.,	   1997),	   providing	   further	   evidence	  
supporting	   the	   thesis	   that	  a	  diet	   rich	   in	   fruit	  and	  vegetables	   lowers	  BP.	  The	  DASH	  
study	  enrolled	  459	  drug-­‐naïve	  subjects	  (systolic	  BP	  (SBP)	  <160	  mmHg	  and	  diastolic	  
BP	  (DBP)	  80-­‐95	  mmHg)	  and	  provided	  a	  control	  diet	  for	  3	  weeks.	  Subjects	  were	  then	  
randomized	  to	  a	  receive	  a	  further	  dietary	  pattern	  for	  8	  weeks:	  control	  diet;	  fruit	  and	  
vegetable-­‐rich	  diet;	  or	  a	  ‘combination’	  diet	  rich	  in	  fruits	  and	  vegetables	  and	  low	  in	  
saturated	  fat	  (Appel	  et	  al.,	  1997).	  The	  remarkable	  findings	  from	  the	  study	  included	  
the	  demonstration	  that	  provision	  of	  a	   fruit	  and	  vegetable-­‐rich	  diet	   (~5	  portions	  of	  
fruit	   and	   vegetables	   more	   than	   the	   control	   diet	   per	   day)	   caused	   significant	  
reductions	   in	   both	   SBP	   (~2.8	  mmHg)	   and	   DBP	   (~1.1	  mmHg)	   in	   a	   population	  with	  
high-­‐normal	  BP	   (mean	  BP	  ~131/85	  mmHg),	  with	  even	   larger	   reductions	   (SBP	  ~7.2	  
mmHg;	  DBP	  ~2.8	  mmHg)	  in	  the	  subset	  of	  subjects	  with	  a	  diagnosis	  of	  hypertension	  
(SBP	  >140	  mmHg	  or	  DBP	  >90	  mmHg)	  (Appel	  et	  al.,	  1997).	  
	  
Although	  these	  reductions	   in	  BP	  may	  at	   first	  glance	  seem	  trivial,	   it	   is	   important	  to	  
appreciate	   the	   large	   reductions	   in	   vascular	   mortality	   that	   could	   occur	   if	   these	  
changes	   were	   applied	   to	   a	   whole	   population.	   In	   treated	   hypertensive	   patients,	  
every	  2	  mmHg	  increase	  in	  SBP	  results	  in	  a	  7%	  increase	  in	  the	  risk	  of	  mortality	  due	  to	  
ischaemic	  heart	  disease	  and	  a	  10%	   increase	   in	   the	   risk	  of	  mortality	  due	   to	   stroke	  
(Lewington	  et	  al.,	  2002).	  Separately,	  it	  has	  been	  estimated	  that	  lowering	  SBP	  by	  10	  
mmHg	   or	  DBP	   by	   5	  mmHg	   reduces	   the	   risk	   of	   ischaemic	   heart	   disease	   events	   by	  
~20%	   and	   ischaemic	   stroke	   by	   35-­‐40%	   (Law	   et	   al.,	   2003,	   2009).	   Further,	   larger	  
cohort	   studies	   have	   extended	   these	   observations	   to	   demonstrate	   that	   fruit	   and	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vegetable-­‐rich	   diets	   reduce	   cardiovascular	   morbidity	   and	   mortality.	   Willett	   and	  
colleagues	  have	  published	  a	  series	  of	  papers	  detailing	  the	  effects	  of	  dietary	  fruit	  and	  
vegetable	   intake	  in	  a	  cohort	  of	  over	  114,000	  American	  health	  professionals	  with	  a	  
minimum	  of	  8	  years	  follow	  up	  who	  were	  all	  free	  of	  CVD	  at	  baseline.	  Their	  analyses	  
demonstrated	   that	   those	   in	   the	   highest	   quintile	   for	   daily	   fruit	   and	   vegetable	  
consumption	  had	  ~30%	   reduced	   risk	   for	   ischaemic	   stroke	   (Joshipura	   et	   al.,	   1999),	  
~20%	   reduced	   risk	   for	   ischaemic	   heart	   disease	   (Joshipura	   et	   al.,	   2001)	   and	   ~30%	  
reduced	   risk	   of	   total	   CVD	   (Hung	   et	   al.,	   2004)	   compared	   to	   those	   in	   the	   lowest	  
quintile.	  Also,	  each	  additional	  daily	  serving	  of	  fruits	  and	  vegetables	  was	  associated	  
with	  an	   incremental	  6%	  lower	  risk	  of	   ischaemic	  stroke	  (Joshipura	  et	  al.,	  1999)	  and	  
4%	  lower	  risk	  of	  ischaemic	  heart	  disease	  (Joshipura	  et	  al.,	  2001).	  These	  results	  have	  
been	  replicated	  in	  other	  even	  larger	  cohorts,	  including	  most	  recently	  the	  European-­‐
based	  EPIC	  cohort,	  which	  analysed	  data	  from	  over	  310,000	  persons	  over	  mean	  8.4	  
years.	   In	   this	   study,	   there	   was	   a	   similar	   4%	   risk	   reduction	   for	   ischaemic	   heart	  
disease	  deaths	  for	  1	  additional	  daily	  serving	  of	  fruits	  and	  vegetables	  (Crowe	  et	  al.,	  
2011).	  Similar	  estimates	  for	  cardiovascular	  risk	  reduction	  with	  fruit	  and	  vegetable-­‐
rich	   diets	   have	   also	   been	   confirmed	   in	   very	   large	   meta	   analyses	   (>	   230,000	  
participants)	  for	  both	  ischaemic	  heart	  disease	  (Dauchet	  et	  al.,	  2006;	  He	  et	  al.,	  2007)	  
and	   ischaemic	   stroke	   (Dauchet	   et	   al.,	   2005;	   He	   et	   al.,	   2006).	   Given	   the	   strong	  
evidence	  base	  for	  the	   inverse	  relationship	  between	  fruit	  and	  vegetable	   intake	  and	  
CVD	   risk	   described	   in	   the	   studies	   above,	   it	   may	   be	   no	   surprise	   that	   the	   global	  
burden	  of	  CVD	  due	  to	  low	  consumption	  of	  fruit	  and	  vegetables	  has	  been	  estimated	  
to	   account	   for	   31%	   of	   all	   CVD	   leading	   to	   an	   excess	   of	   2.6	   million	   CVD	   deaths	  
annually	  (Lock	  et	  al.,	  2005).	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1.2	  Proposed	  mechanisms	  of	  the	  beneficial	  effects	  of	  fruit	  and	  vegetable-­‐rich	  diets	  
Whilst	   the	   BP-­‐lowering	   and	   cardioprotective	   effects	   of	   a	   fruit	   and	   vegetable-­‐rich	  
diet	  are	  unequivocal,	  the	  exact	  mechanisms	  of	  this	  effect	  remain	  uncertain	  (Fraser,	  
2009).	  Specific,	  individual	  components	  found	  in	  abundance	  in	  fruits	  and	  vegetables,	  
including	   potassium	   (K+)	   and	   other	   cations,	   dietary	   fibre,	   and	   non-­‐nutrient	  
phytocemicals	   such	   as	   anti-­‐oxidant	   vitamins	   have	   been	   proposed	   to	   underlie	   the	  
benefits	  of	   such	  diets	   (Berkow	  and	  Barnard,	  2005).	  One	  of	   the	  major	  problems	   in	  
this	  strand	  of	  research	  is	  the	  ability	  to	  provide	  an	  adequate	  blinded,	  placebo	  control	  
to	   the	  dietary	   intervention	  and	  also	   the	  heterogeneity	  between	  ostensibly	   similar	  
interventions	  in	  different	  studies.	  
	  
1.2.1	  Dietary	  fibre	  
Dietary	   fibre	   is	   classed	   as	   the	   indigestible	   fraction	   of	   plant	   foodstuffs.	   Fruits	   and	  
vegetables	  are,	  along	  with	  nuts	  and	   legumes,	   the	  primary	  dietary	   sources	  of	   fibre	  
(Bingham	   et	   al.,	   1979).	   Dietary	   fibre	   intake	   is	   therefore	   higher	   in	   those	   who	  
consume	  more	   fruits	   and	   vegetables,	   such	   as	   vegetarians	   (Haddad	   and	   Tanzman,	  
2003).	  A	  recent	  meta	  analysis	  of	  22	  short-­‐term	  (4-­‐8	  weeks)	  randomized	  clinical	  trials	  
(RCTs)	  investigating	  the	  effects	  of	  soluble	  fibre	  supplementation	  (in	  particular,	  with	  
psyllium	  or	  oat	  β-­‐glucan)	   in	  ~1000	  total	  patients	   revealed	  significant	  reductions	   in	  
low-­‐density	   lipoprotein	   (LDL)	  cholesterol	  of	  ~5.5%	  (Anderson	  et	  al.,	  2009).	  Dietary	  
fibre	   may	   also	   reduce	   BP,	   though	   this	   effect	   was	   only	   apparent	   in	   recent	  meta	  
analyses	   in	  hypertensive	  subjects,	  with	  pooled	  estimates	  suggesting	  10-­‐15g/day	  of	  
soluble	   fibre	   supplementation	  may	   reduce	  BP	   in	  hypertensive	   individuals	  by	  ~2.5-­‐
6/2-­‐4	  mmHg	   in	   short-­‐term	  RCTs	   (Streppel	   et	  al.,	   2005;	  Whelton	   et	  al.,	   2005).	   The	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mechanism	  of	   dietary	   fibre	  modulation	   of	   cholesterol	   is	   thought	   to	   be	   related	   to	  
binding	  of	  bile	  acids	  in	  the	  gastro-­‐intestinal	  (GI)	  tract	  and	  increasing	  excretion	  in	  the	  
faeces	  (Kirby	  et	  al.,	  1981).	  However,	  there	  is	  no	  current	  consensus	  on	  the	  potential	  
mechanisms	  by	  which	  dietary	  fibre	  may	  lower	  BP,	  with	  some	  researchers	  suggesting	  
beneficial	   modulation	   of	   insulin	   resistance	   (Fukagawa	   et	   al.,	   1990),	   whilst	   others	  
suggest	   it	   is	   secondary	   to	   associated	  weight	   loss	   that	   occurs	  with	   fibre-­‐rich	   diets	  
(Solum	  et	  al.,	  1987).	  
	  
1.2.2	  K+	  and	  other	  cations	  
Fruit	   and	   vegetables	   contain	   large	   amounts	   of	   K+	   and	   other	   cations	   such	   as	  
magnesium	   (Food	   and	  Nutrition	   Board,	   2005).	   Population	   studies	   have	   shown	   an	  
inverse	   relationship	   between	   K+	   intake	   and	   BP	   (Intersalt	   Cooperative	   Research	  
Group,	   1988)	   and	   small	   scale	   clinical	   studies	   have	   demonstrated	   that	   dietary	   K+	  
depletion	   both	   increases	   BP	   in	   normotensive	   subjects	   (Krishna	   et	   al.,	   1989)	   and	  
worsens	   hypertension	   in	   hypertensive	   patients	   (Krishna	   and	   Kapoor,	   1991).	   The	  
mechanisms	   involved	   in	   the	   detrimental	   effects	   of	   K+	   depletion	   are	   complex	   and	  
involve	   alterations	   in	   sodium	   reabsorption	   in	   the	   kidney,	   with	   concomitant	  
increases	   in	   circulatory	   volume,	   and	   the	   activation	   of	   both	   the	   renin-­‐angiotensin-­‐
aldosterone	   and	   sympathetic	   nervous	   systems	   (Adrogué	   and	   Madias,	   2007).	   In	  
addition,	  it	  has	  been	  recognized	  for	  3	  decades	  that	  short-­‐term	  K+	  supplementation,	  
as	  potassium	  chloride	  (KCl)	  or	  potassium	  citrate,	  ameliorates	  raised	  BP	  (MacGregor	  
et	  al.,	  1982;	  He	  et	  al.,	  2005)	  and	  indeed	  a	  large	  meta	  analysis	  including	  33	  RCTs	  of	  K+	  
supplementation	  revealed	  a	  pooled	  estimate	  BP	  reduction	  of	  ~3/2	  mmHg	  (Whelton	  
et	  al.,	  1997).	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However,	  a	  more	  recent	  meta	  analysis	  failed	  to	  find	  conclusive	  overall	  evidence	  of	  
significant	   BP	   reduction	   with	   K+	   supplementation	   due,	   in	   part,	   to	   large	  
heterogeneity	  between	  trials	  and	  the	  short	  duration	  of	  many	  of	  the	  trials	  included	  
in	   the	   previous	   analysis	   (Dickinson	   et	   al.,	   2006).	   In	   addition,	   it	   has	   been	   shown	  
recently	  that	  the	  provision	  of	  magnesium,	  K+	  and	  fibre	  in	  hypertensive	  subjects	  does	  
not	   fully	   account	   for	   the	   beneficial	   effects	   of	   a	   fruit	   and	   vegetable-­‐rich	   diet.	  
Hypertensive	  subjects	  were	  fed	  both	  the	  standard	  DASH	  diet	  and	  a	  control	  diet	  that	  
was	   supplemented	   with	   magnesium,	   K+	   and	   fibre	   to	   match	   the	   DASH	   diet	   for	   3	  
weeks	   in	   a	   randomized,	   cross-­‐over	   design.	   The	   standard	   DASH	   diet	   was	   more	  
effective	   at	   lowering	   BP	   (~6/4	   mmHg)	   than	   the	   control-­‐supplemented	   diet.	   The	  
control-­‐supplemented	   diet	   did	   not	   lower	   BP	   on	   its	   own,	   suggesting	   alternative	  
nutritional	   factors	   must	   play	   a	   significant	   beneficial	   role	   in	   the	   DASH	   diet	   (Al-­‐
Solaiman	  et	  al.,	  2010).	  	  
	  
1.2.3	  Anti-­‐oxidant	  vitamins	  
Oxidative	  stress	  has	  long	  been	  established	  to	  be	  a	  critical	  part	  of	  the	  initiation	  and	  
progression	   of	   atherosclerotic	   disease.	   (Steinberg	   and	   Witztum,	   1990).	   The	  
oxidative-­‐modification	  hypothesis	  of	  atherosclerosis	  implicates	  superoxide	  (O2
-­‐)	  and	  
other	  oxidative	  free	  radicals	  in	  the	  oxidation	  of	  LDL-­‐cholesterol	  (Hessler	  et	  al.,	  1983)	  
within	   the	   vessel	   wall,	   representing	   a	   master	   step	   in	   the	   accumulation	   of	   LDL-­‐
cholesterol	   in	   recruited	   macrophages	   that	   eventually	   become	   foam	   cells	   in	   the	  
plaque	   (Brown	   and	   Goldstein,	   1983;	   Steinbrecher	   et	   al.,	   1984;	   Heinecke	   et	   al.,	  
1986).	  The	  corollary	  of	  such	  a	  paradigm	  is	  that	  anti-­‐oxidants	  should	  be	  beneficial	  at	  
some	  point	  in	  the	  pathological	  process.	  This	  has	  spurred	  much	  interest	  and	  research	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on	  the	  candidature	  of	  non-­‐nutrient	  phytochemicals	  (Liu,	  2003),	  such	  as	  anti-­‐oxidant	  
vitamins	   (Bruckdorfer,	   2008)	   as	   a	   potential	  mediator	   of	   beneficial	   effects	   and	   are	  
particularly	   relevant	   to	   this	   thesis	   as	   fruit	   and	   vegetables	   are	   the	   primary	   dietary	  
source	  of	  anti-­‐oxidant	  vitamins	  (Halvorsen	  et	  al.,	  2002).	  	  
	  
Prospective	   studies	   in	   which	   nutrient	   status	   was	   measured	   many	   years	   before	  
disease	  onset	  provided	  some	  evidence	  that	  there	  is	  an	  inverse	  relationship	  between	  
dietary	  and	  supplementary	  intake	  of	  such	  anti-­‐oxidant	  vitamins,	  including	  vitamin	  E	  
(α-­‐tocopherol),	  β-­‐carotene	  and	  vitamin	  C	  (reviewed	  in	  Stanner	  et	  al.,	  2004).	  A	  few	  
RCTs	  have	  purported	  to	  show	  that	  supplementation	  with	  anti-­‐oxidant	  vitamins	  have	  
beneficial	   effects	   on	   risk	   of	   CVDs.	   For	   example,	   the	   CHAOS	   trial	   involved	   ~2000	  
patients	  with	  ischaemic	  heart	  disease	  and	  randomized	  them	  to	  receive	  vitamin	  E	  or	  
placebo	  and	  participants	  were	   followed	   for	  up	   to	  2	  years.	   In	   this	   study,	   vitamin	  E	  
use	   was	   associated	   with	   47%	   reduction	   in	   risk	   of	   CVD	   events	   and	   mortality	  
(Stephens	  et	  al.,	  1996).	  However	  recent	  observational	  cohort	  studies	  have	  failed	  to	  
replicate	  these	  same	  results	  (Rautiainen	  et	  al.,	  2010;	  Mursu	  et	  al.,	  2011).	  Similarly,	  
several	   large	   RCTs,	   including	   the	   Heart	   Protection	   Study	   (Heart	   Protection	   Study	  
Collaborative	  Group,	  2002),	  HOPE	   (Yusuf	  et	  al.,	  2000)	  and	  HOPE-­‐TOO	  (Lonn	  et	  al.,	  
2005)	   studies	   have	   failed	   to	   show	   a	   beneficial	   effect	   of	   anti-­‐oxidant	   vitamin	  
supplementation.	   Indeed,	   recent	   meta	   analyses,	   involving	   80,000-­‐300,000	  
participants,	  have	  challenged	   this	  anti-­‐oxidant	  hypothesis,	  with	   the	  pooled	   results	  
of	   large-­‐scale	  RCTs	  of	  several	  different	  antioxidant	  vitamins	  failing	  to	  replicate	  the	  
same	  cardioprotective	  effects	  as	  a	   fruit	  and	  vegetable-­‐rich	  diet	   (Vivekananthan	   et	  
al.,	  2003;	  Bjelakovic	  et	  al.,	  2007),	  with	  some	  suggestion	  of	  a	  3-­‐4%	  increased	  risk	  of	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mortality	  in	  those	  who	  were	  supplemented	  with	  anti-­‐oxidant	  vitamins	  (Bjelakovic	  et	  
al.,	  2008,	  2012).	  
	  
1.2.4	  Dietary	  nitrate	  (NO3
-­‐)	  
These	   failures	   have	   spurred	   many	   others	   on	   to	   identify	   alternative,	   likely	  
candidates.	   One	   constituent,	   of	   particularly	   vegetables,	   that	   has	   been	   proposed	  
recently	  is	  inorganic	  NO3
-­‐	  (Lundberg	  et	  al.,	  2006).	  The	  majority	  of	  NO3
-­‐	  intake	  (~80%)	  
in	   humans	   comes	   from	   vegetable	   consumption	   (Table	   1.1),	   with	   a	  minor	   portion	  
coming	   from	   drinking	   water,	   animal	   products	   and	   grain	   (World	   Cancer	   Research	  
Fund/American	   Institute	   for	   Cancer	   Research,	   2007).	   Daily	   intakes	   of	   NO3
-­‐	   in	  




-­‐	   intake	  is	  regulated	  and	  there	  is	  an	  acceptable	  daily	  intake	  (ADI)	  that	  is	  set	  by	  
the	   World	   Health	   Organization	   and	   the	   European	   Food	   Safety	   Authority	   at	   3.7	  
mg/kg	  per	  day	  (Speijers	  and	  van	  den	  Brandt,	  2003;	  European	  Food	  Safety	  Authority,	  
2008),	  which	  is	  equivalent	  to	  ~4.2	  mmol	  per	  day	  in	  a	  70	  kg	  person.	  Water	  supplies	  in	  
the	  European	  Union	  are	  legally	  required	  by	  directive	  91/676/EEC	  (European	  Union	  
Council,	   1991)	   to	   have	   less	   than	   50	  mg/L	   NO3
-­‐	   (=0.8	  mM	   [NO3
-­‐])	   due	   to	   2	  major	  
















Artichoke	   Broccoli	   Cabbage	   Celeriac	   Celery	  
Asparagus	   Carrot	   Raddichio	   Fennel	   Lettuce	  
Mushroom	   Cauliflower	   Turnip	   Kohlrabi	   Radish	  
Pepper	   Cucumber	   	   Chicory	   Beetroot	  
Potato	   Pumpkin	   	   Leek	   Spinach	  
Tomato	   	   	   	   Swiss	  chard	  
Table	   1.1	   Classification	   of	   vegetables	   according	   to	   NO3
-­‐	   content	   (NO3
-­‐=nitrate).	   (data	  
adapted	  from	  Santamaria,	  2006).	  
	  
1.2.4.1	  NO3
-­‐	  and	  methaemoglobinaemia	  
Initial	   concerns	   regarding	   the	  aetiological	   role	  of	  NO3
-­‐	   and	  methaemoglobinaemia	  
were	  first	  reported	  in	  the	  early	  1900s	   in	  children	  treated	  with	  bismuth	  subnitrate,	  
(cited	  in	  English	  by	  Beck,	  1909).	  It	  was	  recognized	  by	  these	  early	  clinician-­‐scientists	  
that	  many	  people	  could	  tolerate	  very	   large	  doses	  of	  NO3
-­‐	  with	  no	   ill	  effects	   (Beck,	  
1909).	   However,	   children,	   and	   those	   will	   intestinal	   infections,	   were	   particularly	  
prone	   to	  methaemoglobinaemia.	   It	  was	   discovered	   that	  NO3
-­‐	  was	  metabolized	   to	  
nitrite	  (NO2
-­‐)	  and	  that	  the	  problems	  of	  methaemoglobinaemia	  after	  NO3
-­‐	   ingestion	  
were	   synonymous	  with	   that	   of	   NO2
-­‐	   ingestion,	   as	   first	   described	   by	  Gamgee	   (see	  
section	   1.5.3),	  which	   could	   lead	   to	   death	   especially	   in	   young	   infants	   (Roe,	   1933).	  
Surveys	   of	   NO3
-­‐	   levels	   in	   well	   water	   and	   associated	   cases	   of	   infant	  
methaemoglobinaemia	  after	  World	  War	   II	   (Comly,	  1945;	  Walton,	  1951)	   led	   to	   the	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establishment	  of	  regulatory	  frameworks	  to	  control	  the	  NO3
-­‐	  level	  in	  such	  water	  (U.S.	  
Public	   Health	   Service,	   1962)	   at	   levels	   <50	   mg/L	   that	   we	   still	   currently	   have	   as	  
discussed	   above.	   The	   reactions	   of	   NO2
-­‐	   with	   haemoglobin	   (Hb)	   to	   induce	  
methaemoglobinaemia	  will	  be	  discussed	  in	  section	  1.5.3.	  
	  
1.2.4.2	  NO3
-­‐	  and	  carcinogenesis	  
NO3
-­‐	  itself	  is	  not	  thought	  to	  be	  carcinogenic	  (Speijers	  and	  van	  den	  Brandt,	  2003)	  but	  
requires	   the	   endogenous	   conversion	   to	   the	   chemically	   related	   anion,	   NO2
-­‐	   (see	  
section	  1.6.4)	   and	   the	   further	   reaction	  of	  NO2
-­‐	  with	   secondary	  amines	   to	   form	  N-­‐
nitrosamines.	  N-­‐nitrosoamines	  were	  first	  recognized	  to	  be	  carcinogenic	  more	  than	  
60	  years	  ago.	  Dimethylnitrosoamine	  (50	  ppm)	  was	  found	  to	  produce	  large,	  necrotic	  
hepatocellular	  carcinoma	  in	  rats	  after	  6	  months	  feeding	  (Magee	  and	  Barnes,	  1956)	  
and	  other	  related	  N-­‐nitrosoamines	  have	  been	  shown	  to	  cause	  malignant	  tumours	  of	  
the	  liver,	  kidney,	  stomach	  and	  oesophagus	  in	  rats	  when	  given	  orally	  over	  prolonged	  
periods	  (Magee	  and	  Barnes,	  1967).	  Further	  studies	  have	  revealed	  there	  are	  over	  38	  
animal	   species	   in	   which	   N-­‐nitrosoamines	   are	   directly	   carcinogenic	   (Bogovski	   and	  
Bogovski,	  1981).	  N-­‐nitrosoamines	  can	  be	   formed	   in	  humans	   in	   vitro	   by	   incubating	  
gastric	  juice,	  NO2
-­‐	  and	  secondary	  amines	  (Sen	  et	  al.,	  1969)	  and	  in	  vivo	  after	  dietary	  
ingestion	   of	   NO2
-­‐-­‐containing	   foods	   (Fine	   et	   al.,	   1977).	   Although	   there	   has	   been	  
much	  epidemiological	  research	  aimed	  at	  exploring	  the	  link	  between	  NO3
-­‐	  intake	  and	  
human	  cancer,	  much	  of	  it	  is	  equivocal	  (as	  reviewed	  in	  McKnight	  et	  al.,	  1999)	  and	  a	  
comprehensive	  review	  by	  the	  World	  Health	  Organization	  and	  other	  parties	  in	  2003	  
concluded	   that	   there	   was	   no	   evidence	   that	   NO3
-­‐	   ingestion	   was	   associated	   with	  
carcinogenesis	   in	   humans	   (Speijers	   and	   van	   den	   Brandt,	   2003).	   Moreover,	   those	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with	  the	  highest	  NO3
-­‐	  intake	  in	  large	  (>100,000	  subject)	  cohorts,	  have	  no	  increased	  
cancer	  incidence	  or	  mortality	  (Hung	  et	  al.,	  2004);	  in	  fact	  the	  converse	  may	  be	  true	  
(World	   Cancer	   Research	   Fund/American	   Institute	   for	   Cancer	   Research,	   2007;	  
Boffetta	  et	  al.,	  2010).	  
	  
1.2.4.3	  Potential	  beneficial	  role	  of	  inorganic	  NO3
-­‐	  
Despite	   these	  negative	  views	  of	   inorganic	  NO3
-­‐,	  possible	   clues	   that	   inorganic	  NO3
-­‐	  
may	  have	  beneficial	  effects	  on	  the	  cardiovascular	  system	  were	  provided	  by	  Willett	  
and	   colleagues	   in	   their	   large	   cohort	   (>100,000	   subjects)	   studies,	   in	   which	   they	  
suggested	   that	   the	  greatest	  protection	  against	   ischaemic	  heart	  disease,	   ischaemic	  
stroke	   and	   CVD	  was	   afforded	   by	   a	   diet	   particularly	   rich	   in	   green	   leafy	   vegetables	  
(Joshipura	   et	   al.,	   1999,	   2001;	  Hung	   et	   al.,	   2004).	   Although	   green-­‐leafy	   vegetables	  
contain	   numerous	   nutrients,	   they	   are	   also	   particularly	   rich	   in	   inorganic	   (dietary)	  
NO3
-­‐	  content	  (Table	  1.1).	  This	  observation	  has	   led	  some	  to	  consider	  the	  possibility	  
that	   inorganic	   NO3
-­‐	   may	   contribute	   to	   the	   vasoprotective	   effects	   of	   fruits	   and	  
vegetables	   (Lundberg	   et	   al.,	   2006;	  Webb	   et	   al.,	   2008a;	   Ralt,	   2009),	   since	   recently	  
described	   reductive	   pathways	   in	   humans	   (Gladwin	   et	   al.,	   2005)	   suggest	   that	  
physiologically	  relevant	  production	  of	  NO3
-­‐-­‐derived	  nitric	  oxide	  (NO)	  can	  be	  attained	  




NO	   was	   discovered	   by	   the	   pre-­‐eminent	   British	   chemist,	   Joseph	   Priestley,	   at	   the	  
same	   time	  as	  he	  discovered	  oxygen	   (O2)	   in	  1776.	  For	   the	  next	  200	  years,	  NO	  was	  
largely	   thought	   of	   as	   an	   atmospheric	   pollutant	   (Spicer,	   1977).	   The	   discovery	   of	  
mammalian	   NO	   production	   and	   the	   protean	   systems	   it	   had	   effects	   on	   radically	  
changed	  this	  view.	  	  
	  
1.3.1	  Discovery	  of	  NO	  as	  an	  endogenous	  gasotransmitter	  
In	   1998,	   Furchgott,	   Ignarro	   and	   Murad	   shared	   the	   Nobel	   Prize	   in	   Physiology	   or	  
Medicine	   (http://nobelprize.org/nobel_prizes/medicine/laureates/1998/illpres)	   for	  
their	  seminal	  roles	  in	  the	  discovery	  “concerning	  NO	  as	  a	  signalling	  molecule	  in	  the	  
cardiovascular	   system”.	   The	   critical	   role	   of	   the	   endothelium	   in	   permitting	  
vasorelaxation	   of	   blood	   vessels	   was	   elucidated	   by	   Robert	   Furchgott.	   He	   was	  
intrigued	   by	   the	   observation	   that	   acetylcholine	   (ACh)	   reduced	   BP	   in	   vivo,	   yet	  
contracted	  isolated	  spiral	  aortic	  preparations.	  On	  changing	  methodology	  to	  the	  use	  
of	   isolated	  aortic	  rings,	  he	  observed	  ACh-­‐induced	  vasorelaxation	  for	  the	  first	  time,	  
in	  accord	  with	  its	  potent	  vasodilating	  action	  in	  vivo	  (Furchgott	  and	  Zawadzki,	  1980)	  
because	   of	   preservation	   of	   intact	   endothelium	   during	   the	   preparation	   of	   aortic	  
rings.	   Furthermore,	   elegant	   ‘sandwich’	   experiments	   demonstrated	   that	   an	  
endothelium-­‐denuded	  aortic	  strip	   (that	  would	  not	  dilate	  on	   its	  own	  to	  ACh)	  could	  
be	  made	  to	  relax	  in	  response	  to	  ACh	  if	  it	  was	  placed	  in	  contact	  with	  an	  intact	  aortic	  
strip	   (Furchgott	   and	   Zawadzki,	   1980).	   Furchgott	   coined	   the	   term	   endothelium-­‐
derived	  relaxing	  factor	  (EDRF)	  (Cherry	  et	  al.,	  1982)	  to	  describe	  the	  unknown,	  soluble	  
entity	  produced	  by	   the	  endothelium	   that	   caused	   smooth	  muscle	   relaxation.	   EDRF	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was	   subsequently	   demonstrated	   to	   activate	   the	   enzyme	   soluble	   guanylyl	   cyclase	  
(sGC)	   to	   elevate	   tissue	   levels	   of	   the	   signalling	   molecule,	   cyclic	   guanosine	  
monophosphate	   (cGMP),	   in	   various	   vascular	   tissues,	   including	   bovine	   coronary	  
artery	  (Holzmann,	  1982),	  rat	  (Rapoport	  and	  Murad,	  1983;	  Rapoport	  et	  al.,	  1983)	  and	  
rabbit	  aorta	   (Diamond	  and	  Chu,	  1983),	  and	  bovine	  pulmonary	  artery	  preparations	  
(Ignarro	  et	  al.,	  1984).	  	  
	  
By	   this	   time,	   it	   was	   already	   established	   that	   ‘nitrovasodilators’	   (such	   as	   glyceryl	  
trinitrate	   (GTN)	   and	   sodium	   nitroprusside)	   and	   NO	   itself	   activated	   sGC	   and	  were	  
associated	   with	   the	   accumulation	   of	   cGMP	   in	   tissue	   supernatants	   (Arnold	   et	   al.,	  
1977;	   Katsuki	   et	   al.,	   1977b).	   This	   was	   followed	   by	   the	   demonstration	   that	  
nitrovasodilators	  and	  NO	  caused	  accumulation	  of	  cGMP	  in,	  and	  relaxation	  of,	  non-­‐
vascular	  (Katsuki	  et	  al.,	  1977a)	  and	  vascular	  (Gruetter	  et	  al.,	  1979)	  smooth	  muscle	  
preparations.	   One	   of	   the	   key	   pieces	   of	   evidence	   demonstrating	   the	   link	   between	  
EDRF	   and	   the	   nitrovasodilators/NO	   was	   the	   finding	   that	   their	   effect	   on	   smooth	  
muscle	   and	   subsequent	   cGMP	   accumulation	   in	   the	   tissues	   could	   be	   inhibited	   by	  
both	   methylene	   blue	   (Gruetter	   et	   al.,	   1981;	   Ignarro	   et	   al.,	   1984,	   1986)	   and	   Hb	  
(Furchgott	  et	  al.,	  1984).	  
	  
In	  further	  cascade-­‐perfusion	  bioassay	  experiments	  using	  known	  inhibitors	  of	  EDRF,	  
the	  short	  half-­‐life	  (t1/2)	  of	  EDRF	  was	  not	  only	  demonstrated,	  but	  also	  prolonged	  by	  
superoxide	  dismutase	  (SOD),	  suggesting	  a	  key	  role	  for	  the	  redox	  properties	  of	  EDRF	  
and	  for	  O2
-­‐	  in	  terminating	  the	  effects	  of	  EDRF	  (Gryglewski	  et	  al.,	  1986;	  Moncada	  et	  
al.,	  1986).	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Further	  experiments	  in	  Furchgott’s	  group	  using	  acidified	  sodium	  nitrite	  (NaNO2)	  as	  a	  
NO	  donor	  and	  electron	  paramagnetic	  resonance	  (EPR)	  spectroscopy	  experiments	  by	  
Ignarro’s	  group	  revealed	  the	  incredibly	  close	  similarity	  between	  EDRF	  and	  NO.	  This	  
similarity	  was	  first	  suggested	  simultaneously	  at	  a	  conference	  in	  1987	  (Ignarro	  et	  al.,	  
1987;	   Furchgott,	   1988).	   The	   first	   direct	   measurement	   of	   NO	   production	   was	  
conducted	  by	  Moncada’s	  group.	  They	  used	  the	  chemiluminescent	  signal	  produced	  
by	  the	  reaction	  of	  ozone	  (O3)	  and	  NO	  (Downes	  et	  al.,	  1976)	  and	  detected	  authentic	  
concentration-­‐dependent	   NO	   release	   from	   bradykinin	   (BK)-­‐stimulated	   endothelial	  
cells	  in	  sufficient	  quantities	  to	  account	  for	  the	  action	  of	  EDRF	  (Palmer	  et	  al.,	  1987).	  	  
	  
1.3.2	  NO	  and	  NO-­‐related	  chemistry	  
NO	   is	   a	   small	  diatomic,	   amphipathic,	   free	   radical	  molecule	   that	   is	   freely-­‐diffusible	  
and	  membrane-­‐permeable	  and	  has	  been	  demonstrated	  to	  have	  important	  effects	  in	  
almost	   every	   physiological	   system	   in	   the	  body,	   including	   in	   neurotransmission,	  GI	  
physiology,	   genito-­‐urinary	   function,	   innate	   immunity	   as	   well	   as	   on	   the	  
cardiovascular	  system.	  	  
	  
NO	  is	  a	  highly	  reactive	  radical	  that	  can	  be	  oxidized	  or	  reduced	  to	  generate	  a	  variety	  
of	   different	   nitrogen	   species	   in	   biological	   systems	   (Figure	   1.1).	   This	   reactivity	  
underlies	   the	  complexity	  of	  NO	  functions,	  endowing	  NO	  with	  a	  potent	  ability	  as	  a	  
free-­‐radical	  agent	  to	  react	  with	  other	  biological	  species.	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Figure	  1.1	  Redox	  relationship	  of	  NO	  and	  other	  nitrogen	  species	  (NO=nitric	  oxide).	  
	  
NO	   rapidly	   reacts	   with	   species	   that	   possess	   unpaired	   electrons	   (e-­‐),	   such	   as	   O2,	  
which	  is	  the	  main	  oxidative	  mechanism	  to	  form	  NO3
-­‐	  in	  aqueous	  solutions	  (Bonner	  
and	   Hughes,	   1988;	   Ignarro	   et	   al.,	   1993),	   and	   radicals	   such	   as	   O2
-­‐	   (Blough	   and	  
Zafiriou,	   1985).	   In	   addition,	   NO	   quenches	   radical-­‐type	   reactions,	   such	   as	   lipid	  
peroxidation	  (Rubbo	  et	  al.,	  1996).	  
	  
NO	  reacts	  with	  a	  variety	  of	  metals	  to	  form	  nitrosyl	  complexes,	  most	  commonly	  with	  
iron	  (Fe)	  but	  also	  copper	  (Cu)	  (Fukuto	  et	  al.,	  2000).	  One	  classic	  Fe-­‐nitrosyl	  reaction	  
that	   occurs	   has	   already	   been	   described	   above;	   namely,	   the	   activation	   of	   haem-­‐
containing	   protein,	   sGC.	   However,	   there	   are	   other	   haem-­‐containing	   proteins	   that	  
have	  important	  interactions	  with	  NO,	  including	  cytochrome	  P450	  and	  Hb	  itself.	  The	  
facileness	  of	   these	   reactions	  means	   that	  NO	  can	  be	  produced	   in	   separate	   cells	  or	  
even	  tissues	  to	  the	  target	  protein	  (Fukuto	  et	  al.,	  2000).	  
	  
Thiols	   represent	   a	   third	   chemical	   group	   that	   reacts	   with	   NO	   to	   generate	  
nitrosothiols	  in	  biological	  systems.	  These	  nitrosothiols	  have	  been	  proposed	  to	  act	  as	  
NO	  donors,	   releasing	  NO	  when	  coming	   into	  contact	  with	  other	  thiols	   (Ignarro	  and	  
Gruetter,	  1980;	  Ignarro	  et	  al.,	  1980a,	  b).	  There	  has	  also	  been	  some	  suggestion	  that	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nitrosothiols	  have	  direct	  effects	  binding	  to	  an,	  as	  yet,	  unidentified	  receptor	  (Ohta	  et	  
al.,	  1997;	  Lipton	  et	  al.,	  2001).	  
	  
The	   termination	   of	   action	   of	   NO	   in	   vivo	   is	   achieved	   through	   its	   oxidation.	   The	  
reaction	   of	   NO	   and	   oxyhaemoglobin	   (oxyHb)	   was	   first	   described	   more	   than	   140	  
years	  ago	  by	  Hermann	  in	  1865	  (as	  cited	  in	  Gladwin	  et	  al.,	  2005)	  and	  produces	  NO3
-­‐	  
and	  methaemoglobin	  (metHb)	  (Equation	  1.1).	  
	  
oxyHb	   	   nitric	  oxide	   	   metHb	   	   nitrate	  
Fe(II)HbO2	   +	   NO	   ⇒ Fe(III)Hb	   +	   NO3-­‐	  
Equation	   1.1	  Oxidative	   termination	   of	   NO	   activity	   with	   Hb.	   (Hb=haemoglobin;	   NO=nitric	  
oxide).	  
	  
It	  is	  now	  understood	  that	  this	  reaction	  represents	  an	  incredibly	  fast	  and	  avid	  sink	  (6-­‐
8	   x	  107	  M-­‐1	   s-­‐1)	   for	  NO	   (Feelisch	  and	  Noack,	  1987;	  Eich	   et	  al.,	   1996;	  Herold	   et	  al.,	  
2001).	   This	   reaction	   is	   so	   fast	   that	   there	   were	   concerns	   that	   NO	   could	   not	   be	   a	  
functional	  in	  vivo	  EDRF	  (Lancaster,	  1994).	  However,	  the	  discovery	  of	  a	  cell-­‐free	  layer	  
of	  blood	  flowing	  adjacent	  to	  the	  endothelium	  (Liao	  et	  al.,	  1999),	  and	  the	  recognition	  
that	  the	  encapsulation	  of	  Hb	  within	  the	  erythrocyte	  limits	  the	  speed	  of	  the	  reaction	  
due	  to	  the	  need	  for	  diffusion	  through	  the	  erythrocyte	  membrane	  (Liu	  et	  al.,	  1998;	  
Vaughn	   et	   al.,	   1998,	   2000;	   Han	   et	   al.,	   2002)	   have	   allayed	   these	   concerns	   for	   the	  
most	  part.	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In	   pure	   aqueous	   solutions,	   the	   oxidation	   of	   NO	   occurs	   slowly	   and	   the	   primary	  
product	   is	   NO2
-­‐	   (Ignarro	   et	   al.,	   1993),	   however,	   with	   the	   addition	   of	  
oxyhaemoproteins,	  such	  as	  oxyHb,	  then	  the	  predominant	  product	  is	  NO3
-­‐	  (Ignarro	  et	  
al.,	  1993)	  and	  thus	  NO3
-­‐	  is	  the	  predominant	  oxidative	  metabolite	  of	  NO	  in	  biological	  
systems.	   There	   is	   recent	   evidence	   of	   a	  NO	  oxidase/NO2
-­‐	   synthase	   function	   of	   the	  
multi-­‐function	   Cu-­‐containing	   enzyme,	   caeruloplasmin	   (Shiva	   et	   al.,	   2006)	   but	   the	  
importance	   of	   this	   pathway	   in	   terminating	   NO	   activity	   and	   regulating	   basal	   NO	  
levels	  is	  unclear	  at	  this	  time.	  
	  
1.3.3	   Classical	   NO	   production	   and	   canonical	   signalling	   through	   the	   sGC/cGMP	  
pathway	  
Pioneering	  work	   on	   rat	   brain	   and	   neuroblastoma	   cell	   homogenates	   revealed	   that	  
there	   was	   a	   soluble	   activator	   of	   sGC	   whose	   activity	   could	   be	   blocked	   by	   Hb	  
(Deguchi,	  1977).	   Its	   identity	  was	  later	  confirmed	  as	  the	  amino	  acid,	  L-­‐arginine,	  but	  
not	  D-­‐arginine,	   by	   EPR	   spectroscopy	   and	   chromatography	   (Deguchi	   and	   Yoshioka,	  
1982).	   Further	   work	   on	   macrophage	   cell	   lines	   revealed	   that	   L-­‐arginine	   was	   the	  
critical	  factor	  required	  for	  the	  production	  of	  NO2
-­‐	  and	  NO3
-­‐	  (collectively	  termed	  NOx)	  
(Hibbs	  et	  al.,	  1987b;	  Iyengar	  et	  al.,	  1987)	  and	  that	  this	  process	  could	  be	  inhibited	  by	  
a	   chemically	   similar	   structure	   to	   L-­‐arginine;	   L-­‐NG-­‐monomethyl-­‐arginine	   (L-­‐NMMA)	  
(Hibbs	   et	   al.,	   1987a,	   b).	   Further	   experiments	   in	   cultured	   endothelial	   cells	   in	   the	  
absence	  of	  L-­‐arginine	  (using	  bioassays	  and	  chemiluminescence	  to	  detect	  authentic	  
NO	  production)	  revealed	  a	  decrease	  in	  NO	  production	  that	  could	  be	  restored	  with	  L-­‐	  
but	   not	   D-­‐arginine;	   and	   could	   be	   blocked	   by	   L-­‐NMMA	   (Palmer	   et	   al.,	   1988).	  
Similarly,	  use	  of	  15N-­‐labeled	  L-­‐arginine	  and	  mass	  spectroscopy	  revealed	  that	  NO	  was	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produced	  from	  the	  terminal	  guanido	  N-­‐atom	  of	  L-­‐arginine	  (Palmer	  et	  al.,	  1988).	  The	  
obligatory	  role	  of	  calcium	  (Ca2+)	  in	  the	  so-­‐called	  ‘L-­‐arginine:NO	  pathway’	  (Moncada	  
et	   al.,	   1989)	   was	   discovered	   by	   the	   use	   of	   Ca2+	   chelators	   (Knowles	   et	   al.,	   1989;	  
Palacios	   et	   al.,	   1989)	   and	   the	   importance	   of	   molecular	   O2	   confirmed	   by	   the	  
incorporation	   into	  both	  NO	  and	  L-­‐citrulline	  from	  18O2	  (Kwon	  et	  al.,	  1990;	  Leone	  et	  
al.,	  1991;	  Stuehr	  et	  al.,	  1991)	  (Equation	  1.2).	  
	  
NO	  has	  multiple	  downstream	  targets	  to	  transduce	  its	  biological	  activity	  (Figure	  1.2).	  
NO	  regulates	  gene	  expression	  and	  messenger	  ribonucleic	  acid	  (mRNA)	  transcription	  
via	   binding	   to	   Fe	   response	   elements	   (Pantopoulos	   and	  Hentze,	   1995;	   Khan	   et	   al.,	  
1996).	  NO	  also	  causes	  post-­‐translational	  modifications	  to	  proteins	  via	  S-­‐nitrosation,	  
via	  peroxynitrite	   (ONOO-­‐)	  as	  an	   intermediate	   (Ridnour	   et	  al.,	   2004).	  However,	   the	  
main	  molecular	   target	   for	   the	   beneficial	   effects	   of	   NO	   had	   been	   elucidated	   even	  
before	   the	   identification	  of	  EDRF	  as	  outlined	  previously.	   sGC	   is	  a	  haem-­‐containing	  
protein	   that	   can	   form	   Fe-­‐NO	   adducts	   and	   activate	   the	   enzyme	   to	   catalyse	   the	  
conversion	   of	   guanosine	   triphosphate	   (GTP)	   to	   cGMP,	   which	   is	   the	   canonical	  
intracellular	  secondary	  messenger	  for	  NO	  (Hobbs	  and	  Stasch,	  2010).	  cGMP	  itself	  has	  
a	  molecular	  target	  identified	  more	  than	  35	  years	  ago	  as	  a	  cGMP-­‐dependent	  protein	  
kinase	  (now	  commonly	  known	  as	  protein	  kinase	  G	  (PKG))	  (Greengard,	  1975).	  There	  
are	  various	  substrates	  identified	  for	  PKG	  of	  which	  an	  important	  few	  are	  summarized	  





Equation	   1.2	   The	   oxidation	   of	   L-­‐arginine	   to	   produce	   NO.	   (NO=nitric	   oxide;	   H20=water;	  
O2=oxygen;	  NADP




Figure	  1.2	  NO-­‐sGC-­‐cGMP	  and	  downstream	  pathways.	  Coloured	  arrows	  indicate:	  inhibition;	  
stimulation,	   catalysis.	   (cGMP=cyclic	   guanosine	   monophosphate;	   CNG=cyclic	   nucleotide-­‐
gated	   ion	   channel;	   eNOS=endothelial	   nitric	   oxide	   synthase;	   NO=nitric	   oxide;	  
PDE=phosphodiesterase;	  PKG=protein	  kinase	  G;	  sGC=soluble	  guanylyl	  cyclase).	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Integrin	  signal	  transduction	  
Inositol	  phosphate	  
receptor	  
Modulation	  of	  Ca2+	  release	  in	  smooth	  muscle	  cells	  
Myosin	  binding	  subunit	   Modulation	  of	  myosin	  light	  chain	  phosphatase	  
Heat-­‐shock	  protein	  20	   Modulation	  of	  contractility	  of	  smooth	  muscle	  cells	  
Thromboxane	  receptor	   Inhibition	  of	  G-­‐protein	  coupled	  receptor	  (GPCR)-­‐
mediated	  inositol	  phosphate	  formation	  in	  platelets	  
Table	   1.2	   Important	   substrates	   for	   PKG.	   (adapted	   from	   Lincoln	   and	   Komalavilas,	   2000).	  
(Ca2+=calcium;	  GPCR=G-­‐protein	  coupled	  receptor;	  PKG=protein	  kinase	  G).	  
	  
cGMP	  also	   acts	   directly	   on	  non-­‐specific	   cation	   ion	   channels,	   particularly	   in	   retinal	  
and	  olfactory	  tissues,	  though	  there	  is	  some	  suggestion	  for	  a	  role	  of	  cGMP-­‐mediated	  
ion	   channel	   activity	   in	   spermatozoa	   and	   kidney	   tubular	   cells	   in	   vertebrates	   (for	   a	  
detailed	   review	   of	   this	   subject	   see	   Kaupp	   and	   Seifert,	   2002).	   These	   channels	   are	  
termed	  cyclic	  nucleotide-­‐gated	  ion	  channels	  (CNGs).	  
	  
Lastly,	   cGMP	  has	  effects	  on	  cGMP-­‐dependent	  phosphodiesterases	   (PDEs)	   that	  can	  
cross	   talk	   with	   another	   biological	   secondary	   messenger,	   cyclic	   adenosine	  
monophosphate	   (cAMP).	   PDE	   II	   and	   III	   (of	   11	   so	   far	   discovered)	   are	   regulated	   by	  




1.3.4	  NO	  synthase	  (NOS)	  enzymes	  
Garthwaite	  and	  colleagues	  demonstrated	   that	   in	  cell	   suspensions	  of	   rat	   cerebella,	  
glutamate	   stimulation	   of	   the	   N-­‐methyl-­‐D-­‐aspartate	   (NMDA)	   receptor	   released	   a	  
diffusible	  factor	  that	  was	  Ca2+	  dependent	  and	  was	  responsible	  for	  cGMP	  elevations	  
both	   in	  the	  cell	  preparations	  themselves	  and	  also	   in	  detector	  cells	  perfused	   in	  the	  
medium	   from	   the	   stimulated	   cerebellar	   cells	   (Garthwaite	   et	   al.,	   1988).	   All	   these	  
features	  pointed	  to	  NO	  release	  from	  the	  neural	  tissues.	  This	  was	  quickly	  followed	  by	  
the	   isolation	  by	  affinity	   chromatography	  of	   the	   first	  enzyme	  capable	  of	  producing	  
NO	  from	  L-­‐arginine,	  which	  was	  called	  at	  the	  time	  NO	  synthetase	  (Bredt	  and	  Snyder,	  
1990).	  We	  now	   know	   this	   enzyme	   as	  NOS-­‐1	   or	   neuronal	   (n)NOS.	  Within	   this	   first	  
report	  of	  nNOS	  was	  the	  elucidation	  of	  the	  critical	  co-­‐factor,	  calmodulin	  (Cam)	  that	  
acts	  as	  a	  Ca2+-­‐binding	  messenger	  protein	  for	  all	  NOSs	  (EC	  1.14.13.39)	  and	  is	  required	  
for	   catalytic	  activity	   (Bredt	  and	  Snyder,	  1990).	  This	  nNOS	  protein	  was	   successfully	  
cloned	   in	   1991	   (Bredt	   et	   al.,	   1991)	   and	   noted	   to	   be	   structurally	   similar	   to	  
nicotinamide	   adenine	   dinucleotide	   phosphate	   (NADPH)-­‐cytochrome	   P450	  
reductase.	  Since	  then,	  there	  has	  been	  the	   identification	  of	  2	  further	  NOSs,	  named	  
after	   the	   tissues	   in	   which	   there	   were	   discovered	   and	   purified:	   inducible	   (i)NOS	  
(NOS-­‐2)	   (Stuehr	  et	  al.,	  1991)	  and	  endothelial	   (e)NOS	  (NOS-­‐3)	   (Pollock	  et	  al.,	  1991)	  
(see	  Table	  1.3	  for	  comparisons	  of	  the	  NOS	  isoforms).	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Enzymatic	  Property	   nNOS	   iNOS	   eNOS	  
Expression	   Constitutive	   Inducible	   Constitutive	  
Ca2+-­‐dependency	   Dependent	   Independent	   Dependent	  













of	  platelet	  aggregation;	  
inhibition	  of	  leucocyte-­‐
endothelium	  adhesion	  







Table	   1.3	   Properties	   of	   mammalian	   NOS	   isoforms	   (Ca2+=calcium;	   CVD=cardiovascular	  
disease;	   eNOS=endothelial	   nitric	   oxide	   synthase;	   iNOS=inducible	   nitric	   oxide	   synthase;	  
nNOS=neuronal	  nitric	  oxide	  synthase;	  NOS=nitric	  oxide	  synthase)	   (adapted	   from	  Masters,	  
2000;	  Forstermann	  and	  Sessa,	  2012).	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All	   isoforms	   of	   NOS	   are	   functional	   as	   homodimers	   (Klatt	   et	   al.,	   1996;	   List	   et	   al.,	  
1997)	   and	   use	   L-­‐arginine	   and	   molecular	   O2	   as	   previously	   described	   above.	   In	  
addition,	   however,	   a	   number	   of	   other	   cofactors	   are	   also	   required	   (Figure	   1.3	   A).	  
NADPH	   is	   essential	   and	   acts	   as	   an	   e-­‐	   donor	   (Knowles	   et	   al.,	   1989;	   Palacios	   et	   al.,	  
1989;	   Stuehr	   et	   al.,	   1989).	   Flavin	   mononucleotide	   (FMN)	   and	   flavin	   adenine	  
dinucleotide	  (FAD)	  are	  present	  in	  1:1	  stoichiometry	  (Bredt	  et	  al.,	  1991;	  Mayer	  et	  al.,	  
1991)	   and	   are	   important	   for	   e-­‐	   transfer	   the	   reductase	   domain	   on	   one	  monomer	  
(Klatt	  et	  al.,	  1992;	  Stuehr	  and	  Ikeda-­‐Saito,	  1992;	  White	  and	  Marletta,	  1992),	  to	  the	  
haem/oxygenase	   domain	   on	   the	   opposite	   NOS	   monomer	   (Abu-­‐Soud	   and	   Stuehr,	  
1993;	  Brunner	   et	  al.,	   1998).	   Finally	   the	  pterin	   co-­‐factor,	   tetrahydrobiopterin	   (H4B)	  
(Tayeh	  and	  Marletta,	  1989;	  Mayer	  et	  al.,	  1991)	  is	  essential	  for	  coupling	  of	  haem,	  O2	  
and	  e-­‐	  transfer	  to	  NO	  production	  (Vásquez-­‐Vivar	  et	  al.,	  1998).	  In	  its	  absence,	  NOS	  is	  
said	   to	   be	   uncoupled,	   and	   can	   produce	   O2
-­‐	   instead	   (Vásquez-­‐Vivar	   et	   al.,	   1998;	  
Landmesser	  et	  al.,	  2003)	  (Figure	  1.3	  B).	  
	  
Each	  NOS	  monomer	  contains	  a	  C-­‐terminal	  reductase	  (binding	  site	  for	  FMN,	  FAD	  and	  
NADPH)	  and	  an	  N-­‐terminal	  oxygenase	  domain	  (binds	  haem,	  O2,	  L-­‐arginine	  and	  H4B).	  
In	   the	   functional	   homodimeric	   configuration,	   these	  monomers	   run	   antiparallel	   so	  
that	  the	  reductase	  domain	  of	  one	  monomer	  is	  adjacent	  to	  the	  oxygenase	  domain	  of	  





Figure	   1.3	   Coupled	   and	   uncoupled	   dimeric	   eNOS.	   Representation	   of	   the	   domains	   and	  
cofactors	  required	  for	  (A)	  coupled	  eNOS	  synthesis	  of	  NO	  and	  (B)	  the	  uncoupled	  production	  of	  
O2
-­‐.	  In	  the	  presence	  of	  H4B	  (A),	  e
-­‐	  flow	  from	  the	  reduction	  of	  NADPH	  through	  FAD	  and	  FMN	  
and	  are	  transferred	  to	  oxidase	  domain	  of	  the	  corresponding	  monomer	  and	  are	  coupled	  to	  
the	  oxidation	  of	  L-­‐arginine	  to	  liberate	  NO.	  In	  the	  absence	  of	  H4B	  (B),	  e
-­‐	  no	  longer	  flow	  to	  the	  
corresponding	  monomer	  and	  instead	  facilitates	  the	  production	  of	  O2
-­‐.	   (Cam=calmodulin;	  e-­‐
=electron;	   eNOS=endothelial	   nitric	   oxide	   synthase;	   FAD=flavin	   adenine	   dinucleotide;	  
FMN=flavin	   mononucleotide;	   H4B=tetrahydrobiopterin;	   NADP
+/H=nicotinamide	   adenine	  




NO	  generation	  within	  the	  circulation	  is	  thought	  to	  be	  largely	  produced	  largely	  from	  
eNOS	   that	   resides	   within	   the	   endothelial	   cell.	   eNOS-­‐derived	   NO	   is	   generated	   in	  
response	   to	   circulating	   hormones	   such	   as	   ACh	   and	   BK	   (Furchgott	   and	   Zawadzki,	  
1980;	  Cherry	  et	  al.,	  1982);	  and	  in	  response	  to	  mechanical	  shear	  stress	  (Pohl	  et	  al.,	  
1986;	   Rubanyi	   et	   al.,	   1986;	   Joannides	   et	   al.,	   1995).	   The	   former	   results	   in	   eNOS	  
activation	  following	  GPCR	  activation	  (Flavahan	  et	  al.,	  1989;	  Liao	  and	  Homcy,	  1992),	  
triggering	  Ca2+	  influx	  (Busse	  et	  al.,	  1988;	  Danthuluri	  et	  al.,	  1988)	  and	  further	  release	  
of	   intracellular	   Ca2+	   stores	   (Freay	   et	   al.,	   1989).	   Shear	   stress,	   sensed	   by	  
mechanoreceptors	   on	   the	   endothelial	   cell	   surface	   (Lansman	   et	   al.,	   1987),	   triggers	  
eNOS	  activity	  primarily	   through	  protein	  kinase	  B	   (Akt)-­‐dependent	  phosphorylation	  
of	  eNOS,	  independent	  of	  intracellular	  Ca2+	  rises	  (Dimmeler	  et	  al.,	  1999;	  Fulton	  et	  al.,	  




Figure	   1.4	   Agonist-­‐dependent	   and	   -­‐independent	   stimulation	   of	   eNOS	   activity.	  
(ACh=acetylcholine;	   Akt=Protein	   kinase	   B;	   BK=bradykinin;	   CAM=calmodulin;	   Ca2+=calcium;	  
cGMP=cyclic	   guanosine	   monophosphate;	   eNOS=endothelial	   nitric	   oxide	   synthase;	  
GTP=guanosine	   triphosphate;	   GPCR=G-­‐protein	   coupled	   receptor;	   NO=nitric	   oxide;	   PI3K=	  
phosphoinositide	  3-­‐kinase;	  sGC=soluble	  guanylyl	  cyclase).	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However,	  it	  was	  largely	  with	  the	  advent	  and	  use	  of	  the	  NOS	  inhibitor,	  L-­‐NMMA,	  that	  
the	  fundamental	  roles	  of	  endogenous	  NO	  were	  elucidated	  within	  the	  cardiovascular	  
system.	  Experiments	  using	  rabbit	  aorta	  ex	  vivo	  demonstrated	  that	  application	  of	  L-­‐
NMMA	   caused	   dose-­‐dependent,	   endothelium-­‐dependent	   smooth	   muscle	  
contraction,	  suggesting	  for	  the	  first	  time,	  continuous	  NO-­‐release	  was	  responsible	  in	  
part	   for	  regulating	  vascular	   tone	  (Rees	  et	  al.,	  1989a).	  These	  seminal	   findings	  were	  
confirmed	   in	   whole	   animal	   studies.	   Infusion	   of	   L-­‐NMMA	   caused	   dose-­‐dependent	  
increases	   in	  BP	   in	   anaesthetized	   rabbits	   that	  were	   reversed	  with	   co-­‐infusion	  of	   L-­‐
arginine,	  but	  not	  D-­‐arginine	  (Rees	  et	  al.,	  1989b).	  Similarly,	  L-­‐NMMA	  pre-­‐treatment	  
prevented	  the	  expected	  BP	  reduction	  with	  an	  endothelium-­‐dependent	  agonist,	  ACh,	  
but	   did	   not	   change	   the	   response	   an	   endothelium-­‐independent	   vasodilator,	   GTN	  
(Rees	  et	  al.,	  1989b).	  	  
	  
Similar	  studies	  were	  then	  conducted	  in	  healthy	  subjects	  where	  infusion	  of	  L-­‐NMMA	  
into	   the	   brachial	   artery	   caused	   a	   reduction	   in	   forearm	   blood	   flow	   (FBF)	   and,	  
similarly,	  attenuated	  the	  increase	  in	  FBF	  produced	  in	  response	  to	  ACh	  (Vallance	  et	  
al.,	  1989).	  These	  studies	  demonstrated	  the	  dependence	  of	  baseline	  blood	  flow	  and	  
vessel	   tone	   in	   humans	   on	   endothelial	   production	  of	  NO.	  The	  development	   of	   the	  
eNOS	  knockout	  mouse	  has	  demonstrated	   that	   the	  dependence	  of	   the	  vasculature	  
on	  eNOS-­‐derived	  NO	  ultimately	  impacts	  on	  BP,	  with	  the	  demonstration	  of	  a	  raised	  
mean	   arterial	   pressure	   (MAP)	   of	   117±10	   mmHg	   compared	   to	   97±8	   mmHg	   in	  
littermate	   controls,	   as	  well	   as	   a	   complete	   absence	   of	   vasodilation	   in	   response	   to	  
ACh	   (Huang	   et	   al.,	   1995).	   Conversely,	   mice	   with	   eNOS	   over-­‐expression	   have	  
constitutively	  low	  BP	  (Ohashi	  et	  al.,	  1998).	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In	   addition	   to	   vasodilation,	   NO	   possesses	   several	   other	   potentially	   advantageous	  
properties.	   Cascade-­‐perfusion	   experiments	   of	   ACh-­‐stimulated	   aortic	   strips	  
demonstrated	  that	  the	  effluent	  of	  such	  circuits	  (i.e.	  eNOS-­‐derived	  NO)	  was	  not	  only	  
able	   to	   relax	   endothelium-­‐denuded	   aortic	   tissues	   (as	   had	   been	   previously	  
demonstrated)	  but	  also	  attenuated	  the	  aggregation	  response	  of	  washed	  platelets	  to	  
arachidonic	   acid	   (Azuma	   et	   al.,	   1986).	   Furthermore,	   stimulation	   of	   bovine	  
endothelial	  cell	  monolayer	  cultures	  with	  the	  endothelium-­‐dependent	  agonist	  BK,	  or	  
by	  superfusion	  of	  exogenous	  NO,	  attenuated	  platelet	  adhesion	   to	   the	  monolayers	  
(Radomski	  et	  al.,	  1987).	  
	  
In	   addition	   to	   preventing	   platelet	   adhesion	   to	   the	   endothelium,	   which	   is	  
increasingly	  recognized	  as	  a	  fundamental	  primary	  event	  in	  atherogenesis	  (Davì	  and	  
Patrono,	  2007),	  further	  studies	  have	  also	  revealed	  the	  critical	  role	  of	  eNOS-­‐derived	  
NO	   on	   leucocyte	   adhesion	   to	   the	   endothelium.	   Superfusion	   of	   cat	   mesenteric	  
preparations	   with	   L-­‐NNMA	   and	   other	   NOS	   inhibitors	   substantially	   increased	   the	  
leucocyte	  adherence	  and	  emigration	  detected	  by	  intravital	  microscopy	  (Kubes	  et	  al.,	  
1991),	   suggesting	   that	   basal	   eNOS-­‐derived	  NO	  might	   be	   involved	   in	   producing	   an	  
anti-­‐inflammatory	  endothelial	  phenotype.	  
	  
1.3.4.2	  Endothelial	  dysfunction	  
Traditional	   risk	   factors	   for	   CVD	   including	   smoking,	   hypertension,	   male	   sex	   and	  
diabetes	  are	  all	   associated	  with	   impaired	  ability	   to	  produce	  adequate	  amounts	  of	  
bioavailable	   endogenous	   NO	   (reviewed	   in	   Brunner	   et	   al.,	   2005),	   suggesting	   that	  
reduced	  bioavailable	  NO	  is	  a	  key	  first	  step	  in	  the	  development	  of	  CVDs.	  This	  concept	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is	   now	   synonymous	   with	   the	   term	   endothelial	   dysfunction	   (Moncada	   and	   Higgs,	  
2006).	  A	   variety	  of	  mechanisms	  have	  been	  proposed	   to	  underlie	   this	   reduced	  NO	  
bioavailability,	   in	   particular,	   increased	   reactive	   oxygen	   species	   (ROS)	   production,	  
such	  as	  O2
-­‐.	  Increased	  ROS	  production	  can	  come	  from	  many	  sources,	  such	  as	  NADPH	  
oxidases	   (Warnholtz	   et	   al.,	   1999),	   xanthine	   oxidoreductase	   (XOR)	   (Ohara	   et	   al.,	  
1993)	  and	  the	  mitochondrial	  respiratory	  chain	  (Turrens	  et	  al.,	  1985).	  However,	  O2
-­‐	  
can	  also	  be	  produced	  from	  eNOS	  uncoupling	  (Xia	  et	  al.,	  1998).	  
	  
A	   number	   of	   different	   mechanisms	   themselves	   have	   been	   implicated	   in	   bringing	  
about	  eNOS	  uncoupling.	  Perhaps	  the	  most	  important	  pathway	  relates	  to	  insufficient	  
levels	   of	   H4B.	   Although	   NOS	   dimers	   can	   form	   in	   the	   absence	   of	   H4B	   (Rodríguez-­‐
Crespo	  et	  al.,	  1996;	  Ghosh	  et	  al.,	  1997),	  H4B	  stabilizes	  and	  promotes	  the	  activity	  of	  
NOS	   dimers	   through	   structural	   means	   (Giovanelli	   et	   al.,	   1991;	   Baek	   et	   al.,	   1993;	  
Klatt	  et	  al.,	  1995)	  as	  well	  as	  improving	  affinity	  for	  L-­‐arginine	  binding	  to	  NOS	  (Klatt	  et	  
al.,	  1994).	  Whilst	  oxidized	  biopterin	  (H2B)	  does	  bind	  eNOS	  and	  stabilizes	  the	  eNOS	  
dimer,	  it	  is	  unable	  to	  couple	  e-­‐	  transfer	  to	  NO	  production	  (Ghosh	  et	  al.,	  1997;	  Presta	  
et	  al.,	  1998)	  and	  increasing	  H2B	  levels	  leads	  to	  eNOS	  uncoupling	  and	  O2
-­‐	  production	  
(Vásquez-­‐Vivar	  et	  al.,	  2002;	  Crabtree	  et	  al.,	  2009).	  
	  
The	   rate	  of	  NO	  production	   in	  endothelial	   cells	   is	   closely	  correlated	   to	   intracellular	  
H4B	  levels	  (Werner-­‐Felmayer	  et	  al.,	  1993;	  Rosenkranz-­‐Weiss	  et	  al.,	  1994).	  In	  animal	  
models,	   depletion	   of	   H4B,	   by	   pre-­‐treating	  with	   an	   inhibitor	   of	   H4B	   synthesis,	   2,4-­‐
diamino-­‐6-­‐hydroxypyrimidine,	  produced	  endothelial	  dysfunction	  in	  vivo	  (Yamashiro	  
et	   al.,	   2002).	   Conversely,	   i.v.	   supplementation	   with	   H4B	   improved	   endothelial	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function,	  as	  measured	  by	  the	  increases	  in	  FBF	  to	  endothelium-­‐dependent	  stimuli,	  in	  
human	   subjects	   with	   diabetes	   (Heitzer	   et	   al.,	   2000)	   hypertension	   (Higashi	   et	   al.,	  
2002),	  hypercholesterolaemia	  (Stroes	  et	  al.,	  1997)	  and	  intra-­‐arterial	  H4B	  prevented	  
ACh-­‐induced	  vasoconstriction	  in	  coronary	  arteries	  of	  patients	  with	  ischaemic	  heart	  
disease	   (Maier	   et	   al.,	   2000).	   However,	   more	   recently,	   the	   highly	   oxidative	  
environment	   that	   is	   apparent	   in	   CVD	   states	   has	   proved	   challenging	   to	   the	  
therapeutic	   exploitation	   of	   H4B.	   In	   patients	   waiting	   to	   undergo	   coronary	   artery	  
bypass	  grafting	   for	   ischaemic	  heart	  disease,	  oral	   supplementation	  of	  H4B	   (400mg-­‐
700mg	  /day	   for	  2-­‐6	  weeks)	  elevated	  plasma	  and	  venous	  tissue	  H4B	   levels	  but	  was	  
associated	   with	   a	   similar	   increase	   in	   H2B	   as	   well,	   thus	   not	   altering	   the	   overall	  
H2B:H4B	  ratio.	  This	  was	  associated	  with	  no	  change	   in	  vascular	   function	  or	  vascular	  
redox	   state	   (Cunnington	   et	   al.,	   2012),	   suggesting	   alternative	   strategies	   to	   target	  
endothelial	  function	  in	  established	  CVDs	  may	  be	  required.	  	  
	  
Other	   potential	   causes	   of	   reduced	   bioavailable	   NO	   production	   in	   endothelial	  
dysfunction	  include	  accumulation	  of	  asymmetric	  dimethylarginine	  (ADMA),	  which	  is	  
an	  endogenous	  inhibitor	  of	  eNOS	  (Vallance	  et	  al.,	  1992a,	  b)	  and	  may	  lead	  to	  eNOS	  
uncoupling	  (Antoniades	  et	  al.,	  2009)	  as	  well	  as	  directly	  inhibiting	  NO	  synthesis	  from	  
functional	  eNOS	  (reviewed	  in	  Sydow	  and	  Münzel,	  2003).	  An	   interesting	  concept	   in	  
this	   field	   is	   the	   ‘arginine	   paradox’.	   This	   is	   the	   unexpected	   phenomenon	   that	  
exogenous	  provision	  of	  L-­‐arginine	  increases	  endothelium-­‐dependent	  vasodilation	  in	  
many	  human	  equivalents	  of	  endothelial	  dysfunction	  (Drexler	  et	  al.,	  1991;	  Hishikawa	  
et	  al.,	  1993).	  This	  is	  despite	  normal	  intracellular	  L-­‐arginine	  levels	  being	  several	  fold	  
higher	   (~100μM)	   (Closs	   et	   al.,	   2000)	   than	   the	   KM	   of	   eNOS	   for	   L-­‐arginine	   (~3μM)	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(Pollock	  et	  al.,	  1991)	  It	  has	  been	  suggested	  that	  the	  paradox	  may	  be	  explained	  by	  an	  
increased	   arginase	   activity	   situated	   in	   close	   proximity	   to	   eNOS	   in	   disease	   states	  
(Bachetti	   et	   al.,	   2004;	  Ming	   et	   al.,	   2004)	  but	   also	  more	   recently	   to	   the	   activity	  of	  
arginosuccinate	  lyase	  that	  co-­‐localizes	  to	  eNOS	  in	  a	  complex	  protein	  structure	  (Erez	  
et	  al.,	  2011).	  
	  
Recently,	  S-­‐glutathionylation	  of	  eNOS	  (Chen	  et	  al.,	  2010b)	  has	  been	  shown	  to	  be	  an	  
important	   down-­‐regulator	   of	   eNOS	   function	   that	   is	   particularly	   activated	   by	   ROS	  
and	  leads	  to	  further	  eNOS	  uncoupling	  and	  eNOS-­‐derived	  O2
-­‐	  production,	  which	  itself	  
can	  scavenge	  NO	  and	  further	  reduce	  bioavailable	  NO	  (Chen	  et	  al.,	  2010b).	  	  
	  
As	   stated	   earlier,	   endothelial	   dysfunction	   is	   synonymous	   with	   the	   reduced	  
production	  of	  eNOS-­‐derived	  NO.	  Over	  the	  last	  30	  years,	  there	  have	  been	  a	  series	  of	  
different	   techniques	   to	   study	   this	   phenomenon	   in	   humans	   in	   vivo.	   One	   of	   the	  
earliest	   demonstrations	   of	   endothelial	   dysfunction	   in	   CVD	   was	   in	   patients	  
undergoing	   invasive	   epicardial	   coronary	   angiography	   due	   to	   suspected	   ischaemic	  
heart	  disease	   (Ludmer	   et	  al.,	   1986).	   In	   this	   study,	   in	  patients	  with	  no	  evidence	  of	  
coronary	   artery	   disease	   at	   angiography,	   it	   was	   shown	   that	   infusion	   of	   both	   the	  
endothelium-­‐dependent	   agonist	   ACh	   and	   the	   non-­‐endothelium-­‐dependent	   NO-­‐
donor	   GTN,	   both	   effected	   concentration-­‐dependent	   coronary	   artery	   dilation.	  
However,	  in	  patients	  with	  either	  mild	  (<20%	  angiographic	  stenoses)	  or	  severe	  (>50%	  
stenoses)	   atherosclerosis,	   ACh	   caused	   concentration-­‐dependent	   constriction	  
(Ludmer	   et	   al.,	   1986),	   similar	   to	   that	   observed	   by	   Furchgott	   in	   ex	   vivo	   denuded	  
aortic	   strips	   (Furchgott	   and	   Zawadzki,	   1980).	   GTN	   still	   produced	   concentration-­‐
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dependent	  relaxation	  in	  patients	  with	  angiographic	  stenoses	  (Ludmer	  et	  al.,	  1986).	  
These	  findings	  in	  patients	  with	  atherosclerotic	  stenoses	  demonstrate	  that	  the	  ability	  
of	   the	   smooth	   muscle	   to	   respond	   to	   NO	   was	   not	   impaired,	   whilst	   endothelial	  
dysfunction	  was	  apparent	   in	  both	  early	  and	  late	  stages	  of	  atherosclerosis	  (Ludmer	  
et	   al.,	   1986).	   These	   findings	   were	   further	   explored	   in	   patients	   who	   had	   received	  
allogeneic	   cardiac	   transplantation	   (Fish	   et	   al.,	   1988),	   who	   commonly	   develop	  
accelerated	  atherosclerosis	  in	  the	  allogeneic	  epicardial	  arteries	  (Nitkin	  et	  al.,	  1985).	  
In	   this	   study,	   the	   angiographically	   normal	   epicardial	   arteries	   of	   allogeneic	   heart	  
transplant	  recipients	  demonstrated	  vasoconstriction	  to	  ACh	  but	  normal	  dilation	  to	  
GTN,	   revealing	   the	  presence	  of	   endothelial	   dysfunction	   in	   the	  arteries	  of	  patients	  
known	   to	  be	  at	  much	  higher	   risk	  of	   atherosclerosis	   (Fish	   et	   al.,	   1988).	   It	   has	  now	  
also	  been	  established	  in	  patients	  free	  of	  angiographic	  atherosclerosis	  that	  epicardial	  
coronary	  endothelial	  dysfunction	   is	  associated	  with	  all	   the	  classical	   risk	   factors	   for	  
CVD	   such	   as	   age,	   male	   sex,	   hypercholesterolaemia,	   positive	   family	   history	   of	  
ischaemic	  heart	  disease	  (Vita	  et	  al.,	  1990)	  and	  hypertension	  (Treasure	  et	  al.,	  1992);	  
again	   suggesting	   that	   endothelial	   dysfunction	   is	   both	   pathogenic	   in	   and	   precedes	  
CVD.	   Furthermore,	   it	   is	   also	   now	   accepted	   that	   epicardial	   coronary	   endothelial	  
dysfunction	   is	   an	   independent	   predictor	   of	   the	   future	   likelihood	   of	   developing	  
coronary	  events	   in	  patients	  with	   ischaemic	  heart	  disease	  but	  also	   in	   those	   free	  of	  
disease	  (Halcox	  et	  al.,	  2002;	  Targonski	  et	  al.,	  2003).	  	  
	  
Whilst	   this	   coronary	   angiography-­‐based	   technique	   has	   been	   very	   useful	   in	  
articulating	   the	   presence	   of	   endothelial	   dysfunction,	   the	   invasive	   nature	   of	   the	  
method	  has	   inevitably	   limited	  mechanistic	  studies.	  One	  technique	  that	  overcomes	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some	   of	   these	   issues	   is	   venous	   occlusion	   plethysmography.	   Venous	   occlusion	  
plethysmography	  was	  first	  described	  by	  Brodie	  and	  Russell	  in	  1905	  to	  determine	  the	  
rate	  of	  flow	  of	  blood	   into	  an	  organ	  or	   limb	  by	  preventing	  venous	  blood	  escape	  by	  
the	  means	  of	  a	  pneumatic	  cuff	   inflated	   to	  sub-­‐diastolic	   levels	   (Brodie	  and	  Russell,	  
1905).	  This	  technique	  has	  since	  been	  modified	  with	  the	  introduction	  of	  mercury-­‐in-­‐
silastic	   stretch	   gauges	   (Hokanson	   et	   al.,	   1975)	   and	   has	   been	   coupled	   with	  
cannulation	   of	   the	   brachial	   artery	   to	   permit	   the	   application	   of	   endothelium-­‐
dependent	  agonists,	  such	  as	  ACh	  and	  NOS-­‐inhibitors,	  such	  as	  L-­‐NMMA	  (Vallance	  et	  
al.,	   1989).	   Through	   this	   moderately	   less-­‐invasive	   technique,	   it	   has	   been	  
demonstrated	   that	   endothelium-­‐dependent	   increases	   in	   FBF	   are	   attenuated	   in	  
patients	   with	   hypertension	   (Linder	   et	   al.,	   1990;	   Panza	   et	   al.,	   1993)	   and	  
hypercholesterolaemia	   (Chowienczyk	   et	   al.,	   1992).	  Moreover,	   prospective	   studies	  
show	  that	  the	  magnitude	  of	  the	  changes	  in	  ACh-­‐induced	  FBF	  is	  predictive	  of	  future	  
events	   in	   hypertensive	   patients	   (Perticone	   et	   al.,	   2001)	   and	   patients	   with	  
established	  ischaemic	  heart	  disease	  (Heitzer	  et	  al.,	  2001;	  Fichtlscherer	  et	  al.,	  2004).	  
	  
Whilst	  again	  this	  technique	  is	  useful,	  the	  invasive	  nature	  of	  the	  method	  is	  less	  than	  
ideal.	   The	   advent	   of	   ultrasound	   assessment	   of	   brachial	   artery	   diameter	   has	   now	  
superseded	  both	   the	  above	  techniques	  due	  to	   its	   reproducibility	  and	  non-­‐invasive	  
nature,	  and	  is	  currently	  accepted	  as	  a	  gold-­‐standard	  technique	  for	  the	  assessment	  
of	  endothelial	  dysfunction	   (Deanfield	  et	  al.,	  2005).	  This	   technique	  uses	  ultrasound	  
to	  detect	  brachial	  artery	  dilation	  in	  response	  to	  reactive	  hyperaemia	  (flow-­‐mediated	  
dilatation,	   FMD).	   By	   taking	   advantage	   of	   the	   response	   of	   the	   endothelium	   to	  
produce	   NO	   in	   response	   to	   flow/shear	   stress	   (Pohl	   et	   al.,	   1986;	   Rubanyi	   et	   al.,	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1986),	   Deanfield	   and	   Celermajer	   developed	   an	   entirely	   non-­‐invasive	   test	   of	  
endothelial	   function	  by	  using	  ultrasound	  detection	  of	  arterial	  dilation	  after	  a	  brief	  
period	  of	  arterial	  occlusion	  by	  a	  pneumatic	  cuff	  (Celermajer	  et	  al.,	  1992).	  Using	  this	  
technique,	   they	   established	   that	   FMD	  was	   diminished	   (i.e.	   there	   was	   endothelial	  
dysfunction)	   in	   children	   and	   adults	   with	   risk	   factors	   for	   atherosclerosis,	   such	   as	  
hypercholesterolaemia	  and	  smoking,	  prior	  to	  anatomically-­‐evident	  atherosclerosis,	  
and	  also	  in	  patients	  with	  ischaemic	  heart	  disease	  (Celermajer	  et	  al.,	  1992).	  Further	  
studies	  revealed	  that	  FMD	  was	  impaired	  in	   individuals	  expressing	  all	  of	  the	  known	  
traditional	  cardiovascular	  risk	  factors	  and	  that	  the	  magnitude	  of	  the	  impairment	  of	  
endothelial	   function	   increased	   with	   an	   increased	   number	   of	   independent	   risk	  
factors	   (Celermajer	   et	   al.,	   1994).	   Importantly,	   experiments	   using	   brachial	   artery	  
infusion	  of	  the	  NOS	  inhibitor,	  L-­‐NMMA,	  abolished	  radial	  artery	  FMD,	  confirming	  the	  
requirement	   for	   endothelial	   NO	   production	   to	   produce	   the	   FMD	   response	  
(Joannides	   et	   al.,	   1995;	  Mullen	   et	   al.,	   2001).	   Furthermore,	   just	   as	   with	   coronary	  
angiographic	   and	   forearm	   plethysmographic	   techniques	   above,	   ultrasound	  
assessment	   of	   FMD	  has	   been	  demonstrated	   to	   be	  predictive	   of	   CVD	  outcomes	   in	  
prospective	   patient	   populations	   with	   peripheral	   arterial	   disease,	   hypertension	  
(Gokce	  et	  al.,	  2003)	  and	  ischaemic	  heart	  disease	  (Neunteufl	  et	  al.,	  2000).	  
	  
Whilst	   all	   the	   studies	   and	   results	   described	   above	   confirm	   the	   importance	   of	  
endothelial	   dysfunction	   as	   an	   entity	   that	   precedes	   CVD	   and	   is	   also	   part	   of	   the	  
pathogenesis	  of	  CVD,	  additional	  evidence	   for	   the	   importance	  of	  eNOS-­‐derived	  NO	  
comes	  from	  intervention	  trials.	  Treatment	  of	  major	  CVD	  risk	  factors	  which	  improve	  
CVD	   mortality,	   such	   as	   LDL-­‐cholesterol	   lowering	   with	   hydroxymethylglutaryl-­‐
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coenzyme	   A	   reductase	   inhibitors	   (commonly	   known	   as	   ‘statins’)	   and	   BP	   lowering	  
with	   drugs	   that	   interfere	   with	   the	   renin-­‐angiotensin-­‐aldosterone	   system,	   reverse	  
endothelial	  dysfunction	  with	  prolonged	  treatment	  (Treasure	  et	  al.,	  1995;	  Mancini	  et	  
al.,	  1996;	  John	  et	  al.,	  1998)	  and	  increase	  bioavailable	  NO	  (Imanishi	  et	  al.,	  2008).	  	  
	  
Therefore,	  other	  strategies	  to	  replace	  the	  ‘lost’	  NO	  in	  CVD	  have	  obvious	  therapeutic	  
potential	   (Herman	   and	   Moncada,	   2005).	   The	   organic	   nitrates,	   such	   as	   GTN	   and	  
isosorbide	  mononitrate,	  represent	  the	  first	  class	  of	  NO	  donors	  to	  reach	  the	  clinical	  
setting,	   although	  a	  number	  of	   issues	  have	   limited	   their	   clinical	   utility	   (see	   section	  
1.4).	   Currently	   there	   is	   a	   trend	   towards	   the	   invention	   of	   novel,	   hybrid	   small	  
chemical	   entities	   with	   NO-­‐releasing	   properties	   and	   also	   combining	   drugs	   already	  
used	  clinically	  with	  the	  added	  improvement	  of	  an	  NO-­‐releasing	  moiety	  such	  as	  the	  
NO-­‐non	  steroidal	  anti-­‐inflammatory	  drugs	  (NSAIDs)	  (del	  Soldato	  et	  al.,	  1999).	  More	  
recently,	  it	  has	  been	  hypothesized	  that	  provision	  of	  inorganic	  NO3
-­‐,	  given	  either	  by	  
dietary	   or	   inorganic	   supplementary	   route	   may	   obviate	   the	   need	   for	   these	   costly	  
drugs	  and	  this	  class	  of	  ‘NO	  donor’	  is	  the	  focus	  of	  this	  thesis.	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1.4	  Use	  of	  organic	  NO-­‐releasing	  compounds	  on	  the	  cardiovascular	  system	  
Strategies	   that	  provide	  exogenous,	   synthesized	  sources	  of	  NO	  have	  been	  used	   for	  
medical	  purposes	  for	  more	  than	  120	  years	  before	  the	  discovery	  of	  endogenous	  NO	  
synthesis.	   The	   advent	   of	   organic	   chemistry	   and	   the	   new	   scientific	   discipline	   of	  
detailing	  physiological	  processes,	  aided	  through	  the	  invention	  of	  devices	  such	  as	  the	  
sphygmograph,	  led	  to	  an	  explosion	  in	  the	  field	  of	  organic	  NO	  therapeutics	  in	  the	  late	  
19th	   century,	   which	   eventually	   led	   to	   physicians	   studying	   the	   effects	   of	   related	  
inorganic	  compounds.	  	  
	  
1.4.1	  Organic	  nitrites	  and	  nitrates	  
The	  first	  compounds	  that	  we	  would	  now	  recognize	  to	  be	  nitrovasodilators	  that	  were	  
synthesized	  and	  used	   for	  medical	  purposes	  were	   the	  organic	  nitrites	  and	  nitrates.	  
Guthrie’s	   seminal	   observations	   of	   the	   ‘flushing’	   (vasodilation)	   and	   ‘acceleration’	  
(tachycardia)	   after	   exposure	   to	   amyl	   nitrite	   (Guthrie,	   1859)	   led	   Gamgee	   and	  
Brunton	   to	   prescribe	   amyl	   nitrite	   (Brunton,	   1867),	   and	  Murrell	   to	   prescribe	   GTN	  
(Murrell,	  1879a,	  b,	  c,	  d)	  to	  patients	  with	  angina	  with	  good	  results.	  However,	  despite	  
these	  early	  successes,	  the	  utility	  of	  organic	  nitrites	  and	  nitrates	  has	  been	  limited	  to	  
some	  degree	  by	  their	  chemistry.	  
	  
1.4.1.1	  Chemistry	  and	  bioactivation	  of	  organic	  nitrites	  and	  nitrates	  
Organic	  nitrites	  and	  nitrates	  are	  distinguished	  by	  the	  presence	  of	  an	   -­‐ONO2	  group	  
(or	  in	  the	  isolated	  case	  of	  ethyl	  nitrite,	  -­‐ONO),	  which	  is	  the	  pharmacophore	  of	  their	  
actions	  by	  liberating	  NO	  (Thatcher	  et	  al.,	  2004).	  These	  groups	  can	  be	  bound	  to	  any	  
organic	  residue	  and	  it	  is	  the	  stereochemistry	  and	  complexity	  of	  the	  organic	  residue	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that	   determines	   lipophilicity	   and	   potency	   of	   the	   organic	   nitrites	   and	   nitrates	  
(Thatcher	  et	  al.,	  2004;	  Koenig	  et	  al.,	  2007)	  (Figure	  1.5).	  
	  
Figure	  1.5	  Typical	  organic	  nitrite	  and	  nitrate	  structure	  
	  
Since	  the	  pharmacophore	  is	  covalently	  bound	  to	  the	  organic	  residue,	  bioactivation	  
of	   its	   nitrosovasodilating	   action	   requires	   enzymatic	   conversion	   to	   release	   the	  NO	  
from	   the	   –ONO2	   moiety.	   There	   are	   thought	   to	   be	   2	   main	   pathways	   for	   organic	  
nitrate	  bioactivation:	  the	  low	  and	  high	  potency	  pathways.	  The	  low	  potency	  pathway	  
produces	  measurable	   NO	   from	  GTN	   at	   high	   doses	   (Kleschyov	   et	   al.,	   2003)	   and	   is	  
largely	   thought	   to	   be	   mediated	   by	   enzymes	   of	   the	   cytochrome	   P450	   system	  
(McDonald	   and	  Bennett,	   1990).	  More	   recently,	   however,	   a	  high	  potency	  pathway	  
for	  GTN	  bioactivation,	  involving	  the	  mitochondrial	  isoform	  of	  the	  enzyme,	  aldehyde	  
dehydrogenase-­‐2	  (ALDH-­‐2),	  was	  elucidated	  by	  using	  the	  specific	  ALDH-­‐2	  inhibitors,	  
chloral	  hydrate	  and	  cyanamide	   (Chen	   et	  al.,	   2002).	  The	  ALDH-­‐2	   inhibitors	  blocked	  
the	  production	  of	  NO2
-­‐	  and	  glyceryl	  dinitrate	  (GDN)	  from	  GTN,	  which	  had	  previously	  
been	   shown	   to	   be	   important	   intermediates	   in	   producing	   NO-­‐related	   vasodilation	  
(Sage	   et	   al.,	   2000).	   ALDH-­‐2	   inhibitors	   also	   attenuated	   the	   vasodilating	   and	  
hypotensive	  properties	  of	  GTN	  in	  anaesthetized	  rabbits	  (whilst	  having	  no	  effect	  on	  
NO	   released	   from	   donors	   such	   as	   sodium	   nitroprusside)	   (Chen	   et	   al.,	   2002)	   and	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attenuated	   increases	   in	   cGMP	   and	   phosphoVASP	   as	   indicators	   of	   reduced	  
throughput	  of	  the	  NO-­‐dependent	  sGC/PKG	  signalling	  pathways	  (Daiber	  et	  al.,	  2004).	  	  
	  
However,	  one	  of	  the	  major	  problems	  with	  the	  organic	  nitrates	  is	  the	  occurrence	  of	  
tolerance	  or	  tachyphylaxis.	  This	   is	  the	  progressive	  reduction	   in	  the	  haemodynamic	  
effects	  of	  organic	  nitrates	  with	  prolonged	  treatment	   (Elkayam	  et	  al.,	  1987),	  which	  
also	   leads	   to	   endothelial	   dysfunction.	   Endothelial	   dysfunction	   can	   be	   observed	   in	  
humans	  after	  prolonged	  exposure	   to	  organic	  nitrates.	   In	  one	   such	   study,	   patients	  
with	  ischaemic	  heart	  disease	  were	  randomized	  to	  receive	  5	  days	  of	  continuous	  GTN	  
transdermally	   or	   nothing.	   ACh	   caused	   greater	   coronary	   artery	   vasoconstriction	   in	  
the	   GTN-­‐treated	   group,	   revealing	   the	   development	   of	   endothelial	   dysfunction	   in	  
response	  to	  prolonged	  GTN	  administration	  (Caramori	  et	  al.,	  1998).	  The	  same	  group	  
revealed	   similar	   results	   in	   the	   forearm	   circulation	   of	   healthy	   individuals	   using	  
venous	   occlusion	   plethysmography	   (Gori	   et	   al.,	   2001).	   The	   exact	   mechanisms	   of	  
organic	   nitrate	   tolerance	   are	   debated	  but	   there	   are	   some	   compelling	   theses.	   The	  
molecular	   mechanisms	   underlying	   organic	   nitrate-­‐induced	   tolerance	   and	  
endothelial	   dysfunction	   are	   largely	   thought	   to	   relate	   to	   increased	   production	   of	  
ROS,	  including	  O2
-­‐.	  Rabbit	  aortae	  from	  animals	  treated	  with	  transdermal	  GTN	  for	  3	  
days	  have	  double	  the	  amount	  of	  O2
-­‐	  (as	  measured	  by	  lucigenin	  chemiluminescence)	  
as	  control	  animals	  (Münzel	  et	  al.,	  1995a),	  and	  elevated	  levels	  of	  ONOO-­‐	  (assayed	  by	  
nitrotyrosine	  accumulation)	   (Skatchkov	   et	  al.,	   1997).	  ONOO-­‐	   is	   a	  powerful	  oxidant	  
product	  of	  reaction	  between	  NO	  and	  O2
-­‐	  (Huie	  and	  Padmaja,	  1993)	  and	  oxidizes	  the	  
critical	  factor	  H4B	  (Laursen	  et	  al.,	  2001)	  and	  therefore	  can	  uncouple	  eNOS	  and	  cause	  
increased	   production	   of	   eNOS-­‐derived	   O2
-­‐	   (Münzel	   et	   al.,	   2000)	   and	   increase	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oxidative	   stress	   in	   a	   positive	   feedback	   mechanism.	   These	   increases	   in	   O2
-­‐	   and	  
concomitant	  endothelial	  dysfunction	  could	  be	  detected	  ex	  vivo	  in	  segments	  of	  graft	  
arteries	   of	   patients	   (pre-­‐treated	   with	   GTN)	   undergoing	   coronary	   artery	   bypass	  
operations	  (Schulz	  et	  al.,	  2002).	  Another	  mechanism	  that	  has	  been	  proposed	  is	  the	  
increased	   sensitivity	   to	   receptor	   dependent	   vasoconstrictors.	   In	   animals	   treated	  
with	  GTN	   for	  prolonged	  periods	   there	  was	   increased	  sensitivity	   to	  vasoconstrictor	  
substances	   such	   as	   angiotensin-­‐II	   and	   phenylephrine	   (Münzel	   et	   al.,	   1995b).	  
Similarly,	  in	  the	  forearm	  circulation	  of	  patients	  with	  ischaemic	  heart	  disease	  treated	  
for	  48	  h	  continuously	  with	  GTN,	  the	  vasoconstrictor	  responses	  to	  angiotensin-­‐II	  and	  
phenylephrine	  were	   enhanced	   (Heitzer	   et	   al.,	   1998).	   It	   is	   possible,	   however,	   that	  
this	   effect	   is	   simply	   due	   to	   the	   loss	   of	   bioavailable	   NO	   that	   normally	   opposes	  
vasoconstriction.	  	  
	  
These	  problems	  of	   tolerance	   and	  endothelial	   dysfunction	  have	   largely	   limited	   the	  
utility	  of	  organic	  nitrates	  and	  perhaps	  partly	  explains	  the	  lack	  of	  efficacy	  of	  organic	  
nitrates	   in	   large	   scale	   clinical	   trials	   (ISIS-­‐4	   Collaborative	  Group,	   1995).	   The	   use	   of	  
organic	   nitrates	   has	   diminished	   over	   time	   and	   they	   are	   now	   predominantly	  
restricted	  in	  terms	  of	  clinical	  utility	  to	  symptomatic	  relief	  in	  angina	  and	  heart	  failure	  
(British	  Medical	  Association	  and	  the	  Royal	  Pharmaceutical	  Society	  of	  Great	  Britain,	  
2012).	   Whilst	   these	   limiting	   effects	   of	   organic	   nitrites	   and	   nitrates	   have	   been	  
disappointing,	  recent	  proposals	  suggest	  that	  exploiting	  NO	  donors	  in	  CVD	  may	  still	  
be	   an	   option	   using	   inorganic	   NO2
-­‐	   and	   NO3
-­‐.	   This	   possibility	   has	   been	   raised	   as	  
potentially	  offering	  a	  better	  option	  since	  their	  clinical	  utility	  seems	  not	  to	  be	  limited	  





The	  monographs	  published	  on	  the	  excellent	  anti-­‐anginal	  properties	  of	  amyl	  nitrite	  
by	  Lauder	  Brunton	  and	  GTN	  by	  Murrell	   led	  other	  physicians	  of	  the	  time	  to	  explore	  
related	  chemicals,	  including	  inorganic	  NO2
-­‐	  salts.	  
	  
1.5.1	  Historical	  uses	  of	  inorganic	  NO2
-­‐	  
Reichert	  and	  Mitchell	  published	  an	  extensive	  treatise	  on	  the	  physiological	  actions	  of	  
potassium	  nitrite	  (KNO2)	  in	  1880	  (Reichert	  and	  Mitchell,	  1880).	  Reichert	  started	  this	  
monograph	  with	   these	  words	   to	  explain	  why	  he	  was	  using	  a	   related	  substance	   to	  
amyl	  nitrite	  (Reichert	  and	  Mitchell,	  1880):	  
“The very great value of amyl nitrite in warding off impending paroxysms of epileptic 
convulsions, angina pectoris, and asthma, has been so generally recognized by the 
profession, that the discovery of a new salt whose physiological action is identical 
with… that of amyl nitrite, but whose effects would be more permanent and therefore 
suitable for maintaining a continuous systemic influence, we would have an addition to 
our materia medica which would fill a very apparent therapeutic void.”  
	  
Whilst	  much	  of	   the	  monograph	   is	   filled	  with	  experimental	   detail	   of	   the	  effects	  of	  
KNO2	  on	  the	  central	  and	  peripheral	  nervous	  system,	  respiration	  and	  muscles,	  there	  
was	   also	   extensive	   reporting	   on	   the	   effects	   of	   KNO2	   on	   the	   pulse	   and	   arterial	  
tension.	  Mitchell’s	   human	  experiments	   revealed	   that	   the	  effects	  of	   KNO2	  were	  of	  
similar	  effect	  to	  that	  of	  amyl	  nitrite,	  whilst	  Reichert’s	  experiments	  on	  dogs	  and	  cats	  
revealed	   that	   large	   doses	   of	   KNO2	   could	   reduce	   the	   BP	   so	   drastically	   and	   over	  
extended	   periods	   as	   to	   cause	   death	   of	   the	   animal	   (Reichert	   and	  Mitchell,	   1880).	  
These	  observations	  were	  followed	  by	  a	  detailed	  comparative	  analysis	  of	  the	  effects	  
of	  NaNO2	  and	  organic	  nitrites,	  including	  amyl	  nitrite	  (Wallace	  and	  Ringer,	  1909)	  and	  
GTN	   (Matthew,	  1909;	  Wallace	  and	  Ringer,	   1909).	   In	   subjects	  with	  normal	  BP,	   the	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hypotensive	  effects	  of	  organic	  nitrites	  and	  nitrates	  was	  observed	  for	  up	  to	  7-­‐30	  min	  
post-­‐administration	  but	  a	  similar	  level	  of	  BP	  reduction	  was	  maintained	  for	  up	  to	  60-­‐
65	  min	  following	  inorganic	  NO2
-­‐	  dosing	  (Matthew,	  1909;	  Wallace	  and	  Ringer,	  1909).	  
The	   effects	   were	   much	   larger	   (25%	   reduction	   in	   SBP)	   in	   patients	   with	   severely	  
elevated	   BP	   (SBP>	   170mmHg)	   compared	   to	   healthy	   individuals	   (13%	   reduction	   in	  
SBP)	   (Wallace	   and	   Ringer,	   1909),	   with	   maximal	   SBP	   reductions	   in	   hypertensive	  
patients	  of	  up	  to	  50	  mmHg	  (Matthew,	  1909;	  Wallace	  and	  Ringer,	  1909).	  The	  use	  of	  
inorganic	  NO2
-­‐	  for	  the	  treatment	  of	  BP	  was	  established	  in	  the	  early	  part	  of	  the	  20th	  
century	   and	   appeared	   in	   materiae	   medicae	   and	   were	   produced	   by	   several	  
pharmaceutical	  suppliers	  for	  use	  in	  hypertension	  (in	  Butler	  and	  Feelisch,	  2008).	  
	  
1.5.2	  Historical	  uses	  of	  inorganic	  NO3
-­‐	  
Inorganic	   NO3
-­‐	   has	   been	   used	   to	   treat	   CVD	   for	   over	   a	   millennium	   in	   traditional	  
Chinese	   medicine.	   The	   following	   passage	   is	   a	   translation	   from	   an	   8th	   century	   CE	  
manuscript	   that	  was	   discovered	   in	   the	  Mogao	   caves	   near	   to	   Dunhuang	   in	   Gansu	  
province	  of	  China	  (Butler	  and	  Moffett,	  2005):	  
“Putting under the tongue to cause heart qi to flow freely for treating symptoms such as 
struck by evil, acute heart pains and cold in the hands and feet which can kill a patient in 
an instant. Look at the patient’s fingers and those with greenish-black nails are such 
cases. Take saltpeter [xiaoshi, potassium nitrate] (5 measures of a bi spoon) and realgar 
[xiongshi, arsenic sulphide] (1 measure of a bi spoon) and combine the two into a fine 
powder. Lift the patient’s tongue and sprinkle one measure of a bi spoon under the 
tongue. If saliva is produced, have the patient swallow it. This is a certain cure.”  
 
What	  is	  most	  interesting	  in	  this	  description	  of	  a	  medical	  condition	  that	  is	  thought	  to	  
represent	   symptomatic	   angina	   is	   the	   command	   in	   the	   last	   line	   regarding	   the	  
production	   of	   saliva	   and	   the	   importance	   of	   swallowing	   of	   it,	   as	   this	   relates	   to	   an	  
important	  bioactivation	  step	  for	  inorganic	  NO3
-­‐	  (section	  1.6.4).	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It	   took	   a	   great	   deal	   of	   time	   before	   a	   modern,	   Western	   physician	   would	   be	  
interested	   in	   the	   same	   chemical	   entities	   as	   the	   pre-­‐medieval	   Chinese	   physicians.	  
Stieglitz	   produced	   a	   body	   of	   work	   in	   the	   1920-­‐30’s	   relating	   to	   his	   studies	   and	  
treatments	   of	   patients	   with	   bismuth	   subnitrate	   (chemical	   formula:	  
Bi5O(OH)9(NO3)4).	  Bismuth	  subnitrate	  was	  already	  an	  established	  and	  recommended	  
treatment	  for	  peptic	  ulcer	  disease	  and	  diarrhoea	  but	  prolonged	  use	  was	  cautioned	  
against	   due	   to	   the	   risk	   of	   hypotension	   (Frick,	   1924).	   Stieglitz	   noted	   in	   his	   first	  
monograph	   on	   the	   treatment	   of	   hypertension	   with	   bismuth	   subnitrate	   his	  
reasoning	  for	  use	  of	  this	  medication	  (Stieglitz,	  1927):	  
“The idea to use bismuth subnitrate as an auxiliary to break the vicious circle of vascular 
fatigue arose from the observation of three cases of nitrate poisoning resulting from the 
liberal use of bismuth subnitrate in severe diarrhoeas.” 
	  
Stieglitz	  was	  aware	  of	  the	  discovery	  that	  symbiotic	  colonic	  bacteria,	  such	  as	  E.	  Coli	  
(at	   that	   time	   known	   as	   B.	   Coli),	   were	   able	   to	   metabolize	   inorganic	   NO3
-­‐	   to	   NO2
-­‐	  
(Salen,	  1925;	  Zobell,	  1932).	  He	  thus	  surmised	  the	  following	  (Stieglitz,	  1927):	  
“Therefore, theoretically, small frequent doses should lead to the liberation of small 
amounts of nitrite, uniformly and continuously absorbed. The effect of this is quite 
different from the violent, very transient vasodilatory effect of other forms of nitrite, 
such as nitroglycerol, amyl nitrite and sodium nitrite. The action to be expected is a 
gradually increasing vascular relaxation, with localized physiological rest to the arteriolar 
musculature.” 
	  
His	   reports	  of	   the	  sustained	  hypotensive	  effects	   in	  almost	  1000	  patients	   (Stieglitz,	  
1927,	   1928,	   1930,	   1932)	   were	   followed	   by	   methodological	   improvements	   to	   the	  
colorimetric	   techniques	   available	   at	   the	   time	   to	  measure	  NO2
-­‐	   levels	   in	   biological	  
fluids	   (Stieglitz	   and	   Palmer,	   1934).	  He	  was	   then	   able	   to	   determine	   that	   the	   basal	  
levels	   of	   NO2
-­‐	   in	   whole	   blood	   as	   0.5-­‐1.0	   μg	   NO2
-­‐/100	   mL	   blood	   (~110-­‐220	   nM)	  
(Stieglitz	   and	   Palmer,	   1937).	   Additionally,	   he	   demonstrated	   that	   NO2
-­‐	   was	   not	   a	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normal	   constituent	  of	   fresh	  urine	   (Stieglitz	   and	  Palmer,	   1937)	  but	  was	  detectable	  
after	  an	  inorganic	  NO3
-­‐	  load	  (Stieglitz	  and	  Palmer,	  1937),	  in	  keeping	  with	  significant	  
elevations	   in	   blood	   NO2
-­‐	   after	   ingestion	   of	   inorganic	   NO3
-­‐	   (Stieglitz	   and	   Palmer,	  
1936).	   Lastly,	   he	   expended	  much	   effort	   into	   in	   vitro	   determination	   of	   the	   rate	   of	  
NO2
-­‐	  formation	  from	  NO3
-­‐	  under	  the	  action	  of	  NO3
-­‐-­‐reducing	  bacteria	  to	  hypothesize	  
that	   bacterial	   reduction	   of	   NO3
-­‐	   could	   be	   responsible	   for	   significant	   physiological	  
effects	  in	  vivo	  (Stieglitz	  and	  Palmer,	  1936).	  
	  
1.5.3	  Traditional	  views	  of	  the	  chemistry	  of	  inorganic	  NO2
-­‐	  and	  NO3
-­‐	  
Despite	   these	   early	   studies,	   the	   view	   of	   NO3
-­‐	   has	   been	   as	   a	   chemically	   inert	  
metabolite	   of	   endogenous	   NO	   metabolism	   that	   does	   not	   participate	   in	   any	  
important	   chemical	   reactions	   (Bonner	   and	   Hughes,	   1988;	   Ignarro	   et	   al.,	   1993),	  
whilst	   there	  are	  a	  number	  of	   in	  vivo	   chemical	   reactions	   that	  occur	  with	  NO2
-­‐.	  The	  
most	  widely	  described	  reaction	  of	  NO2
-­‐	   in	  mammalian	  systems	   is	   its	   reaction	  with	  
oxyHb	  to	  generate	  metHb	  and	  NO3
-­‐	  with	  1:1	  stoichiometry	  of	  all	  the	  constituents	  of	  
the	  reaction	  (Kosaka	  et	  al.,	  1979)	  (Equation	  1.3).	  
	  
oxyHb	   	   nitrite	   	   metHb	   	   nitrate	  
Fe(II)HbO2	   +	   NO2
-­‐	   ⇒ Fe(III)Hb	   +	   NO3-­‐	  
Equation	  1.3	  Reaction	  of	  NO2
-­‐	  with	  oxyHb	  (NO2
-­‐=nitrite;	  oxyHb=oxyhaemoglobin).	  
	  
Gamgee	  made	  the	  first	  reports	  of	  this	  reaction	  (Gamgee,	  1868):	  
“My attention was directed to the peculiar action of nitrites upon the blood-colouring 
matter by observing that the blood of mice poisoned by exposure to an atmosphere 
impregnated with the vapour of nitrite of amyl presented a chocolate-colour.” 
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In	   a	   series	   of	   detailed	   experiments	   involving	   fractional	   gas	   determination	   and	  
optical	  characteristics	  of	  blood	  exposed	  to	  inorganic	  NO2
-­‐	  (both	  NaNO2	  and	  KNO2),	  
Gamgee	   was	   able	   to	   determine	   that	   the	   reactions	   of	   NO2
-­‐	   with	   oxyHb	   produced	  
changes	   in	   the	   Hb	   species	   that	   although	   had	   the	   same	   crystalline	   structure	   as	  
oxyHb,	  had	  different	  optical	  characteristics	  (i.e.	  dark	  brown)	  but	  more	  importantly	  
had	  now	  lost	  the	  ability	  to	  bind	  and	  release	  O2	  (Gamgee,	  1868).	  The	  Fe	  of	  metHb	  is	  
in	   the	   ferric	   (Fe3+)	   form	   that	   is	   unable	   to	   carry	  O2	   (Darling	   and	   Roughton,	   1942).	  
MetHb	   is	   physiologically	   reduced	   back	   to	   ferrous	   (Fe2+)	   Hb	   predominantly	   by	   the	  
enzyme,	   cytochrome	  b5	   reductase	   (Gibson,	   1948)	  which	  physiologically	  maintains	  
normal	  metHb	   levels	   at	   less	   than	  1%	   (Wright	   et	  al.,	   1999).	  However,	   in	   situations	  
where	  metHb	  levels	  rise	  >10%,	  the	  O2	  content	  of	  the	  Hb	  becomes	  insufficient,	  thus	  
provoking	   symptomatic	   hypoxaemia	   despite	   adequate	   oxygenation	   (Skold	   et	   al.,	  
2011).	  This	  reaction	  of	  NO2
-­‐	  with	  ferrous	  oxyHb	  to	  form	  metHb	  is	  used	  clinically	  to	  
treat	  cyanide	  poisoning	   (British	  Medical	  Association	  and	  the	  Royal	  Pharmaceutical	  
Society	   of	   Great	   Britain,	   2012).	   Cyanide	   is	   a	   potent	   inhibitor	   of	   cytochrome	   c	  
oxidase	   in	   the	   mitochondrial	   respiratory	   chain	   (Antonini	   et	   al.,	   1971)	   but	  
preferentially	  binds	  to	  metHb	  (Smith	  et	  al.,	  1977).	  Thus	  NO2
-­‐	  can	  be	  used	  to	  increase	  
metHb	  levels	  to	  act	  as	  a	  cyanide	  sink.	  Nevertheless,	  concerns	  about	  organic	  nitrite	  
and	   inorganic	   NO2
-­‐-­‐induced	   acquired	  methaemoglobinaemia	   continue	   to	   this	   day	  
and	   have	   been	   a	   large	   part	   of	   the	   reduced	   use	   of	   these	   medications	   in	   clinical	  
practice	  (Pierce	  and	  Nielsen,	  1989;	  Finan	  et	  al.,	  1998;	  Modarai	  et	  al.,	  2002).	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1.6	  The	  fate	  of	  NO3
-­‐	  in	  humans	  
The	  view	  that	  the	  oxidation	  of	  NO	  to	  NO2
-­‐	  and	  NO3
-­‐	  represents	  a	  termination	  of	  the	  
pathway	   has	   needed	   revision	   with	   the	   publication	   of	   numerous	   studies	  
demonstrating	  bioactivity	  of	  a	  reductive	  pathway	  prevalent	  in	  vivo	  whereby	  NO3
-­‐	  is	  
reduced	  to	  NO2
-­‐	  and	  thence	  to	  the	  biologically	  active	  NO.	  	  
	  
NO3
-­‐	  is	  found	  in	  the	  plasma	  of	  healthy	  individuals,	  concentrations	  measured	  ranging	  
between	  20-­‐40	  μM	  (Gladwin	  et	  al.,	  2000;	  Lundberg	  and	  Govoni,	  2004;	  Webb	  et	  al.,	  
2008a).	   In	  vivo,	  NO3
-­‐	  originates	   from	  two	  potential	   sources	   i.e.	   from	  the	  oxidative	  
metabolism	   of	   NO,	   but	   also	   from	   NO3
-­‐	   ingested	   orally	   in	   the	   diet	   as	   previously	  
discussed	   in	   section	   1.2.4.	   Nitrogen-­‐balance	   studies	   (lasting	   up	   to	   14	   weeks),	   in	  
which	   participants	   were	   provided	   all	   food	   and	   fluid	   intake	   by	   the	   investigators	  
(providing	  <180	  μmol	  NO3
-­‐	  per	  day)	  have	  estimated	  from	  24	  h	  urine	  NO3
-­‐	  collections	  
that	  endogenous	  biosynthesis	  of	  NO3
-­‐	   is	  ~0.6-­‐0.9	  mmol	  per	  day	   in	  healthy	  people	  
(Green	  et	  al.,	  1981),	  though	  this	  may	  be	  much	  higher	  when	  iNOS	  has	  been	  induced	  
(Stichtenoth	   et	   al.,	   1994).	   Estimates	   of	   average	   daily	   ingestion	   of	   NO3
-­‐,	   which	   is	  
predominantly	   due	   to	   vegetable	   intake	   (World	   Cancer	   Research	   Fund/American	  
Institute	  for	  Cancer	  Research,	  2007),	  suggest	  that	  total	  daily	  NO3
-­‐	  intake	  is	  between	  
1.5-­‐2	  mmol	  across	  different	  European	  countries	   (European	  Food	  Safety	  Authority,	  
2008),	   though	   individual	   intake	   may	   vary	   depending	   on	   the	   types	   of	   vegetables	  
consumed.	   The	   WHO	   recommends	   a	   daily	   intake	   of	   400	   g	   of	   mixed	   vegetables	  
which	  would	   lead	   to	  an	  estimated	  daily	  NO3
-­‐	   intake	   from	  all	   food	   sources	  of	  ~2.5	  
mmol	  (European	  Food	  Safety	  Authority,	  2008),	  whilst	  the	  DASH	  study	  diet	  has	  been	  
estimated	  to	  contain	  up	  to	  ~20	  mmol	  NO3
-­‐	  (Hord	  et	  al.,	  2009).	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1.6.1	  Pharmacokinetics	  of	  NO3
-­‐	  
Orally	  ingested	  NO3
-­‐	  is	  rapidly	  absorbed	  across	  the	  upper	  GI	  tract	  (Hawksworth	  and	  
Hill,	   1971;	   Witter	   et	   al.,	   1979;	   Miyoshi	   et	   al.,	   2003)	   and	   bypasses	   first-­‐pass	  
metabolism	  with	  close	  to	  100%	  bioavailability	   (van	  Velzen	  et	  al.,	  2008).	  Significant	  
elevations	   of	   plasma	   NO3
-­‐	   levels	   are	   noted	  within	   15	  min	   of	   oral	   ingestion	   of	   an	  
inorganic	  NO3
-­‐	   (as	  a	   salt)	   (McKnight	   et	  al.,	   1997;	   Lundberg	  and	  Govoni,	  2004;	   van	  
Velzen	  et	  al.,	  2008)	  or	  dietary	  NO3
-­‐	  load	  (Lundberg	  and	  Govoni,	  2004;	  van	  Velzen	  et	  
al.,	  2008;	  Webb	  et	  al.,	  2008a).	  After	  a	  single	  oral	  dose	  of	  inorganic	  or	  dietary	  NO3
-­‐,	  
peak	  plasma	  levels	  seem	  to	  be	  reached	  between	  30-­‐60	  min	  (Lundberg	  and	  Govoni,	  
2004;	  van	  Velzen	  et	  al.,	  2008;	  Webb	  et	  al.,	  2008a).	  The	  effective	  t1/2	  for	  NO3
-­‐	  in	  the	  
plasma	  after	   consumption	  of	  different	  vegetable	   sources	  of	  NO3
-­‐	   (spinach,	   lettuce	  
and	  beetroot)	  has	  been	  calculated	  to	  be	  5.7-­‐6.7	  h	  (van	  Velzen	  et	  al.,	  2008).	  
	  
1.6.2	  Urinary	  excretion	  of	  NO3
-­‐	  
The	   fate	   of	   NO3
-­‐	   in	   the	   plasma	   is	   two-­‐fold.	   Studies	   with	   15NO3
-­‐	   supplementation	  
reveal	  that	  most	  (50-­‐65%)	  is	  excreted	  in	  the	  urine	  (with	  peak	  excretion	  occurring	  ~6	  
h	  following	  supplementation)	  (Green	  et	  al.,	  1981;	  Packer	  et	  al.,	  1989;	  Wennmalm	  et	  
al.,	  1993;	  Pannala	  et	  al.,	  2003),	  with	  small	  amounts	  accounted	  for	   in	  sweat	  (up	  to	  
10%)	   or	   faeces	   (<1%)	   (Wagner	   et	   al.,	   1983;	   Bartholomew	   and	  Hill,	   1984).	   NO3
-­‐	   is	  
freely	  filtered	  at	  the	  glomerulus	  and	  clearance	  from	  the	  plasma	  has	  been	  estimated	  
as	  ~20	  mL/min	  in	  healthy	  subjects	  (Wennmalm	  et	  al.,	  1993).	  This	  relatively	  low	  rate	  
of	  clearance	  (taking	  into	  consideration	  that	  normal	  glomerular	  filtration	  rate	  (GFR)	  
is	  between	  100-­‐125	  mL/min)	  suggests	  that	  much	  of	  the	  filtered	  NO3
-­‐	  is	  reabsorbed	  
(Kahn	   et	   al.,	   1975;	   Rahman	   et	   al.,	   2001).	   As	   such,	   in	   anaesthetized	   dogs,	   renal	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reabsorption	   of	   NO3
-­‐	   increases	   with	   increasing	   filtered	   NO3
-­‐	   level	   with	   no	   clear	  
transport	   limit	   (Godfrey	  and	  Majid,	  1998).	  Using	  clearance	  and	  stop-­‐flow	  methods	  
in	  anaesthetized	  dogs,	  Abe	  and	  colleagues	  utilized	  2	  diuretics	  with	  different	  sites	  of	  
action,	   mannitol	   (that	   works	   in	   the	   proximal	   convoluted	   tubule)	   and	   furosemide	  
(that	   works	   in	   the	   ascending	   limb	   of	   Henle),	   to	   delineate	   the	   sites	   of	   NO3
-­‐	  
reabsorption	   (Rahman	   et	   al.,	   2001).	   In	   clearance	   experiments,	   both	  mannitol	   and	  
furosemide	   inhibited	   tubular	   reabsorption	   of	   NO3
-­‐,	   suggesting	   that	   NO3
-­‐	  
reabsorption	   occurs	   across	   the	  whole	   tubule.	   Stop-­‐flow	   experiments	   also	   suggest	  
that	  NO3
-­‐	   is	  avidly	  reabsorbed	  at	  the	  same	  location	  as	  sodium	  in	  the	  distal	  tubule,	  
suggesting	  co-­‐transport	  (Rahman	  et	  al.,	  2001).	  	  
	  
1.6.3	  The	  entero-­‐salivary	  circulation	  of	  NO3
-­‐	  
The	   entero-­‐salivary	   circulation	   of	   NO3
-­‐	   relates	   to	   the	   concentration	   from	   the	  
circulation	   to	   the	   salivary	   glands	  of	  NO3
-­‐,	   and	   then	   the	   secretion	  of	  NO3
-­‐	   into	   the	  
oral	   cavity	   resulting	   in	  NO3
-­‐-­‐rich	   saliva	   and	   its	   further	  metabolism	   (Duncan	   et	   al.,	  
1995).	  Much	  of	  the	  early	  work	  in	  this	  area	  was	  performed	  by	  the	  Japanese	  groups	  of	  
Ishiwata,	  Maruyuma	  and	  Sasaki.	  Ishiwata’s	  group	  first	  demonstrated	  that	  ingestion	  
of	   both	   dietary	  NO3
-­‐	   (as	   Chinese	   cabbage)	   and	   inorganic	  NO3
-­‐	   (as	   sodium	  nitrate,	  
NaNO3)	   caused	   significant	   elevations	   in	   NO3
-­‐	   measurable	   in	   the	   saliva	   within	   1	   h	  
after	  NO3
-­‐	  consumption	   (Harada	  et	  al.,	  1974;	   Ishiwata	  et	  al.,	  1975b),	   though	  more	  
recent	  work	  has	  demonstrated	   that	   salivary	  NO3
-­‐	   levels	   increase	  within	  20	  min	  of	  
oral	  NO3
-­‐	  ingestion	  (McKnight	  et	  al.,	  1997).	  It	  has	  since	  been	  estimated	  that	  25%	  of	  
ingested	  NO3
-­‐	   (taking	   into	   account	   urinary	   and	   other	   excretory	   routes)	   is	   actually	  
concentrated	  in	  the	  salivary	  glands	  (Spiegelhalder	  et	  al.,	  1976;	  Tannenbaum	  et	  al.,	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1976;	  Kortboyer	  et	  al.,	  1994)	  and	  when	  secreted	  into	  the	  saliva	  results	  in	  NO3
-­‐	  levels	  
that	   are	   10-­‐fold	   greater	   than	   plasma	   NO3
-­‐	   levels	   (Spiegelhalder	   et	   al.,	   1976;	  
Lundberg	   and	   Govoni,	   2004).	   The	   mechanism	   that	   relates	   to	   NO3
-­‐	   uptake	   in	   the	  
salivary	   glands	  was	   initially	   thought	   to	  be	   related	   to	   competitive	   inhibition	  of	   the	  
anionic	   iodide	   transporter	   in	   the	   salivary	   glands	   (Edwards	   et	   al.,	   1954)	   but	   very	  
recently,	   sialin	   (a	   sialic	   acid	   transporter),	   has	   been	   identified	   as	   a	   2NO3
-­‐/H+	   co-­‐




Although	   there	   was	   no	   suggestion	   at	   the	   time	   that	   the	   discovery	   of	   the	   entero-­‐
salivary	  circulation	  of	  NO3
-­‐	  may	  represent	  an	  important	  physiological	  mechanism,	  it	  
was	   demonstrated	   that	   rises	   in	   salivary	   NO3
-­‐	   concentrations	   were	   similarly	  
associated	   with	   rises	   in	   chemically	   related	   but	   distinct	   anion,	   NO2
-­‐.	   Indeed,	   the	  
measurement	   of	   NO2
-­‐	   levels	   post-­‐NO3
-­‐	   ingestion	   was	   the	   primary	   aim	   of	   these	  
investigations,	  to	  determine	  whether	  NO3
-­‐	   ingestion	  might	  result	   in	  sufficient	  NO2
-­‐	  
generation	   and	   thus	   derivation	   of	   N-­‐nitroso	   compounds	   that	   were	   linked	   to	  
carcinogenesis	  (Harada	  et	  al.,	  1974;	  Tannenbaum	  et	  al.,	  1974,	  1976;	  Eisenbrand	  et	  
al.,	  1980)	  as	  discussed	  in	  section	  1.2.4.2.	  	  
	  
Analysis	   of	   saliva	   taken	   directly	   from	   salivary	   gland	   ducts,	   as	   opposed	   to	   mixed	  
saliva	   in	   the	   oral	   cavity,	   revealed	   that	  within	   the	   salivary	   gland	   there	   is	   no	   NO2
-­‐,	  
suggesting	  that	  conversion	  of	  NO3
-­‐	  to	  NO2
-­‐	  within	  the	  oral	  cavity	  was	  responsible	  for	  
salivary	  NO2
-­‐	  levels	  (Ishiwata	  et	  al.,	  1975d).	  Ishiwata	  was	  the	  first	  to	  suggest	  that	  the	  
appearance	   of	   NO2
-­‐	   in	   the	   saliva	   may	   be	   due	   to	   the	   presence	   of	   NO3
-­‐-­‐reducing	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bacteria	   (Ishiwata	   et	   al.,	   1975d)	   similar	   to	   the	   symbiotic,	   NO3
-­‐	   reducing	   bacteria	  
identified	  in	  the	  GI	  tract	  (Salen,	  1925;	  Zobell,	  1932;	  Stieglitz	  and	  Palmer,	  1936).	  It	  is	  
recognized	   that	   some	   anaerobic	   bacteria	   can	   use	   NO3
-­‐	   as	   a	   terminal	   e-­‐	   donor	   in	  
respiration	  instead	  of	  O2	  and,	  thereby,	  reduce	  NO3
-­‐	  to	  NO2
-­‐	  (as	  reviewed	  in	  Moreno-­‐
Vivian	  et	  al.,	  1999;	  Lundberg	  et	  al.,	  2004).	  
	  
Ex	  vivo	  studies	  with	  human	  saliva	  at	  37oC	  demonstrated	  an	  apparent	  consumption	  
of	   NO3
-­‐,	   with	   corresponding	   increases	   in	   NO2
-­‐	   levels	   (Goaz	   and	   Biswell,	   1961;	  
Ishiwata	  et	  al.,	  1975a).	  These	  increases	  in	  NO2
-­‐	  levels	  were	  prevented	  by	  heating	  the	  
saliva	   to	   100oC	   or	   by	   passing	   the	   saliva	   through	   a	   filter	   (Goaz	   and	   Biswell,	   1961;	  
Ishiwata	   et	  al.,	   1975a).	   If	   the	   filter	   residue	  was	   returned	   to	   the	   saliva	   filtrate,	   the	  
changes	   in	   salivary	   NO3
-­‐	   and	   NO2
-­‐	   levels	   were	   restored	   (Goaz	   and	   Biswell,	   1961;	  
Ishiwata	   et	   al.,	   1975a).	   These	   findings	   suggested	   that	   there	   was	   a	   denaturable,	  
biological	   element	   in	   the	   residue	   fraction	   that	   was	   necessary	   for	   NO3
-­‐	   reduction.	  
Tannenbaum	   and	   colleagues	   used	   a	   commercially	   available	   anti-­‐bacterial	  
mouthwash	  to	  determine	  whether	  bacteria	  might	  underlie	  this	  oral	  NO3
-­‐	  reduction.	  
In	   this	   study,	   it	   was	   shown	   that	   after	   a	   single	   instillation	   of	   anti-­‐bacterial	  
mouthwash,	   there	  were	  significantly	   lower	   (80-­‐90%	  reduction)	  salivary	  NO2
-­‐	   levels	  
after	  a	  dietary	  NO3
-­‐	  (celery	  juice)	  load	  when	  compared	  to	  basal	  levels	  (Tannenbaum	  
et	  al.,	  1976).	  
	  
Following	   these	   indirect	   evidences	   of	   oral	   bacterial	   NO3
-­‐	   reduction,	   Maruyuma’s	  
group	  isolated	  the	  first	  species	  of	  human	  NO3
-­‐-­‐reducing	  bacteria	  in	  the	  oral	  cavity	  by	  
growing	   saliva	   samples	   anaerobically	   on	   NO3
-­‐-­‐containing	   blood	   agar.	   The	   first	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species	   identified	   was	   Bacillus	   coagulans	   (Maruyuma	   et	   al.,	   1976)	   and	   later,	  
Veilonella,	   Lactobacillus,	   Microccous,	   Corynebacterium,	   Propionibacterium,	  
Neisseria	   (Murumatsu	   et	   al.,	   1979),	   Actinomyces,	   commensal	   Staphylcoccus	   and	  
Rothia	   spp.	   (Doel	   et	   al.,	   2005)	   were	   identified.	   Sasaki	   and	  Matano	   used	   a	   filter-­‐
paper	  technique	  to	  identify	  particular	  areas	  of	  the	  oral	  cavity	  that	  were	  responsible	  
for	   NO3
-­‐	   reduction	   (Sasaki	   and	   Matano,	   1979).	   They	   impregnated	   small	   1.5	   cm2	  
pieces	  of	  filter	  paper	  with	  potassium	  nitrate	  (KNO3)	  and	  placed	  them	  on	  particular	  
areas	  of	  the	  oral	  cavity	  for	  90	  s.	  On	  removal,	  they	  agitated	  the	  paper	  squares	  with	  
distilled	   water	   and	   determined	   NO2
-­‐	   accumulation	   colorimetrically	   (Sasaki	   and	  
Matano,	  1979).	  Their	   investigations	  revealed	  that	  only	  the	  posterior,	  dorsal	  aspect	  
of	   the	   tongue	  was	   a	   location	   that	  was	   associated	  with	   significant	   NO3
-­‐	   reduction	  
(Sasaki	  and	  Matano,	  1979).	  They	  further	  developed	  their	  techniques	  to	  investigate	  
NO3
-­‐	   reduction	   in	  whole	   saliva	  ex	   vivo	   (Sasaki	   and	  Matano,	   1980)	   and	   also	  whole	  
cavity	   oral	  NO3
-­‐	   reduction	   (Sasaki	   et	   al.,	   1981).	   This	   latter	   technique	   involved	   the	  
instillation	  of	  a	  fixed	  volume	  and	  concentration	  of	  inorganic	  NO3
-­‐	  solution	  in	  the	  oral	  
cavity	   for	   a	   fixed	   time.	   At	   the	   end	   of	   this	   time,	   the	   entire	  mouth	   contents	   were	  
expelled	   and	   NO2
-­‐	   levels	   were	   determined.	   A	   control	   experiment	   was	   performed	  
with	   distilled	   water	   for	   each	   subject	   so	   that	   the	   extra	   NO2
-­‐	   production	   due	   to	  
inorganic	  NO3
-­‐	  instillation	  could	  be	  determined	  (Sasaki	  et	  al.,	  1981).	  
	  
The	  importance	  of	  oral	  microflora	  in	  effecting	  NO3
-­‐	  reduction	  has	  been	  confirmed	  in	  
more	   recent	   investigations.	   Both	   chlorhexidine-­‐based	   antiseptic	   mouthwash	   use	  
(Duncan	  et	  al.,	  1995;	  Govoni	  et	  al.,	  2008)	  and	  systemic	  antibiotic	  use	   (amoxicillin)	  
(Dougall	  et	  al.,	  1995)	  reduced	  salivary	  NO2
-­‐	   levels	   in	  response	  to	  an	  inorganic	  NO3
-­‐	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load.	  The	  location	  of	  NO3
-­‐	  reduction	  was	  confirmed	  to	  take	  place	  almost	  exclusively	  
in	  the	  posterior	  third	  of	  the	  dorsal	  aspect	  of	  the	  tongue	  in	  rats	  (Duncan	  et	  al.,	  1995).	  
This	  activity	  was	  completely	  absent	  in	  any	  part	  of	  the	  oral	  cavity	  of	  rats	  raised	  in	  a	  
germ	  free	  environment	  (Duncan	  et	  al.,	  1995).	  Incubation	  of	  rat	  tongue	  sections	  with	  
NO3
-­‐	  solutions	  ex	  vivo	  revealed	  abundant	  NO3
-­‐	  reduction	  (Duncan	  et	  al.,	  1995;	  Li	  et	  
al.,	  1997)	  that	  could	  be	  totally	  attenuated	  by	  boiling	  the	  tongue	  sections	  (Duncan	  et	  
al.,	   1995)	   and	   histological	   examinations	   of	   such	   sections	   demonstrated	   the	  
presence	  of	  abundant	  bacteria	  in	  the	  deep,	  interpapillary	  sulci	  in	  the	  posterior	  third	  
of	   the	   tongue	   and	   relatively	   less	   elsewhere	   (Duncan	   et	   al.,	   1995),	   reflecting	   the	  
distribution	   of	   NO3
-­‐	   reductase	   activity	   (Sasaki	   and	   Matano,	   1979;	   Duncan	   et	   al.,	  
1995;	  Li	  et	  al.,	  1997).	  Recently,	  it	  has	  been	  confirmed	  that	  bacteria	  in	  human	  dental	  
plaque	   are	   capable	   of	   NO3
-­‐	   reduction	   (Schreiber	   et	   al.,	   2010),	   but	   the	   relative	  
contribution	  from	  this	  site	   is	  not	  thought	  to	  be	  of	  overall	   importance	  to	  total	  oral	  
cavity	  NO3
-­‐	  reduction.	  	  
	  
Although	   it	  has	  been	   largely	  accepted	  that	  mammals	   lack	   the	  enzymes	  capable	  of	  
undertaking	   NO3
-­‐	   reduction	   to	   NO2
-­‐	   and	   are	   therefore	   reliant	   on	   functioning	   oral	  
microflora	  for	  this	  crucial	   initial	  step	   in	  NO3
-­‐	  bioactivation,	   there	   is	  some	  evidence	  
that	  mammalian	  NO3
-­‐	   reductases	  may	  have	  a	   role.	  Using	  metHb	  as	  a	  bioassay	   for	  
NO2
-­‐	  production,	  Walker	  and	  colleagues	  demonstrated	  NO3
-­‐	  reduction	  in	  germ-­‐free	  
rats	  and	  showed	  in	  tissues	  that	  NO3
-­‐	  reduction	  was	  inactivated	  by	  heat	  (Ward	  et	  al.,	  
1986).	   Indeed,	  recent	  evidence	  in	  rats	   in	  vivo	  suggests	  XOR	  is	  a	  functional,	   if	  slow,	  
mammalian	  NO3
-­‐	  reductase	  (Jansson	  et	  al.,	  2008).	  XOR	  demonstrates	  NO3
-­‐	  reduction	  
activity	  in	  vitro	  under	  anoxic	  conditions	  that	  can	  be	  abrogated	  by	  the	  XOR	  inhibitor,	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oxypurinol	   (Li	   et	   al.,	   2003).	   In	   normoxic	   wild-­‐type	   rats,	   administration	   of	   NO3
-­‐	  
resulted	   in	  elevated	  NO2
-­‐	   levels	  and	  this	   rise	  was	   inhibited	  by	  allopurinol	   (another	  
XOR	   inhibitor)	   (Jansson	   et	   al.,	   2008).	   Similar	   results	  were	   demonstrated	   in	   eNOS-­‐
deficient	  and	  germ-­‐free	  mice	  (Jansson	  et	  al.,	  2008),	  thereby	  excluding	  bacterial	  NO3
-­‐	  
reduction	   and	   vascular	   NOS	   activation	   as	   the	   source	   of	   NO2
-­‐.	   Germ-­‐free	   mice	  
exhibited	   greater	   tissue	   levels	   of	   XOR,	   suggesting	   that	   this	   may	   represent	   a	  
functional	   compensatory	   response	   to	  uphold	  NO2
-­‐	  production	   in	   the	  absence	  of	  a	  
commensal	  microflora	   (Huang	   et	   al.,	   2010).	   These	   studies	   seem	   to	   confirm	  much	  
earlier	   studies	   on	   ex	   vivo	   mammalian	   liver/muscle	   homogenates	   (Bernheim	   and	  
Dixon,	  1928),	   suggesting	   that	  XOR	  may	  exhibit	  NO3
-­‐	   reducing	  capability.	  However,	  
the	  presence	   and	   importance	  of	   putative	  NO3
-­‐	   reductases	   in	   human	  physiology	   is	  
yet	  to	  be	  established.	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1.7	  Bioactivation	  of	  NO2
-­‐	  
The	   prevailing	   view	   until	   recently	   on	   the	   above	   salivary	   processes	   was	   that	   oral	  
reduction	   of	   NO3
-­‐	   to	   NO2
-­‐	   served	   no	   physiological	   role	   and	   was	   harmful	   due	   to	  
concerns	   over	   oral	   and	   intra-­‐gastric	   N-­‐nitrosamine	   formation	   and	   consequent	  
carcinogenesis	  (Harada	  et	  al.,	  1974;	  Tannenbaum	  et	  al.,	  1974,	  1976;	  Eisenbrand	  et	  
al.,	  1980).	  However,	  remarkable	  investigations	  in	  the	  early	  1990s	  revealed	  that	  this	  
view	   might	   be	   presumptive.	   Two	   groups	   simultaneously	   demonstrated	   that	  
following	  a	  dietary	  NO3
-­‐	  load,	  some	  of	  the	  swallowed	  NO2
-­‐	  is	  directly	  protonated	  in	  
the	  acidic	  environment	  of	   the	   stomach	   to	   release	   free	  NO	   (Benjamin	   et	  al.,	  1994;	  
Lundberg	   et	   al.,	   1994),	   thus	  describing	  non-­‐enzymatic	  NO	  production	   for	   the	   first	  
time.	  NO2
-­‐	  reduction	  to	  NO	  represents	  a	  1	  e-­‐	  reduction	  step	  (Equations	  1.4-­‐1.6)	  and	  
it	   is	   hypothesized	   dinitrogen	   trioxide	   (N2O3)	   is	   formed	   as	   an	   intermediate	   that	   is	  
unstable	  and	  dissociates	  to	  nitrogen	  dioxide	  (NO2)	  and	  NO	  (Benjamin	  et	  al.,	  1994).	  
	  
nitrite	   	   proton	   	   nitrous	  acid	  
NO2
-­‐	   +	   H+	   ⇔ HNO2	  
Equation	  1.4	  NO2
-­‐	  acidification	  to	  form	  HNO2.	  (NO2
-­‐=nitrite,	  HNO2=nitrous	  acid).	  
	  
nitrous	  acid	   	   water	   	   dinitrogen	  trioxide	  
2	  HNO2	   ⇔ H2O	   +	   N2O3	  
Equation	  1.5	  Dehydration	  of	  HNO2.	  (HNO2=nitrous	  acid).	  
	  
dinitrogen	  trioxide	   	   nitric	  oxide	   	   nitrogen	  dioxide	  
N2O3
-­‐	   ⇔ NO	   +	   NO2	  
Equation	  1.6	  N2O3	  dissociation	  to	  NO.	  (N2O3=dinitrogen	  trioxide;	  NO=nitric	  oxide).	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Benjamin	   and	   colleagues	   demonstrated	   that	   after	   ingestion	   of	   2	   mmol	   KNO3,	  
salivary	   NO2
-­‐	   levels	   were	   elevated	   10-­‐fold	   above	   basal	   levels	   (~1	   mM).	   In	   vitro	  
studies	   incubating	  NO2
-­‐	  with	   acid	   at	   pH	   2	   (approximate	   to	   stomach	   pH)	   revealed	  
concentration-­‐dependent	   NO	   generation,	   with	   ~600	   nM	   NO	   generated	   from	   200	  
μM	   NO2
-­‐	   (Benjamin	   et	   al.,	   1994),	   a	   level	   far	   in	   excess	   of	   NO	   levels	   required	   for	  
biological	  effects	  (Palmer	  et	  al.,	  1987).	  This	  group	  also	  demonstrated	  anti-­‐microbial	  
effects	   of	   NO2
-­‐	   under	   acidic	   conditions	   on	   both	   yeast	   (Candida	   albicans)	   and	  
bacterial	   (E.	   Coli)	   growth	   (Benjamin	   et	   al.,	   1994).	   The	   authors	   suggested	   that	   the	  
direct	  chemical	  acidification	  of	  NO2
-­‐	  to	  NO	  may	  be	  a	  useful	  process	  for	  controlling	  
the	   risk	   of	   GI	   infection	   (Benjamin	   et	   al.,	   1994)	   and	   decreasing	   pathogen	   growth	  
(Benjamin	  et	  al.,	  1994;	  Dykhuizen	  et	  al.,	  1996,	  1998)	  and	  it	  has	  subsequently	  been	  
demonstrated	   that	   NO2
-­‐-­‐derived	   NO	   is	   bacteriocidal	   (Björne	   et	   al.,	   2006).	   The	  
Karolinska	  group	  of	  Weitzberg	  and	  Lundberg	  simultaneously	  published	  their	  results	  
showing	  almost	  identical	  effects	  (Lundberg	  et	  al.,	  1994).	  In	  their	  experiments,	  they	  
used	   NO3
-­‐-­‐rich	   lettuce	   as	   a	   NO3
-­‐	   source	   and	   demonstrated	   that	   authentic	   NO	  
production	   could	   be	   detected	   in	   expelled	   gastric	   air	   after	   ingestion	   of	   lettuce.	  
Further	   in	  vitro	   tests	  on	  acidified	  saliva	  or	  chewed	   lettuce	  revealed	  pH	  dependent	  
production	  of	  NO,	  with	  very	  little	  NO	  produced	  with	  pH>3	  (Lundberg	  et	  al.,	  1994).	  
To	   confirm	   that	   this	   was	   biologically	   relevant,	   they	   demonstrated	   that	   pre-­‐
treatment	   with	   a	   proton	   pump	   inhibitor,	   omeprazole,	   prevented	   NO	   production	  
after	  ingestion	  of	  NO3
-­‐-­‐rich	  lettuce	  (Lundberg	  et	  al.,	  1994).	  
	  
In	  addition	  to	  protection	  against	  micro-­‐organisms,	  intra-­‐gastric	  NO	  generation	  from	  
NO2
-­‐	  may	  have	  other	   important,	   local	  gastroprotective	  effects	   that	  are	  dependent	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on	   elevations	   in	   cGMP,	   including	   increasing	  mucus	   formation	   and	  mucosal	   blood	  
flow	   (Björne	   H	   et	   al.,	   2004;	   Petersson	   et	   al.,	   2007).	   Furthermore,	   it	   has	   been	  
substantiated	   that	   NO2
-­‐-­‐derived	   NO	   protects	   against	   animal	   models	   of	   stress-­‐
induced	  and	  NSAID-­‐induced	  gastric	  ulceration	  (Miyoshi	  et	  al.,	  2003;	  Jansson	  et	  al.,	  
2007).	  
	  
1.7.1	  Pathways	  for	  systemic	  NO2
-­‐	  absorption	  
Although	  NO2
-­‐	  that	  is	  produced	  in	  the	  oral	  cavity	  is	  swallowed	  and	  may	  be	  directly	  
acidified	   to	   increase	   local	   NO	   levels,	   a	   significant	   proportion	   of	   swallowed	   NO2
-­‐	  
appears	   to	   survive	   passage	   into	   the	   stomach	   and	   enters	   the	   systemic	   circulation.	  
The	  disappearance	  of	  NO2
-­‐	  from	  the	  gastric	  lumen	  is	  a	  rapid	  process	  with	  decline	  of	  
NO2
-­‐	   levels	   by	   half	   within	   10	   min,	   with	   most	   of	   this	   estimated	   to	   be	   related	   to	  
absorption	  rather	  than	  chemical	  reactions	  of	  NO2
-­‐	  or	  gastric	  emptying	  (Licht	  et	  al.,	  
1986).	  Exactly	  how	  NO2
-­‐	  enters	  the	  circulation	  is	  uncertain.	  As	  a	  charged	  anion,	  an	  
active	  uptake	  mechanism	  is	  likely	  to	  be	  involved	  but	  this	  is	  yet	  to	  be	  proven.	  Whilst	  
little	  work	  has	  been	  done	   looking	   at	   active	  uptake	  mechanism	   in	   gastric	   environs	  
specifically,	   there	   have	   been	   some	   studies	   attempting	   to	   discern	   uptake	  
mechanisms	   across	   membranes	   in	   erythrocytes	   or	   erythrocyte	   ghosts.	   In	  
erythrocyte	   ghosts,	   NO2
-­‐	   exchange	  with	   bicarbonate	   (HCO3
-­‐)	  was	   inhibited	   by	   the	  
non-­‐specific	  anion-­‐exchange	   inhibitor,	  diidothiocyanotostilbene	  disulfonate	   (DIDS),	  
suggesting	   that	   at	   least	   for	   erythrocytes,	   there	   may	   be	   a	   role	   for	   the	   anion-­‐
exchange	   transporter-­‐1	   (AE-­‐1)	   for	   the	   movement	   of	   NO2
-­‐	   across	   the	   membrane	  
(Shingles	  et	  al.,	  1997;	  Vitturi	  et	  al.,	  2009;	  Jensen	  and	  Rohde,	  2010).	  A	  similar	  AE-­‐1	  
dependency	  for	  NO2
-­‐	  transport	  has	  been	  demonstrated	  in	  pancreatic	  acini	  (Zhao	  et	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al.,	  1994).	  However,	  other	  researchers	  have	  failed	  to	  demonstrate	  the	  same	  effect	  
of	  DIDS	   (Zavodnik	   et	   al.,	   1999;	  May	   et	   al.,	   2000;	   Jensen,	  2005).	  Additionally,	  May	  
and	   colleagues	   demonstrated	   that	  NO2
-­‐	   uptake	  was	   dependent	   upon	   sodium	   and	  
phosphate	   levels	   and	   therefore	   suggested	   that	   the	   sodium-­‐dependent	   phosphate	  
transporter	  was	  important	  (May	  et	  al.,	  2000).	  	  
	  
However,	  in	  the	  gastric	  lumen,	  pH	  is	  between	  1.0-­‐2.5	  (Evans	  et	  al.,	  1988).	  The	  pKa	  of	  
nitrous	   acid	   (HNO2)	   in	   aqueous	   solutions	   is	   3.3-­‐3.4	   (Butler	   and	   Ridd,	   2004)	   and	  
therefore	  most	  of	  the	  NO2
-­‐	  will	  be	  in	  the	  neutral,	  lipophilic	  HNO2	  form.	  It	  has	  been	  
hypothesized	   that	   the	   passive	   movement	   of	   HNO2	   from	   the	   acidic	   gastric	  
environment	   into	   the	   neutral	   circulation	  may	   underlie	   the	   apparent	   transport	   of	  
NO2
-­‐	  across	  the	  gastric	  wall	  (Webb	  and	  Ahluwalia,	  2010),	  a	  possibility	  demonstrated	  
to	  occur	  across	  the	  erythrocyte	  membrane	  (Samouilov	  et	  al.,	  2007).	  	  
	  
The	  exact	  contribution	  of	  passive	  diffusion	  of	  HNO2	  and/or	  active	  uptake	  of	  NO2
-­‐	  is	  
still	   to	   be	   fully	   determined	   and	   quantified.	   However,	   what	   is	   apparent	   is	   that	  
ingestion	   of	   inorganic	   NO3
-­‐,	   via	   the	   entero-­‐salivary	   circulation	   and	   bacterial	   NO3
-­‐	  
reduction,	   eventually	   leads	   to	   increases	   in	   plasma	   and	   tissue	   NO2
-­‐	   levels.	  
Interestingly,	   it	   is	   now	  apparent	   that	   tissue	   levels	  of	  NO2
-­‐	   can	  be	  widely	  different	  
and	  that	  plasma	  NO2
-­‐	  levels	  are	  in	  general	  the	  lowest	  in	  vivo,	  with	  potentially	  most	  
of	  ‘blood’	  NO2
-­‐	  carried	  inside	  the	  erythrocyte	  (Dejam	  et	  al.,	  2005)	  and	  much	  higher	  
NO2
-­‐	  levels	  in	  certain	  tissues	  of	  the	  body,	  particularly	  the	  blood	  vessel	  wall	  (Bryan	  et	  
al.,	  2005).	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1.7.2	  The	  entero-­‐salivary	  circulation	  modulates	  plasma	  NO2
-­‐	  levels	  
Elevation	   of	   systemic	   NO2
-­‐	   levels	   after	   ingestion	   of	   inorganic	   NO3
-­‐	   has	   been	  
demonstrated	  to	  occur	  across	  a	  range	  of	  species	  as	  well	  as	  in	  healthy	  subjects.	  For	  
example,	  provision	  of	  1	  g/L	  inorganic	  NO3
-­‐	  (=16.2	  mM	  [NO3
-­‐])	  in	  the	  drinking	  water	  
in	  wild-­‐type	  mice	  increased	  steady	  state	  plasma	  NO2
-­‐	  levels	  by	  ~50%	  (from	  ~0.8	  μM	  
to	  1.2	  μM)	  but	  increased	  tissue	  levels	  (for	  example	  heart	  tissue)	  by	  500%	  (from	  ~3	  
μM	  to	  18	  μM)	  (Bryan	  et	  al.,	  2007),	  highlighting	  that	  plasma	  NO2
-­‐	  levels	  may	  not	  be	  
indicative	   of	   tissue-­‐specific	   levels	   or	   changes	   in	   levels.	   Interestingly,	  
supplementation	   of	   drinking	   water	   in	   Sprague-­‐Dawley	   rats	   with	   much	   lower	  
amounts	  of	  NO3
-­‐	  (to	  provide	  total	  daily	  NO3
-­‐	  intake	  of	  0.1	  mmol/kg	  and	  1	  mmol/kg)	  
for	   7	   days	   increased	   plasma	   NO2
-­‐	   levels	   from	   0.4	   μM	   to	   0.6	   μM	   and	   2.6	   μM	  
respectively	   (Jansson	   et	   al.,	   2007).	   The	   differences	   reflected	   in	   these	   two	   studies	  
reveal	  that	  the	  pharmacokinetics	  and	  handling	  of	  NO3
-­‐	  may	  be	  species	  dependent.	  
Thus,	   studies	   in	   humans	   are	   important	   to	   determine	   the	   impact	   of	   NO3
-­‐	  
supplementation	  on	  systemic	  NO2
-­‐	  levels.	  In	  these	  studies,	  systemic	  NO2
-­‐	  levels	  have	  
largely	   been	   only	   examined	   in	   saliva,	   plasma	   and	   urine	   as,	   understandably,	   it	   is	  
difficult	   to	   get	   tissue	   samples	   in	   healthy	   subject	   studies.	   Although	   Stieglitz	   had	  
shown	  more	  than	  70	  years	  ago	  that	  inorganic	  NO3
-­‐	  supplementation	  acutely	  (within	  
1	  h)	  and	  chronically	  (up	  to	  14	  days)	  elevated	  blood	  NO2
-­‐	  levels	  (Stieglitz	  and	  Palmer,	  
1936),	   it	   is	   only	   more	   recently	   that	   researchers	   have	   studied	   systemic	   NO2
-­‐	  
elevations	   after	   inorganic	   NO3
-­‐	   supplementation	   in	   depth,	   trying	   to	   elucidate	   if	  
sufficient	  NO3
-­‐-­‐derived	  NO2
-­‐	  from	  the	  oral	  cavity	  reaches	  the	  circulation	  in	  humans.	  
One	  of	  the	  first	  explorations	  of	  this	  phenomenon	  was	  conducted	  in	  healthy	  subjects	  
who	  were	  supplemented	  with	  ~120	  μmol/kg	  NaNO3	  (equivalent	  to	  ~8	  mmol	  NaNO3	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for	  a	  70	  kg	  person)	   in	  a	  single	  dose	  (Lundberg	  and	  Govoni,	  2004).	  Salivary,	  plasma	  
and	  urinary	  NOx	  levels	  were	  assayed	  for	  up	  to	  3	  h	  post-­‐ingestion.	  In	  contrast	  to	  the	  
very	  rapid	  appearance	  of	  NO3
-­‐	  in	  the	  plasma	  (within	  15	  min	  as	  previously	  discussed	  
above)	   and	   early	   plateau	   phase	   (within	   1	   h),	   plasma	   NO2
-­‐	   levels	   were	   only	  
significantly	  detected	  above	  basal	  values	  after	  30	  min	  and	  were	  still	  rising	  at	  90	  min.	  
In	  this	  experiment,	  some	  subjects	  were	  asked	  to	  refrain	  from	  swallowing	  their	  saliva	  
(by	  spitting	  all	  saliva	  out)	  to	  interrupt	  the	  entero-­‐salivary	  circulation	  (Lundberg	  and	  
Govoni,	   2004).	   In	   these	   subjects,	   whilst	   there	   was	   no	   difference	   in	   plasma	   NO3
-­‐	  
levels	   compared	   to	   control	   (swallowing	   saliva),	   plasma	   NO2
-­‐	   levels	   did	   not	   rise	  
(Lundberg	  and	  Govoni,	  2004).	  However,	   following	  resumption	  of	  swallowing	  saliva	  
after	   1	   h,	   plasma	   NO2
-­‐	   levels	   started	   to	   rise	   again	   (Lundberg	   and	   Govoni,	   2004).	  
Weitzberg	   and	   Lundberg	   also	   demonstrated	   that	   plasma	   NO2
-­‐	   levels	   were	  
significantly	  higher	   (219±105	  nM)	  after	  3	  days	  supplementation	  with	  0.1	  mmol/kg	  
NaNO3,	   compared	   to	   after	   3	   days	   of	   matched	   placebo	   (0.1	   mmol/kg	   sodium	  
chloride,	   NaCl)	   supplementation	   (138±38	   nM)	   (Larsen	   et	   al.,	   2006).	   The	   ~1.5-­‐fold	  
increases	   in	   plasma	   NO2
-­‐	   levels	   from	   baseline	   after	   supplementation	   with	   0.1	  
mmol/kg	   in	   humans	   (Larsen	   et	   al.,	   2006)	   was	   similar	   to	   that	   observed	   in	   rats	  
described	   above	   (Jansson	   et	   al.,	   2007).	   Furthermore,	   Ahluwalia	   and	   colleagues	  
demonstrated	   similar	   effects	   after	   the	   ingestion	   of	   NO3
-­‐	   in	   a	   dietary	   form	   of	  
beetroot	   juice	  (Webb	  et	  al.,	  2008a).	  Although	  beetroot	   is	  purple-­‐red,	   it	   is	  a	  green-­‐
leafy	  vegetable	  and	  contains	  significant	  NO3
-­‐	  levels	  (Santamaria,	  2006).	  In	  this	  study,	  
ingestion	  of	  500	  mL	  beetroot	  juice	  beetroot	  juice	  (mean	  [NO3
-­‐]=	  45.0	  mM)	  provided	  
~22.5	  mmol	   NO3
-­‐	   (~0.32	  mmol/kg	   NO3
-­‐)	   and	  was	   associated	  with	   an	   elevation	   of	  
plasma	  NO2
-­‐	  levels	  from	  0.4	  μM	  to	  0.6	  μM	  (Webb	  et	  al.,	  2008a).	  Plasma	  NO2
-­‐	  levels	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were	  slower	  to	  rise	  than	  plasma	  NO3
-­‐	  levels,	  with	  peak	  plasma	  NO2
-­‐	  levels	  apparent	  
3	  h	  after	   ingestion,	   compared	   to	  peak	  plasma	  NO3
-­‐	   levels	  at	  90	  min	   (Webb	   et	  al.,	  
2008a).	   Similarly,	   interruption	   of	   the	   entero-­‐salivary	   circulation	   by	   avoidance	   of	  
swallowing	   saliva	  prevented	   the	   rises	   in	  plasma	  NO2
-­‐,	   but	  not	  plasma	  NO3
-­‐,	   levels	  
(Webb	   et	   al.,	   2008a)	   confirming	   the	   critical	   importance	   of	   oral	   NO3
-­‐	   reduction	   in	  
modulating	   systemic	  NO2
-­‐	   levels	  after	  dietary	  NO3
-­‐	   ingestion.	  Further	  evidence	   for	  
the	   importance	   of	   the	   oral	   microflora	   in	   facilitating	   this	   process	   is	   taken	   from	  
studies	  that	  have	  sought	  to	  impair	  the	  bacteria	  responsible	  for	  NO3
-­‐	  reduction.	  Prior	  
treatment	  with	  a	  chlorhexidine	  anti-­‐septic	  mouthwash	  in	  animals	  (Petersson	  et	  al.,	  
2009;	  Jädert	  et	  al.,	  2012)	  and	  humans	  (Govoni	  et	  al.,	  2008)	  prevented	  the	  increases	  
in	  plasma	  NO2
-­‐	  levels	  associated	  with	  NO3
-­‐	  ingestion.	  
	  
In	  summary,	   in	  humans	  ~1	  h	  after	  a	  dietary	  NO3
-­‐-­‐load,	  plasma	  NO2
-­‐	   levels	  rise	   in	  a	  
slow	  and	  sustained	  manner,	  peaking	   in	   the	  circulation	  after	  2.5-­‐3	  h,	   reflecting	  the	  
ingestion	   and	   entero-­‐salivary	   processing	   of	   inorganic	  NO3
-­‐	   (Lundberg	   and	  Govoni,	  
2004;	  Webb	  et	  al.,	  2008b).	  
	  
1.7.3	  Sources	  and	  pharmacokinetics	  of	  NO2
-­‐	  in	  the	  circulation	  
Plasma	  NO2
-­‐	  levels	  in	  the	  circulation	  are	  much	  lower	  than	  NO3
-­‐,	  with	  measurements	  
from	  several	  different	  research	  groups	  falling	  in	  the	  0.2-­‐0.5	  μM	  range	  under	  basal,	  
fasting	   conditions	   (as	   reviewed	  by	  Grau	   et	   al.,	   2007).	  NO2
-­‐	   is	   estimated	   to	  have	  a	  
very	  short	  t1/2	   in	  the	  circulation,	  ranging	  between	  ~15-­‐45	  min	  (Dejam	  et	  al.,	  2007;	  
Hunault	  et	  al.,	  2009).	   In	  addition,	  NO2
-­‐	   levels	  measured	   in	  the	  plasma	  are	   likely	  to	  
reflect	  multiple	  different	  sources.	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NO2
-­‐	   is	   formed	   by	   oxidation	   of	   NO	   as	   previously	   described	   above	   and	   has	   been	  
suggested	   to	   sensitively	   reflect	   regional	   eNOS	   activity.	   In	   the	   human	   forearm	  
circulation,	  stimulation	  of	  eNOS	  with	  ACh	  or	  inhibition	  with	  L-­‐NMMA	  rapidly	  altered	  
venous	  plasma	  NO2
-­‐	  levels	  up	  or	  down	  respectively	  but	  without	  changes	  in	  plasma	  
NO3
-­‐	   levels	   (Lauer	   et	   al.,	   2001).	   Furthermore	   basal	   plasma	   NO2
-­‐	   levels	   in	   several	  
species	   were	   found	   to	   be	   similar,	   suggesting	   similar	   levels	   of	   constitutive	   NOS	  
activity,	   and	   application	   of	   several	   different	   NOS	   inhibitors	   demonstrated	   cross-­‐
species	  increases	  in	  vascular	  resistance	  that	  correlated	  to	  decreases	  in	  plasma	  NO2
-­‐	  
levels	   but	   not	   plasma	   NO3
-­‐	   levels	   (Kleinbongard	   et	   al.,	   2003).	   Genetically	   eNOS	  
deficient	  mice	  had	  70%	  lower	  plasma	  NO2
-­‐	  levels	  than	  wild-­‐type,	  littermate	  controls,	  
which	   could	   be	   closely	   approximated	   in	   wild-­‐type	   controls	   by	   the	   systemic	  
application	   of	   NOS	   inhibition	   activity	   (Kleinbongard	   et	   al.,	   2003).	   These	   findings	  
suggest	  that	  70%	  of	  plasma	  NO2
-­‐	   is	   likely	  derived	  from	  eNOS.	  Similarly,	   in	  humans	  
with	  CVD	  risk	  factors,	   it	  has	  been	  shown	  that	  plasma	  NO2
-­‐	  concentration	   inversely	  
correlates	  to	  increasing	  number	  of	  cardiovascular	  risk	  factors	  and	  correlates	  directly	  
to	   brachial	   artery	   FMD,	   suggesting	   that	   plasma	   NO2
-­‐	   levels	   could	   be	   used	   as	   a	  
surrogate	   for	   endothelial	   function	   in	   those	  with	  CVD	   risk	   factors	   (Kleinbongard	   et	  
al.,	  2006b).	  
	  
However,	  in	  addition	  to	  eNOS	  activity,	  plasma	  NO2
-­‐	  levels	  will	  also	  be	  determined	  by	  
dietary	  NO2
-­‐	  and	  NO3
-­‐	  consumption.	  Dietary	  NO2
-­‐	  intake	  levels	  in	  humans	  are	  not	  as	  
substantial	  as	  dietary	  NO3
-­‐,	  with	  the	  major	  contributions	  from	  cured	  meats,	  cereals	  
and	   vegetables,	   and	   with	   minimal	   intake	   occurring	   from	   drinking	   water	  
(Schuddeboom,	   1993).	   Estimates	   of	   daily	   NO2
-­‐	   intake	   are	   relatively	   similar	   across	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Europe	  and	  North	  America	  at	  0.3-­‐0.9	  mg/day	  (Schuddeboom,	  1993),	  which	  equates	  
to	  6-­‐20	  μmol	  NO2
-­‐	  ingested	  per	  day.	  	  
	  
However,	  mean	   salivary	  volume	  swallowed	   is	  estimated	   to	  be	  ~1.5	   L/day	   (Dawes,	  
1972;	  Lagerlöf	  and	  Dawes,	  1984)	  and	  mean	  basal	  salivary	  NO2
-­‐	  levels	  are	  ~100-­‐250	  
μM	   (Lundberg	   and	  Govoni,	   2004;	   Govoni	   et	   al.,	   2008).	   Thus,	   swallowing	   of	   saliva	  
could	  be	  responsible	  for	  total	  amounts	  of	  intra-­‐gastric	  NO2
-­‐	  in	  the	  order	  of	  150-­‐300	  
μmol	   daily.	  Mean	  plasma	  NO2
-­‐	   levels	   as	   stated	   are	   0.2-­‐0.5	  μM,	   suggesting	   a	   total	  
circulatory	  NO2
-­‐	   levels	   of	   1-­‐2.5	   μmol.	   Thus	   the	   same	   total	   amount	   of	  NO2
-­‐	  would	  
enter	  the	  stomach	  every	  10-­‐25min.	  Although	  not	  all	  of	  the	  swallowed	  NO2
-­‐	  survives	  
to	  appear	  in	  the	  circulation,	  even	  if	  a	  fraction	  entered	  the	  circulation,	  it	  would	  make	  
an	   important	   contribution	   to	   plasma	   NO2
-­‐	   levels	   under	   basal	   conditions.	   It	   is	  
possible	   that	   this	   salivary	   NO2
-­‐	   may	   account	   for	   the	   other	   30%	   of	   plasma	   NO2
-­‐	  
concentration	   that	   cannot	   be	   accounted	   for	   by	   eNOS	   activity	   (Lauer	   et	   al.,	   2001;	  
Kleinbongard	  et	  al.,	  2003).	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1.8	  Mechanisms	  of	  NO2
-­‐	  bioactivity	  
It	   had	   been	   suggested	   from	   the	   early	   work	   of	   Reichert,	   Mitchell	   and	   Stieglitz	  
described	  earlier	  that	  elevations	  in	  systemic	  NO2
-­‐	  levels	  after	  ingestion	  of	  inorganic	  
NO2
-­‐	   or	  NO3
-­‐	   (via	   bacterial	  NO3
-­‐	   reduction)	  was	   potentially	   useful	   in	   hypertension	  
and	  other	  CVDs.	  However,	   their	  mechanism	  of	  action	  was	  not	  known	  at	   the	  time.	  
With	  the	  discovery	  that	  direct	  chemical	  acidification	  can	  release	  authentic	  NO	  from	  
NO2
-­‐	   in	   the	   stomach	   (Benjamin	   et	   al.,	   1994;	   Lundberg	   et	   al.,	   1994),	   substantial	  
research	  effort	  has	  focused	  on	  identifying	  other	  biochemical	  pathways	  that	  may	  be	  
involved	  in	  mammalian	  NO2




As	   stated	   previously,	   NO2
-­‐	   can	   be	   directly	   acidified	   to	   NO	   in	   the	   stomach	   as	  
described	   in	   Equations	   1.4-­‐1.6.	   Whilst	   this	   process	   relies	   on	   high	   proton	  
concentrations	  that	  are	  readily	  available	   in	  the	  stomach,	  this	  pathway	  may	  not	  be	  
that	  apparent	   in	  other	  healthy	   tissues	   that	  do	  not	  attain	   such	   levels	  of	   acidaemic	  
stress.	  However,	  in	  ischaemic	  insults,	  acidosis	  accompanies	  significant	  hypoxia,	  with	  
pH	   levels	   in	   ischaemic	  rat	  Langendorff	  heart	  preparations	  measuring	  as	   low	  as	  pH	  
5.5	   (Zweier	   et	   al.,	   1995;	   Gabel	   et	   al.,	   1997).	   Since	   eNOS	   activity	   is	  O2	   dependent	  
(Leone	  et	  al.,	  1991;	  Abu-­‐Soud	  et	  al.,	  1996),	  under	   ischaemic	  conditions	  one	  would	  
suspect	  NO	  generation	  would	  decrease.	  Indeed,	  global	  ischaemia	  in	  rat	  Langendorff	  
heart	  preparations	  reduces	  eNOS	  activity	  by	  ~75%	  (Giraldez	  et	  al.,	  1997).	  However,	  
some	  NO	  generation	  still	  occurs.	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In	   1995,	   Zweier	   and	   colleagues	   published	   a	   seminal	   paper	   in	   the	   NO2
-­‐	   field	  
investigating	  this	  residual	  NO	  generation.	  Using	  EPR	  spectroscopy,	  they	  surprisingly	  
demonstrated	   a	   10-­‐fold	   increase	   in	   NO	   production	   from	   NO2
-­‐	   (1	   mM)	   in	   the	  
ischaemic	   Langendorff	   rat	   heart	   preparation	   compared	   to	   the	   normoxic	   control	  
(Zweier	   et	   al.,	   1995).	   This	   NO	   production	   could	   not	   be	   fully	   inhibited	   by	   NOS	  
inhibition	   (only	   ~65%	   inhibition),	   suggesting	   there	   was	   non-­‐NOS	   mediated	   NO	  
production	   (Zweier	   et	   al.,	   1995).	   They	   performed	   further	   experiments	  
demonstrating	   that	  NO2
-­‐	   levels	   in	   the	  heart	  were	  ~20	  μM	  but	  also	   that	   treatment	  
with	   15NO2
-­‐	   produced	   15NO	   (Zweier	   et	   al.,	   1995).	   This	   study	   was	   the	   first	  
demonstration	   of	   NO2
-­‐-­‐derived	   NO	   production	   within	   the	   cardiovascular	   system	  
(Zweier	  et	  al.,	  1995).	  The	  authors	  of	  this	  paper	  suggested	  that	  the	  reduction	  of	  NO2
-­‐	  
to	  NO	  was	  simply	  a	  consequence	  of	  disproportionation	  due	  to	  the	  acidosis.	  	  
	  
It	  has	  also	  been	  suggested	  that	  several	  other	  dietary	  constituents	  may	  modulate	  the	  
chemical	   acidification	   of	   NO2
-­‐	   to	   NO.	   Vitamin	   C	   is	   a	   potent	   reducing	   agent	   that	  
reduces	  nitrite-­‐induced	  nitrosation	  in	  the	  stomach	  (Licht	  et	  al.,	  1988)	  and	  increases	  
NO	   generation	   from	  NO2
-­‐	   in	   human	   urine	   at	   pH	   between	   4.5-­‐6.0	   (Carlsson	   et	   al.,	  
2001)	   and	   also	   increases	   salivary	   NO2
-­‐-­‐derived	   NO	   in	   vitro	   (Peri	   et	   al.,	   2005).	   In	  
addition,	  dietary	  polyphenols,	  from	  red	  wine	  and	  other	  fruit	  and	  vegetable	  sources,	  
similarly	   increase	   NO	   generation	   from	   salivary	   NO2
-­‐	   in	   vitro	   (Peri	   et	   al.,	   2005),	   in	  
simulated	  gastric	  juice	  supplemented	  with	  NO2
-­‐	  and	  polyphenols	  (Gago	  et	  al.,	  2007)	  
and	   in	   expelled	   gastric	   air	   in	   healthy	   human	   subjects	   who	   have	   consumed	  
polyphenol-­‐containing	  drinks	   (Gago	   et	   al.,	   2007;	  Rocha	   et	   al.,	   2009).	  NO2-­‐-­‐derived	  
NO	  that	   is	  accentuated	  by	  polyphenolic	  contents	  under	  acidic	  conditions	  has	   local	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effects	   on	   gastric	   physiology,	   including	   gastric	   smooth	   muscle	   relaxation	   ex	   vivo	  
(Rocha	  et	  al.,	  2009).	  	  
	  
Whilst	   acidosis	   is	   essential	   for	   all	   of	   these	   pathways,	   it	   is	   now	   clear	   that	   NO2
-­‐	  
reduction	   can	   occur	   under	   physiological	   conditions	   and	   that	   acidosis	   cannot	   fully	  
account	   for	   all	   NO2
-­‐	   reduction.	   We	   now	   know	   that	   NO2
-­‐	   reduction	   is	   also	   a	  
phenomenon	  dependent	  upon	  the	  presence	  of	  mammalian	  NO2
-­‐	  reductases.	  	  
	  
1.8.2	  Enzymatic	  NO2
-­‐	  reduction	  to	  NO	  
The	   discovery	   of	   significant	   human	   artery-­‐vein	   gradients	   of	   NO2
-­‐	   in	   the	   forearm	  
circulation	  of	  healthy	  subjects	  suggested	  that	  there	  was	  consumption	  of	  NO2
-­‐	  within	  
the	  human	  circulation	  under	  physiological	  conditions	  and	  suggested	  a	  possible	  role	  
in	   the	   regulation	   of	   vascular	   tone	   (Gladwin	   et	   al.,	   2000).	   Further	   evidence	   was	  
provided	   by	   the	   apparent	   endocrine	   activity	   of	   inhaled	   NO.	   In	   healthy	   human	  
subjects,	   inhalation	  of	  NO	  led	  to	  increases	  in	  FBF	  under	  continuous	  NOS	  inhibition	  
(Cannon	  et	  al.,	  2001),	  an	  effect	  that	  could	  not	  be	  related	  to	  NO	  directly	  inhaled	  into	  
the	   lungs	  due	  to	   its	   incredibly	  short	   t1/2	  as	  mentioned	  previously.	  These	  effects	  of	  
inhaled	   NO	   were	   paralleled	   by	   increases	   in	   both	   plasma	   NO2
-­‐	   and	   Fe-­‐nitrosyl-­‐Hb	  
(HbNO)	  levels	  (Cannon	  et	  al.,	  2001).	  In	  this	  paper,	  it	  was	  suggested	  that	  these	  NO-­‐
adducts	  could	  serve	  as	  intravascular,	  endocrine	  sources	  of	  NO,	  distant	  to	  the	  site	  of	  
production	   (i.e.	   in	   this	   case,	   the	   pulmonary	   circulation)	   (Cannon	   et	   al.,	   2001).	  
However,	  for	  NO2
-­‐	  to	  be	  bioactive	  in	  the	  human	  circulation,	  there	  would	  have	  to	  be	  
other	   mechanisms	   for	   NO2
-­‐	   reduction	   to	   NO	   that	   are	   not	   solely	   dependent	   on	  
acidosis,	   or	   NO2
-­‐	   would	   have	   to	   be	   bioactive	   by	   non-­‐NO	   dependent	   means.	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Confirmation	  that	  NO2
-­‐	  did	  affect	  vascular	  tone	  under	  physiological	  conditions	  was	  
provided	  by	  (Cosby	  et	  al.,	  2003)	  and	  will	  be	  discussed	  in	  section	  1.9.	  
	  
There	   is	   also	   some	  evidence	   that	  NO2
-­‐	  may	  have	   some	  direct	  effects	   that	   are	  not	  
mediated	  via	   conversion	   to	  NO.	  Application	  of	  NO2
-­‐	   to	   tissue	  homogenates	   in	   the	  
presence	   of	   NO	   scavengers,	   oxyHb	   and	   2-­‐(4-­‐carboxyphenyl)-­‐4,4,5-­‐
teramethylimidazoline-­‐1-­‐oxyl-­‐3-­‐oxide	   (C-­‐PTIO),	   did	   not	   alter	   NO2
-­‐-­‐mediated	   S-­‐
nitrosation	   reactions	   with	   thiol-­‐containing	   proteins	   or	   haem,	   suggesting	   that	   NO	  
was	  not	  an	  obligate	   intermediate	  of	  this	  reaction	  (Bryan	  et	  al.,	  2005).	   In	  the	  same	  
manuscript,	  data	  was	  presented	  showing	  NO2
-­‐	   induced	  dose-­‐dependent	  decreases	  
in	   haem	   oxygenase-­‐1	   (HO-­‐1)	   activity	   (Bryan	   et	   al.,	   2005),	   in	   contrast	   to	   the	  
recognized	  upregulatory	  effects	  of	  NO	  on	  HO-­‐1	  activity	  (Motterlini	  et	  al.,	  2002).	  	  
	  
However,	  in	  the	  main	  it	  is	  now	  accepted	  that	  the	  bioactivity	  of	  NO2
-­‐	  is	  reliant	  on	  its	  
reduction	   to	  NO	  and	   that	   this	  process	   can	  be	   facilitated	  by	  a	  number	  of	  different	  
NO2
-­‐	  reductases	  discussed	  below.	  
	  
1.8.2.1	  XOR	  
One	  of	  the	  first	  enzymes	  proposed	  to	  act	  as	  a	  mammalian	  NO2
-­‐	  reductase	  was	  XOR.	  
Studies	  with	  purified	  bovine	  XOR	  incubated	  with	  NO2
-­‐	  and	  the	  reducing	  agent	  NADH	  
in	  almost	  total	  anoxia	  (aqueous	  O2	  levels	  <1%)	  for	  20	  h,	  produced	  NO	  detectable	  by	  
gas-­‐phase	   chemiluminescence	   in	   the	   headspace,	   that	   was	   inhibited	   by	   the	   XOR	  
inhibitor,	   allopurinol,	   (Zhang	   et	   al.,	   1998).	  Whilst	   XOR-­‐mediated	   NO2
-­‐-­‐derived	   NO	  
production	  was	   greater	   in	   anoxia/hypoxia,	   significant	  NO	  was	   produced	   from	   the	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same	   aqueous	   experiment	   under	   ambient	   O2	   tensions	   (Zhang	   et	   al.,	   1998).	   Later	  
studies	  in	  cell-­‐free	  preparations,	  and	  in	  rat	  and	  human	  tissues	  have	  provided	  further	  
evidence	  that	  XOR	  is	  a	  NO2
-­‐	  reductase	  whose	  activity	  is	  greatly	  enhanced	  in	  acidosis	  
and	  hypoxia.	  Zweier	  and	  colleagues	  incubated	  15NO2
-­‐	  with	  purified	  XOR	  or	  rat	  heart	  
sections	  under	  different	  O2	   tensions,	   in	   the	  presence	  of	  XOR	   co-­‐factors	   and	   L-­‐N
G-­‐
nitroarginine	  methyl	   ester	   (L-­‐NAME,	   a	   NOS	   inhibitor),	   and	   demonstrated	   that	   O2	  
behaved	  as	  a	  competitive	  inhibitor	  to	  XOR-­‐mediated	  NO2
-­‐	  reduction	  but	  that	  XOR-­‐
mediated	  NO2
-­‐	  reduction	  occurred	  under	  aerobic	  conditions	  (Li	  et	  al.,	  2004).	  	  
	  
In	  rat	  and	  human	  heart	  homogenates,	  addition	  of	  NO2
-­‐	   (10-­‐100	  μM)	  increased	  NO	  
production	   in	   a	   concentration–dependent	   manner,	   as	   measured	   by	   gas	   phase	  
chemiluminescence.	  This	  NO2
-­‐-­‐derived	  NO	  production	  was	  enhanced	  by	  acidosis	  (pH	  
6	  vs.	  pH	  5)	  and	  also	  in	  anoxia	  (bubbled	  with	  nitrogen	  gas	  (N2))	  compared	  to	  ambient	  
O2	   tension	   (bubbled	   with	   room	   air)	   (Webb	   et	   al.,	   2004).	   These	   effects	   were	  
prevented	   by	   boiling	   the	   tissue,	   confirming	   the	   enzymatic	   nature	   of	   the	   process	  
(Webb	   et	  al.,	  2004).	  Pre-­‐incubation	  of	   samples	   for	  30	  min	  with	  L-­‐NAME	  (300	  μM)	  
had	  no	  effect,	  whilst	  allopurinol	  (100	  μM),	  or	  another	  XOR	  inhibitor	  that	  works	  at	  a	  
different	   site	   on	   the	   enzyme,	   (-­‐)BOF-­‐4272	   (10μM),	   attenuated	   NO2
-­‐-­‐derived	   NO	  
production	  by	  ~50%	  (Webb	  et	  al.,	  2004).	  Incubation	  of	  rat	  heart	  sections	  with	  NO2
-­‐	  
(10	  μM)	  under	  2%	  O2	  demonstrated	  50%	  greater	  NO2
-­‐	  reduction	  than	  under	  5%	  O2	  
and	   both	   effects	   could	   be	   largely	   attenuated	   by	   pre-­‐incubation	   with	   the	   XOR	  
inhibitor,	  oxypurinol	  (Li	  et	  al.,	  2004).	  NO2
-­‐	  infusions	  (10-­‐1000	  μM)	  caused	  time	  and	  
concentration	  dependent	   increases	   in	  NO	  production	   (sampled	   in	   the	  head	   space	  
and	   measured	   by	   gas-­‐phase	   chemiluminescence)	   in	   the	   presence	   of	   global	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ischaemia	  in	  Langendorff	  isolated	  heart	  preparations,	  which	  could	  be	  abrogated	  by	  
XOR	   inhibition	   (Webb	   et	   al.,	   2004).	   Further	   studies	   in	   hypoxia	   and	   acidotic	  
conditions	   have	   revealed	   similar	   effects	   of	   XOR	   inhibition	   on	   NO2
-­‐-­‐derived	   NO	  
production	   in	   rat	   liver	   (Liu	   et	   al.,	   2007)	   and	   kidney	   (Tripatara	   et	   al.,	   2007)	  
homogenates.	  
	  
Removal	  of	  the	  myocardial	  endothelium	  in	  the	  Langendorff	  heart	  preparation	  also	  
attenuated	  NO2
-­‐-­‐derived	  NO	   (Webb	   et	   al.,	   2004),	   suggesting	  XOR-­‐dependent	  NO2
-­‐	  
reduction	  in	  the	  heart	  at	   least	   in	  part	  occurred	  at	  the	   level	  of	  the	  endothelial	  cell.	  
Further	  studies	  have	  demonstrated	  XOR-­‐dependent	  NO2
-­‐	  reduction	  in	  homogenates	  
of	   rat	   aortae	   and	   vena	   cavae,	   human	   internal	   mammary	   artery	   segments	   and	  
human	   erythrocytes	   under	   hypoxia	   and	   acidosis	   (Webb	   et	   al.,	   2008b).	   The	   most	  
abundant	  source	  of	  XOR	  is	  the	  liver	  and	  during	  periods	  of	  physiological	  stress,	  XOR	  
is	   released	   into	   the	   circulation	   (Terada	   et	   al.,	   1992)	   and	   can	   bind	   to	   distant	   cell	  
types	   via	   heparan	   sulphate	   proteoglycans,	   such	   as	   on	   erythrocytes	   (Webb	   et	   al.,	  
2008b)	  and	  the	  vascular	  endothelium	  (Spiekermann	  et	  al.,	  2003;	  Kelley	  et	  al.,	  2004),	  
where	   it	   may	   be	   responsible	   for	   NO2
-­‐	   reduction	   in	   conditions	   of	   acidosis	   and	  
hypoxia,	   reflecting	   its	   role	   as	   potentially	   the	   main	   NO2
-­‐	   reductase	   in	  
pathophysiological	  conditions	  (Webb	  and	  Ahluwalia,	  2010).	  	  
	  
1.8.2.2	  Aldehyde	  oxidase	  (AO)	  
AO	   has	   95%	   exonic	   homology,	   86%	   amino	   acid	   sequence	   homology	   and	   similar	  
tertiary	  structure	  homology	  to	  XOR	  (Calzi	  et	  al.,	  1995;	  Turner	  et	  al.,	  1995;	  Terao	  et	  
al.,	  1998)	  and	  accordingly	  has	  been	  identified	  as	  a	  NO2-­‐	  reductase	  in	  various	  tissues.	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The	   AO	   inhibitor,	   raloxifene	   (50	   μM)	   was	   shown	   to	   attenuate	   NO2
-­‐-­‐derived	   NO	  
production	  by	  ~35%	  in	  rat	  liver	  and	  heart	  homogenates,	  under	  anoxia	  and	  acidosis	  
(pH	  7.0)	  (Li	  et	  al.,	  2008).	  Furthermore,	  this	  group	  demonstrated	  that	  combination	  of	  
AO	  and	  XOR	  inhibition	  abrogated	  the	  vast	  majority	  of	  tissue	  NO2
-­‐	  reduction	  to	  NO,	  
suggesting	   that	  XOR	  and	  AO	  may	  be	  the	  key	  NO2
-­‐	   reductases	   in	   tissues,	  especially	  
with	  decreasing	  O2	  tension	  and	  pH	  (Li	  et	  al.,	  2008).	  
	  
1.8.2.3	  Mitochondrial	  respiratory	  chain	  enzymes	  
Over	   the	   last	   decade,	   it	   has	   been	   established	   that	   various	   elements	   of	   the	  
mammalian	  mitochondrial	  respiratory	  chain	  function	  as	  NO2
-­‐	  reductases.	  Incubation	  
of	  rat	  liver	  isolated	  mitochondria	  in	  anoxic	  conditions	  under	  mild	  acidosis	  (pH	  7.25)	  
with	  NO2
-­‐	  (50	  μM)	  produced	  NO,	  detected	  by	  EPR	  spectroscopy,	  that	  was	  partially	  
abrogated	   by	   complex	   I	   inhibition	   with	   rotenone	   (concentration	   not	   stated)	   and	  
fully	   attenuated	   by	   complex	   III	   inhibition	   with	   myxothiazole	   (concentration	   not	  
stated)	   (Kozlov	   et	   al.,	   1999;	   Nohl	   et	   al.,	   2000).	   The	   importance	   of	   complex	   I-­‐
mediated	   NO2
-­‐	   reduction	   in	   the	   presence	   of	   complex	   III	   inhibition	   has	   not	   been	  
studied.	  	  
	  
Incubation	  of	   rat	   liver	  mitochondria	  at	  pH	  6.5	  with	  NO2
-­‐	   (100-­‐1000	  μM)	  produced	  
NO	   (measured	  by	  NO	  electrode)	   that	   could	  be	  enhanced	  by	  pre-­‐bubbling	  with	  N2	  
instead	  of	  ambient	  air	  (Castello	  et	  al.,	  2006).	  Although	  inhibition	  of	  the	  respiratory	  
chain	  with	  complex	   III	   inhibitors	  prevented	  NO	  generation,	  giving	  an	  e-­‐	  donor	  that	  
provided	   reducing	   power	   directly	   to	   cytochrome	   c	   oxidase	   (complex	   IV)	   caused	   a	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resumption	   in	   NO	   generation	   that	   could	   be	   inhibited	   by	   carbon	   monoxide,	  
suggesting	  that	  complex	  IV	  is	  a	  NO2
-­‐	  reductase	  under	  anoxia	  (Castello	  et	  al.,	  2006).	  	  
	  
1.8.2.4	  Globins	  
The	  globin	  family,	  including	  Hb,	  myoglobin	  (Mb),	  neuroglobin	  and	  cytoglobin,	  have	  
all	  been	  described	  as	  potential	  NO2
-­‐	  reductases.	  
	  
The	  reactions	  of	  globins	  with	  NO2
-­‐	  have	  been	  studied	   for	  over	  100	  years.	  Haldane	  
discovered	   that	  NO	   bound	   to	  Mb	   from	   the	   interaction	   of	  NO2
-­‐,	  Mb	   and	   reducing	  
agents	  (vitamin	  C	  in	  citrus	  juice)	  was	  responsible	  for	  the	  bright	  red	  colour	  of	  cured	  
meats	   (Haldane,	   1901).	   Brooks	   in	   the	   1930s	   and	   Doyle	   in	   the	   1980s	   further	  
characterized	   this	   reaction	   and	  were	   able	   to	   determine	   that	   the	   reaction	   of	  NO2
-­‐	  
and	  deoxyhaemoglobin	   (deoxyHb)	  produces	  NO,	  metHb	  and	  HbNO	   (Equation	  1.7)	  
(Brooks,	   1937;	   Doyle	   et	   al.,	   1981).	   More	   recent	   characterization	   of	   this	   reaction	  
suggests	   that	   the	  majority	  of	   the	  NO	  may	  be	  weakly	  bound	   to	   ferric	  haem	  rather	  
than	  avidly	  bound	  to	  ferrous	  haem,	  allowing	  for	  the	  potential	  facile	  release	  of	  free	  
NO	  (Nagababu	  et	  al.,	  2003).	  
	  
deoxyHb	   	   nitrite	   	   metHb	   	   iron-­‐nitrosyl-­‐Hb	   	   nitric	  oxide	  
2	  Fe(II)Hb	   +	   2	  NO2
-­‐	   ⇒ Fe(III)Hb	   +	   Fe	  (II)Hb-­‐NO	   +	   NO	  
Equation	  1.7	  Reaction	  of	  NO2
-­‐	  with	  deoxyHb.	  (NO2
-­‐=nitrite;	  deoxyHb=deoxyhaemoglobin).	  	  
	  
Gladwin	  and	  colleagues	  have	  demonstrated	  that	  addition	  of	  NO2
-­‐	  (100-­‐200	  μM)	  to	  
deoxygenated	   erythrocytes	   in-­‐line	   with	   a	   gas-­‐phase	   chemiluminescence	   analyzer	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produces	  bursts	  of	  NO	  production,	  whilst	  NO2
-­‐	  on	  its	  own	  has	  no	  effect	  (Cosby	  et	  al.,	  
2003).	  In	  further	  experiments,	  they	  modulated	  the	  oxygenation	  state	  of	  cell-­‐free	  Hb	  
(at	   pO2=	   15	   mmHg)	   with	   the	   addition	   of	   inositol	   hexaphosphate	   (IHP).	   In	   the	  
absence	  of	  IHP,	  Hb	  at	  such	  O2	  tension	  would	  be	  fully	  oxygenated.	  However,	  with	  the	  
addition	  of	  IHP,	  Hb	  remains	  in	  a	  deoxygenated	  state.	  The	  addition	  of	  IHP	  to	  keep	  Hb	  
in	   the	   deoxyHb	   state	   reduced	   the	   concentration	   of	   NO2
-­‐	   that	   was	   required	   to	  
facilitate	   relaxation	   of	   pre-­‐contracted	   aortic	   rings	   by	   3	   orders	   of	   magnitude	  
compared	  to	  that	  which	  was	  required	  in	  control	  preparations	  of	  oxyHb	  (100	  nM	  vs.	  
100	  μM),	  suggesting	  a	  physiologically	  relevant	  model	  for	  NO2
-­‐	  reduction	  to	  NO	  by	  its	  
reaction	  with	  erythrocyte	  Hb	  (Cosby	  et	  al.,	  2003).	  
	  
The	   kinetics	   of	   this	   reaction	   are	   complicated	   and	   reflect	   differential	   rates	  of	  NO2
-­‐	  
reduction	  and	  affinities	  of	  tetrameric	  Hb	  for	  NO	  depending	  on	  the	  individual	  R	  (oxy-­‐
haem)	   and	   T	   (deoxy-­‐haem)	   co-­‐ordination	   of	   each	   of	   the	  Hb	   tetramers	  within	   the	  
erythrocyte	   (Huang	   et	   al.,	   2005;	  Grubina	   et	   al.,	   2007).	   This	   process	   leads	   to	  NO2
-­‐	  
reduction	  by	  erythrocytic	  Hb	  being	  fastest	  when	  50%	  of	  haem	  groups	  are	  bound	  to	  
O2,	   which	   is	   the	   p50	   for	   oxy-­‐haem	   (Nagababu	   et	   al.,	   2003;	   Huang	   et	   al.,	   2005;	  
Crawford	  et	  al.,	  2006).	  
	  
However,	   one	   of	   the	  major	   problems	   of	   such	   chemistry	   is	   that	   any	  NO	  produced	  
intra-­‐erythrocytically	  by	  such	  reductive	  chemistry	  should	  be	  scavenged	  by	  oxyHb	  to	  
form	  NO3
-­‐	   (Equation	  1.3)	   as	   previously	  mentioned,	   especially	   as	  NO2
-­‐	   reduction	   is	  
maximal	  at	  p50,	  when	  there	  will	  be	  abundant	  oxyHb.	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One	  suggestion	   to	   this	  challenge	  has	  been	   the	  proposal	   that	   there	   is	  concomitant	  
generation	  of	  an	  NO	  intermediate	  that	  is	  less	  reactive	  than	  NO	  that	  is	  able	  to	  diffuse	  
away	  from	  the	  site	  of	  production	  (Robinson	  and	  Lancaster,	  2005).	  One	  idea	  that	  has	  
gained	  popularity	  is	  the	  thought	  that	  Hb	  may	  act	  as	  a	  NO2
-­‐	  anhydrase	  (Basu	  et	  al.,	  
2007;	  Hopmann	  et	  al.,	  2011).	  The	  overall	  stoichiometry	  suggested	  of	  such	  a	  reaction	  
reveals	  that	  Hb	  is	  dehydrating	  2	  molecules	  of	  NO2
-­‐	  with	  the	  addition	  of	  a	  proton	  and	  
is	  thus	  an	  anhydrase	  reaction.	  N2O3	  could	  therefore	  escape	  the	  cellular	  confines	  of	  
the	   erythrocyte	   and	   dissociate	   to	   NO	   and	   NO2	   or	   participate	   in	   S-­‐nitrosation	   of	  
thiols	   to	  export	  NO-­‐like	  activity	   (Robinson	  and	  Lancaster,	  2005;	  Basu	  et	  al.,	  2007).	  
This	  reaction	  has	  recently	  been	  shown	  in	  theoretical	  computational	  chemical	  terms	  
to	  be	  energetically	  favourable	  and	  therefore	  potentially	  relevant	  in	  vivo	  (Hopmann	  
et	  al.,	  2011).	  
	  	  
Mb	  is	  another	  globin	  protein	  that	  can	  bind	  O2	  and	  NO	  (Flögel	  et	  al.,	  2001)	  and	  has	  
attracted	  much	  interest	  as	  a	  potential	  NO2
-­‐	  reductase.	  Deoxymyoglobin	  (deoxyMb)	  
forms	   Fe-­‐nitrosyl-­‐Mb	   (MbNO)	   adducts	   after	   incubation	   with	   NO2
-­‐	   in	   a	  
concentration-­‐dependent	  manner,	  synonymous	  with	  the	  reactions	  noted	  above	  for	  
Hb	  (Rassaf	  et	  al.,	  2007).	  NO2
-­‐-­‐derived	  NO	  production	  ([NO2
-­‐]	  100	  μM	  at	  pH	  5)	  was	  
65%	  lower	  in	  heart	  homogenates	  from	  Mb	  knockout	  compared	  to	  wild-­‐type	  (Rassaf	  
et	  al.,	  2007).	   In	  the	  same	  Mb	  knockout	  tissues,	  NO2
-­‐-­‐derived	  NO	  production	  could	  
be	  restored	  to	  control	  levels	  by	  the	  addition	  of	  exogenous	  Mb	  (Rassaf	  et	  al.,	  2007).	  
Mb-­‐dependent	  NO2
-­‐	  reduction	   increases	  with	  decreasing	  pH	  and	  O2	  tension	  (Shiva	  
et	   al.,	   2007a)	   and	   may	   be	   particularly	   important	   in	   the	   response	   to	   ischaemic	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myocardial	  injury	  due	  to	  abundant	  Mb	  (Shiva	  et	  al.,	  2007a)	  and	  NO2
-­‐	  stores	  (Bryan	  
et	  al.,	  2005).	  
	  
Recently,	   neuroglobin	   has	   been	   investigated	   for	   its	   NO2
-­‐	   reductase	   activity.	  
Incubation	  of	  purified	  mouse	  neuroglobin	  under	  hypoxic	  conditions	  also	  facilitated	  
NO2
-­‐	  reduction	  to	  NO	  measured	  by	  EPR	  spectroscopy,	  though	  the	  related	  cytoglobin	  
did	  not	  (Petersen	  et	  al.,	  2008).	  	  
	  
1.8.2.5	  eNOS	  
A	  surprising	  addition	   to	   the	   list	  of	   functional	  mammalian	  NO2
-­‐	   reductases	   is	  eNOS	  
itself,	   suggesting	   not	   all	   NO2
-­‐-­‐derived	   NO	   is	   NOS-­‐independent	   as	   once	   thought.	  
Slama-­‐Schwok	  and	  colleagues	  demonstrated	   that	  eNOS	   in	  anoxic	  conditions	  could	  
produce	  NO	  (Gautier	  et	  al.,	  2006).	   Incubation	  of	  eNOS	  at	  physiological	  pH	   (7.6)	   in	  
anoxia,	  with	  NADPH	  and	  NO2
-­‐	  (500	  μM)	  revealed	  Fe-­‐nitrosyl	  formation	  of	  the	  haem	  
group	   within	   eNOS	   measured	   by	   EPR	   spectroscopy	   (Gautier	   et	   al.,	   2006).	  	  
Simultaneous	   recording	   with	   a	   NO	   electrode	   demonstrated	   a	   burst	   of	   NO	  
production	   that	   did	   not	   occur	   in	   the	   absence	   of	   NADPH	   or	   eNOS	   respectively	  
(Gautier	   et	   al.,	   2006).	   Further	   experiments	   with	   15NO2
-­‐	   demonstrated	   15NO	  
production,	  confirming	  that	  NO	  was	  produced	  from	  NO2
-­‐	  rather	  than	  14N-­‐labelled	  L-­‐
arginine	  that	  was	  also	  present	  (Gautier	  et	  al.,	  2006).	  This	  reaction	  is	  specific	  for	  the	  
eNOS	  isoform	  and	  is	  not	  evident	  with	  iNOS	  or	  nNOS,	  and	  geminate	  recombination	  
studies	   have	   revealed	   that	   NO2
-­‐	   reduction	   occurs	   at	   a	   site	   2-­‐5	   Å	   adjacent	   to	   the	  
haem	  site	  (Mikula	  et	  al.,	  2009).	  Furthermore,	  confocal	  microscopy	  (Kleinbongard	  et	  
al.,	   2006a)	   and	   Western	   blotting	   (Webb	   et	   al.,	   2008b)	   have	   demonstrated	   the	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presence	  of	  eNOS	  on	  human	  erythrocytes	  and	  incubation	  of	  erythrocytes	  with	  NOS	  
inhibitors	   (L-­‐NAME	   and	   L-­‐NMMA,	   300	   μM)	   attenuated	   NO2
-­‐	   (10-­‐100	   μM)-­‐derived	  
NO	  production	  detected	  by	  gas-­‐phase	  chemiluminescence	  (Webb	  et	  al.,	  2008b).	  
	  
The	  relative	  contribution	  of	  each	  of	  these	  pathways	  may	  vary	  dependent	  upon	  the	  
prevalent	  conditions.	  It	  has	  been	  suggested	  that	  under	  physiological	  pH	  and	  pO2	  the	  
globins	   predominate	   as	   the	   primary	   NO2
-­‐	   reductase	   in	   the	   cardiovascular	   system,	  
however,	  as	  conditions	  progressively	  move	   into	   the	  pathological	   realm	  of	  acidosis	  
and	  hypoxia	  that	  other	  reductases	  predominate	  such	  as	  XOR	  (Gladwin	  et	  al.,	  2005;	  
van	  Faassen	  et	  al.,	  2009;	  Webb	  and	  Ahluwalia,	  2010).	  	  
	  
In	   summary,	   it	   is	   now	   clear	   that	   the	   conversion	   of	   NO2
-­‐	   to	   NO	   increases	   with	  
increasing	  acidosis	  and	  hypoxia	  (Zweier	  et	  al.,	  1995;	  Cosby	  et	  al.,	  2003;	  Webb	  et	  al.,	  
2004;	  Li	  et	  al.,	  2008),	  environments	  in	  which	  the	  classical	  L-­‐arginine/eNOS	  pathway	  
is	  dysfunctional	  (Giraldez	  et	  al.,	  1997).	  This	  particular	  finding	  has	  led	  to	  the	  proposal	  
that	  this	  alternative	  pathway	  for	  NO	  generation	  may	  act	  as	  a	  complementary,	  back-­‐
up	   system	   (Figure	   1.6)	  when	   conventional	  NO	   generation	   has	   been	   compromised	  
(Lundberg	  et	  al.,	  2008).	  In	  addition,	  a	  number	  of	  in	  vivo	  enzymatic	  NO2
-­‐	  reductases	  




Figure	   1.6	   NO	   cycle	   in	   humans.	   Coloured	   arrows	   indicate:	   oxidation	   and	   reduction.	  
(Cu=copper;	   NO=nitric	   oxide,	   NO3
-­‐=nitrate;	   NO2
























1.9	  Therapeutic	  utility	  of	  the	  NO3
-­‐-­‐NO2
-­‐-­‐NO	  pathway	  
Initially	  these	  pathways	  were	  dubbed	  non-­‐NOS	  but	  since	  the	  discovery	  noted	  above	  
of	   eNOS-­‐mediated	   NO2
-­‐-­‐derived	   NO,	   these	   pathways	   are	   best	   described	   as	   an	  
alternative	  pathway	  for	  NO	  generation,	  or	  the	  NO3
-­‐-­‐NO2
-­‐-­‐NO	  pathway	  (Lundberg	  et	  
al.,	   2008).	   Overwhelming	   evidence	   supporting	   the	   existence	   of	   this	   alternative	  
endogenous	   pathway	   for	   NO	   generation	   has	   raised	   interest	   with	   respect	   to	  
determining	   the	   potential	   of	   exploiting	   this	   pathway	   to	   ‘rescue’	   levels	   of	   NO	   in	  
diseases,	   particularly	   CVD,	   where	   decreased	   L-­‐arginine-­‐derived	   NO	   generation	   is	  
thought	   to	   contribute	   to	   pathology.	   In	   this	   respect	   a	   number	   of	   studies	   have	  
evaluated	   the	   potential	   of	   provision	   of	   inorganic	  NOx,	   via	   the	   diet	   or	   by	   systemic	  
application,	  to	  serve	  to	  increase	  intravascular	  NO2
-­‐	  to	  modulate	  the	  cardiovascular	  
system	  and	  CVD	  risk	  factors.	  	  
	  
NO2
-­‐	  has	  been	  used	  as	  a	  cyanide	  antidote	  for	  more	  70	  years	  (as	  reviewed	  in	  Butler	  
and	  Feelisch,	  2008)	  and	  NO2
-­‐	  in	  food	  preservation	  prevents	  oxidation	  of	  fatty	  acids	  
to	   prevent	   rancidity	   and	  malodour	   formation	   (Honikel,	   2008),	   as	  well	   as	   critically	  
controlling	  Clostridium	  botulinum	  growth	  and	  toxin	  production	  (Hustad	  et	  al.,	  1973).	  
Inorganic	   NOx	   have	   been	   used	   in	   the	   cardiovascular	   system	   for	   over	   85	   years	  
(Reichert	  and	  Mitchell,	  1880;	  Stieglitz,	  1927)	  but	  there	  has	  been	  a	  recent	  renewed	  
interest	   in	   these	  anions	   in	  both	  animal	  and	  human	  studies	   seeking	   to	  explore	   the	  
new	  biology	  of	  NO2
-­‐-­‐derived	  NO	  production.	  
	  
It	  was	   in	  2001	   that	   the	  view	   that	  NO2
-­‐	  was	   inert	  at	  physiological	   levels	  within	   the	  
cardiovascular	  system	  was	  finally	  eroded.	  In	  rat	  aortic	  rings,	  application	  of	  low	  µM	  
 107	  
NO2
-­‐	   (2.5	   μM),	   whilst	   inactive	   under	   physiological	   pH,	   were	   shown	   to	   relax	  
contracted	   rat	   aorta	   under	   acidic	   (pH	   6.6)	   conditions	   (Modin	   et	   al.,	   2001).	   The	  
significance	   of	   this	   finding	   was	   finally	   appreciated	   with	   the	   relatively	   recent	  
demonstration	  by	  Gladwin	  and	  colleagues	   that	   infusion	  of	  NaNO2	   into	   the	  human	  
forearm	   causes	   vasorelaxation	   with	   concomitant	   increased	   FBF;	   a	   phenomenon	  
augmented	  by	   the	  mildly	  hypoxic	  conditions	   formed	  during	  exercise	   (Cosby	   et	  al.,	  
2003).	  	  
	  
Following	  these	  first	  demonstrations	  of	  physiological	  activity	  of	  NO2
-­‐,	  there	  are	  now	  
numerous	   studies	   showing	   the	   benefits	   of	   physiologically-­‐relevant	   NO2
-­‐	  
concentrations	   in	   the	   context	   of	   ischaemia-­‐reperfusion	   (IR)	   injury	   of	   solid	   organs,	  
including	  notably	  heart	  (Webb	  et	  al.,	  2004;	  Duranski	  et	  al.,	  2005;	  Bryan	  et	  al.,	  2007;	  
Gonzalez	   et	   al.,	   2008),	   brain	   (Jung	   et	   al.,	   2006),	   kidney	   (Tripatara	   et	   al.,	   2007;	  
Milsom	  et	  al.,	  2010)	  and	  the	  liver	  (Duranski	  et	  al.,	  2005;	  Shiva	  et	  al.,	  2007b).	  	  
	  
Understandably,	   it	   is	   not	   possible	   to	   perform	   mechanistic	   studies	   in	   human	  
myocardial	   IR	   injury	   so	   easily.	   Hence,	   models	   of	   temporary	   IR	   injury	   on	   the	  
endothelium	   of	   the	   human	   circulation	   have	   been	   developed	   (Kharbanda	   et	   al.,	  
2001,	  2002).	  Utilizing	  this	  model	  of	  IR	  injury,	  Ahluwalia	  and	  colleagues	  investigated	  
the	   effect	   of	   dietary	  NO3
-­‐	   supplementation	   (in	   the	   form	   of	   beetroot	   juice)	   on	   IR-­‐
induced	  endothelial	  dysfunction	  (Webb	  et	  al.,	  2008a)	  compared	  to	  water	  placebo.	  
In	  10	  healthy	   subjects,	   IR	   caused	   reductions	   in	  brachial	   artery	   FMD	   that	   could	  be	  
prevented	  by	  ingestion	  of	  a	  single	  dose	  of	  dietary	  NO3
-­‐	  (22.5	  mmol	  dose)	  2	  h	  prior	  
to	  the	  IR	  injury	  (Webb	  et	  al.,	  2008a).	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However,	   the	   focus	  of	   this	   thesis	   is	  on	   the	  effect	  of	  NO3
-­‐-­‐NO2
-­‐-­‐NO	  pathway	  on	  BP	  




-­‐	  and	  BP	  
The	  reported	  effects	  of	  NO2
-­‐	  on	  vascular	  tone	  raise	  the	  possibility	  that	  systemic	  NO2
-­‐
administration	  or	  dietary	  NO3
-­‐	  supplementation	  may	  be	  useful	   in	  the	  treatment	  of	  
hypertension.	   Intra-­‐arterial	   infusion	   of	   NaNO2	   (36	   µmol/min	   for	   15	  min)	   into	   the	  
forearm	  of	  18	  healthy	  subjects	  achieved	   local	   intravascular	  NO2
-­‐	  concentrations	  of	  
~200	  μM	  and	  caused	  NO-­‐dependent	  vasodilation	  of	  the	  forearm	  vasculature	  and	  an	  
increase	  of	  ~175%	  in	  FBF	  (Cosby	  et	  al.,	  2003).	  Systemic	  NO2
-­‐	   levels	   increased	  from	  
0.2-­‐0.4	  µM	  to	  16	  μM	  and	  was	  associated	  with	  a	  7	  mmHg	  drop	  in	  MAP	  (Cosby	  et	  al.,	  
2003).	   Infusion	   of	   approximately	   100-­‐fold	   less	   NaNO2	   (400	   nmol/min)	   to	   achieve	  
lower,	  physiologically	  relevant	  concentrations	  of	  NO2
-­‐	  (local	  venous	  concentrations	  
of	  ~2.5	  µM)	  in	  10	  healthy	  subjects	  increased	  FBF	  by	  ~30%	  (Cosby	  et	  al.,	  2003).	  These	  
effects	  were	  augmented	  by	  exercise,	  and	  were	  all	  associated	  with	  the	  detection	  of	  
increased	  HbNO	  as	   a	  marker	   of	   intravascular	  NO	  production	   (Cosby	   et	   al.,	   2003).	  
This	  publication	  was	  followed	  by	  another	  from	  the	  same	  group	  demonstrating	  that	  
infusion	   into	   the	   brachial	   artery	   of	   increasing	   doses	   of	   NaNO2	   (2-­‐fold	   stepped	  
increases	   in	   5	   min	   intervals,	   with	   starting	   dose	   0.1	   μmol/kg/min	   up	   to	   1.6	  
μmol/kg/min)	   resulting	   in	   local	   venous	  plasma	  NO2
-­‐	   levels	   of	   25-­‐30	  µM,	   caused	   a	  
~10	  mmHg	  drop	  in	  MAP	  that	  persisted	  for	  up	  to	  3	  h	  (Dejam	  et	  al.,	  2007).	  	  
	  
The	   effect	   of	   exercise	   to	   increase	   NO2
-­‐-­‐induced	   vasodilation	   (Cosby	   et	   al.,	   2003)	  
suggested	  to	  the	  authors	  that	  relative	  hypoxia	  might	   increase	  NO2
-­‐-­‐derived	  NO,	   in	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accordance	   with	   the	   activity	   of	   cell-­‐free	   enzyme	   systems	   already	   described.	   This	  
thesis	  was	  further	  developed	  more	  recently	  by	  Frenneaux	  and	  colleagues	  (Maher	  et	  
al.,	   2008).	   Utilizing	   radio-­‐labelled,	   autologous	   blood	   and	   standard	   forearm	  
plethysmographic	   techniques,	   they	   were	   able	   to	   determine	   arterial	   and	   venous	  
vasodilation	   separately.	   Interestingly,	   under	   normoxic	   conditions,	   intra-­‐arterial	  
delivery	   of	   increasing	   doses	   of	   NO2
-­‐	   (314	   nmol/min-­‐7.84	   μmol/min),	   decreased	  
venous	  tone	  in	  a	  dose-­‐dependent	  manner,	  by	  up	  to	  20-­‐35%	  with	  the	  highest	  doses	  
used	  after	  20min	  of	  NO2
-­‐	  infusion	  (Maher	  et	  al.,	  2008).	  However,	  in	  this	  study,	  low	  
dose	  NO2
-­‐	  infusions	  (314	  nmol/min),	  that	  approximated	  doses	  used	  previously	  that	  
were	  associated	  with	  ~30%	  increases	   in	  FBF	  (Cosby	  et	  al.,	  2003)	  did	  not	  dilate	  the	  
arterial	  side	  of	  the	  circulation	  (Maher	  et	  al.,	  2008).	  Indeed,	  arterial	  dilation	  was	  only	  
apparent	   (increasing	   FBF	   by	   60-­‐80%)	   at	  much	   higher	   doses	   (3.14-­‐7.84	   μmol/min)	  
(Maher	  et	  al.,	  2008).	  These	  findings	  replicate	  much	  earlier	  work	  that	  used	  detailed	  
tilt-­‐table	  testing	  to	  elucidate	  the	  role	  of	  dilation	  of	  the	  venous	  circulation	  (and	  not	  
arterial	  circulation)	  as	  the	  cause	  of	  NO2
-­‐	   induced	  cardiovascular	  collapse	  (Weiss	  et	  
al.,	  1937;	  Wilkins	  et	  al.,	  1937).	  	  
	  
However,	  to	  get	  the	  arterial	  side	  of	  the	  circulation	  ‘hypoxic’,	  subjects	  repeated	  the	  
protocol	  after	  arterial	  saturations	  were	  maintained	  at	  SpO2	  of	  83-­‐88%	  by	  breathing	  
12%	  O2	  (Maher	  et	  al.,	  2008).	  In	  this	  situation,	  whilst	  there	  was	  no	  augmentation	  of	  
the	  effects	  on	  venodilation,	  or	  of	  hypoxia	  on	  its	  own,	  infusion	  of	  314	  nmol/min	  NO2
-­‐	  
(which	  had	  no	  effect	  in	  normoxic	  conditions)	  increased	  FBF	  by	  ~40%	  (Maher	  et	  al.,	  
2008).	   Such	   a	   finding	   is	   consistent	  with	   the	   idea	   that	   the	   vasodilator	   potential	   of	  
NO2
-­‐	  is	  not	  solely	  limited	  to	  anoxia	  or	  extreme	  ischaemia	  but	  is	  proportional	  to	  the	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extent	   of	   ‘hypoxia’	   in	   the	   tissues	   and	   blood	   as	   it	   deoxygenates	   from	   arterial	   to	  
venous	  sides.	  
	  
These	  demonstrations	  of	  the	  vasodilator	  potential	  of	  NO2
-­‐	  are	  also	  concordant	  with	  
the	   effects	   of	   NO2
-­‐	   supplementation	   in	   wild-­‐type	   animals	   and	   animal	   models	   of	  
hypertension.	  In	  anaesthetized	  Wistar	  rats,	   i.v.	  NO2
-­‐	  (10-­‐1000	  μmol/kg	  over	  5	  min)	  
caused	   dose-­‐dependent	   reductions	   in	   MAP	   measured	   invasively	   over	   30	   min.	  
(Vleeming	   et	   al.,	   1997).	   In	   free-­‐moving	  Wistar	   rats,	   implantation	   of	   telemetric	   BP	  
recorders	   revealed	   that	   supplementation	   of	   drinking	   water	   with	   NO2
-­‐	   (36	   mM)	  
reduced	   BP,	   and	   that	   this	   effect	   was	   reversed	   immediately	   on	   changing	   drinking	  
water	   supplementation	   to	   NaCl	   control	   (Vleeming	   et	   al.,	   1997).	   Similarly,	   in	  
spontaneously	   hypertensive	   rats,	   prolonged	   (up	   to	   1	   year)	   oral	   administration	   of	  
large	   amounts	   of	   NO2
-­‐	   in	   the	   drinking	   water	   (50-­‐100	   mM)	   ameliorated	   the	   BP	  
phenotype	  in	  a	  dose-­‐dependent	  fashion	  (Beier	  et	  al.,	  1995;	  Haas	  et	  al.,	  1999).	  The	  
authors	  of	  these	  articles	  were	  aware	  of	  the	  bacterial	  conversion	  of	  NO3
-­‐	  to	  NO2
-­‐	  and	  
postulated	   that	   the	   effect	   of	   dietary	   NO3
-­‐	   should	   be	   investigated	   to	   see	  whether	  
elevation	  of	  systemic	  NO2
-­‐	   levels	  from	  NO3
-­‐	  would	  reduce	  BP	  (Classen	  et	  al.,	  1990;	  
Vleeming	  et	  al.,	  1997).	  Indeed,	  there	  is	  now	  a	  substantial	  body	  of	  evidence	  in	  both	  
animal	  models	  and	  humans	  to	  support	  this	  proposal.	  
	  
BP	   was	   measured	   either	   in	   anaesthetized	   (by	   cannulation)	   or	   in	   conscious	  
(telemetrically)	  Sprague-­‐Dawley	  rats	  that	  were	  supplemented	  with	  NO3
-­‐	  (10	  mM)	  or	  
matched	  control	  in	  drinking	  water	  for	  1	  week.	  MAP	  was	  reduced	  by	  ~20	  mmHg	  and	  
~5	  mmHg	  in	  anaesthetized	  and	  conscious	  animals	  respectively	  after	  treatment	  with	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NO3
-­‐	   only	   (Petersson	   et	   al.,	   2009).	   Importantly,	   in	   this	   study,	   the	   significance	   of	  
bacterial	   NO3
-­‐	   reduction	   for	   bioactivity	   of	   NO2
-­‐	   was	   confirmed.	   Treatment	   with	  
antibacterial	  mouthwash	  (chlorhexidine	  0.2%)	  twice	  daily	  during	  the	  same	  week	  as	  
NO3
-­‐	   supplementation	   prevented	   the	   reductions	   in	   BP	   noted	   above,	   but	   had	   no	  
effect	  on	  rats	  supplemented	  with	  NO2
-­‐	  (1	  mM)	  (Petersson	  et	  al.,	  2009).	  	  
	  
Further	  evidence	  for	  the	  utility	  of	  NO3
-­‐	  in	  BP	  control	  comes	  from	  animal	  models	  of	  
hypertension.	   For	   example,	   in	   high-­‐salt	   fed,	   uni-­‐nephrectomized	   Sprague-­‐Dawley	  
rats,	   an	   established	   model	   for	   hypertension	   in	   rats	   (Carlström	   et	   al.,	   2007),	  
supplementation	   of	   the	   diet	   with	   1	   mmol/kg	   inorganic	   NO3
-­‐	   ameliorated	   salt-­‐
induced	  hypertension	  and	  reduced	  associated	  cardiac	  and	  renal	  fibrosis	  (Carlström	  
et	  al.,	  2011).	  
	  
Such	  effects	  of	  dietary	  NO3
-­‐	  have	  been	  translated	  into	  the	  clinical	  setting.	  The	  first	  
demonstration	   of	   this	   was	   published	   by	   the	   Karolinska	   group	   using	   short-­‐term	  
supplementation	   (3	   days)	  with	  NaNO3	   (0.1	  mmol/kg	   daily)	   compared	   to	  matched	  
NaCl	  control	  in	  17	  healthy	  subjects.	  They	  noted	  increased	  plasma	  NO2
-­‐	  levels	  in	  NO3
-­‐
-­‐supplemented	   subjects	   (209±105	   nM)	   compared	   to	   control	   (138±38	   nM)	   and	  
demonstrated	  reductions	   in	  DBP	  by	  3.7mmHg	  compared	  to	  placebo	  (Larsen	  et	  al.,	  
2006).	  	  
	  
Later,	   Ahluwalia	   and	   colleagues,	   in	   an	   open-­‐label	   study,	   used	   a	   dietary	   source	   of	  
NO3
-­‐,	  in	  the	  form	  of	  beetroot	  juice,	  compared	  to	  a	  matched	  volume	  of	  water	  (Webb	  
et	  al.,	  2008a).	  A	  single	  ingestion	  of	  a	  dietary	  NO3
-­‐
	  (500mL,	  [NO3
-­‐]=	  45	  mM)	  reduced	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SBP	  and	  DBP	  over	  24	  h	  with	  peak	   reductions	  of	   ~10.4	  and	  ~8	  mmHg	   respectively	  
occurring	   at	   2.5-­‐3	   h	   post-­‐ingestion;	   effects	   coinciding	   with	   peak	   elevations	   in	  
plasma	  NO2
-­‐,	  but	  not	  NO3
-­‐,	   levels	  (Figure	  1.7).	  SBP	  was	  still	  significantly	  reduced	  at	  
24	   h	   post-­‐ingestion	   by	   ~6	   mmHg.	   Furthermore,	   the	   changes	   in	   SBP	   were	   not	  
correlated	   to	   changes	   in	   either	   plasma	   NO3
-­‐	   or	   K+	   levels	   but	   were	   significantly	  
inversely	  correlated	  to	  changes	  in	  plasma	  NO2
-­‐	  levels,	  suggesting	  that	  the	  change	  in	  
plasma	  NO2
-­‐	   level	  was	  the	  determining	  effect	  in	  changing	  BP	  (Webb	  et	  al.,	  2008a).	  
Changes	   in	   plasma	   NO2
-­‐	   levels	   and	   reductions	   in	   BP	   were	   abolished	   if	   subjects	  
refrained	   from	   swallowing	   their	   saliva,	   thereby	   interrupting	   the	   entero-­‐salivary	  
circulation	  and	  preventing	  the	  rises	  in	  plasma	  NO2
-­‐	  levels	  in	  the	  circulation	  (Webb	  et	  
al.,	   2008a)	  which	   again	   confirms	   the	   functional	   importance	   of	   the	   entero-­‐salivary	  
circulation	  and	  further	  identifies	  NO2
-­‐	  as	  the	  bioactive	  effector	  in	  this	  study	  (Webb	  





Figure	  1.7	  Association	  of	   changes	   in	   plasma	  NOx	   levels	  with	   SBP.	   Changes	   in	   plasma	  NOx	  
levels	  and	  SBP	  over	  24	  h	  after	  dietary	  NO3
-­‐	  ingestion	  (~22.5	  mmol)	  showing	  changes	  in	  SBP	  
to	  baseline	  (lower	  y-­‐	  axis),	  plasma	  NO2
-­‐	  (upper	  right	  y-­‐axis)	  and	  plasma	  NO3
-­‐	  (upper	   left	  y-­‐
axis)	   levels.	   (Data	  adapted	  with	  permission	   from	  Webb	  et	  al.,	   2008a).	   (NO3
-­‐=nitrate;	  NO2
-­‐
=nitrite;	  SBP=systolic	  blood	  pressure).	  
	  	  	  	  	  	  NO3
-­‐,	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  NO2
-­‐,	  	  	  	  	  	  	  	  	  	  	  	  	  	  SBP.	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Importantly,	   these	   effects	   of	   dietary	   NO3
-­‐	   appear	   to	   be	   sustained	   over	   longer	  
periods	   of	   time	   in	   healthy	   subjects.	   Comparison	   of	   the	   effects	   of	   a	   traditional	  
Japanese	   diet,	   which	   is	   commonly	   rich	   in	   NO3
-­‐	   (~18	   mmol/day	   NO3
-­‐),	   with	   a	  
relatively	   low	   NO3
-­‐	   containing	   control	   diet	   (~3.5	   mmol/day	   NO3
-­‐)	   in	   a	   cross-­‐over	  
study	  lasting	  10	  days	  for	  each	  dietary	  intervention,	  demonstrated	  significantly	  lower	  
DBP	  (decrease	  of	  4.5mmHg)	  on	  the	  high-­‐NO3
-­‐	  diet	   in	  25	  healthy	  Japanese	  subjects	  
(Sobko	  et	  al.,	  2010).	  Similarly,	  dietary	  NO3
-­‐	  (as	  beetroot	  juice,	  500	  mL	  providing	  ~5.2	  
mmol/day	  NO3
-­‐	   for	   15	   days)	   lowered	   BP	   acutely	   in	   healthy	   subjects,	   and	   the	   BP-­‐
lowering	  effects	  were	  sustained	  up	   to	  15	  days	  compared	   to	  control	   (Vanhatalo	   et	  
al.,	  2010).	  	  
	  
Whilst	   these	   studies	   suggest	   there	   is	   little	   tolerance	   to	   the	  effect	  of	  dietary	  NO3
-­‐,	  
this	  has	  not	  been	  established	  definitely.	  However,	  there	  is	  supportive	  evidence	  that	  
there	   is	  no	   tolerance	   to	   systemic	  elevations	  of	  NO2
-­‐	   in	   the	  circulation,	  which	   is	  of	  
critical	  importance	  as	  the	  effects	  of	  NO3
-­‐	  are	  mediated	  by	  the	  NO2
-­‐	  anion.	  
	  
In	   non-­‐human	   primates	   that	   received	   a	   continuous	   background	   infusion	   of	   NO2
-­‐	  
(0.18	  μmol/kg/hr),	   repeated	  daily	  bolus	  administration	  of	  a	  relatively	  high	  dose	  of	  
NaNO2	  (0.17	  mmol/kg)	  caused	  decreases	  in	  MAP	  of	  ~18	  mmHg	  that	  did	  not	  diminish	  
over	  2	  weeks	  (Dejam	  et	  al.,	  2007)	  confirming	  a	  lack	  of	  tachyphylaxis	  to	  the	  effects	  of	  
sustained	   elevation	   of	   NO2
-­‐.	   This	   lack	   of	   tolerance	   to	   the	   vasodilatory	   and	   BP-­‐
lowering	  effects	  of	  sustained	  elevations	  of	  NO2
-­‐	  levels	  confirms	  earlier	  reports	  of	  a	  
lack	   of	   tolerance	   to	   prolonged	  NO2
-­‐	   administration.	   In	   hypertensive	   patients	  who	  
were	   treated	   with	   stable	   doses	   of	   NO2
-­‐,	   thrice	   daily,	   for	   periods	   of	   more	   than	   2	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weeks,	   there	   was	   no	   diminution	   of	   the	   hypotensive	   effects	   thereof	   (Matthew,	  
1909).	  Similarly,	   in	  healthy	  subjects,	  oral	  bolus	  doses	  of	  NO2
-­‐	   (2.2-­‐7	  mmol	  NaNO2)	  
produced	   similar	   BP	   reductions	   before	   and	   after	   a	   period	   of	   sustained	   oral	  
administration	  of	  NO2
-­‐	  (4-­‐5	  days)	  (Crandall	  Jr	  et	  al.,	  1931).	  
	  
	  These	   effects	   contrast	   to	   the	   tolerance	   that	   affects	   the	   clinical	   utility	   of	   organic	  
nitrites	   and	   nitrates	   already	   discussed	   (section	   1.4.1.1).	   However,	   in	   the	   previous	  
report,	   once	   tolerance	   to	   the	   headache-­‐inducing	   properties	   of	   an	   organic	   nitrate	  
(ethylene	   glycol	   dinitrate)	  was	   established	   through	   prolonged	   administration,	   this	  
prevented	  BP	  lowering	  with	  an	  inorganic	  NO2
-­‐	  bolus	  that	  was	  apparent	  prior	  to	  the	  
acquired	  tolerance	  (Crandall	  Jr	  et	  al.,	  1931).	  This	  suggests	  that	  tolerance	  formation	  
to	   organic	   nitrates	   could	   affect	   cross-­‐tolerance	   to	   the	   effects	   of	   NO2
-­‐.	   However,	  
more	  detailed	  and	  modern	  investigations	  of	  the	  potential	  cross-­‐tolerance	  between	  
organic	  nitrites	  and	  nitrates	  and	  inorganic	  NO2
-­‐	  have	  not	  been	  performed	  to	  date.	  	  
	  
	  
Thus,	   the	   accumulation	   of	   these	   evidences	   suggest	   that	   there	   is	   a	   functional	  
pathway	   for	   the	   sequential	   reduction	   of	  NO3
-­‐	   to	  NO2
-­‐	   and	   thence	   to	  NO	  which	   is	  






Figure	   1.8	   Entero-­‐salivary	   circulation.	   After	   ingestion	   of	   oral	   inorganic	   NO3
-­‐	   (1),	   NO3
-­‐	   is	  
swallowed	   and	   enters	   the	  GI	   tract	   (2),	  where	   it	   is	   then	   absorbed	   and	   accumulates	   in	   the	  
circulation	  (3).	  Approximately	  75%	  of	   ingested	  NO3
-­‐	   is	  excreted	  via	  the	  kidneys	  (4)	  and	  the	  
remaining	  25%	  concentrated	   in	   salivary	  glands	   (5).	   This	  NO3
-­‐	   enters	   the	   saliva	  where	   it	   is	  
reduced	  to	  NO2
-­‐	  by	  oral	  bacteria	  (6).	  NO2
-­‐	  is	  then	  swallowed	  thereby	  entering	  the	  GI	  tract	  (7)	  
and	   subsequently	   resulting	   in	   the	  accumulation	  of	  NO2
-­‐	   in	   the	   circulation	   (8).	  Once	  within	  
the	  circulation,	  NO2
-­‐	  is	  reduced	  to	  NO	  in	  the	  vasculature	  where	  it	  activates	  sGC	  resulting	  in	  
bioactivity.	   (GI=gastro-­‐intestinal;	   NO3
-­‐=nitrate;	   NO2




However,	  what	  is	  currently	  unknown	  is	  whether	  the	  effects	  of	  NO3
-­‐	  either	  given	  via	  
dietary	  or	  supplementary	  means	  are	  dose-­‐dependent	   in	  terms	  of	  BP	  decreases;	  or	  
whether	  NO	  actually	  mediates	   these	  effects.	   In	  addition,	  although	  the	   importance	  
of	   the	   entero-­‐salivary	   circulation	   after	   NO3
-­‐	   supplementation	   has	   been	  
demonstrated,	   NO3
-­‐	   formed	   from	   NO	   and	   NO2
-­‐	   oxidation	   will	   also	   undergo	  
recirculation,	  and	  thus	  may	  be	  contributing	  to	  vasoregulation	  and	  BP	  control	  under	  
basal	  conditions	   (i.e.	  without	  supplemental	   inorganic	  or	  dietary	  NO3
-­‐)	  and	  this	  has	  
not	  been	  studied	  to	  date.	  Although	  the	  first	  clinical	  applications	  of	  NO3
-­‐	  therapy	  for	  
BP	   control	   in	   man	   have	   taken	   place	   in	   healthy	   subjects,	   it	   is	   currently	   unclear	  
whether	   dietary	   or	   supplementary	   NO3
-­‐	   would	   function	   similarly	   in	   hypertensive	  
subjects.	  	  
	  
Thus	  the	  aims	  of	  this	  thesis	  are	  to	  investigate:	  
1. Whether	   inorganic	   NO3-­‐	   supplementation	   acts	   similarly	   to	   dietary	   NO3-­‐	   in	  
healthy	  subjects,	  with	  respect	  to	  changes	  in	  plasma	  NOx	  levels	  and	  BP	  
2. Whether	  the	  BP-­‐lowering	  effects	  of	  inorganic	  NO3-­‐	  are	  dose-­‐dependent	  
3. The	   importance	   of	   the	   entero-­‐salivary	   circulation	   on	   basal	   plasma	   NO2-­‐	  
levels	  and	  BP	  in	  healthy	  subjects.	  
4. Whether	  dietary	  NO3-­‐	  ingestion	  has	  similar	  effects,	  as	  in	  healthy	  subjects,	  on	  












All	   studies	   were	   performed	   with	   local	   Research	   Ethics	   Committee	   approval	  
(05/Q0512/145	  &	  08/H0703/91)	  and	  were	  conducted	  in	  the	  clinical	  research	  facility	  
of	   the	  William	   Harvey	   Research	   Institute	   and	   were	   conducted	   in	   a	   temperature-­‐
controlled	   environment	   (22-­‐24oC).	   For	   all	   studies,	   subjects	   attended	   clinic	  
appointments	   following	   an	  overnight	   fast	   and	  adherence	   to	   a	   low-­‐NOx	   containing	  
diet	  for	  the	  preceding	  24	  h	  prior	  to	  the	  visit,	  except	  for	  any	  interventions	  provided.	  
Subjects	   were	   provided	   with	   a	   dietary	   information	   sheet	   to	   aid	   food	   choices.	  
Subjects	   were	   given	   a	   low-­‐NOx	   containing	   lunch	   (consisting	   of	   a	   hard-­‐cheese	  
sandwich	  on	  brown	  bread)	  midway	  through	  the	  study	  if	  it	  was	  longer	  than	  4	  h.	  
	  
2.1	  Subjects	  
All	  subjects	  gave	  informed,	  written	  consent.	  	  
	  
2.1.1	  Healthy	  subjects	  
Healthy	  subjects	  were	  recruited	  by	  means	  of	  word	  of	  mouth,	  by	  poster	  advertising	  
and	  by	  advertising	  on	   the	  Vascular	  Pharmacology	  webpage	  of	   the	  William	  Harvey	  
Research	  Institute	  website	  (http://www.whri.qmul.ac.uk/staff/Ahluwalia.html).	  
	  
The	  inclusion	  criteria	  for	  healthy	  subjects	  in	  all	  studies	  were:	  	  
1. Healthy	  male	  or	  female	  adult	  of	  18-­‐45	  years	  of	  age.	  
2. Body	  mass	  index	  (BMI)	  between	  18-­‐40	  kg/m2.	  




2.1.2	  Hypertensive	  subjects	  
Hypertensive	  subjects	  were	  recruited	  from	  the	  outpatient	  department	  of	  Barts	  and	  
the	   London	   Centre	   of	   Excellence	   in	   Hypertension	   and	   by	   means	   of	   poster	   and	  
newspaper	  advertising.	  
	  
	  The	  inclusion	  criteria	  for	  hypertensive	  patients	  were:	  
1. Male	  and	  females	  between	  18	  and	  85	  years	  of	  age,	  inclusive.	  
2. To	  be	  eligible,	  female	  subjects	  required	  to	  state	  that	  they	  are	  not	  pregnant,	  
and	  will	  not	  become	  pregnant	  during	  the	  course	  of	  the	  study.	  
3. BMI	  between	  18	  and	  40	  kg/m2.	  
4. Able	   to	   understand	   and	   comply	   with	   protocol	   requirements,	   instructions	  
and	  protocol-­‐stated	  restrictions.	  
5. Grade	   1	   hypertensive	   defined	   as:	   SBP	   140-­‐159	   or	   DBP	   90-­‐99	   mmHg	  
(determined	  by	  24	  h	  ambulatory	  BP	  (ABP)	  monitoring).	  
6. No	  systemic	  medication	  (other	  than	  the	  oral	  contraceptive	  pill).	  
	  
The	  exclusion	  criteria	  for	  hypertensive	  patients	  were:	  
1. Evidence	   on	   examination	   or	   electrocardiography	   of	   hypertensive	   target	  
organ	  damage.	  
2. History	   of	   symptomatic	   ischaemic	   heart	   disease,	   stroke,	   or	   other	   known	  
atherosclerotic	  disease.	  
3. History	   of	   chronic	   viral	   hepatitis	   (including	   presence	   of	   hepatitis	   B	   surface	  
antigen	  or	  hepatitis	  C	  antibody),	  or	  other	  chronic	  hepatic	  disorders.	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4. History	   of	   increased	   liver	   function	   tests	   due	   to	   acute	   or	   chronic	   liver	  
conditions	   (any	   liver	   enzymes	   >3x	   above	   the	   upper	   limit	   of	   normal	   or	  
bilirubin	  >1.5x	  above	  the	  upper	  limit	  of	  normal).	  
5. Chronic	  kidney	  disease,	  with	  estimated	  GFR	  of	  <50	  mL/min.	  
6. Current	  poorly	  controlled	  diabetes	  mellitus,	  defined	  as	  glycated	  Hb	  >10%	  at	  
screening.	  
7. Subjects	   with	   LDL-­‐cholesterol	   >7.5	   mmol/L	   or	   fasting	   triglyceride	   level	   >6	  
mmol/L.	  
8. History	  of	  heart	  failure	  defined	  as	  New	  York	  Heart	  Association	  class	  II-­‐IV	  or	  
those	   with	   known	   severe	   left	   ventricular	   systolic	   dysfunction	   (ejection	  
fraction	  <30%	  on	  echocardiography)	  regardless	  of	  symptomatic	  status.	  
9. History	   of	   malignancy	   within	   the	   past	   5	   years,	   other	   than	   non-­‐melanoma	  
skin	  cancer.	  
10. Subjects	   with	   rheumatoid	   arthritis,	   connective	   tissue	   disorders	   and	   other	  
conditions	   known	   to	   be	   associated	   with	   chronic	   inflammation	   (e.g.	  
inflammatory	  bowel	  disease).	  
11. Current	   life-­‐threatening	   conditions	   (e.g.,	   very	   severe	   chronic	   airways	  
disease,	   life-­‐threatening	  arrhythmias	  etc.)	   that	  may	  prevent	  a	  subject	   from	  
completing	  the	  study.	  
12. Subjects	  with	  any	  acute	  infection,	  or	  significant	  trauma	  (burns,	  fractures).	  
13. Subjects	  who	  have	  donated	  more	  than	  500	  mL	  of	  blood	  within	  56	  days	  prior	  
to	  the	  study	  commencement.	  
14. Use	  of	  an	   investigational	  device	  or	   investigational	  drug	  within	  30	  days	  or	  5	  
t1/2	  (whichever	  is	  the	  longer)	  preceding	  the	  first	  dose	  of	  study	  medication.	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15. Subjects	  who	  will	  commence	  or	  who	  are	  likely	  to	  commence	  treatment	  with	  
NSAIDs	  from	  screening	  until	  study	  completion.	  
16. Any	   non-­‐stable	   dosing	   of	   ongoing	   medication	   regimens	   throughout	   the	  
study	  trial.	  	  
17. History	  of	  alcohol	  or	  drug	  abuse	  within	  the	  past	  6	  months.	  
18. The	  subject	  has	  a	  three-­‐month	  prior	  history	  of	  regular	  alcohol	  consumption	  
exceeding	  an	  average	  weekly	  intake	  of	  >28	  units	  (or	  an	  average	  daily	  intake	  
of	  greater	  than	  3	  units)	  for	  males,	  or	  an	  average	  weekly	  intake	  of	  >21	  units	  
(or	   an	   average	   daily	   intake	   of	   greater	   than	   2	   units)	   for	   females	   (1	   unit	   is	  
equivalent	  to	  a	  half-­‐pint	  (284	  mL)	  of	  beer/lager;	  25mL	  measure	  of	  spirits	  or	  
125	  mL	  of	  wine);	  or	  a	  positive	  alcohol	  breath	  test	  at	  the	  screening	  visit.	  
19. A	   positive	   urine	   test	   for	   drugs	   of	   abuse	   at	   screening	   or	   prior	   to	   study	  
medication	  administration.	  
20. Any	   other	   subject	   whom	   the	   investigator	   deems	   unsuitable	   for	   the	   study	  
(e.g.,	   due	   to	   either	   medical	   reasons,	   laboratory	   abnormalities,	   expected	  
study	  medication	  non-­‐compliance,	  or	  subject’s	  unwillingness	  to	  comply	  with	  
all	  study-­‐related	  study	  procedures).	  
	  
2.2	  Interventions	  
All	  study	  interventions	  were	  kept	  in	  a	  temperature-­‐controlled	  refrigerator	  (4-­‐7oC)	  as	  
per	  manufacturers’	   recommendations.	   All	   capsules	  were	   taken	  with	   500	  mL	   low-­‐
NOx	   containing	   water	   (purchased	   from	   Zepbrook	   Ltd,	   London,	   UK)	   and	   a	   slice	   of	  




Subjects	   were	   randomly	   assigned	   to	   either	   intervention	   using	   a	   random	   binary	  
number	  table	  (http://www.random.org).	  
	  
2.4	  BP	  measurement	  
BP	   and	   heart	   rate	   (HR,	  measured	   as	   beats	   per	  min	   (bpm))	   were	  measured	   in	   all	  
studies	  using	  digital,	  oscillometric	  devices	  that	  had	  undergone	  British	  Hypertension	  
Society	  (BHS)	  validation	  (http://www.bhsoc.org/blood_pressure_list.stm).	  	  
	  
2.4.1	  Clinic	  BP	  
BP	   and	   HR	   were	   measured	   according	   to	   BHS	   guidelines	   (Williams	   et	   al.,	   2004).	  
Subjects	  were	   seated	   in	  a	  quiet,	   temperature-­‐controlled	  environment	  and	  BP	  and	  
HR	   readings	   were	   taken	   in	   triplicate	   using	   a	   calibrated	   Omron	   715IT	   (Omron	  
Corporation,	  Tokyo,	  Japan)	  and	  an	  appropriately	  sized	  cuff.	  The	  2nd	  and	  3rd	  readings	  
were	  averaged	  to	  determine	  clinic	  BP	  and	  HR	  at	  each	  time-­‐point.	  	  
	  
For	   establishment	   of	   all	   baseline	  measurements,	   subjects	   were	   seated	   for	   5	  min	  
followed	  by	  BP	  and	  HR	  measurements	  in	  triplicate	  every	  15	  min	  for	  1	  h.	  The	  mean	  
of	   the	  averaged	  values	   from	  each	  of	   the	  5	   time-­‐points	  within	   this	  1	  h	  period	  was	  
taken	   to	   represent	   baseline	   BP	   and	   HR.	   In	   studies	   where	   an	   intervention	   was	  
employed,	   further	  measurements	  were	  again	   taken	   in	   triplicate	  at	   specified	   time-­‐
points.	   Both	   the	   investigator	   and	   subject	   were	   blind	   to	   these	   measurements	   by	  
means	  of	  laminating	  coverings	  attached	  to	  the	  printer	  and	  machine	  (Figure	  2.1).	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Figure	   2.1	   Photograph	   of	   modified	   BP	   machine	   and	   printer;	   to	   obscure	   readings	   from	  
investigator	  and	  subject.	  (BP=blood	  pressure;	  HR=heart	  rate).	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2.4.2	  24	  h	  ABP	  
24	  h	  ABP	  and	  HR	  were	  determined	  using	  a	  calibrated	  Spacelabs	  90207	  ABP	  monitor	  
(Spacelabs	  Healthcare,	  Issaquah,	  USA).	  The	  standard	  protocol	  used	  for	  all	  24	  h	  ABP	  
measurements	   was	   used	   of	   1	   reading	   every	   20	   min	   between	   0700-­‐2300	   and	   1	  
reading	  every	  1	  h	  between	  2300-­‐0700.	  Proprietary	  software	  was	  used	  to	  download	  
readings	   and	   produce	   24	   h,	   daytime	   (0700-­‐2300)	   and	   nighttime	   (2300-­‐0700)	   raw	  
and	  mean	  ABP	  and	  HR	  readings	  (90256	  ABP	  Report	  Management	  System,	  Spacelabs	  
Healthcare,	  Issaquah,	  USA).	  	  
	  
ABP	   measurements	   reported	   for	   hypertensive	   subjects	   at	   screening	   have	   been	  
adjusted	  upwards	  by	  10	  mmHg	  systolic	  and	  5	  mmHg	  diastolic	  as	  per	  BHS	  guidelines	  
(Williams	   et	   al.,	   2004).	   Subjects	   were	   defined	   for	   all	   purposes	   as	   having	  
hypertension	   if	   the	   corrected	   daytime	   mean	   systolic	   ABP	   was	   >140	   mmHg	   or	  
diastolic	  ABP	  was	  >90	  mmHg	  as	  per	  BHS	  guidelines	  (Williams	  et	  al.,	  2004).	  
	  
ABP	   results	   reported	   in	   the	   results	   section	   in	   healthy	   subjects	   in	   the	   oral	   NO3
-­‐	  
reductase	  study	  (chapter	  4)	  have	  not	  been	  adjusted.	  	  
	  
2.4.3	  Home	  BP	  
Subjects	  were	  instructed,	  in	  person,	  on	  the	  proper	  use	  of	  a	  calibrated	  Omron	  715IT	  
(Omron	  Corporation,	  Tokyo,	  Japan)	  and	  were	  provided	  with	  an	  appropriately	  sized	  
cuff.	   Subjects	  were	   instructed	   to	   perform	  home	  BP	  measurements	   in	   triplicate	   at	  
the	  same	  time	  daily.	  Results	  were	  self-­‐recorded	   into	  provided	  diaries.	  The	  2nd	  and	  
3rd	  readings	  at	  each	  time-­‐point	  were	  averaged	  to	  determine	  mean	  daily	  home	  BP.	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2.5	  Measurement	  of	  arterial	  stiffness	  
A	   Vicorder	   device	   (Skidmore	   Medical	   Limited,	   Bristol,	   UK)	   was	   used	   to	  
simultaneously	   record	   the	  pulse	  wave	   from	   the	   carotid	   and	   femoral	   site	   using	   an	  
oscillometric	  method	  	  (Hickson	  et	  al.,	  2009).	  A	  small,	  inflatable	  neck	  pad	  was	  placed	  
directly	  over	  a	  single	  carotid	  artery	  and	  secured	  around	  the	  neck	  by	  a	  Velcro™	  tab.	  
A	  further	  cuff	  was	  similarly	  placed	  around	  the	  subject’s	  ipsilateral	  upper	  thigh.	  Both	  
carotid	   and	   femoral	   cuffs	   were	   inflated	   automatically	   to	   65	   mmHg	   and	   the	  
corresponding	  oscillometric	   signal	   from	  each	  cuff	  was	  digitally	  analysed	   to	  extract	  
the	  pulse	  time	  delay.	  The	  distance	  between	  the	  sternal	  notch	  and	  the	  thigh	  cuff	  was	  
measured	   and	   used	   as	   a	   standard	   estimate	   for	   the	   aortic	   length.	   From	   these	  
measurements	   aortic	   pulse	   wave	   velocity	   (PWV),	   which	   is	   the	   gold-­‐standard	  
measurement	  for	  arterial	  stiffness	  (Laurent	  et	  al.,	  2006),	  was	  derived	  according	  to	  




Figure	  2.2	  Determination	  of	  PWV	  using	  Vicorder	  device.	  Carotid	  and	   femoral	  oscillometric	  
signals	  are	  detected	  and	  the	  time	  delay	  from	  the	  foot	  of	  carotid	  pulse	  waveform	  to	  foot	  of	  
femoral	  pulse	  waveform	  is	  used	  as	  the	  pulse	  transit	  delay	  (t).	  Estimation	  of	  aortic	  length	  by	  
sternal-­‐femoral	  distance	  is	  used	  as	  distance	  (d).	  Aortic	  distance/	  pulse	  transit	  delay	  =	  aortic	  
PWV.	  (PWV=pulse	  wave	  velocity).	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2.6	  Blood	  sampling	  
In	  subjects	  in	  whom	  more	  than	  one	  blood	  sample	  was	  to	  be	  taken	  in	  the	  same	  day,	  
a	  21-­‐gauge	  Y-­‐can	  cannula	  (Beldico,	  Marche-­‐en-­‐Famenne,	  Belgium)	  was	  inserted	  into	  
an	   antecubital	   or	   dorsal	   hand	   vein	   prior	   to	   any	   intervention,	   and	   again	   at	   24	  h	   if	  
required,	   and	   secured	   to	   skin.	   Blood	   samples	   were	   taken	   atraumatically,	   via	   the	  
cannula	   or	   by	   standard	   venepuncture,	   into	   pre-­‐chilled	   Lithium-­‐heparin	   vacutainer	  
tubes	   (Becton,	  Dickinson	  &	  Co,	   Franklin	   Lakes,	  USA)	   and	   immediately	   centrifuged	  
(Eppendorf	  chilled	  centrifuge	  5702R,	  Eppendorf	  UK	  Limited,	  Cambridge,	  UK)	  (1300g,	  
4oC,	  10	  min).	  Plasma	  was	  separated	  and	  stored	  at	  -­‐80oC	  until	  measurement	  of	  NOx	  
and	  cGMP	  levels	  were	  undertaken	  (see	  section	  2.10).	  Bloods	  taken	  at	  screening	  for	  
entry	   into	   the	  hypertensive	   study	   (i.e.	   fasting	   lipids,	   glycated	  Hb)	  were	   sent	   to	  Dr	  
Phillip	  Miall,	  Consultant	  in	  Clinical	  Biochemistry,	  Department	  of	  Biochemistry,	  Barts	  
and	  the	  London	  NHS	  Trust	  and	  were	  processed	  as	  per	  standard	  clinical	   laboratory	  
methods.	  
	  
2.7	  Saliva	  sampling	  
Unstimulated,	   whole	   saliva	   samples	   were	   collected	   into	   ice-­‐chilled,	   sterile	  
eppendorfs	  and	  stored	  at	  -­‐80oC	  until	  analysis	  at	  a	  later	  date	  for	  assessment	  of	  NOx	  
levels	  by	  ozone	  chemiluminescence	  (see	  section	  2.10).	  	  
	  
2.8	  Urine	  sampling	  
Mid-­‐stream	   urine	   samples	   were	   collected	   into	   sterile	   containers	   and	   an	   aliquot	  
stored	  at	  -­‐80oC	  until	  analysis	  at	  a	  later	  date	  for	  assessment	  of	  NOx	  levels	  by	  ozone	  
chemiluminescence	  (see	  section	  2.10).	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2.9	  Measurement	  of	  oral	  NO3
-­‐	  reductase	  activity	  
Oral	   NO3
-­‐	   reductase	   activity	   was	   assessed	   by	   modification	   to	   a	   previously	  
established	  protocol	  (Sasaki	  et	  al.,	  1981;	  Doel	  et	  al.,	  2005).	  Subjects	  were	  instructed	  
to	  hold	  10mL	  of	  NOx-­‐free	  water	  (Millipore	  Corporation,	  Billerica,	  USA)	  for	  1,	  3	  and	  5	  
min	  to	  establish	  baseline	  NO3
-­‐	  reductase	  activity.	  Following	  this,	  matched	  volumes	  
of	  KNO3	  solutions	  (Martindale	  Pharmaceuticals,	   Ipswich,	  UK)	  were	  held	   in	  the	  oral	  
cavity	  for	  1,	  3	  and	  then	  5	  min	  in	  a	  randomized	  order.	  At	  the	  specified	  time	  (1-­‐5	  min),	  
the	   total	   oral	   contents	   were	   collected	   into	   a	   sterile	   ice-­‐chilled	   falcon	   tube,	  
centrifuged	  (5500g,	  4oC,	  10min)	  and	  the	  supernatant	  collected	  and	  stored	  at	  -­‐80oC	  
until	  NO2
-­‐	  levels	  were	  determined	  by	  ozone	  chemiluminescence.	  Oral	  cavities	  were	  
rinsed	   with	   10mL	   NOx-­‐free	   water	   in	   between	   every	   experimental	   solution.	   The	  
concentrations	  of	  NO3
-­‐	  solutions	  used	  were	  800	  μM,	  reflecting	  ~near	  physiological	  
salivary	  [NO3
-­‐] (Lundberg	  and	  Govoni,	  2004)	  and	  8	  mM,	  reflecting	  a	  10-­‐fold	  higher	  
salivary	   [NO3
-­‐]	   that	   approximates	   the	   salivary	   [NO3
-­‐]	   after	   ingestion	  of	   a	  NO3
-­‐-­‐rich	  
meal (Lundberg	  and	  Govoni,	  2004;	  Bahra	  et	  al.,	  2012).	  
	  
2.10	  Measurement	  of	  NOx	  levels	  by	  ozone	  chemiluminescence	  
Prior	  to	  ozone	  chemiluminescence,	  plasma	  samples	  were	  filtered	  by	  centrifugation	  
(15000g,	   4oC,	   60min)	   using	   Microcon®	   Ultracel	   YM-­‐3KDa	   filters	   (Millipore	  
Corporation,	   Billerica,	   USA)	   that	   had	   been	   washed	   2	   times	   in	   NOx-­‐free	   water	   to	  
remove	  any	  potential	  NOx	  contamination.	  	  
	  
NOx	  levels	  in	  the	  plasma	  filtrate,	  saliva	  and	  urine	  samples	  were	  determined	  by	  liquid	  
phase	   ozone	   chemiluminescence	   (Downes	   et	   al.,	   1976);	   a	   powerful,	   quantitative	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analytical	   technique	   for	   measuring	   NO	   species	   in	   biological	   fluids	   (Cox,	   1980;	  
Ignarro	  et	  al.,	  1993).	  
	  
The	   apparatus	   consists	   of	   two	   distinct	   components	   (see	   Figure	   2.3	   below):	   the	  
purge	   vessel	   (reaction	   chamber)	   and	   the	  NO	   chemiluminescence	   analyser.	  Within	  
the	  purge	  vessel,	  gaseous	  N2	  is	  continuously	  bubbled	  to	  render	  the	  chamber	  anoxic.	  
Here,	   standards	   and	   biological	   samples	   containing	   NOx	   are	   reduced	   to	   NO	   in	   an	  
equimolar	   fashion.	   The	  NO	  produced	  by	   these	   reactions	   is	   carried	   in	   the	   gaseous	  
phase	   through	   the	   vessel	   into	   the	   NO	   chemiluminescence	   analyser	   (NOA	   280i,	  
Sievers,	  Manchester,	  UK),	  where	  it	  reacts	  with	  ozone.	  Light	  is	  emitted	  as	  a	  result	  of	  
the	   chemical	   reaction	   (Equation	   2.1),	   and	   is	   detected	   by	   the	   analyser,	   thence	  
producing	  a	  digital	  signal	  corresponding	  to	  NO	  concentration	  (therefore	  NOx	  levels	  
as	   appropriate);	   NOx	   levels	   were	   calculated	   by	   comparison	   to	   a	   standard	   curve	  
generated	  daily	  from	  known	  standards.	  	  
	  
ozone	   	   nitric	  oxide	   oxygen	   nitrogen	  dioxide*	   nitrogen	  dioxide	   light	  
O3	   +	   NO	   ⇒ O2	   +	   NO2*	   ⇒ NO2	   +	   hv	  
Equation	   2.1	   Reaction	   of	   ozone	   and	   NO	   to	   chemiluminescent	   light.	   (NO=nitric	   oxide;	  




Figure	   2.3	   Schema	   of	   ozone	   chemiluminescence	   apparatus.	   (KI=potassium	   iodide;	  
N2=nitrogen;	   NaOH=sodium	   hydroxide;	   NO=nitric	   oxide;	   O2=oxygen;	   O3=ozone;	  
VCl3=vanadium	  (III)	  chloride).	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To	   determine	   total	   [NOx],	   samples	   were	   incubated	   in	   a	   strongly	   reducing	  
environment	   using	   0.1	   M	   vanadium	   (III)	   chloride	   (VCl3)	   in	   1	   M	   hydrochloric	   acid	  
refluxing	  at	  95oC	  under	  N2	  which	  results	  in	  a	  sequential	  reduction	  of	  all	  NO3
-­‐	  to	  NO2
-­‐,	  
and	  then	  all	  NO2
-­‐	  to	  NO	  (Cox,	  1980)	  (Equations	  2.2-­‐2.3).	  	  
	  
nitrate	   	   protons	   	   electrons	   	   nitric	  oxide	   	   water	  
NO3
-­‐	   +	   4	  H+	   +	   3	  e-­‐	   ⇒ NO	   +	   2	  H20	  
Equation	   2.2	   Reduction	   of	   NO3
-­‐	   by	   VCl3	   to	   produce	   NO.	   (NO=nitric	   oxide;	   NO3
-­‐=nitrate;	  
VCl3=vanadium	  (III)	  chloride).	  
	  
nitrite	   	   protons	   	   electron	   	   nitric	  oxide	   	   water	  
NO2
-­‐	   +	   2	  H+	   +	   e-­‐	   ⇒ NO	   +	   2	  H20	  
Equation	   2.3	   Reduction	   of	   NO2
-­‐	   by	   VCl3	   to	   produce	   NO.	   (NO=nitric	   oxide;	   NO2
-­‐=nitrite;	  
VCl3=vanadium	  (III)	  chloride).	  
	  
[NO2
-­‐]	   of	   samples	   was	   determined	   by	   addition	   of	   samples	   to	   milder	   reducing	  
conditions,	   1.5%	   potassium	   iodide	   (KI)	   in	   glacial	   acetic	   acid	   under	   N2	   at	   room	  
temperature	  (equation	  2.4),	  which	  is	  unable	  to	  reduce	  NO3
-­‐	  (Cox,	  1980).	  	  
	  
nitrate	   	   protons	   	   electron	   	   nitric	  oxide	   	   water	  
NO3
-­‐	   +	   2	  H+	   +	   e-­‐	   ⇒ NO	   +	   H20	  
Equation	   2.4	   Reduction	   of	   NO2





-­‐]	  was	  calculated	  by	  subtraction	  of	   [NO2
-­‐]	   from	  total	   [NOx]	  determined	  by	  the	  
above	   reactions.	  Typical	   standard	  curves	   for	   the	  analysis	  of	   total	   [NOx]	  and	   [NO2
-­‐]	  




Figure	   2.4	   Standard	   curve	   for	   determination	   of	   total	   NOx	   levels	   by	   ozone	  
chemiluminescence.	   Volumes	   (10-­‐50	   μL)	   of	   known	   standards	   of	   NaNO3	   (1-­‐100	   μM)	   were	  





Figure	   2.5	   Standard	   curve	   for	   determination	   of	   NO2
-­‐	   levels	   by	   ozone	   chemiluminescence.	  
Volumes	  (10-­‐50	  μL)	  of	  known	  standards	  of	  NaNO2	  (100	  nM-­‐10	  μM)	  were	  analysed	  to	  create	  
a	  standard	  curve	  daily.	  (NaNO2=sodium	  nitrite;	  NO2
-­‐=nitrite).	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In	  addition,	   I	  determined	   the	   levels	  of	   contamination	  of	  NOx	  as	  a	   consequence	  of	  
use	   of	   the	   commercially	   available	   blood	   tubes	   and	   ascertained	   a	   [NO2
-­‐]	  
contamination	   of	   102.0±10.3	   nM	   and	   [NO3
-­‐]	   contamination	   of	   1.7±0.1	   µM	   (n=20	  
tubes).	  
	  
2.11	  Measurement	  of	  cGMP	  levels	  
cGMP	   levels	   in	   samples	   were	   determined	   using	   an	   enzyme	   immunoassay	   (cGMP	  
Enzymeimmunoassy	   Biotrak	   System	   RPN226)	   according	   to	   the	   manufacturer’s	  
instructions	   (GE	   Healthcare,	   GE	   Healthcare,	   Little	   Chalfont,	   UK),	   using	   a	   96-­‐well	  
plate	   spectrophotometer.	   Thawed	   samples	   were	   incubated	   with	   a	   competitive,	  
non-­‐selective	  PDE	  inhibitor,	  3-­‐isobutyl-­‐1-­‐methylxanthine	  (IBMX,	  100μM)	  to	  prevent	  
cleavage	  of	  cGMP	   in	  plasma	  samples.	  The	  assay	   is	  based	  on	  competition	  between	  
unlabelled	  cGMP	  and	  a	  fixed	  quantity	  of	  peroxidase-­‐labelled	  cGMP,	  for	  binding	  sites	  
on	  a	   cGMP-­‐specific	  antibody	   (Figure	  2.6).	   Samples	  measured	  were	  compared	   to	  a	  




Figure	  2.6	  Schema	  of	  enzyme	  immunoassay	  for	  measurement	  of	  cGMP	  levels.	  (cGMP=cyclic	  




Figure	  2.7	  Standard	  curve	  for	  determination	  of	  cGMP	  levels.	  (%B/B0=%	  bound;	  cGMP=cyclic	  
guanosine	  monophosphate).	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2.12	  Measurement	  of	  biochemical	  indices	  
An	   aliquot	   of	   separated	   plasma	   was	   sent	   for	   commercial	   analysis	   (Quest	  
Diagnostics,	  UK)	   for	  determination	  of	  K+,	   chloride	   (Cl-­‐),	  HCO3
-­‐,	  urea	  and	  creatinine	  
levels.	  
	  
2.13	  Statistical	  analyses	  
All	  data	  are	  expressed	  as	  mean±standard	  error	  of	  the	  mean	  (SEM)	  and	  significance	  
accepted	   at	   p<0.05.	   Analysis	   was	   performed	   using	   GraphPad™	   Prism	   software	  
version	  5.0	  for	  Mac	  OsX.	  Statistical	  analyses	  were	  conducted	  blind	  to	  the	  treatment	  
groups.	  Power	  calculations	  were	  performed	  using	  G*Power	  v3.0	  and	  are	  presented	  
in	  the	  experimental	  protocols	  in	  each	  chapter.	  
	  
For	  BP	  measurements	  and	  plasma	  NOx	  levels	  (primary	  end-­‐points),	  paired	  Student’s	  
t-­‐tests	   and	   repeated-­‐measures	   2-­‐way	   ANOVA	   were	   used	   where	   appropriate.	  
Dunnett’s	  post-­‐hoc	  test	  was	  used	  for	  comparison	  to	  baseline	  measurements	  (mean	  
of	  1st	  h	  BP	  measurements	  or	  baseline	  plasma	  NOx	   levels)	  and	  Bonferroni	  post-­‐hoc	  
tests	   for	   comparison	  between	  groups	  at	   individual	   time-­‐points	   following	  either	  1-­‐
way	   or	   2-­‐way	   ANOVA	   as	   appropriate.	   For	   post-­‐hoc	   and	   primary	   analyses	   by	   sex,	  
unpaired	   Student’s	   t-­‐tests	   were	   used	   for	   baseline	   differences	   and	   one-­‐sample	  
Student	  t-­‐tests	  used	  for	  analysis	  of	  changes	  from	  baseline.	  
	  
For	   PWV	   and	   cGMP	   level	   measurements,	   repeated-­‐measures	   one-­‐way	   ANOVA	  
followed	  by	  Bonferroni	  post-­‐hoc	  tests	  for	  individual	  group	  comparisons	  were	  used.	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In	   all	   studies,	   determinations	   of	   correlations	   between	   baseline	   and	   changes	   in	  
plasma	  NOx,	  cGMP	  and	  K
+	   levels	  with	  baseline	  and	  changes	   in	  BP	  were	  performed	  
using	   the	   Pearson’s	   correlation	   coefficient	   analysis	   of	   least-­‐squares	   and	   are	  











Investigation	  of	  the	  effect	  of	  inorganic	  NO3
-­‐	  
salt	  supplementation	  on	  plasma	  NOx	  levels	  
and	  BP	  in	  healthy	  subjects	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3.1	  Introduction	  
Recently,	  our	  group	  has	  established	  in	  an	  open-­‐label	  study	  in	  healthy	  subjects	  that	  a	  
single	  dietary	  NO3
-­‐	  load	  (as	  beetroot	  juice,	  500mL,	  NO3
-­‐	  dose	  22.5	  mmol)	  lowers	  BP	  
over	  24	  h	  compared	  to	  water	  control,	  with	  peak	  BP	  reductions	  coinciding	  with	  peak	  
plasma	  NO2
-­‐	  levels	  at	  2.5-­‐3	  h	  post-­‐ingestion	  (Webb	  et	  al.,	  2008a).	  Changes	  in	  BP	  did	  
not	   correlate	   to	   changes	   in	   plasma	   NO3
-­‐	   levels	   but	   did	   correlate	   to	   changes	   in	  
plasma	   NO2
-­‐	   levels,	   implicating	   the	   NO2
-­‐	   anion	   as	   the	   functional	   mediator	   of	   the	  
dietary	   NO3
-­‐-­‐induced	   changes	   in	   BP.	   However,	   beetroot	   juice	   also	   contains	   a	  
number	  of	  other	  potentially	  beneficial	  nutrients	  and,	   in	  particular,	  abundant	  K+	  (in	  
this	  study,	  [K+]=	  93mM)	  (Webb	  et	  al.,	  2008a)	  and	  there	  is	  evidence	  that	  short-­‐term	  
K+	  supplementation	  can	  cause	  reductions	  in	  BP (He	  et	  al.,	  2005).	  	  
	  
Thus,	  the	  aim	  of	  the	  first	  study	  described	  in	  this	  chapter	  was	  to	  establish	  whether	  
administration	  of	  a	  NO3
-­‐	  salt	  might	  mimic	  the	  effect	  of	  beetroot	  juice.	  Secondly,	  for	  
inorganic	  or	  dietary	  NO3
-­‐	  to	  be	  useful	  as	  a	  potential	  treatment	  for	  BP	  or	  other	  CVDs,	  
it	   is	   important	   to	   determine	   whether	   the	   effects	   of	   NO3
-­‐	   are	   dose-­‐dependent.	  
Therefore,	   I	   also	   investigated	   the	   dose-­‐dependency	   of	   inorganic	   NO3
-­‐	  
supplementation	  or	  dietary	  NO3
-­‐	  supplementation	  in	  healthy	  subjects.	  	  
	  
3.2	  Protocols	  
There	  were	  3	  distinct	  sub-­‐studies	  with	  independent	  subject	  recruitment;	  each	  sub-­‐
study	   requiring	   2	   visits	   with	   a	   minimum	   of	   7	   days	   between	   each	   visit.	   Healthy	  
subjects	  were	  entered	  into	  one	  of	  3	  different	  sub-­‐studies	  described	  below.	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3.2.1	   Investigation	   of	   whether	   KNO3	   supplementation	   mimics	   the	   effects	   of	  
dietary	  NO3
-­‐	  on	  plasma	  NOx	  levels	  and	  BP	  (24	  mmol	  KNO3	  vs.	  KCl	  study)	  
Design:	   To	   assess	   whether	   KNO3	   supplementation	   mimics	   dietary	   NO3
-­‐	  
supplementation,	  a	  randomized,	  double-­‐blind,	  cross-­‐over	  study	  of	  KNO3	  compared	  
to	   matched	   amount	   of	   KCl	   placebo	   control	   was	   conducted.	   Subjects	   were	  
randomized	   to	   receive	  24	  mmol	  KNO3	  or	  24	  mmol	  KCl	   capsules	  with	  500	  mL	   low-­‐
NOx	  containing	  water	  ([NO3
-­‐]	  61.2±1.9	  μM;	  [NO2
-­‐]	  0.2±0.03	  μM),	  with	  at	  least	  7	  days	  
between	   each	   limb	   of	   the	   study.	   This	   dose	  was	   chosen	   to	   approximate	   the	   NO3
-­‐	  
dose	  used	  in	  a	  previous	  dietary	  NO3
-­‐	  intervention	  (Webb	  et	  al.,	  2008a).	  	  
	  
Power	   analysis:	   Power	   calculations	   for	   the	   24	   mmol	   KNO3	   vs.	   KCl	   study	   were	  
determined	  from	  the	  previous	  study	  with	  dietary	  NO3
-­‐	  (Webb	  et	  al.,	  2008a).	  In	  this	  
study	  ~22.5	  mmol	  dietary	  NO3
-­‐	   lowered	  BP	  at	  24	  h	  by	  ΔSBP=	  4.4	  mmHg	  (standard	  
deviation	   (SD)=	  5.5	  mmHg).	  Based	  on	   these	  values,	  with	  an	  α=0.05	  and	  1-­‐β=0.90,	  
n=19	  is	  required.	  2	  extra	  subjects	  were	  recruited	  to	  account	  for	  potential	  drop-­‐outs,	  
thus	  the	  final	  number	  recruited	  was	  n=21.	  
	  
Measurements:	  Following	  arrival	  in	  the	  clinic,	  clinic	  BP	  and	  HR	  were	  measured	  for	  1	  
h	   to	  establish	  baseline	  values	   (section	  2.4.1).	  Following	   this,	   subjects	   ingested	   the	  
randomized	   intervention	  with	  a	   light	  breakfast	  and	  500	  mL	  of	   low-­‐NOx	  containing	  
water.	   BP	   and	  HR	  were	  measured,	   and	  blood	   samples	   for	   plasma	  NOx	   and	   cGMP	  
analysis	  collected	  at	  specific	  time-­‐points	  over	  the	  following	  6	  h	  (section	  2.6).	  After	  
this	   time,	   the	   subjects	   left	   and	   then	   returned	   the	   following	   morning	   for	   24	   h	  
measurements	  (see	  Figure	  3.1).	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3.2.2	  Investigation	  of	  the	  dose-­‐response	  of	  inorganic	  NO3
-­‐	  supplementation	  
(Inorganic	  NO3
-­‐	  dose-­‐response	  study)	  
Design:	  To	  establish	  the	  dose-­‐dependent	  effects	  of	  inorganic	  NO3
-­‐	  supplementation,	  
a	   randomized,	   single-­‐blind	   (investigator	  blind),	   cross-­‐over	   study	  of	  different	  doses	  
of	   KNO3	   was	   conducted	   in	   healthy	   subjects	   for	   3	   h	   after	   capsule	   ingestion.	   This	  
duration	  was	  chosen	  since	  previous	  studies	  indicated	  that	  the	  peak	  effects	  occur	  by	  
this	   time	   after	  NO3
-­‐	   ingestion	   (Webb	   et	   al.,	   2008a).	   Subjects	  were	   randomized	   to	  
receive	  either	  4	  mmol	  or	  12	  mmol	  KNO3	  capsules	  with	  500	  mL	  low-­‐NOx	  containing	  
water	  ([NO3
-­‐]	  61.2±1.9	  μM;	  [NO2
-­‐]	  0.2±0.03	  μM),	  with	  at	  least	  7	  days	  between	  each	  
limb	  of	  the	  study.	  These	  doses	  were	  chosen	  to	  reflect	  half	  the	  dose	  used	  above	  and	  
a	  much	   lower	  NO3
-­‐	  dose	  that	  approximates	  to	  the	  ADI	  of	  NO3
-­‐	   (3.7	  mg/kg	  per	  day	  
(Speijers	  and	  van	  den	  Brandt,	  2003;	  European	  Food	  Safety	  Authority,	  2008)	  for	  a	  70	  
kg	  person	  ~4.2	  mmol).	  	  
	  
Power	  analysis:	  For	   the	  dose-­‐response	  study,	   the	  expectation	  was	  that	   the	   lowest	  
dose	  may	  not	   have	   any	   significant	   effects.	   It	  was	   hypothesized	   that	  with	   half	   the	  
dose	  given	  in	  the	  first	  24	  mmol	  cross-­‐over	  study	  (i.e.	  12	  mmol),	  that	  there	  would	  be	  
half	  the	  expected	  rise	  in	  plasma	  NO2
-­‐	  levels	  (expected	  peak	  Δ[NO2
-­‐]	  at	  3	  h	  would	  be	  
1.2	   μM,	   SD=	   0.8).	   Based	   on	   these	   values,	   with	   an	   α=0.05	   and	   1-­‐β=0.90,	   n=6	   is	  
required.	  	  
	  
Measurements:	  Following	  arrival	  in	  the	  clinic,	  clinic	  BP	  and	  HR	  were	  measured	  for	  1	  
h	   to	  establish	  baseline	  values	   (section	  2.4.1).	  Following	   this,	   subjects	   ingested	   the	  
randomized	   intervention	  with	  a	   light	  breakfast	  and	  500	  mL	  of	   low-­‐NOx	  containing	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water.	   BP	   and	   HR	   were	   measured,	   and	   blood	   samples	   for	   plasma	   NOx	   analysis	  
collected	  at	  specific	  time-­‐points	  over	  the	  following	  3	  h	  (section	  2.6)	  (see	  Figure	  3.1).	  
	  
3.2.3	  Investigation	  of	  the	  effect	  of	  a	  reduced	  dose	  of	  dietary	  NO3
-­‐	  on	  BP	  
(Dietary	  NO3
-­‐	  study)	  
Design:	  To	  investigate	  the	  dose-­‐dependent	  effects	  of	  dietary	  NO3
-­‐	  on	  BP	  in	  healthy	  
subjects,	   a	   randomized,	   open	   label,	   cross-­‐over	   study	   was	   conducted	   in	   healthy	  
subjects	   for	   3	   h	   after	   intervention,	   as	   this	   was	   the	   time	   take	   for	   peak	   effects	   to	  
occur	  after	  dietary	  NO3
-­‐	   ingestion	  (Webb	  et	  al.,	  2008a).	  Subjects	  were	  randomized	  
to	  receive	  either	  250	  mL	  dietary	  NO3
-­‐	  (reflecting	  half	  the	  dose	  of	  beetroot	  juice	  used	  
in	  Webb	   et	  al.,	   2008a)	  or	  matched	  volume	  of	   low-­‐NOx	  containing	  water	   (placebo,	  
[NO3
-­‐]	  61.2±1.9	  μM;	  [NO2
-­‐]	  0.2±0.03	  μM),	  with	  at	  least	  7	  days	  between	  each	  limb	  of	  
the	  study.	  
	  
Power	  analysis:	  Peak	  ΔSBP	  at	  2.5-­‐3h	  in	  Webb	  et	  al.,	  2008a	  was	  10.4	  mmHg,	  SD=8.	  A	  
reduced	  dose	  of	  dietary	  NO3
-­‐	  (~half	  of	  the	  dose)	  should	  theoretically	  provide	  ~half	  
the	   change	   in	   SBP	   and	   SD	   with	   an	   α=0.05	   and	   1-­‐β=0.90,	   n=9	   is	   required	   for	   the	  
dietary	  NO3
-­‐	  study	  in	  healthy	  subjects.	  
	  
Measurements:	  Following	  arrival	  in	  the	  clinic,	  BP	  and	  HR	  were	  measured	  for	  1	  h	  to	  
establish	   baseline	   values	   (section	   2.4.1).	   Following	   this,	   subjects	   ingested	   the	  
randomized	   intervention	   with	   a	   light	   breakfast.	   BP	   and	   HR	   were	   measured,	   and	  
blood	  samples	   for	  plasma	  NOx	  and	  cGMP	  analysis	  collected	  at	  specific	   time-­‐points	  




Figure	   3.1	   Timelines	   for	   healthy	   subject	   BP	   studies.	   (BP=blood	   pressure;	   KCl=potassium	  




3.3.1	  Baseline	  characteristics	  
There	  were	  no	  significant	  differences	  in	  the	  general	  characteristics	  of	  the	  individuals	  
recruited	  for	  the	  3	  separate	  sub-­‐studies	  or	  between	  the	  baseline	  BP	  in	  each	  limb	  of	  
each	  sub-­‐study	  (Table	  3.1).	  
	  







	   	   	   	  
Subjects	  (n)	   20	   6	   9	  
Age	  (years)	   22.5±0.9	   28.8±1.7	   25.1±1.1	  






Baseline	  SBP	  (mmHg)	  
(control	  limb)	  
112.9±3.9	   116.7±5.6	   120.7±3.0	  
Baseline	  SBP	  (mmHg)	  
(active	  limb)	  
110.1±3.4	   114.5±4.6	   120.6±4.1	  
Baseline	  DBP	  (mmHg)	  
(control	  limb)	  
68.6±2.0	   70.2±2.2	   71.3±2.2	  
Baseline	  DBP	  (mmHg)	  
(active	  limb)	  
70.1±2.3	   71.0±2.2	   70.9±2.5	  
Table	   3.1	   Demographics	   of	   recruited	   healthy	   subjects	   and	   baseline	   haemodynamic	  
parameters	  for	  the	  3	  distinct	  sub-­‐studies.	  Data	  are	  expressed	  as	  mean±SEM.	  (For	  inorganic	  
NO3
-­‐	   dose-­‐response	   study:	   control=4mmol	   KNO3;	   active=12mmol	   KNO3	   (BMI=body	   mass	  
index;	  DBP=diastolic	  blood	  pressure;	  KCl=potassium	  chloride;	  KNO3=potassium	  nitrate;	  NO3
-­‐
=nitrate;	  SBP=systolic	  blood	  pressure).	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3.3.2	  24	  mmol	  KNO3	  vs.	  KCl	  study	  
Capsules	  were	  well	  tolerated	   in	  general,	  although	  one	  subject,	  who	  had	  not	  taken	  
toast	  with	  the	  capsules,	  was	  treated	  for	  gastritis	  after	  consumption	  of	  capsules.	  This	  
individual	   was	   unblinded	   and	  withdrawn	   from	   the	   study.	   Upon	   unblinding	   it	   was	  
discovered	  that	  gastritis	  occurred	  after	  taking	  KCl	  capsules.	  All	  subsequent	  subjects	  
were	   made	   to	   take	   toast	   with	   the	   capsules	   and	   there	   were	   no	   further	   adverse	  
effects.	  
	  
3.3.2.1	  Plasma	  NOx	  and	  cGMP	  levels	  
Following	   ingestion	  of	  KNO3	  capsules	   (24mmol),	   there	  was	  a	  rapid	   (within	  30	  min)	  
increase	   in	   plasma	   NO3
-­‐	   levels.	   These	   levels	   peaked	   at	   3	   h,	   ~35-­‐fold	   higher	   than	  
basal	  values,	  and	  remained	  significantly	  elevated	  at	  24	  h	  post-­‐ingestion	  (Figure	  3.2	  
A).	  In	  contrast,	  the	  rise	  in	  plasma	  NO2
-­‐	  levels	  was	  moderate	  and	  followed	  a	  slower	  
time-­‐course	   (Figure	   3.2	   B).	   Significantly	   raised	   levels	   were	   first	   evident	   at	   1.5	   h	  
(though	  plasma	  NO2
-­‐	   levels	  were	   elevated	   at	   1	   h	   post-­‐ingestion	   of	   inorganic	  NO3
-­‐	  
capsules)	  and	  appeared	  to	  reach	  a	  plateau	  at	  ~2.5	  h.	  Levels	  were	  sustained	  at	  this	  
plateau	  to	  6	  h	  and	  peaked	  ~4-­‐fold	  higher	  than	  basal	  plasma	  NO2
-­‐	  levels.	  These	  levels	  
remained	   significantly	   elevated	   at	   24	   h	   (Figure	   3.2	   B).	   Plasma	   cGMP	   levels	   were	  
significantly	   raised	   compared	   to	   baseline	   at	   3h	   and	   24h	   after	   ingestion	   of	   KNO3	  
capsules	  (24mmol)	  (Figure	  3.2	  C).	  There	  were	  no	  significant	  changes	  in	  plasma	  NOx	  






Figure	  3.2	  Effect	  of	  inorganic	  NO3
-­‐	  supplementation	  on	  plasma	  NOx	  levels.	  The	  effects	  of	  24	  
mmol	   KNO3	   and	   KCl	   (control)	   capsules	   on	   plasma	   (A)	   NO3
-­‐,	   (B)	   NO2
-­‐	   and	   (C)	   cGMP	   levels	  
(n=20).	   Data	   are	   expressed	   as	   mean±SEM.	   Significance	   shown	   for	   comparisons	   between	  
groups	   as	   ###p<0.001	   for	   2-­‐way	   ANOVA	   followed	   by	   **p<0.01	   and	   ***p<0.001	   for	  
Bonferroni	   post-­‐hoc	   tests;	   and	   †p<0.05	   and	   ††p<0.01	   for	   Dunnett’s	   post-­‐hoc	   tests	  
comparison	   to	   baseline	   (t=	   0	   h)	   following	   1-­‐way	   ANOVA.	   (cGMP=cyclic	   guanosine	  














































































3.3.2.2	  BP	  and	  HR	  
KNO3	  (24mmol)	  ingestion	  caused	  significant	  reductions	  in	  both	  SBP	  and	  DBP	  over	  24	  
h,	  compared	  to	  KCl	  control	  (Figure	  3.3	  A-­‐B).	  SBP	  decreased	  after	  1	  h	  following	  KNO3	  
ingestion,	  with	  sustained,	  significant	  reductions	  in	  SBP	  and	  DBP	  apparent	  between	  
2.5-­‐6	  h	  after	   ingestion.	  The	  peak	  differences	  between	  the	  two	   limbs	  were	  9.4±1.6	  
mmHg	  (at	  6	  h)	  and	  6.0±1.1	  mmHg	  (at	  2.75	  h)	  for	  SBP	  and	  DBP	  respectively.	  SBP	  was	  
still	  significantly	  lower	  24	  h	  after	  KNO3	  ingestion	  compared	  to	  KCl	  control	  ingestion	  
(change	  in	  SBP	  6.1±1.2	  mmHg)	  at	  24	  h.	  SBP	  and	  DBP	  were	  not	  significantly	  altered	  
after	  ingestion	  of	  KCl	  control	  (Figure	  3.3	  A-­‐B).	  There	  was	  no	  significant	  difference	  in	  




Figure	  3.3	  Effect	  of	  inorganic	  NO3
-­‐	  supplementation	  on	  BP.	  The	  effects	  of	  24	  mmol	  KNO3	  and	  
KCl	  (control)	  capsules	  on	  change	  from	  baseline	  in	  (A)	  SBP,	  (B)	  DBP	  and	  (C)	  HR	  (n=20).	  Data	  
are	   expressed	   as	   mean±SEM.	   Significance	   shown	   for	   comparisons	   between	   groups	   as	  
###p<0.001	   for	   2-­‐way	   ANOVA	   followed	   by	   *p<0.05,	   **p<0.01	   and	   ***p<0.001	   for	  
Bonferroni	  post-­‐hoc	  tests.	  (BP=blood	  pressure;	  DBP=diastolic	  blood	  pressure;	  HR=heart	  rate;	  
KCl=potassium	  chloride;	  KNO3=potassium	  nitrate;	  SBP=systolic	  blood	  pressure).	  
























































3.3.2.3	  Correlation	  of	  changes	  in	  BP	  to	  plasma	  NOx	  levels	  and	  baseline	  BP	  
Decreases	   in	   SBP	   following	   24	  mmol	   KNO3	   ingestion	  were	   inversely	   correlated	   to	  
changes	  in	  plasma	  NO2
-­‐	  levels	  (r2=0.122,	  p<0.001)	  but	  not	  to	  changes	  in	  plasma	  NO3
-­‐
levels	   (p=0.946)	   (Figure	   3.4	  A-­‐B).	   In	   addition,	   post-­‐hoc	   analyses	   revealed	   that	   the	  
peak	  decreases	  in	  BP	  were	  also	  significantly	  correlated	  to	  baseline	  BP	  (SBP	  r2=0.530,	  
p<0.001;	  DBP	  r2=0.431,	  p<0.01)	   (Figure	  3.5	  A-­‐B).	  Finally,	  baseline	  BP	  was	   inversely	  
correlated	   to	  baseline	  NO2
-­‐	   levels	   (r2=0.139,	  p<0.05)	  but	  not	  NO3
-­‐	   levels	   (p=0.923)	  




Figure	   3.4	   Changes	   in	   plasma	   NO2
-­‐	   levels	   determine	   reductions	   in	   SBP.	   Correlation	   of	  
changes	  in	  SBP	  from	  baseline	  following	  24	  mmol	  KNO3	  ingestion	  to	  plasma	  (A)	  NO3
-­‐	  and	  (B)	  
NO2
-­‐	  levels.	  All	  graphs	  show	  Pearson’s	  linear	  regression	  of	  best-­‐fit±95%	  confidence	  intervals.	  
(BP=blood	  pressure;	  KNO3=potassium	  nitrate;	  NO2
-­‐=nitrite;	  NO3





Figure	  3.5	  Baseline	  BP	  determines	  magnitude	  of	  BP	  reduction.	  Correlation	  of	  peak	  changes	  
in	   (A)	  SBP	  and	  (B)	  DBP	  following	  24	  mmol	  KNO3	   ingestion	  to	  baseline	  BP.	  All	  graphs	  show	  
Pearson’s	   linear	   regression	   of	   best-­‐fit±95%	   confidence	   intervals.	   (BP=blood	   pressure;	  




Figure	  3.6	  Baseline	  NO2
-­‐	  levels	  inversely	  correlate	  to	  baseline	  BP.	  Correlation	  of	  baseline	  SBP	  
to	  baseline	  plasma	  (A)	  NO3
-­‐	  and	  (B)	  NO2
-­‐	  levels.	  All	  graphs	  show	  Pearson’s	  linear	  regression	  
of	   best-­‐fit±95%	   confidence	   intervals.	   (BP=blood	   pressure;	   KNO3=potassium	   nitrate;	   NO2
-­‐
=nitrite;	  NO3
-­‐=nitrate;	  SBP=systolic	  blood	  pressure).	  
 155	  
3.3.2.4	  Sex	  differences	  in	  response	  to	  inorganic	  NO3
-­‐	  ingestion	  
Interestingly,	   the	  above	  post-­‐hoc	  correlations	  exposed	  a	  prominent	  sex	  difference	  
in	  the	  responses	  to	  NO3
-­‐.	  Separation	  of	  the	  24	  mmol	  KNO3	  vs.	  KCl	  study	  data	  by	  sex	  
demonstrates	   that	   female	   subjects	   had	   significantly	   lower	   baseline	   SBP,	   DBP	   and	  
BMI	  (Table	  3.2)	  compared	  to	  the	  male	  subjects.	  In	  addition,	  whilst	  baseline	  plasma	  
NO3
-­‐	   levels	  were	   similar	   between	   the	   sexes,	   plasma	  NO2
-­‐	   levels	  were	   significantly	  
higher	  in	  the	  females	  (table	  3.2).	  	  
	  
	  
Baseline	  Characteristics	   Male	  (n=8)	   Female	  (n=12)	   Significance	  
Age	  (years)	   23.0±1.4	   22.3±1.2	   p=0.70	  
BMI	  (kg/m2)	   24.2±1.0	   21.4±0.7	   p<0.05	  
SBP	  (mmHg)	   126.4±2.5	   101.5+2.3	   p<0.001	  
DBP	  (mmHg)	   73.3±1.4	   66.7±2.2	   p<0.05	  
Plasma	  [NO3
-­‐]	  µM	   35.0±6.9	   33.8±7.9	   p=0.91	  
Plasma	  [NO2
-­‐]	  µM	   0.362±0.03	   0.536±0.05	   p<0.01	  
Table	   3.2	   Sex	   differences	   in	   demographics,	   baseline	   haemodynamic	   characteristics	   and	  
baseline	  plasma	  NOx	  levels	  for	  24	  mmol	  KNO3	  vs.	  KCl	  study.	  Significance	  values	  for	  unpaired	  
Student	  t-­‐test	  shown	  in	  last	  column.	  Data	  expressed	  as	  mean±SEM.	  (BMI=body	  mass	  index;	  
DBP=diastolic	   blood	   pressure;	   KCl=potassium	   chloride;	   KNO3=potassium	   nitrate;	   NO2
-­‐
=nitrite;	  NO3
-­‐=nitrate;	  NOx=nitrite/nitrate;	  SBP=systolic	  blood	  pressure).	  
	  
 156	  
Additionally,	   the	   rise	   in	   plasma	   NOx	   levels	   in	   males	   following	   KNO3	   ingestion	  
appeared	   significantly	   lower	   compared	   to	   females	   (Figure	   3.7	   A-­‐B).	   However,	   the	  
fold	   increases	   in	   plasma	   NO2
-­‐	   from	   baseline	   were	   similar	   (~3.3	   and	   ~4.1-­‐fold	   for	  
males	   and	   females	   respectively).	   Conversely,	   KNO3-­‐induced	   reduction	   in	   SBP	   and	  
DBP	  was	  substantially	  greater	  in	  males	  compared	  to	  females	  (Figure	  3.8	  A-­‐B).	  There	  
were	  no	  significant	  effects	  on	  HR	  (Figure	  3.8	  C).	  No	  sex	  differences	  in	  the	  response	  
to	  KCl	  with	  respect	  to	  SBP,	  DBP	  or	  HR	  were	  found	  (Figure	  3.9	  A-­‐C).	  
	  
The	  dose/kg	  of	  NO3
-­‐	  administered	  to	  females	  was	  0.45±0.02	  mmol/kg	  and	  for	  males	  
was	   0.32±0.021	  mmol/kg.	   After	   adjusting	   changes	   in	   plasma	   NOx	   levels	   for	   body	  
weight,	  there	  was	  no	  significant	  difference	  in	  changes	  to	  plasma	  NO3
-­‐	  levels	  (Figure	  
3.10	  A).	  However,	  females	  had	  significantly	  higher	  adjusted	  plasma	  NO2
-­‐	  levels	  over	  
the	  24	  h	  study	  compared	  to	  males	  and	  appeared	  to	  be	  able	  to	  sustain	  the	  elevation	  
much	  longer	  than	  males,	  though	  there	  were	  no	  significant	  differences	  at	  any	  time-­‐




Figure	  3.7	  Sex	  differences	   in	  plasma	  NOx	   levels	  after	   inorganic	  NO3
-­‐	   supplementation.	  The	  
effects	  of	  KNO3	  (24mmol)	  on	  plasma	  (A)	  NO3
-­‐	  and	  (B)	  NO2
-­‐	  levels	  in	  males	  and	  females.	  Data	  
are	  expressed	  as	  mean±SEM	  (males	  n=8;	  females	  n=12).	  Significance	  shown	  for	  comparisons	  







Figure	  3.8	  Sex	  differences	   in	  BP	  after	   inorganic	  NO3
-­‐	  supplementation.	  The	  effects	  of	  KNO3	  
(24mmol)	   on	   change	   from	  baseline	   in	   (A)	   SBP,	   (B)	  DBP	  and	   (C)	  HR	   in	  males	   and	   females.	  
Data	   are	   expressed	   as	   mean±SEM	   (males	   n=8;	   females	   n=12).	   Significance	   shown	   for	  
comparisons	   between	   groups	   as	   ##p<0.01,	   ###p<0.001	   for	   2-­‐way	   ANOVA.	   (DBP=diastolic	  




Figure	  3.9	  Sex	  differences	  in	  BP	  after	  placebo.	  The	  effects	  of	  KCl	  control	  (24mmol)	  on	  change	  
from	  baseline	   in	  (A)	  SBP,	  (B)	  DBP	  and	  (C)	  HR	  in	  males	  and	  females.	  Data	  are	  expressed	  as	  
mean±SEM	   (males	   n=8;	   females	   n=12).	   (DBP=diastolic	   blood	   pressure;	   HR=heart	   rate;	  




Figure	  3.10	  Weight-­‐normalized	  plasma	  NOx	  levels	  by	  sex.	  Plasma	  (A)	  NO3
-­‐	  and	  (B)	  NO2
-­‐	  levels	  
relative	   to	   dose/kg	   administered	   following	   24mmol	   KNO3	   administration.	   Data	   are	  
expressed	   as	  mean±SEM	   (males	   n=8;	   females	   n=12).	   Significance	   shown	   for	   comparisons	  






-­‐	  dose-­‐response	  study	  
KNO3	  (4	  and	  12	  mmol)	  capsules	  were	  well	  tolerated.	  
	  
3.3.3.1	  Plasma	  NOx	  levels	  
The	  effects	  of	  KNO3	  were	  dose-­‐dependent	  with	  plasma	  NO3
-­‐	   levels	  elevated	  above	  
baseline	   by	   7	   and	   27-­‐fold	   after	   administration	   of	   4	   and	   12	   mmol	   of	   KNO3	  
respectively	   (Figure	   3.11	   A).	   The	   rises	   in	   plasma	   NO2
-­‐	   levels	   also	   showed	   dose-­‐
dependency,	   albeit	   with	   a	   more	   moderate	   rise	   of	   1.3	   and	   2.0–fold	   increase	  
respectively	  (Figure	  3.11	  B).	  	  
	  
3.3.3.2	  Dose-­‐dependent	  decreases	  in	  BP	  following	  inorganic	  NO3
-­‐	  ingestion	  
The	  effect	  of	  KNO3	  on	  BP	  was	  dose-­‐dependent	  (Figure	  3.12	  A-­‐B).	  Peak	  decreases	  in	  
BP	  after	  4mmol	  KNO3	  were	  ~2.6/4.6	  mmHg,	  whilst	  there	  were	  greater	  decreases	  in	  
BP	   after	   ingestion	   of	   12	   mmol	   KNO3	   of	   ~5.9/4.6	   mmHg.	   3	   h	   after	   capsule	  
consumption,	  changes	  from	  baseline	  in	  BP	  were	  2.0/2.2	  and	  5.5/4.6	  mmHg	  after	  4	  
and	  12	  mmol	  KNO3	  respectively.	  There	  were	  no	  significant	  effects	  of	  either	  dose	  of	  




Figure	  3.11	  Dose-­‐dependent	   effect	   of	   inorganic	  NO3
-­‐	   on	  plasma	  NOx	   levels.	   The	   effects	   of	  
4mmol	   and	   12mmol	   of	   KNO3	   on	   plasma	   (A)	   NO3
-­‐	   and	   (B)	   NO2
-­‐	   levels	   (n=6).	   Data	   are	  
expressed	   as	   mean±SEM.	   Significance	   shown	   for	   comparisons	   as	   †p<0.05,	   ††p<0.01	   and	  
†††p<0.001	   for	   Dunnett’s	   post-­‐hoc	   test	   comparison	   to	   baseline	   (t=	   0	   h)	   following	   1-­‐way	  






Figure	   3.12	   Dose-­‐dependent	   effect	   of	   inorganic	   NO3
-­‐	   on	   BP.	   The	   effects	   of	   4mmol	   and	  
12mmol	  of	  KNO3	  on	   change	   from	  baseline	   in	   (A)	   SBP,	   (B)	  DBP	  and	   (C)	  HR	   (n=6).	  Data	  are	  
expressed	   as	   mean±SEM.	   Significance	   shown	   for	   comparisons	   as	   †p<0.05	   for	   Dunnett’s	  
post-­‐hoc	  test	  comparison	  to	  baseline	  (t=	  0	  h)	  following	  1-­‐way	  ANOVA	  (DBP=diastolic	  blood	  
pressure;	   HR=heart	   rate;	   KNO3=potassium	   nitrate;	   NO3






-­‐	  was	  generally	  well	  tolerated	  by	  the	  subjects.	  The	  [NO3
-­‐]	  in	  the	  dietary	  
NO3
-­‐	  was	  22.4±3.8	  mM,	  whereas	  [NO2
-­‐]	  was	  <50nM	  (n=9).	  
	  
3.3.4.1	  Effects	  of	  reduced	  dose	  of	  dietary	  NO3
-­‐	  on	  plasma	  NOx	  levels	  
Following	   dietary	   NO3
-­‐	   ingestion	   (~5.5	   mmol	   NO3
-­‐	   dose)	   plasma	   NO3
-­‐	   levels	   rose	  
rapidly,	  peaking	  at	  1	  h	  post-­‐ingestion	  ~11-­‐fold	  higher	  than	  basal	  plasma	  NO3
-­‐	  levels	  
(Figure	  3.13	  A).	  Plasma	  NO3
-­‐	   levels	   remained	  elevated	   in	  a	  sustained	  manner	  over	  
the	  entire	  3	  h	  time	  course,	  compared	  to	  water	  control	  (Figure	  3.13	  A).	  Plasma	  NO2
-­‐	  
levels	   also	   increased	   after	   NO3
-­‐	   ingestion,	   peaking	   at	   2.5	   h	  with	   an	   ~1.6-­‐fold	   rise	  
above	   baseline	   levels	   and	   also	   remaining	   significantly	   elevated	   over	   the	   3	   h	   time	  
course	   compared	   to	  water	   control	   (Figure	   3.13	   B).	   In	   addition,	   cGMP	   levels	  were	  
elevated	   at	   3	   h	   compared	   to	   baseline	   after	   dietary	   NO3
-­‐	   ingestion	   compared	   to	  
water	  control	   (Figure	  3.13	  C).	  There	  were	  no	  significant	  changes	   in	  plasma	  NOx	  or	  
cGMP	  levels	  after	  water	  control	  ingestion	  (Figure	  3.13	  A-­‐C).	  
	  
3.3.4.2	  Effects	  of	  reduced	  dose	  of	  dietary	  NO3
-­‐	  on	  BP	  and	  HR	  
SBP	  decreased	  with	  a	  peak	  reduction	  in	  SBP	  of	  5.4±1.5	  mmHg	  compared	  to	  baseline	  
and	  7.2±1.8	  mmHg	  compared	  to	  water	  control	  at	  3	  h	  post-­‐ingestion	  (Figure	  3.14	  A).	  
There	  were	  no	  significant	  changes	   in	  either	  DBP	  or	  HR	  after	  dietary	  NO3
-­‐	  or	  water	  





Figure	   3.13	  Dietary	  NO3
-­‐	   supplementation	   raises	   plasma	  NOx	   levels	   The	   effects	   of	   dietary	  
NO3
-­‐	  (250	  mL	  as	  beetroot	  juice;	  5.5mmol	  NO3
-­‐)	  or	  water	  control	  on	  plasma	  (A)	  NO3
-­‐,	  (B)	  NO2
-­‐	  
and	   (C)	   cGMP	   levels.	   Data	   are	   expressed	   as	   mean±SEM	   (n=9).	   Significance	   shown	   for	  
comparisons	   between	   groups	   as	   ###p<0.001	   for	   2-­‐way	   ANOVA,	   and	   by	   **p<0.01,	  







Figure	  3.14	  Dietary	  NO3
-­‐	   lowers	  BP.	  The	  effects	  of	  dietary	  NO3
-­‐	   (250	  mL	  as	  beetroot	   juice;	  
5.5mmol	  NO3
-­‐)	  or	  water	  control	  on	  plasma	  (A)	  SBP,	  (B)	  DBP	  and	  (C)	  HR.	  Data	  are	  expressed	  
as	  mean±SEM	  (n=9).	  Significance	  shown	  for	  comparisons	  between	  groups	  as	  #p<0.05	  for	  2-­‐
way	   ANOVA	   followed	   by	   *p<0.05	   and	   **p<0.01,	   for	   Bonferroni	   post-­‐hoc	   tests.	   (BP=blood	  
pressure;	   DBP=diastolic	   blood	   pressure;	   HR=heart	   rate;	   NO3
-­‐=nitrate;	   SBP=systolic	   blood	  
pressure).	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3.4	  Results	  from	  amalgamation	  of	  data	  
3.4.1	  Baseline	  cGMP	  levels	  determine	  baseline	  SBP	  in	  healthy	  subjects	  
Amalgamating	  all	   the	  subjects	  across	  the	  two	  studies	  (n=29)	   in	  which	  cGMP	  levels	  
were	   measured	   (24	   mmol	   KNO3	   vs.	   KCl	   and	   dietary	   NO3
-­‐	   studies),	   baseline	   SBP	  
inversely	  correlated	  with	  plasma	  cGMP	  levels	  at	  baseline	  (p=0.024,	  r2=0.203	  Figure	  
3.15	  A)	  but	  baseline	  DBP	  was	  not	  significantly	  correlated	  to	  plasma	  cGMP	  levels	  at	  
baseline	  (p=0.053,	  r2=0.153,	  Figure	  3.15	  B)	  though	  there	  equally	  appeared	  to	  be	  a	  
trend	  towards	  this.	  	  
	  
3.4.2	  BP-­‐lowering	  effects	  of	  NO3
-­‐	  are	  dose-­‐dependent	  
For	   increasing	   doses	   of	   inorganic	   NO3
-­‐,	   in	   the	   form	   of	   KNO3	   capsules	   (4,	   12	   and	  
24mmol)	   or	   from	   increasing	   doses	   of	   dietary	   NO3
-­‐	   as	   beetroot	   juice	   (250mL,	  
~5.5mmol	  NO3
-­‐,	  there	  is	  a	  graded	  reduction	  in	  SBP	  irrespective	  of	  the	  formulation	  of	  
NO3




Figure	  3.15	  Plasma	  cGMP	  levels	  inversely	  correlate	  with	  baseline	  BP.	  Correlation	  of	  baseline	  
cGMP	   levels	   to	   (A)	   baseline	   SBP	   and	   (B)	   baseline	   DBP.	   All	   graphs	   show	   Pearson’s	   linear	  
regression	  of	  best-­‐fit±95%	  confidence	   intervals	   (n=29	   from	  2	   separate	   studies).	   (BP=blood	  
pressure;	   cGMP=cyclic	   guanosine	   monophosphate;	   DBP=diastolic	   blood	   pressure;	  




Figure	   3.16	   Inorganic	   or	   dietary	   NO3
-­‐	   supplementation	   lowers	   SBP	   in	   a	   dose-­‐dependent	  
manner.	  The	  effects	  of	  KNO3	  (4,	  12	  or	  24mmol)	  and	  dietary	  NO3
-­‐	  as	  beetroot	  juice	  (250	  mL,	  
~5.5	  mmol	  NO3
-­‐)	  on	  change	  in	  SBP	  from	  baseline	  over	  3	  h.	  (n=6-­‐20).	  Data	  are	  expressed	  as	  
mean	  only.	  (KNO3=potassium	  nitrate;	  NO3
-­‐=nitrate;	  SBP=systolic	  blood	  pressure).	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3.5	  Summary	  
1. Inorganic	  NO3-­‐	  supplementation	  mimics	  the	  effects	  of	  dietary	  NO3-­‐,	  causing	  
a. Rapid	  elevations	  in	  plasma	  NO3-­‐	  levels.	  
b. Delayed,	  sustained	  elevations	  in	  plasma	  NO2-­‐	  levels.	  
c. Significant	  reductions	  in	  both	  SBP	  and	  DBP.	  
2. Inorganic	  NO3-­‐	  supplementation	  is	  associated	  with	  increases	  in	  plasma	  cGMP	  
levels.	  
3. Baseline	  BP	  and	  changes	  in	  BP	  are	  inversely	  correlated	  to	  NO2-­‐,	  but	  not	  NO3-­‐,	  
levels.	  
4. Sex	   differences	   exist	   in	   plasma	   NO2-­‐	   levels	   at	   baseline	   and	   after	   NO3-­‐	  
supplementation.	  
5. Inorganic	  NO3-­‐	  supplementation	  causes	  dose-­‐dependent	  increases	  in	  plasma	  
NOx	  levels,	  and	  dose-­‐dependent	  decreases	  in	  BP.	  
6. A	  reduced	  dose	  of	  dietary	  NO3-­‐	  causes	  elevations	   in	  plasma	  NOx	  and	  cGMP	  
levels	  and	  reductions	  in	  SBP.	  
7. Overall,	   NO3-­‐	   whether	   in	   salt	   form	   or	   dietary	   form	   reduces	   BP	   in	   a	   dose-­‐
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4.1	  Introduction	  
There	  is	  now	  much	  evidence,	   including	  that	  presented	  in	  chapter	  3,	  that	   inorganic	  
(Larsen	  et	  al.,	  2006)	  and	  dietary	   (Webb	  et	  al.,	  2008a)	  NO3
-­‐	   lowers	  BP	   through	  the	  
elevation	   of	   systemic	   NO2
-­‐	   levels	   in	   humans.	   Moreover,	   the	   importance	   of	   oral	  
conversion	   to	   this	   process	   has	   been	   established	   in	   a	   few	   human	   studies	   that	  
demonstrate	   that	   interruption	  of	   the	  entero-­‐salivary	   circulation,	  by	   the	  avoidance	  
of	  swallowing,	  prevents	   the	  elevations	   in	  systemic	  NO2
-­‐	   levels	  after	  NO3
-­‐	   ingestion	  
(Lundberg	   and	   Govoni,	   2004;	   Webb	   et	   al.,	   2008a)	   and	   the	   BP-­‐lowering	   effects	  
thereof	   (Webb	   et	   al.,	   2008a).	   However,	   up	   to	   ~1	  mmol	   of	   NO3
-­‐	   is	   synthesized	   in	  
humans	  on	  a	  daily	  basis	  (Green	  et	  al.,	  1981)	  by	  the	  oxidation	  of	  NO	  produced	  by	  the	  
action	   of	   NOS	   enzymes.	   Thus,	   under	   basal	   conditions	   without	   NO3
-­‐	  
supplementation,	   this	   endogenously-­‐derived	   NO3
-­‐	   should	   still	   enter	   the	   entero-­‐
salivary	   circulation	   to	  produce	  NO2
-­‐	   that	  may	   contribute	  not	  only	   to	  basal	  plasma	  
NO2
-­‐	  levels	  but,	  since	  NO2
-­‐	  is	  bioactive	  in	  the	  circulation,	  may	  also	  regulate	  BP.	  	  
	  
Thus,	   the	  aim	  of	   this	   study	  was	   to	  establish	   the	  basal	   rate	  of	  oral	  NO3
-­‐	   reductase	  
activity	   at	   different	   salivary	   NO3
-­‐	   levels	   that	   may	   be	   encountered	   in	   normal	  
physiological	   situations.	   In	   addition,	   the	   impact	   of	   disrupting	   the	   oral	   microflora	  
responsible	   for	  oral	  NO3
-­‐	   reductase	  activity	  on	  systemic	  NO2
-­‐	   levels	  and	  BP.	  Lastly,	  
the	  influence	  of	  sex	  on	  the	  above	  responses	  was	  also	  investigated.	  
	  	  
4.2	  Protocol	  
For	  this	  oral	  NO3
-­‐	  reductase	  activity	  study,	  the	  following	  exclusion	  criteria	  were	  used	  
to	  those	  previously	  stated:	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1. Self-­‐reported	  use	  of	  mouthwash	  or	  tongue	  scrapes.	  
2. Recent	  or	  current	  antibiotic	  use	  (within	  3	  months).	  
3. History,	  or	  recent	  treatment	  of	  (within	  last	  3	  months)	  of	  any	  oral	  condition	  
(excluding	  caries),	  including	  gingivitis,	  periodontitis	  and	  halitosis.	  
	  
Design:	  To	  assess	  the	  contribution	  of	  the	  entero-­‐salivary	  circulation	  of	  NO3
-­‐	  to	  NO2
-­‐	  
(under	   basal	   conditions)	   to	   systemic	  NO2
-­‐	   levels,	   and	   to	   determine	   the	   impact	   of	  
interruption	  of	  this	  pathway	  on	  the	  regulation	  of	  basal	  BP,	  an	  open-­‐label,	  cross-­‐over	  
study	   of	   a	   chlorhexidine-­‐based,	   antiseptic	   mouthwash	   was	   performed	   in	   healthy	  
subjects.	   Subjects	   were	   instructed	   to	   instill	   10mL	   0.2%	   chlorhexidine-­‐based	  
mouthwash	  (Corsodyl™,	  purchased	  from	  GlaxoSmithKilne	  Company,	  Stevenage,	  UK)	  
orally	  and	  hold	  in	  the	  oral	  cavity	  for	  1	  min,	  twice	  daily,	  12	  h	  apart	  for	  7	  days	  in	  the	  
2nd	   week	   of	   the	   oral	   NO3
-­‐	   reductase	   study	   to	   disrupt	   the	   activity	   of	   the	   oral	  
microflora	  (Petersson	  et	  al.,	  2009).	  
	  
Power	  analysis:	  Previous	  data	  from	  the	  24	  mmol	  KNO3	  vs.	  KCl	  study	  gave	  a	  baseline	  
value	   of	   plasma	  NO2
-­‐	   levels	   of	   0.418	   µM	   in	   20	   healthy	   subjects.	   Based	   upon	   this	  
value,	   it	  was	  postulated	  that	  there	  would	  be	  a	  30%	  reduction	  following	  repression	  
of	   the	   bacterial	   NO3
-­‐-­‐reductase	   pathway,	   as	   according	   to	   published	   evidence	   it	   is	  
thought	  that	  30%	  of	  plasma	  NO2
-­‐	  levels	  is	  not	  derived	  from	  eNOS-­‐derived	  oxidation	  
of	  NO	  (Kleinbongard	  et	  al.,	  2003).	  Therefore	  a	  change	  in	  plasma	  NO2
-­‐	  levels	  of	  0.126	  
µM	  (SD=0.169)	  was	  expected.	  Based	  on	  these	  values,	  with	  an	  α=0.05	  and	  1-­‐β=0.9	  
power	   calculations	   determined	   that	   n=22	   is	   required.	   2	   extra	   subjects	   were	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recruited	   to	   account	   for	  potential	   drop-­‐outs,	   thus	   the	   final	   number	   recruited	  was	  
n=24.	  
	  
Measurements:	   On	   arrival,	   baseline	   clinic	   BP	   was	   measured	   (section	   2.4.1).	  
Following	   this,	   baseline	   blood,	   urine	   and	   whole	   saliva	   samples	   were	   collected	  
(sections	   2.6-­‐2.8).	  Oral	  NO3
-­‐	   reductase	   capacity	  was	   ascertained	   (section	   2.9)	   and	  
then	  a	  24	  h	  ABP	  monitor	  attached	  (section	  2.4.2),	  to	  be	  returned	  the	  following	  day.	  
Subjects	  were	  then	  instructed	  to	  measure	  BP	  on	  a	  daily	  basis	  whilst	  at	  home	  (home	  
BP)	  for	  2	  weeks	  (section	  2.4.3).	  However,	  after	  7	  days,	  subjects	  were	  instructed	  to	  
introduce	  rinsing	  of	  their	  oral	  cavities	  with	  10	  mL	  Corsodyl™	  antiseptic	  mouthwash	  
twice	  daily	  for	  the	  remaining	  7	  days.	  After	  this	  time	  subjects	  returned	  for	  a	  repeat	  
assessment	   of	   clinic	   BP	   measurement,	   blood,	   urine	   and	   whole	   saliva	   sample	  
collection	  and	  oral	  NO3
-­‐	  reductase	  capacity	  assessment.	  A	  further	  24	  h	  ABP	  monitor	  
was	  attached	  and	   returned	   the	   following	  day	   (Figure	  4.1).	  Subjects	   recorded	  daily	  
nutritional	   intake	   during	   the	   2	   weeks	   using	   self-­‐reported	   dietary	   diaries.	   The	  




Figure	  4.1	  Timeline	  for	  oral	  NO3






4.3.1	  General	  characteristics	  
24	  healthy	  subjects	  were	  recruited;	  5	  dropped	  out	  during	  the	  course	  of	  the	  study	  (2	  
were	  unable	  to	  complete	  2	  weeks	  of	  home	  BP	  monitoring,	  3	  withdrew	  voluntarily),	  
hence	   19	   subjects	   completed	   the	   protocol	   (see	   Table	   4.1	   for	   baseline	  
demographics).	   Power	   analyses	   with	   this	   sample	   size	   estimated	   1-­‐β=0.86.	   BP	  
measured	  by	  24	  h	  ABP	  was	  significantly	  greater	  than	  clinic	  or	  home	  SBP	  (p<0.05	  and	  
p><0.001	  for	  Bonferroni	  post-­‐hoc	  test	  following	  1-­‐way	  ANOVA,	  Table	  4.1).	  Similarly,	  
DBP	  measured	  by	  24	  h	  ABP	  was	  greater	  than	  clinic	  DBP	  (p<0.01)	  but	  not	  home	  BP	  
(Table	  4.1).	  Estimated	  daily	  portion	  intake	  of	  fruit,	  high-­‐NO3
-­‐	  containing	  vegetables,	  
low-­‐NO3
-­‐containing	  vegetables	  (Hord	  et	  al.,	  2009)	  and	  processed	  meat	  did	  not	  differ	  
between	  the	  two	  study	  periods	  (Table	  4.2).	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Baseline	  characteristic	   	  
Subjects	  (n)	   19	  (8	  female)	  
Age	  (years)	   23.8±0.5	  
BMI	  (kg/m2)	   23.0±0.6	  
Clinic	  SBP	  (mmHg)	   110.4±1.8	   Plasma	  [NO3
-­‐]	  (µM)	   26.7±2.4	  
Clinic	  DBP	  (mmHg)	   66.2±1.6	   Plasma	  [NO2
-­‐]	  (nM)	   284.2±16.9	  
Home	  SBP	  (mmHg)	   115.3±1.7	   Salivary	  [NO3
-­‐]	  (µM)	   441.8±68.6	  
Home	  DBP	  (mmHg)	   67.3±1.1	   Salivary	  [NO2
-­‐]	  (µM)	   316.1±30.7	  
Ambulatory	  SBP	  (mmHg)	   119.2±1.6	   Urinary	  [NO3
-­‐]	  µM	   1462.0±64.9	  
Ambulatory	  DBP	  (mmHg)	   70.3±1.3	   Urinary	  [NO2
-­‐]	  nM	   203.1±8.8	  
Table	   4.1	   Baseline	   characteristics	   in	   oral	   NO3
-­‐	   reductase	   activity	   study.	   Demographics,	  
haemodynamics	   and	   baseline	   NOx	   levels.	   Data	   are	   expressed	   as	   mean±SEM	   (n=19).	  
(BMI=body	   mass	   index;	   DBP=diastolic	   blood	   pressure;	   NO3
-­‐=nitrate;	   NO2
-­‐=nitrite;	  





Baseline	   Post-­‐mouthwash	   Significance	  (p)	  
Fruit	   0.5±0.2	   0.5±0.2	   0.205	  
Low-­‐NO3
-­‐	  vegetables	   0.6±0.1	   0.6±0.1	   0.928	  
High-­‐NO3
-­‐	  vegetables	   0.2±0.1	   0.2±0.1	   0.245	  
Processed	  meat	   0.7±0.1	   0.7±0.1	   0.793	  
Table	  4.2	  Self-­‐reported	  daily	   food	  estimates	   in	   oral	  NO3
-­‐	   reductase	  activity	   study.	   Specific	  
food	  groups	  mean	  portion	  daily	   intake	   in	   the	  7	  day	   study	  periods.	  Data	  are	   expressed	  as	  





4.3.2	  Antiseptic	  mouthwash	  use	  abrogates	  oral	  NO3
-­‐	  reductase	  activity	  
Prior	  to	  mouthwash	  treatment,	  oral	  NO3
-­‐	  reduction	  was	  found	  to	  be	  concentration	  
dependent	  (p<0.001)	  with	  levels	  increasing	  in	  a	  linear	  fashion	  with	  respect	  to	  time	  
the	   solutions	   were	   held	   in	   the	   oral	   cavity	   (Figure	   4.2	   A).	   The	   calculated	   rates	   of	  
reduction	  increased	  with	  increasing	  NO3
-­‐	  concentration	  (Table	  4.3).	  After	  antiseptic	  
mouthwash	   use	   for	   7	   days,	   oral	  NO3
-­‐	   reduction	  was	   near	   abolished	   (~90%	   lower,	  
p<0.001	  for	  all	  solutions	  compared	  to	  baseline	  rates	  by	  2-­‐way	  ANOVA,	  Figure	  4.2	  B	  
and	  Table	  4.3	  for	  calculated	  rates).	  	  
	  
	   Rate	  of	  oral	  NO3
-­‐	  reductase	  activity	  (nmol/min)	  
Solution	   Baseline	   	  Post-­‐mouthwash	  
NOx-­‐free	  water	   19±3	   	  2±1	  
0.8	  mM	  [NO3
-­‐]	   113±25	   	  11±3	  
8	  mM	  [NO3
-­‐]	   212±31	   	  28±7	  
Table	   4.3	   Rates	   of	   oral	   NO3
-­‐	   reductase	   activity	   at	   baseline	   and	   after	   7	   days	   antiseptic	  






Figure	   4.2.	   Antiseptic	   mouthwash	   use	   abrogates	   oral	   NO3
-­‐	   reductase	   ability.	   Oral	   NO3
-­‐	  
reductase	  activity	  after	   instillation	  of	  NO3
-­‐-­‐containing	  solutions	   for	  1-­‐5	  min	  at	   (A)	  baseline	  
and	   (B)	   after	   daily	   use	   of	   antiseptic	   mouthwash	   for	   7	   days.	   Data	   are	   expressed	   as	  





4.3.3	  Antiseptic	  mouthwash	  use	  attenuates	  systemic	  NO2
-­‐	  levels	  
Following	  use	  of	  antiseptic	  mouthwash	  for	  7	  days,	  salivary,	  urinary	  and	  plasma	  NO2
-­‐	  
levels	   were	   significantly	   attenuated	   (Figure	   4.3	   A-­‐C).	   Salivary	   NO2
-­‐	   levels	   were	  
reduced	  by	  ~90%	  (change	  in	  salivary	  NO2
-­‐	  levels:	  282±35	  µM,	  p<0.001).	  Plasma	  and	  
urinary	  NO2
-­‐	   levels	  were	  similarly	  reduced	  by	  ~25%	  (change	   in	  plasma	  NO2
-­‐	   levels:	  
71±15	   nM,	   p<0.001;	   and	   change	   in	   urinary	   NO2
-­‐	   levels:	   51±12	   nM,	   p<0.001	  
respectively).	  In	  contrast,	  salivary,	  plasma	  and	  urinary	  NO3
-­‐	  levels	  were	  significantly	  




Figure	  4.3	  Disruption	  of	  oral	  NO3
-­‐	  reductase	  activity	  reduces	  systemic	  NO2
-­‐	  levels.	  The	  effect	  
of	  daily	  antiseptic	  mouthwash	  use	  for	  7	  days	  on	  (A)	  salivary	  (B)	  plasma	  and	  (C)	  urinary	  NO2-­‐	  







Figure	   4.4	   Disruption	   of	   oral	   NO3
-­‐	   reductase	   activity	   increases	   systemic	   NO3
-­‐	   levels.	   The	  
effect	   of	   daily	   antiseptic	   mouthwash	   use	   for	   7	   days	   on	   (A)	   salivary	   (B)	   plasma	   and	   (C)	  
urinary	  NO3




4.3.4	  Disruption	  of	  the	  entero-­‐salivary	  circulation	  elevates	  BP	  
Daily	   use	   of	   antiseptic	   mouthwash	   for	   7	   days	   was	   associated	   with	   significant	  
increases	  in	  both	  SBP	  and	  DBP	  (Figure	  4.5-­‐4.7).	  These	  changes	  in	  BP	  were	  of	  similar	  
magnitude,	  irrespective	  of	  the	  method	  of	  BP	  measurement	  (Table	  4.4).	  There	  were	  
no	  significant	  changes	  in	  HR	  following	  mouthwash	  use	  (Table	  4.5).	  
	  
	   Method	  of	  BP	  measurement	   	  
	   Clinic	   Home	   ABP	   Significance	  (p)	  
Change	  in	  SBP	  (mmHg)	   3.5±1.1	   2.9±0.4	   2.4±0.9	   0.542	  
Change	  in	  DBP	  (mmHg)	   2.2±1.0	   2.0±0.5	   2.2±0.8	   0.984	  
Table	  4.4	  Change	  in	  BP	  following	  antiseptic	  mouthwash	  use	  for	  7	  days.	  Data	  are	  expressed	  
as	   mean±SEM	   (n=19).	   Significance	   shown	   for	   1-­‐way	   ANOVA.	   (BP=blood	   pressure;	   DBP-­‐
diastolic	  blood	  pressure;	  SBP=systolic	  blood	  pressure).	  
	  
	   Method	  of	  HR	  measurement	  
	   Clinic	   Home	   ABP	  
Change	  in	  HR	  (bpm)	   2.0±1.7	   1.3±1.0	   2.4±0.9	  
Significance	  (p)	   0.252	   0.179	   0.172	  
Table	  4.5	  Change	  in	  HR	  following	  antiseptic	  mouthwash	  use	  for	  7	  days.	  Data	  are	  expressed	  
as	   mean±SEM	   (n=19).	   Significance	   shown	   for	   paired	   Student’s	   t-­‐test,	   comparing	   HR	   at	  






Figure	  4.5	  Effects	  of	  antiseptic	  mouthwash	  use	  on	  clinic	  BP.	  Clinic	   (A)	  SBP	  and	   (B)	  DBP	  at	  
baseline	   and	   following	   7	   days	   use	   of	   antiseptic	   mouthwash.	   Data	   are	   expressed	   as	  
mean±SEM	   (n=19)	   and	   statistical	   significance	   determined	   using	   paired	   Student’s	   t-­‐test.	  




Figure	  4.6	  Effects	  of	  antiseptic	  mouthwash	  use	  on	  home	  BP.	  Home	  (A)	  SBP	  and	  (B)	  DBP	  prior	  
to	  and	  during	  7	  days	  use	  of	  antiseptic	  mouthwash.	  Data	  are	  expressed	  as	  mean±SEM	  (n=19)	  
and	   statistical	   significance	   determined	   using	   paired	   Student’s	   t-­‐test.	   (BP=blood	   pressure;	  





Figure	  4.7	  Effects	  of	  antiseptic	  mouthwash	  use	  on	  24	  h	  ABP.	  (A)	  SBP	  and	  (B)	  DBP	  measured	  
by	  ABP	  at	  baseline	  and	  following	  7	  days	  use	  of	  antiseptic	  mouthwash.	  Data	  are	  expressed	  as	  
mean±SEM	  (n=19)	  and	  statistical	  significance	  determined	  using	  paired	  Student’s	  t-­‐test.	  
(ABP=ambulatory	  blood	  pressure;	  BP=blood	  pressure;	  DBP=diastolic	  blood	  pressure;	  
SBP=systolic	  blood	  pressure).	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Home	  SBP	  and	  DBP	  measurements	  over	  the	  course	  of	  the	  first	  7	  days	  (baseline)	  did	  
not	   change	   significantly	   from	   day	   to	   day	   (Figure	   4.8	   A-­‐B).	   However,	   following	  
initiation	  of	  a	  single	  day’s	  use	  of	  mouthwash,	  both	  home	  SBP	  and	  DBP	  were	  raised	  
compared	  to	  prior	  to	  mouthwash	  use	  and	  remained	  elevated	  over	  the	  entire	  7	  day	  
treatment	  period	  (p<0.001	  for	  both	  SBP	  and	  DBP),	  with	  no	  apparent	  tachyphylaxis	  
(Figure	  4.8	  A-­‐B).	  
	  
Separation	   of	   ABP	   data	   into	   daytime	   and	   nighttime	   means	   demonstrated	   that	  
daytime	  ambulatory	  SBP	  and	  DBP	  were	  both	  increased	  post-­‐mouthwash	  (Table	  4.6),	  
whilst	  daily	  use	  of	  antiseptic	  mouthwash	  was	  associated	  with	   increased	  nighttime	  
SBP,	  but	  not	  DBP	  (Table	  4.6).	  
	  
	   Daytime	   Nighttime	  
	   SBP	   DBP	   SBP	   DBP	  
Change	  in	  ABP	  (mmHg)	   2.9±0.9	   3.0±0.8	   2.2±0.9	   1.3±1.5	  
Significance	  (p)	   0.004§§	   0.002§§	   0.022§	   0.404	  
Table	  4.6	  Effects	  of	  a	  7	  day	  intervention	  with	  antiseptic	  mouthwash	  on	  24	  h	  ABP,	  separated	  
into	  daytime	  and	  nighttime	  periods.	  Data	  are	  expressed	  as	  mean±SEM	  (n=19)	  and	  statistical	  
significance	  determined	  using	  paired	  Student’s	  t-­‐test	  and	  shown	  as	  §p<0.05	  and	  §§p<0.01.	  





Figure	  4.8	  Disruption	  of	  oral	  microflora	  elevates	  BP	  within	  1	  day.	  The	  daily	  profiles	  of	   (A)	  
home	   SBP	   and	   (B)	   DBP	   during	   the	   7	   day	   study	   periods	   in	   healthy	   subjects.	   Data	   are	  
expressed	   as	   mean±SEM	   (n=19).	   Statistical	   significance	   shown	   as	   ###p<0.001	   for	   2-­‐way	  
ANOVA.	  (BP=blood	  pressure;	  DBP=diastolic	  blood	  pressure;	  SBP=systolic	  blood	  pressure).	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4.3.5	  Baseline	  BP	  and	  changes	  in	  plasma	  NO2
-­‐	  levels	  determine	  changes	  in	  BP	  
Daily	  use	  of	  antiseptic	  mouthwash	   for	  7	  days	  was	  associated	  with	  both	  significant	  
attenuation	   of	   plasma	   NO2
-­‐	   levels	   (Figure	   4.3	   B)	   and	   elevations	   in	   SBP	   by	   all	   3	  
methods	   that	  were	  employed	   to	  measure	  BP	   (Figure	  4.5-­‐4.7).	  Moreover,	   for	  each	  
method	   of	   BP	   measurement,	   the	   change	   in	   plasma	   NO2
-­‐	   levels	   was	   inversely	  
correlated	  to	  the	  changes	  in	  SBP	  (Figure	  4.9	  A-­‐C).	  In	  addition,	  the	  magnitude	  of	  BP	  
elevation	  was	   also	   inversely	   correlated	   to	  baseline	  BP,	   i.e.	   the	   lower	   the	  baseline	  




Figure	  4.9	  Reduction	   in	  plasma	  NO2
-­‐	   levels	  determines	  elevation	   in	  BP.	  The	   relationship	   in	  
change	  in	  plasma	  NO2
-­‐	  levels	  and	  changes	  in	  SBP	  measured	  in	  (A)	  clinic,	  (B)	  at	  home	  and	  by	  
(C)	  24h	  ABP	  after	  7	  days	  intervention	  with	  antiseptic	  mouthwash	  use.	  Significance	  shown	  for	  
correlations	   determined	   using	   Pearson’s	   linear	   regression	   of	   best-­‐fit±95%	   confidence	  
intervals.	  (ABP=ambulatory	  BP;	  NO2




Figure	  4.10	  Baseline	  BP	  determines	  elevation	  in	  BP.	  The	  relationship	  between	  baseline	  SBP	  
and	   changes	   in	   SBP	  measured	   in	   (A)	   clinic,	   (B)	   at	   home	   and	   by	   (C)	   24h	  ABP	   after	   7	   days	  
intervention	  with	  antiseptic	  mouthwash	  use.	  Significance	  shown	  for	  correlations	  determined	  
using	  Pearson’s	  linear	  regression	  of	  best-­‐fit±95%	  confidence	  intervals.	  (ABP=ambulatory	  BP;	  
SBP=systolic	  blood	  pressure).	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4.3.6	  Sex-­‐specific	  differences	  after	  disruption	  of	  oral	  microflora	  
4.3.6.1	  General	  characteristics	  
Pre-­‐specified	  sub-­‐group	  analyses	  of	  the	  data	  were	  conducted	  to	  stratify	  the	  results	  
by	  sex.	  In	  the	  cohort	  that	  completed	  the	  study,	  there	  were	  11	  males	  and	  8	  females.	  
Self-­‐reported	  daily	  estimates	  of	  fruit,	  vegetable	  and	  processed	  meat	  intake	  were	  no	  
different	  between	  sexes	  at	  baseline	  or	  after	  the	  treatment	  period	  (Table	  4.7).	  There	  
were	  some	  significant	  sex	  differences	  in	  baseline	  characteristics,	  with	  BMI	  and	  SBP	  
(by	  all	  3	  methods)	  higher	  in	  males,	  and	  both	  plasma	  and	  salivary	  NO2
-­‐	  levels	  greater	  
in	  females	  (Table	  4.8).	  	  
	  
Baseline	   Post-­‐mouthwash	  Food	  group	  
(mean	  portions/day)	  
Male	   Female	   Male	   Female	  
Fruit	   0.3±0.2	   0.8±0.3	   0.3±0.2	   0.8±0.3	  
Low-­‐NO3
-­‐	  vegetables	   0.7±0.1	   0.5±0.1	   0.6±0.2	   0.5±0.1	  
High-­‐NO3
-­‐	  vegetables	   0.3±0.1	   0.2±0.1	   0.3±0.2	   0.3±0.1	  
Processed	  meat	   0.7±0.2	   0.7±0.1	   0.8±0.2	   0.6±0.1	  
Table	   4.7	   Self-­‐reported	   daily	   food	   estimates	   stratified	   by	   sex.	   Data	   are	   expressed	   as	  
mean±SEM	   (n=11	   males,	   n=8	   females).	   No	   significant	   differences	   found	   after	   Bonferroni	  





Baseline	  characteristic	   Male	   Female	   Significance	  (p)	  
Subjects	  (n)	   11	   8	   	  
Age	  (years)	   22.8±10.3	   23.8±1.2	   0.377	  
BMI	  (kg/m2)	   22.4±0.6	   25.3±1.0	   0.023§	  
Clinic	  SBP	  (mmHg)	   113.9±1.9	   105.5±2.4	   0.012§	  
Clinic	  DBP	  (mmHg)	   65.9±2.0	   66.6±2.6	   0.818	  
Home	  SBP	  (mmHg)	   119.0±1.9	   110.2±2.1	   0.007§§	  
Home	  DBP	  (mmHg)	   67.0±0.8	   67.8±2.3	   0.727	  
Ambulatory	  SBP	  (mmHg)	   121.9±2.0	   115.6±2.1	   0.046§	  
Ambulatory	  DBP	  (mmHg)	   70.2±1.2	   70.4±2.7	   0.930	  
Plasma	  [NO3
-­‐]	  (µM)	   25.1±1.4	   28.8±5.4	   0.471	  
Plasma	  [NO2
-­‐]	  (nM)	   255.9±9.7	   323.1±34.3	   0.045§	  
Salivary	  [NO3
-­‐]	  (µM)	   392.4±47.5	   509.8±252.2	   0.413	  
Salivary	  [NO2
-­‐]	  (µM)	   260.3±32.9	   392.8±46.7	   0.029§	  
Urinary	  [NO3
-­‐]	  (µM)	   1392±66.1	   1558±122.0	   0.217	  
Urinary	  [NO2
-­‐]	  (nM)	   202.5±7.6	   203.8±19.0	   0.948	  
Table	   4.8	   Baseline	   characteristics	   stratified	   by	   sex.	   Demographics,	   haemodynamics	   and	  
baseline	   NOx	   levels.	   Data	   are	   expressed	   as	   mean±SEM	   (n=11	   males,	   n=8	   females).	  
Significance	   shown	   for	   unpaired	   Student’s	   t-­‐test	   in	   last	   column	  as	   §p<0.05	  and	  §§p<0.01.	  
(BMI=body	   mass	   index;	   DBP=diastolic	   blood	   pressure;	   NO3
-­‐=nitrate;	   NO2
-­‐=nitrite;	  
NOx=nitrite/nitrate;	  SBP=systolic	  blood	  pressure).	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4.3.6.2	  Females	  exhibit	  greater	  oral	  NO3
-­‐	  reductase	  activity	  under	  basal	  conditions	  
There	  appeared	  to	  be	  little	  sex	  difference	  in	  oral	  NO3
-­‐	  reduction	  after	  instillation	  of	  
NOx-­‐free	   water	   (Figure	   4.11-­‐4.12)	   but	   females	   had	   significantly	   higher	   oral	   NO3
-­‐	  
reduction	   after	   instillation	   of	   KNO3	   solutions.	   After	   instillation	   of	   0.8mM	   KNO3	  
solution,	   oral	   NO3
-­‐	   reductase	   activity	   was	   ~2.5-­‐fold	   higher	   (Table	   4.9)	   in	   females	  
compared	  to	  males	  (p<0.01	  by	  2-­‐way	  ANOVA,	  Figure	  4.11-­‐4.12)	  (Table	  4.9)	  and	  after	  
8mM	  KNO3	  solutions,	  ~1.4-­‐fold	  higher	  (Table	  4.9)	  compared	  to	  males	  (p<0.05	  by	  2-­‐
way	  ANOVA,	  Figure	  4.11-­‐4.12).	  
	  
Rate	  of	  oral	  NO3
-­‐	  reductase	  activity	  (nmol/min)	   	  Solution	  
Male	   Female	  
NOx-­‐free	  water	   20±4	   17±5	  
0.8mM	  [NO3
-­‐]	   69±16	   173±43	  
8mM	  [NO3
-­‐]	   183±29	   252±51	  
Table	  4.9	  Rates	  of	  oral	  NO3
-­‐	  reductase	  activity	  at	  baseline	  stratified	  by	  sex.	  Data	  expressed	  
as	  mean±SEM	  (males,	  n=11;	  females	  n=8).	  (NO3
-­‐=nitrate;	  NOx=nitrite/nitrate).	  
	  
Antiseptic	  mouthwash	  use	  diminished	  oral	  NO3
-­‐	  reductase	  activity	  similarly	  by	  ~90%	  





Figure	  4.11	  Effects	  of	  antiseptic	  mouthwash	  use	  on	  oral	  NO3
-­‐	  reductase	  activity	  in	  females.	  
Oral	  NO3
-­‐	  reductase	  activity	  after	  instillation	  of	  NO3
-­‐-­‐containing	  solutions	  for	  1-­‐5	  min	  at	  (A)	  
baseline	  and	  (B)	  after	  daily	  use	  of	  antiseptic	  mouthwash	  for	  7	  days.	  Significance	  shown	  as	  








Figure	  4.12	  Effects	  of	   antiseptic	  mouthwash	  use	  on	  oral	  NO3
-­‐	   reductase	  activity	   in	  males.	  
Oral	  NO3
-­‐	  reductase	  activity	  after	  instillation	  of	  NO3
-­‐-­‐containing	  solutions	  for	  1-­‐5	  min	  at	  (A)	  
baseline	  and	  (B)	  after	  daily	  use	  of	  antiseptic	  mouthwash	  for	  7	  days.	  Data	  are	  expressed	  as	  





4.3.6.3	  Sex-­‐specific	  effects	  of	  mouthwash	  use	  on	  systemic	  NOx	  levels	  
Following	  7	  days	  continuous	  use	  of	  antiseptic	  mouthwash,	  salivary	  NO2
-­‐	  levels	  were	  
reduced	  (Table	  4.10)	  in	  relative	  terms	  by	  85±10%	  and	  87±6%	  in	  males	  and	  females	  
respectively	   (p<0.001	   for	   both).	   Plasma	   NO2
-­‐	   levels	   were	   reduced	   by	   21±2%	   in	  
males,	   but	   there	   was	   a	   greater	   relative	   reduction	   of	   29±3%	   in	   females	   (p<0.05,	  
unpaired	  Student	  t-­‐test).	  The	  absolute	  decrease	  in	  plasma	  NO2
-­‐	  levels	  was	  greater	  in	  
females	  compared	  to	  males	  (Table	  4.10)	  with	  post-­‐mouthwash	  plasma	  NO2
-­‐	  levels	  in	  
males:	  202.2±14.6	  nM	  and	  in	  females:	  228.8±24.6	  nM.	  Similarly,	  there	  was	  a	  20±5%	  
reduction	   in	   urinary	   NO2
-­‐	   levels	   in	   males	   (p<0.01)	   and	   a	   corresponding	   30±8%	  
reduction	   in	   urinary	   NO2
-­‐	   levels	   in	   females	   (p<0.05),	   though	   the	   relative	   and	  
absolute	  decreases	  in	  urinary	  NO2
-­‐	  levels	  in	  females	  were	  not	  greater	  than	  in	  males.	  
	  
Salivary	   NO3
-­‐	   levels	   were	   elevated	   by	   ~2-­‐fold	   in	   males	   and	   ~2.5-­‐fold	   in	   females	  
respectively	   after	   7	   days	   continuous	   use	   of	   antiseptic	   mouthwash	   (Table	   4.10).	  
There	  was	   no	   significant	   change	   in	   plasma	  NO3
-­‐	   levels	   in	   both	   sexes	   (Table	   4.10).	  
The	   change	   in	   urinary	   NO3
-­‐	   levels	   was	   significant	   in	   both	  males	   (p<0.05,	   by	   one-­‐




Baseline	  characteristic	   Female	   Male	  
Subjects	  (n)	   8	   11	  
ΔPlasma	  [NO3
-­‐]	  (µM)	   7.7±3.5	   6.6±2.9	  
ΔPlasma	  [NO2
-­‐]	  (nM)	   -­‐94.4±15.8§	   -­‐53.7±9.3	  
ΔSalivary	  [NO3
-­‐]	  (µM)	   765.2±180.1	   432.1±92.1	  
ΔSalivary	  [NO2
-­‐]	  (µM)	   -­‐353.7±57.0	   -­‐231.5±39.7	  
ΔUrinary	  [NO3
-­‐]	  (µM)	   599.6±152.9	   386.2±138.2	  
ΔUrinary	  [NO2
-­‐]	  (nM)	   -­‐64.4±23.3	   -­‐41.6±12.5	  
Table	  4.10	  Sex-­‐specific	  changes	  in	  systemic	  NOx	  levels	  following	  antiseptic	  mouthwash	  use.	  
Data	  are	  expressed	  as	  mean±SEM	  (n=11	  male,	  n=8	  female).	  Significance	  shown	  as	  §p<0.05	  





4.3.6.4	  Sex-­‐specific	  effects	  of	  mouthwash	  use	  on	  BP	  
Home	   SBP	   and	   DBP	   increased	   in	   both	   sexes	   after	   mouthwash	   use	   (Table	   4.11).	  
However,	   the	   increases	   in	  clinic	  BP	  and	  ABP	  were	  only	  apparent	   in	   females	  (Table	  
4.11).	  
	  
Characteristic	   Female	   Male	  
Subjects	  (n)	   8	   11	  
ΔClinic	  SBP	  (mmHg)	   5.2±1.2§§	   2.2±1.4	  
ΔClinic	  DBP	  (mmHg)	   4.3±1.4§	   0.7±1.2	  
ΔHome	  SBP	  (mmHg)	   3.1±0.5§§§	   2.7±0.6§§	  
ΔHome	  DBP	  (mmHg)	   2.0±0.8§	   2.0±0.7§	  
ΔAmbulatory	  SBP	  (mmHg)	   4.4±0.9§§	   1.3±1.3	  
ΔAmbulatory	  DBP	  (mmHg)	   3.7±1.4§	   1.1±0.8	  
Table	  4.11	  Changes	   in	  BP	  after	  antiseptic	  mouthwash	  use	  stratified	  by	  sex.	  Changes	   in	  BP	  
after	  7	  days	  use	  of	  antiseptic	  mouthwash	  measured	  in	  the	  clinic,	  at	  home	  and	  by	  24	  h	  ABP;	  
Data	  are	  expressed	  as	  mean±SEM	  (n=11	  male,	  n=8	  female).	  Significance	  shown	  as	  §p<0.05,	  
§§p<0.01	  and	  §§§p<0.001	  for	  one-­‐sample	  Student	  t-­‐test.	  (ABP=ambulatory	  blood	  pressure;	  




1. Reduction	  of	  NO3-­‐	  to	  NO2-­‐	  in	  the	  oral	  cavity	  can	  be	  abrogated	  by	  twice-­‐daily	  
use	  of	  antiseptic	  mouthwash	  in	  healthy	  subjects.	  
2. Interruption	  of	  the	  entero-­‐salivary	  circulation	  by	  antiseptic	  mouthwash	  use	  
attenuates	  plasma	  NO2
-­‐	  levels	  by	  ~25%.	  
3. These	   changes	   in	   plasma	   NO2-­‐	   levels	   are	   significantly	   inversely	   correlated	  
with	  small,	  significant	  elevations	  in	  BP	  of	  2-­‐3.5	  mmHg	  in	  magnitude.	  
4. Females	   have	   higher	   baseline	   plasma	   NO2-­‐	   levels	   and	   oral	   NO3-­‐	   reductase	  
activity	  than	  males.	  
5. Interruption	   of	   the	   entero-­‐salivary	   circulation	   has	   a	   greater	   effect	   on	  
lowering	  plasma	  NO2
-­‐	  levels	  in	  females	  than	  in	  males.	  
6. Changes	  in	  clinic	  BP	  and	  ABP	  after	  antiseptic	  mouthwash	  were	  only	  apparent	  











Investigation	  of	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  effect	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systemic	  NO2





Elevations	   of	   plasma	   NO2
-­‐	   levels,	   via	   inorganic	   or	   dietary	   NO3
-­‐	   supplementation,	  
have	   been	   demonstrated	   to	   produce	   robust,	   dose-­‐dependent	   BP	   reductions	   in	  
healthy	  subjects	  over	  3-­‐24	  h	  in	  the	  studies	  described	  in	  chapter	  3,	  confirming	  earlier	  
reports	  of	  the	  BP-­‐lowering	  effects	  of	  NO3
-­‐	   ingestion.	   (Larsen	  et	  al.,	  2006;	  Webb	  et	  
al.,	  2008a).	  
	  
Although	  BP	  represents	  a	  continuous	  variable,	  with	  increasing	  risk	  of	  CVDs	  related	  
to	  increasing	  levels	  of	  BP	  in	  a	  strong	  linear	  relationship	  down	  to	  a	  nadir	  of	  ~115/75	  
mmHg	   (Lewington	   et	   al.,	   2002),	   national (Williams	   et	   al.,	   2004) and	   international	  
(Mancia	  et	  al.,	  2007)	  guidelines	  do	  not	  suggest	  treatment	  of	  BP	  until	  levels	  reach	  a	  
threshold,	  most	  commonly	  determined	  to	  be	  >140/90	  mmHg.	  Thus	   it	   is	   important	  
to	   establish	   the	   efficacy	   of	   inorganic	   NO3
-­‐	   supplementation	   in	   lowering	   BP	   in	   a	  
hypertensive	   cohort,	   as	   this	   is	   the	   cohort	   most	   likely	   to	   benefit	   from	   such	   a	  
therapeutic	  strategy.	  Thus	  the	  aim	  of	  this	  study	  was	  to	  determine	  whether	  dietary	  
NO3
-­‐	   ingestion	   has	   similar	   effects	   on	   plasma	   NOx	   levels	   and	   BP	   in	   hypertensive	  
subjects	  as	  in	  healthy	  subjects.	  
	  
5.2	  Protocol	  
Design:	   To	   investigate	   the	   effects	   of	   inorganic	   NO3
-­‐	   supplementation	   in	   a	  
hypertensive	   cohort,	   a	   randomized,	   open	   label,	   cross-­‐over	   study	   was	   performed	  
with	   subjects	   receiving	   250	   mL	   of	   dietary	   NO3
-­‐	   (beetroot	   juice;	   purchased	   from	  
James	  White	  Drinks,	  Ipswich,	  UK)	  or	  an	  equal	  volume	  of	  low-­‐NOx	  containing	  water	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(placebo,	  [NO3
-­‐]=	  70.9±10.0	  μM;	  [NO2
-­‐]	  <50	  nM),	  with	  at	  least	  7	  days	  between	  each	  
limb	  of	  the	  study.	  
	  
Power	   analysis:	   Given	   the	   higher	   pre-­‐treatment	   BP	   in	   hypertensives,	   it	   was	  
hypothesized	  that	  a	  similar	  BP	  reduction	  would	  be	  found	  as	   in	  the	  24	  mmol	  KNO3	  
vs.	   KCl	   study.	   Observed	   peak	   decrease	   in	   SBP	   occurred	   at	   2.5-­‐3	   h,	   post-­‐KNO3	  
ingestion	  with	  peak	  ΔSBP	  7.4	  mmHg	  (SD	  7.2).	  Based	  on	  these	  values	  and	  an	  α=0.05	  
and	   1-­‐β=0.90,	   power	   calculations	   determined	   n=13	   is	   required.	   An	   additional	   2	  
subjects	  were	  recruited	  to	  a	  final	  n=15	  to	  account	  for	  potential	  dropouts.	  
	  
Measurements:	  Following	  arrival	  in	  the	  clinic,	  clinic	  BP	  and	  HR	  were	  measured	  for	  1	  
h	   to	  establish	  baseline	  values	   (section	  2.4.1).	  Following	   this,	   subjects	   ingested	   the	  
randomized	  intervention	  with	  a	  light	  breakfast.	  BP,	  HR	  and	  arterial	  stiffness	  (section	  
2.5)	   were	   measured,	   and	   blood	   samples	   for	   plasma	   NOx	   and	   cGMP	   analysis	  
collected	  (section	  2.6)	  at	  specific	  time-­‐points	  over	  the	  following	  6	  h.	  After	  this	  time,	  
the	  subjects	   left	  and	  then	  returned	  the	  following	  morning	  for	  24	  h	  measurements	  
(see	  Figure	  5.1).	  
	  




Figure	  5.1	  Timeline	  for	  hypertensive	  study.	  (BP=blood	  pressure;	  PWV=pulse	  wave	  velocity).	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5.3	  Results	  	  
5.3.1	  General	  characteristics	  	  
All	   individuals	   recruited	   were	   classified	   on	   the	   screening	   visit	   as	   having	   grade	   1	  
hypertension	  assessed	  according	  to	  the	  BHS	  guidelines	  (Williams	  et	  al.,	  2004)	  (Table	  
5.1).	   There	   were	   no	   significant	   differences	   in	   the	   general	   characteristics	   of	   the	  
individuals	   recruited	  between	   the	   separate	   limbs	  of	   the	   study	   (Table	  5.2).	  Dietary	  
NO3
-­‐,	   as	   beetroot	   juice,	   was	   well	   tolerated	   by	   the	   subjects.	   The	   [NO3
-­‐]	   of	   the	  
beetroot	  juice	  was	  13.2±0.94	  mM,	  [NO2
-­‐]	  was	  <50	  nM	  (n=15).	  
	  
Characteristic	   	   	  
Subjects	  (n)	   	   15	  (7	  female)	  
ABP	  (daytime	  mean)	  (mmHg)	   SBP	   151.5±1.8	  
	   DBP	   89.7±2.2	  
estimated	  GFR	  (MDRD)	  (mL/min)	   	   77.3±3.3	  
total	  serum	  [cholesterol]	  (fasting)	  (mM)	  	   	   5.7±0.3	  
serum	  [LDL-­‐cholesterol]	  (fasting)	  (mM)	   	   3.3±0.3	  
plasma	  [glucose]	  (fasting)	  (mM)	   	   5.5±0.3	  
Table	   5.1	  Haemodynamic/biochemical	   parameters	   of	   hypertensive	   subjects	   at	   screening.	  
Data	   are	   shown	   as	   mean±SEM.	   ABP	   values	   adjusted	   as	   per	   British	   Hypertension	   Society	  
guidelines	   (Williams	   et	   al.,	   2004).	   (ABP=ambulatory	   BP;	   BP=blood	   pressure;	  DBP=diastolic	  
blood	   pressure;	   GFR=glomerular	   filtration	   rate;	   LDL=low-­‐density	   lipoprotein;	  
MDRD=Modification	  of	  Diet	  in	  Renal	  Disease	  formula;	  SBP=systolic	  blood	  pressure).	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Subjects	  (n)	   	   15	   	   	  
Age	  (years)	   	   52.9±3.7	   	   	  
BMI	  (kg/m2)	   	   26.2±0.9	   	   	  
Serum	  [creatinine]	  (μM)	   	   89.4±3.8	   	   	  
Baseline	  clinic	  SBP	  (mmHg)	   140.2±3.6	   139.9±3.9	   0.90	  
Baseline	  clinic	  DBP	  (mmHg)	   86.2±2.7	   86.5±2.6	   0.80	  
Plasma	  [NO3
-­‐]	  (μM)	   33.7±4.6	   46.8±10.3	   0.15	  
Plasma	  [NO2
-­‐]	  (μM)	   0.41±0.05	   0.43±0.04	   0.68	  
Table	   5.2	   Demographic	   characteristics	   and	   baseline	   (pre-­‐treatment)	   haemodynamic	   /	  
biochemical	   parameters	   in	   hypertensive	   subject	   study.	   Data	   are	   shown	   as	   mean±SEM.	  
Significance	  values	  for	  paired	  Student	  t-­‐test	  shown	   in	   last	  column.	   (BMI=body	  mass	   index;	  
DBP=diastolic	  blood	  pressure;	  NO3
-­‐=nitrate;	  NO2
-­‐=nitrite;	  SBP=systolic	  blood	  pressure).	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5.3.2	  Dietary	  NO3
-­‐	  elevates	  plasma	  NOx	  levels	  
Following	  dietary	  NO3
-­‐	   ingestion	  (~3.3	  mmol),	  plasma	  NO3
-­‐	   levels	  rapidly	   increased	  
with	  significant	  elevations	  above	  baseline	  evident	  at	  30	  min	   (p<0.05).	   Increases	   in	  
plasma	  NO3
-­‐	   levels	   peaked	   at	   2	   h	   (peak	   ~5.5-­‐fold	   increase	   from	  baseline:	   156.8	   ±	  
22.9	   µM;	   p<0.001)	   and	   remained	   elevated	   for	   the	   first	   6	   h	   of	   measurement,	  
returning	   to	   baseline	   at	   24	   h	   (Figure	   5.2	  A).	   Plasma	  NO2
-­‐	   levels	   had	   a	   slower	   rise	  
following	  dietary	  NO3
-­‐	  ingestion,	  becoming	  significantly	  elevated	  compared	  to	  water	  
control	  at	  4	  h	  (peak	  ~1.5-­‐fold	  increase	  from	  baseline:	  0.24±0.06	  µM,	  p<0.05;	  Figure	  
5.2	  B),	  with	  NO2
-­‐	  levels	  approaching	  baseline	  levels	  by	  24	  h.	  In	  contrast	  there	  were	  




-­‐	  elevates	  plasma	  cGMP	  levels	  
Consumption	  of	  NO3
-­‐,	  with	  subsequent	  formation	  of	  NO2
-­‐,	  was	  associated	  with	  NO-­‐
like	  bioactivity	  as	  evidenced	  by	  rises	  in	  plasma	  cGMP	  levels	  measured	  at	  24	  h	  post-­‐
NO3




Figure	  5.2	  Dietary	  NO3
-­‐	   supplementation	  elevates	  plasma	  NOx	  and	  cGMP	   levels	   in	  grade	  1	  
hypertension	  The	  effects	  of	  dietary	  NO3
-­‐	  ingestion	  (beetroot	  juice	  250	  mL)	  or	  placebo	  (water	  
250	  mL)	  on	  plasma	  (A)	  NO3
-­‐,	  (B)	  NO2
-­‐	  and	  (C)	  cGMP	  levels.	  Data	  are	  expressed	  as	  mean±SEM	  
(n=15).	   Significance	   shown	   for	   comparisons	   between	   groups	   as	   ###p<0.001	   for	   2-­‐way	  
ANOVA;	  and	  *p<0.05,	  **p<0.01,	  and	  ***p<0.001	  for	  Bonferroni	  post-­‐hoc	  tests	  following	  1-­‐






-­‐	  lowers	  BP	  in	  grade	  1	  hypertensive	  subjects	  
Consumption	  of	  dietary	  NO3
-­‐	  caused	  a	  significant	  decrease	  in	  SBP	  and	  DBP	  (p<0.001	  
vs.	  water	  control,	  Figure	  5.3	  A-­‐B).	  SBP	  started	  to	  fall	  after	  1.5	  h,	  with	  the	  greatest	  
reductions	   in	   SBP	   occurred	   between	   3	   and	   6	   h	   post-­‐NO3
-­‐	   ingestion.	   The	   peak	  
decrease	  was	  11.2±2.6	  mmHg	  versus	  0.7±1.9	  mmHg	  in	  the	  water	  control.	  At	  24	  h,	  
SBP	  was	  still	  significantly	  lower	  than	  the	  water	  control	  (difference	  NO3
-­‐	  versus	  water	  
of	   8.5±1.3	   mmHg,	   p<0.01,	   Figure	   5.3	   A)	   and	   significantly	   reduced	   from	   baseline	  
(7.2±2.1	  mmHg,	  p<0.05	  Dunnett’s	  post-­‐hoc	  test	  of	  comparison	  to	  baseline	  (t=	  0	  h)	  
following	   1-­‐way	   ANOVA).	   The	   greatest	   change	   in	   DBP	   occurred	   at	   4	   h	   post-­‐NO3
-­‐	  
ingestion	  with	  a	  drop	  of	  9.6±1.2	  mmHg	  versus	  2.9±1.4	  mmHg	  in	  the	  water	  control.	  
DBP	   remained	   lower	   in	   the	  NO3
-­‐-­‐treated	   limb	  up	   to	   6	  h	   and	   returned	   to	   the	  pre-­‐
treatment	  pressure	  after	  24	  h	  (Figure	  5.3	  B).	  No	  significant	  differences	  in	  HR	  were	  
observed	  after	  ingestion	  of	  dietary	  NO3




Figure	  5.3	  Dietary	  NO3
-­‐	  supplementation	  reduces	  BP	  in	  grade	  1	  hypertension.	  The	  effects	  of	  
dietary	  NO3
-­‐	  ingestion	  (beetroot	  juice	  250	  mL)	  or	  placebo	  (water	  250	  mL)	  on	  changes	  from	  
baseline	   in	   (A)	   SBP,	   (B)	   DBP	   and	   (C)	   HR.	   Data	   are	   expressed	   as	   mean±SEM	   (n=15).	  
Significance	  shown	  for	  comparisons	  between	  groups	  as	  ###p<0.001	  for	  2-­‐way	  ANOVA;	  and	  
as	   *p<0.05,	   **p<0.01	   and	   ***p<0.001	   for	   Bonferroni	   post-­‐hoc	   tests.	   (BP=blood	   pressure;	  
DBP=diastolic	  blood	  pressure;	  HR=heart	  rate;	  NO3
-­‐=nitrate;	  SBP=systolic	  blood	  pressure).	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5.3.5	  Dietary	  NO3
-­‐	  ingestion	  lowers	  PWV	  
Aortic	   stiffness,	   measured	   by	   PWV,	   was	   significantly	   decreased	   at	   3	   h	   following	  
dietary	   NO3
-­‐	   ingestion	   (change	   in	   PWV:	   0.83±0.31	   ms-­‐1);	   there	   were	   no	   changes	  
after	   consumption	   of	   water	   and	   importantly,	   there	   were	   no	   differences	   in	   PWV	  
between	  the	  two	  groups	  at	  baseline	  (Figure	  5.4).	  	  
	  
5.3.6	  Electrolyte	  and	  renal	  indices	  following	  dietary	  NO3
-­‐	  ingestion	  
In	   these	   subjects,	   both	   serum	   K+	   and	   Cl-­‐	   levels	   were	   greater	   after	   dietary	   NO3
-­‐	  
ingestion	  that	  after	  placebo	  ingestion.	  (Figure	  5.5	  A-­‐B).	  No	  significant	  differences	  in	  
serum	  HCO3
-­‐,	  urea	  or	  creatinine	  levels	  were	  observed	  between	  the	  two	  limbs	  over	  





Figure	  5.4	  Dietary	  NO3
-­‐	  supplementation	  reduces	  arterial	  stiffness	  in	  hypertensive	  subjects.	  
The	  effects	  of	  dietary	  NO3
-­‐	  ingestion	  (beetroot	  juice	  250	  mL)	  or	  placebo	  (water	  250	  mL)	  on	  
aortic	  PWV.	  Data	  are	  expressed	  as	  mean±SEM	  (n=15).	  Significance	  shown	   for	  *p<0.05	   for	  
Bonferroni	  post-­‐hoc	  tests	  following	  1-­‐way	  ANOVA.	  (NO3





Figure	   5.5	   Elevated	   serum	   K+	   and	   Cl-­‐	   levels	   following	   dietary	   NO3
-­‐	   ingestion.	   Changes	   in	  
serum	  (A)	  K+	  and	  (B)	  Cl-­‐	  levels	  after	  dietary	  NO3
-­‐	  or	  water	  control	  ingestion	  over	  24	  h.	  Data	  
are	   expressed	   as	  mean±SEM	   (n=15).	   Significance	   shown	   for	   comparisons	   between	  groups	  
#p<0.05	   and	   ###p<0.001	   for	   2-­‐way	   ANOVA;	   followed	   by	   *p<0.05	   for	   Bonferroni	   post-­‐hoc	  






Figure	  5.6	  Renal	   indices	  do	  not	  change	  following	  dietary	  NO3
-­‐	   ingestion.	  Changes	  in	  serum	  
(A)	  HCO3
-­‐,	  (B)	  urea	  and	  (C)	  creatinine	  after	  dietary	  NO3
-­‐	  or	  water	  control	  ingestion	  over	  24	  h.	  
Data	   are	   expressed	   as	   mean±SEM	   (n=15).	   Significance	   shown	   for	   comparisons	   between	  






5.3.7	  Changes	  in	  BP	  are	  correlated	  with	  plasma	  NO2
-­‐	  levels	  
Despite	  higher	  serum	  K+	  and	  plasma	  NO3
-­‐	   levels	  after	  dietary	  NO3
-­‐	   ingestion,	  there	  
were	   no	   correlations	   between	   changes	   in	   SBP	   with	   either	   changes	   in	   serum	   K+	  
(p=0.396)	   or	   plasma	   NO3
-­‐	   (p=0.120)	   levels	   observed	   (Figure	   5.7	   A-­‐B).	   However,	  
linear	  regression	  analysis	  showed	  a	  significant	  inverse	  correlation	  between	  changes	  
in	   plasma	   NO2
-­‐	   levels	   and	   changes	   in	   SBP	   (p<0.001,	   r2=0.078;	   Figure	   5.7	   C).	   In	  
addition,	   the	  peak	  decreases	   in	   SBP	   and	  DBP	   coincided	  with	   the	  peak	   increase	   in	  
plasma	  NO2
-­‐,	  not	  NO3
-­‐,	   levels	   (Figures	  5.2	  A-­‐B;	  5.3	  A-­‐B).	  The	  peak	  decrease	   in	  SBP	  
was	   correlated	   to	  baseline	   SBP	   (p=0.029,	   r2=0.315;	   Figure	  5.8	  A),	   although	   such	  a	  
correlation	  was	   not	   evident	   for	  DBP	   (p=0.890,	   Figure	   5.8	   B).	   Finally,	   baseline	   SBP	  
inversely	  correlated	  to	  baseline	  plasma	  NO2





Figure	  5.7	  Changes	  in	  plasma	  NO2
-­‐	   levels	  determine	  change	  in	  BP	  in	  hypertensive	  subjects.	  
Correlation	  of	  changes	  in	  (A)	  K+,	  (B)	  NO3
-­‐	  and	  (C)	  NO2
-­‐	  levels	  to	  changes	  in	  SBP	  from	  baseline	  
after	   dietary	   NO3
-­‐	   ingestion.	   All	   of	   the	   graphs	   show	   Pearson’s	   linear	   regression	   of	   best-­‐
fit±95%	  confidence	  intervals.	  (BP=blood	  pressure;	  K+=potassium;	  NO3
-­‐=nitrate;	  NO2
-­‐=nitrite;	  




Figure	   5.8	   Baseline	   BP	   determines	   response	   to	   dietary	   NO3
-­‐	   and	   is	   related	   to	   baseline	  
plasma	  NO2
-­‐	  levels.	  Correlation	  of	  peak	  changes	  from	  baseline	  in	  (A)	  SBP	  and	  (B)	  DBP	  after	  
dietary	   NO3
-­‐	   ingestion	   against	   baseline	   BP;	   and	   (C)	   baseline	   plasma	   NO2
-­‐	   levels	   against	  
baseline	  SBP.	  All	  of	  the	  graphs	  show	  Pearson’s	  linear	  regression	  of	  best-­‐fit±95%	  confidence	  
intervals.	   (BP=blood	   pressure;	   DBP=diastolic	   blood	   pressure;	   NO3
-­‐=nitrate;	   NO2
-­‐=nitrite;	  
SBP=systolic	  blood	  pressure).	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5.4	  Summary	  
1. Dietary	  inorganic	  NO3-­‐	  elevates	  plasma	  NOx	  levels	  in	  hypertensive	  subjects	  in	  
a	  similar	  manner	  to	  normotensive	  subjects.	  
2. Elevations	  of	  plasma	  NO2-­‐	   levels	  coincide	  with	  significant	   reductions	   in	  SBP	  
and	  DBP	  in	  hypertensive	  individuals	  3-­‐4	  h	  post-­‐ingestion	  of	  dietary	  NO3
-­‐,	  the	  
magnitude	  of	  which	  are	  related	  to	  baseline	  BP	  levels,	  and	  therefore	  greater	  
than	  in	  normotensive	  individuals.	  
3. SBP	  was	  still	  significantly	  reduced	  24	  h	  post-­‐dietary	  NO3-­‐	   ingestion	  and	  was	  
associated	  with	  significant	  increases	  in	  plasma	  cGMP	  levels.	  
4. Additionally,	   3	   h	   post-­‐dietary	   NO3-­‐	   ingestion,	   arterial	   stiffness	   was	  
significantly	  reduced	  compared	  to	  baseline	  values.	  	  
5. Although	   ingestion	   of	   dietary	   NO3-­‐	   additionally	   results	   in	   significant	  
differences	   in	   serum	  K+	   levels,	   elevations	   in	   serum	   levels	   of	   this	   cation	   do	  
not	  appear	  to	  be	  responsible	  for	  the	  BP-­‐lowering	  effects	  of	  dietary	  NO3
-­‐.	  
6. Changes	   in	  plasma	  NO2-­‐	   levels	   inversely	   correlate	   to	   changes	   in	   SBP	  whilst	  
the	  same	  is	  not	  true	  for	  changes	  in	  plasma	  NO3
-­‐	  levels.	  
7. Similar	   to	   normotensive	   individuals,	   baseline	   plasma	   NO2-­‐	   is	   inversely	  












6.1	  Introductory	  remarks	  
The	   elucidation	   of	   the	   identity	   of	   EDRF	   as	   NO	   and	   its	   protean	   roles	   in	   human	  
physiology	  and	  pathophysiology	  has	  been	  one	  of	  the	  seminal	  discoveries	  in	  biology	  
in	  the	  late	  20th	  century.	  It	  was	  designated	  ‘molecule	  of	  the	  year’	  by	  Science	  in	  1992	  
(Koshland,	   1992),	   and	   its	   ‘discoverers’	   were	   awarded	   the	   Nobel	   Prize	   in	   1998	  
(section	  1.3).	  Over	  the	  past	  25	  years,	  there	  has	  been	  a	  remarkable	  escalation	  in	  the	  
volume	  of	  NO	  research,	  especially	  in	  the	  realm	  of	  cardiovascular	  health	  and	  disease	  
(Moncada	  and	  Higgs,	  2006).	  A	  simple	  PubMed	  search	  with	   the	  search	   term	   ‘Nitric	  
Oxide’	   (http://www.ncbi.nlm.nih.gov/pubmed?term=nitric%20oxide)	   reveals	   6063	  
citations,	  from	  the	  beginning	  of	  its	  records,	  up	  to	  and	  including	  1993;	  in	  2011	  alone,	  
there	  were	  6762	  citations.	  	  
	  
Until	   recently,	   a	   catholic	   view	   of	   mammalian	   NO	   biology	   would	   include	   the	  
production	  of	  NO	  uniquely	  from	  the	  5	  e-­‐	  oxidation	  of	  the	  amino	  acid,	  L-­‐arginine	  by	  
NOS	  enzymes	  (Stuehr,	  1999).	  In	  recent	  years,	  there	  have	  been	  increasing	  evidences	  
of	  a	  complementary	  system	  for	  NO	  production	  from	  the	  1	  e-­‐	  reduction	  of	  NO2
-­‐	  (and,	  
with	  the	  involvement	  of	  symbiotic,	  facultative,	  anaerobic,	  oral	  bacteria,	  from	  NO3
-­‐)	  
that	   is	   especially	   prominent	   in	   situations	   of	   hypoxia	   and	   acidosis	   when	   the	  
traditional	  NOS	  enzymes	  are	  dysfunctional.	  As	  such,	  the	  NO3
-­‐-­‐NO3
-­‐-­‐NO	  pathway	  can	  
be	   considered	   to	  be	  a	  back-­‐up	   system	   for	  NO	  generation	   (Lundberg	   et	   al.,	   2008).	  
Prior	   to	   the	   appreciation	   of	   this	   alternative	   pathway,	   NO	  metabolism	   ended	   in	   a	  
one-­‐way,	   linear	   termination	   of	   activity	   by	   the	   oxidation	   to	   both	   NO2
-­‐	   and	   NO3
-­‐.	  
However,	   this	   novel	   paradigm	   reveals	   the	  2	   species	   to	  be	   in	   a	   ‘NO	   cycle’	   (Reutov	  
and	  Sorokina,	  1998)	  (Figure	  1.6).	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Over	   the	   past	   25	   years	   there	   have	   been	   many	   attempts	   to	   manipulate	   the	   L-­‐
arginine:NO	   pathway,	   through	   provision	   of	   substrate	   or	   co-­‐factors	   to	   the	   NOS	  
system,	   to	   facilitate	   greater	   NO	   production	   (reviewed	   in	   Zhang	   et	   al.,	   2011).	  
However,	  the	  discovery	  of	  authentic	  NO	  production	  from	  NO2
-­‐	  reduction	  (Benjamin	  
et	   al.,	   1994;	   Lundberg	   et	   al.,	   1994;	   Zweier	   et	   al.,	   1995)	   has	   provided	   a	   further	  
avenue	  within	  which	   to	   explore	   NO-­‐based	   therapeutics	   that	  was	   explored	   in	   this	  
thesis.	  
	  
The	  data	  presented	  in	  this	  thesis	  reveal	  robust,	  dose-­‐dependent	  decreases	  in	  BP	  in	  
healthy	  subjects	  after	   ingestion	  of	  dietary	  NO3
-­‐	  or	  supplementation	  with	   inorganic	  
NO3
-­‐	  salts	  and,	  for	  the	  first	  time,	  BP-­‐lowering	  effects	  of	  dietary	  NO3
-­‐	  in	  hypertensive	  
subjects.	   These	   effects	   are	  dependent	  on	  elevation	  of	   plasma	  NO2
-­‐	   levels,	   via	   the	  
entero-­‐salivary	   circulation,	   and	   conversion	   of	   this	   NO2
-­‐	   to	   bioactive	   NO	   in	   the	  
circulation.	   Moreover,	   I	   have	   shown	   that	   interruption	   of	   the	   entero-­‐salivary	  
circulation	   of	   NO3
-­‐	   to	   NO2
-­‐	   under	   basal	   conditions	   has	   important,	   detrimental	  
consequences	  on	  BP	  in	  healthy	  subjects.	  
	  
This	   thesis	   suggests	   that	   dietary	   or	   endogenously-­‐derived	   NO3
-­‐,	   and	   its	   oral	  
conversion	   to	   NO2
-­‐	   and	   subsequent	   appearance	   in	   the	   circulation	   and	   thence	  
reduction	  to	  NO,	  via	  the	  alternative	  pathways	  described	  (see	  section	  1.8),	  plays	  an	  
important	   part	   in	   regulating	   BP	   and	   potentially,	   vascular	   health.	   This	   thesis	   also	  
proposes	  a	  physiologically	  balanced	  reasoning	  for	  the	  hitherto	  unexplained	  actions	  
of	   the	   salivary	   glands	   selectively	   concentrating	   NO3
-­‐	   from	   the	   circulation	   and	  
secreting	  NO3
-­‐-­‐rich	  saliva	  into	  the	  oral	  cavity.	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6.2	  NO3
-­‐	  supplementation	  to	  elevate	  plasma	  NO2
-­‐	  levels	  and	  produce	  bioactive	  NO	  
6.2.1	  Dose-­‐dependent	   elevations	  of	   plasma	  NO2
-­‐	   levels	   in	   healthy	   subjects	   after	  
NO3
-­‐	  supplementation	  
In	  chapter	  3,	  I	  demonstrated	  that	  ingestion	  of	  KNO3	  capsules	  caused	  rises	  in	  plasma	  
NO3
-­‐	   levels	  and	   thence	  NO2
-­‐	   levels	   that	  were	  dose	  and	   time-­‐dependent	   in	  healthy	  
subjects.	   After	   ingestion	   of	   24	   mmol	   KNO3,	   significant	   elevations	   in	   plasma	   NO3
-­‐	  
levels	  were	  evident	  after	  30	  min,	  whilst	  it	  took	  1.5	  h	  for	  plasma	  NO2
-­‐	   levels	  to	  rise	  
significantly.	   This	   lag	   with	   respect	   to	   time	   for	   elevation	   in	   plasma	   NO2
-­‐	   levels	   is	  
consistent	   with	   previous	   reports	   in	   healthy	   subjects	   describing	   the	   effects	   of	  
inorganic	   or	   dietary	   NO3
-­‐	   ingestion	   on	   plasma	   NO2
-­‐	   levels	   (Lundberg	   and	   Govoni,	  
2004;	  Webb	  et	  al.,	  2008a)	  and	  reflects	  the	  time	  required	  for	  circulation	  through	  the	  
entero-­‐salivary	  pathway	  and	   reduction	  of	  NO3
-­‐	   to	  NO2
-­‐	   by	  oral	  microflora.	   Plasma	  
NO3
-­‐	   levels	   peaked	   at	   ~35-­‐fold	   higher	   than	  basal	   levels,	  whilst	   plasma	  NO2
-­‐	   levels	  
peaked	   at	   ~4-­‐fold	   higher	   than	   basal	   levels.	   This	   difference	   also	   reflects	   passage	  
through	  the	  entero-­‐salivary	  circulation	  and	  demonstrates	  that	  not	  all	  plasma	  NO3
-­‐	  is	  
eventually	  converted	  to	  plasma	  NO2
-­‐	  through	  the	  entero-­‐salivary	  circulation.	  It	  has	  
been	  estimated	  that	  the	  bioavailability	  of	  inorganic	  NO3
-­‐	  is	  100%	  after	  an	  oral	  load	  
(van	  Velzen	  et	  al.,	  2008)	  and	  that	  ~75%	  of	  an	  oral	  dose	  of	  inorganic	  NO3
-­‐	  is	  excreted	  
in	  the	  urine	  (Packer	  et	  al.,	  1989;	  Wennmalm	  et	  al.,	  1993;	  Pannala	  et	  al.,	  2003).	  The	  
remaining	   25%	   is	   concentrated	   by	   the	   salivary	   glands	   and	   is	   present	   in	   NO3
-­‐-­‐rich	  
saliva	   as	   substrate	   for	   the	   oral	   microflora	   to	   reduce	   to	   NO2
-­‐	   in	   the	   oral	   cavity	  
(Spiegelhalder	  et	  al.,	  1976;	  Kortboyer	  et	  al.,	  1994).	  Approximately	  ⅓	  of	  salivary	  NO3
-­‐	  
is	  converted	  to	  NO2
-­‐	  in	  the	  mouth	  (Lundberg	  and	  Govoni,	  2004;	  Webb	  et	  al.,	  2008a).	  
Indeed	   it	   has	   been	   estimated	   that	   ~5-­‐8%	   of	   an	   oral,	   inorganic	   NO3
-­‐	   dose	   is	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converted	   finally	   to	   plasma	   NO2
-­‐	   (Spiegelhalder	   et	   al.,	   1976;	   Eisenbrand	   et	   al.,	  
1980),	   which	   explains	   the	   reduced	   fold	   increases	   in	   plasma	   NO2
-­‐	   compared	   to	  
plasma	  NO3
-­‐	  levels	  after	  an	  oral	  inorganic	  NO3
-­‐	  load	  as	  noted	  above	  and	  previously	  
(Lundberg	  and	  Govoni,	  2004;	  Webb	  et	  al.,	  2008a).	  
	  
The	  time-­‐course	  for	  the	  changes	  in	  plasma	  NOx	  levels	  were	  similar	  with	  lower	  doses	  
of	   NO3
-­‐	   provided	   by	   either	   KNO3	   capsule	   (4	   and	   12	  mmol)	   or	   in	   dietary	   form	   as	  
beetroot	   juice	   (~5.5	  mmol).	   Peak	  plasma	  NO3
-­‐	   levels	  were	  evident	  within	  1	  h	  and	  
peak	   plasma	   NO2
-­‐	   levels	   were	   evident	   between	   2-­‐3	   h	   post-­‐NO3
-­‐	   ingestion.	   In	  
addition,	  the	  changes	  in	  plasma	  NOx	  levels	  were	  also	  dose-­‐dependent.	  Indeed,	  the	  
fold	   increase	   from	  basal	   levels	   in	  plasma	  NO3
-­‐	  after	   ingestion	  of	  4	   (inorganic	  salt),	  
5.5	  (dietary	  form	  as	  beetroot	  juice)	  and	  12	  (inorganic	  salt)	  mmol	  NO3
-­‐	  were	  ~7,	  ~11	  
and	  ~27-­‐fold	  respectively.	  These	  findings	  indicate	  that	  irrespective	  of	  source	  of	  NO3
-­‐	  
i.e.	   in	   salt	  or	   in	  dietary	   form,	   the	  pharmacokinetics	  of	  NO3
-­‐	   following	  an	  oral	  NO3
-­‐	  
load	  are	   similar.	   There	  were	   also	  dose-­‐dependent	   increases	   in	  plasma	  NO2
-­‐	   levels	  
irrespective	  of	  formulation.	  The	  fold	  increase	  in	  plasma	  NO2
-­‐	  levels	  from	  basal	  levels	  
after	   ingestion	   of	   4	   (inorganic	   salt),	   5.5	   (dietary	   form	   as	   beetroot	   juice)	   and	   12	  
(inorganic	  salt)	  mmol	  NO3
-­‐	  were	  ~1.3,	  ~1.6	  and	  ~2-­‐fold	  respectively.	  
	  
6.2.2	  NO3
-­‐	  supplementation	  elevates	  plasma	  NO2
-­‐	  levels	  in	  hypertension	  
In	  chapter	  5,	  I	  showed	  that	  a	  similar	  profile	  in	  the	  pharmacokinetics	  of	  NO3
-­‐	  was	  also	  
evident	   in	   hypertensive	   subjects.	   Following	   dietary	   NO3
-­‐	   ingestion,	   plasma	   NOx	  
levels	  were	  raised	  with	  respect	  to	  basal	  levels.	  Similar	  to	  healthy	  subjects,	  the	  rise	  in	  
plasma	  NO2
-­‐	  levels	  was	  delayed	  relative	  to	  plasma	  NO3
-­‐	  levels,	  with	  the	  peak	  rise	  in	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plasma	  NO2
-­‐	   levels	   occurring	   4	   h	   post-­‐NO3
-­‐	   consumption.	   This	   time-­‐lag	   relative	   to	  
the	  very	  rapid	  (30	  min)	  appearance	  of	  NO3
-­‐	  again	  reflects	  the	  dependence	  upon	  the	  
entero-­‐salivary	  circuit	   for	  the	  reduction	  of	  NO3
-­‐	  to	  NO2
-­‐	   in	  humans.	  Comparison	  of	  
these	  present	   findings	   to	  healthy	   subjects	   suggests	   that	   the	   time-­‐course	  of	   travel	  
and	  appearance	  within	  the	  circulation	  of	  the	  two	  distinct	  anions	  is	  similar	  between	  
normotensive,	  healthy	  subjects	  and	  grade	  1,	  drug-­‐naïve	  hypertensive	  subjects.	  	  
	  
The	   relative	   rise	   in	   plasma	  NO3
-­‐	   levels	   between	  normotensives	   and	  hypertensives	  
also	  followed	  a	  similar	  pattern.	  After	  ingestion	  of	  a	  ~3.3	  mmol	  dietary	  NO3
-­‐	  load	  in	  
hypertensive	   subjects,	   plasma	   NO3
-­‐	   levels	   were	   elevated	   above	   baseline	   by	   ~5.5-­‐
fold,	  which	  fits	  well	  with	  the	  data	  obtained	  from	  healthy	  subjects,	  in	  whom	  plasma	  
NO3
-­‐	  levels	  increased	  ~7,	  ~11	  and	  ~27-­‐fold	  after	  ingestion	  of	  4,	  5.5	  and	  12	  mmol	  of	  
NO3
-­‐	  as	  discussed	  previously.	  	  
	  
Perhaps	   more	   importantly,	   the	   relative	   rises	   in	   plasma	   NO2
-­‐	   levels	   after	   NO3
-­‐	  
ingestion	  in	  hypertensive	  subjects	  fitted	  well	  with	  the	  profiles	  in	  healthy	  subjects.	  In	  
normotensive	   subjects,	   a	   4	  mmol	   dose	   of	   KNO3	   caused	   a	   ~1.3-­‐fold	   peak	   increase	  
from	  baseline	  in	  plasma	  NO2
-­‐	  levels.	  The	  hypertensive	  subjects	  in	  this	  study	  received	  
a	  relatively	  smaller	  dose	  of	  ~3.3	  mmol	  NO3
-­‐	  with	  a	  peak	  fold	  increase	  of	  plasma	  NO2
-­‐	  
levels	  of	  ~1.5-­‐fold	  rise	  suggesting	  that	  if	  anything	  the	  processing	  of	  NO3
-­‐	  to	  NO2
-­‐	  is	  
improved	   in	   hypertensives,	   although	   a	   prospective	   study	   comparing	   age-­‐matched	  
normotensives	   and	   hypertensives	   would	   be	   required	   to	   confirm	   this,	   as	   the	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pharmacokinetics	  of	  drugs	  may	  be	  altered	  by	  the	  many	  physiological	  changes	  that	  
occur	  with	  normal	  ageing	   (Mangoni	  and	   Jackson,	  2004)	  and	   the	  mean	  ages	   in	   the	  
cohorts	   studied	   were	   appreciably	   different	   (mean	   age:	   52.9±3.7	   years	  
(hypertensive)	   vs.	   28.8±1.7	   years	   (4	   mmol	   KNO3	   normotensive	   cohort).	   These	  
similarities	  indicate	  that	  hypertension	  per	  se	  does	  not	  result	  in	  substantial	  changes	  
in	   the	   bioconversion	   rate	   and	   extent	   of	   NO3
-­‐	   processing	   via	   the	   entero-­‐salivary	  
circuit.	   However,	   it	   is	   important	   to	   note	   that	   the	   relative	   importance	   of	   renal	  
handling	  of	  these	  products	  was	  beyond	  the	  scope	  of	  these	  studies	  and	  deserves	  its	  
own	   investigation.	   The	   pathways	   for	   renal	   tubular	   transport	   of	   NOx	   are	   poorly	  
understood	   and	   clearly	   may	   be	   important	   when	   discussing	   similarities	   and	  
differences	   in	   plasma	   levels	   of	   these	   anions	   after	  NO3




-­‐	  supplementation	  results	  in	  bioactive	  NO	  generation	  in	  the	  circulation	  
Interpretation	   of	   plasma	   NOx	   levels	   is	   challenging	   due	   to	   the	   fact	   that	   multiple	  
pathways	  for	  the	  generation	  and	  destruction	  of	  NOx	  and	  NO	  exist	  (Lundberg	  et	  al.,	  
2008).	  Indeed,	  changes	  in	  plasma	  NO2
-­‐	  levels	  may	  reflect	  eNOS	  activity	  (Lauer	  et	  al.,	  
2001;	   Kleinbongard	   et	   al.,	   2003,	   2006b)	   NO	   oxidation	   (Ignarro	   et	   al.,	   1993),	   NO3
-­‐	  
reduction	   (Lundberg	   and	   Govoni,	   2004;	  Webb	   et	   al.,	   2008a)	   and,	   most	   likely,	   all	  
three	  at	  once.	  
	  
Whilst	   it	   is	   largely	  accepted	   that	  NO	  underlies	   the	  bioactivity	  of	  NO2
-­‐	   this	  has	  not	  
been	  clearly	  demonstrated	  in	  humans	  in	  vivo	  previously.	  In	  this	  current	  work	  I	  have	  
 227	  
demonstrated	  a	  temporal	  relationship	  between	  the	  rise	  in	  plasma	  NO2
-­‐	  levels	  with	  a	  
rise	  in	  cGMP	  levels,	  both	  after	  dietary	  NO3
-­‐	  and	  inorganic	  NO3
-­‐	  supplementation	  in	  
both	   normotensive	   and	   hypertensive	   subjects.	   These	   observations	   confirm	   the	  
formation	   of	   bioactive	   NO	   within	   the	   human	   circulation.	   cGMP	   is	   an	   exquisitely	  
sensitive	   indicator	  of	  NO	  production,	  via	  activation	  of	  NO-­‐sensitive	  sGC	  (Batchelor	  
et	  al.,	  2010).	  Thus	  detection	  of	  elevated	  levels	  of	  cGMP	  provides	  strong	  evidence	  of	  
the	  generation	  of	  bioactive	  NO	  (Hobbs,	  1997;	  Hobbs	  and	  Stasch,	  2010)	   from	  both	  
formulations	  of	  NO3
-­‐	  in	  healthy	  and	  hypertensive	  subjects.	  However,	  there	  is	  some	  
evidence	  suggesting	  that	  NO2
-­‐	  may	  exert	  direct	  effects	  on	  sGC	   independent	  of	  NO	  
formation	   (Bryan	   et	   al.,	   2005),	   a	   possibility	   that	   cannot	   be	   excluded	   by	   the	  
detection	  of	  elevated	  cGMP	  levels	  in	  these	  studies.	  
	  
What	  cannot	  be	  deduced	  from	  the	  studies	  in	  this	  thesis	  is	  the	  exact	  location	  of	  NO2
-­‐	  
reduction	   to	   NO.	   There	   are	   lines	   of	   evidence	   that	   purport	   to	   demonstrate	   NO2
-­‐	  
reduction	   inside	   erythrocytes	   (Cosby	   et	   al.,	   2003),	   at	   the	   level	   of	   erythrocyte	  
membranes	   (Webb	   et	   al.,	   2008b)	   and	   within	   the	   vascular	   wall	   (Liu	   et	   al.,	   2007;	  
Alzawahra	   et	   al.,	   2008;	   Feelisch	   et	   al.,	   2008),	   but	   these	   studies	   have	   used	   either	  
isolated	  cell	  or	  tissue	  preparations	  and	  have	  not	  addressed	  NO2
-­‐	  reduction	   in	  vivo.	  
This	   is	   challenging	   because	   of	   the	   numerous,	   putative	   NO2
-­‐	   reductases	   described	  
earlier	   in	   section	   1.8	   and	   difficulty	   in	   measuring	   both	   NOx	   and	   cGMP	   in	   specific	  
acellular,	  cellular	  and	  sub-­‐cellular	  fractions.	  	  
	  
As	   well	   as	   uncertainty	   regarding	   cellular	   location	   of	   NO2
-­‐	   reduction,	   there	   is	   also	  
uncertainty	   regarding	   the	   identity	   of	   the	   NO2
-­‐	   reductase	   that	   might	   mediate	   NO	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formation	   from	   NO2
-­‐.	   Whilst	   a	   number	   of	   NO2
-­‐	   reductases	   have	   been	   described	  
within	   the	   circulating	   elements	   and	   within	   tissues	   in	   pre-­‐clinical	   models	   (section	  
1.8),	   confirmation	   of	   many	   of	   these	   pathways	   in	   humans	   is	   limited,	   except	   for	  
deoxyHb	  (Cosby	  et	  al.,	  2003)	  and	  XOR	  (Webb	  et	  al.,	  2008b).	  It	  has	  been	  previously	  
shown	   that	   in	   deoxygenated	   human	   erythrocytes,	   addition	   of	   NO2
-­‐	   (100-­‐200	   μM)	  
was	   associated	   with	   a	   liberation	   of	   NO	   detectable	   by	   gas-­‐phase	   ozone	  
chemiluminescence	   (Cosby	   et	   al.,	   2003).	   In	   human	   internal	   mammary	   artery	  
homogenates,	   prepared	   from	   arteries	   harvested	   at	   the	   time	   of	   coronary	   artery	  
bypass	   surgery,	   and	   also	   in	   washed	   erythrocytes	   from	   healthy	   subjects,	   the	  
liberation	   of	   NO	   after	   the	   addition	   of	   NO2
-­‐	   (100	   μM)	   was	   attenuated	   by	   pre-­‐
treatment	  with	  the	  XOR	  inhibitor,	  allopurinol	  (100	  μM)	  (Webb	  et	  al.,	  2008b).	  	  
	  
It	  is	  also	  possible	  that	  the	  effects	  seen	  may	  relate	  to	  the	  activity	  of	  newly	  formed	  S-­‐
nitrosothiols	  in	  blood	  and	  tissue;	  compounds	  known	  to	  be	  potent	  transducers	  of	  NO	  
bioactivity	  and	  of	  particular	  relevance	  to	  vasodilation	  (Stamler	  et	  al.,	  1997).	  Indeed,	  
interactions	   between	   haem-­‐containing	   proteins,	   such	   as	   Hb,	   and	   NO2
-­‐	   have	   been	  
shown	   to	   promote	   the	   formation	   of	   S-­‐nitrosothiols	   (Angelo	   et	   al.,	   2006).	   In	   the	  
studies	  presented	   in	   this	   thesis,	  no	  other	  NO-­‐species	  besides	  NO2
-­‐	   and	  NO3
-­‐	  were	  
measured.	  Indeed,	  all	  plasma	  samples	  were	  subject	  to	  low	  molecular	  weight	  cut-­‐off	  
filtration	   to	   enable	   specific	   estimation	   of	   plasma	   NO2
-­‐	   levels.	   This	   method,	  
therefore,	   excluded	   the	   possibility	   of	   measurement	   of	   major	   NO-­‐adducts	   found	  
within	  the	  circulation	  that	  others	  have	  proposed	  might	  underlie	  the	  effects	  of	  NO2
-­‐	  
such	  as	  S-­‐nitrosothiols	   (particularly	  S-­‐nitroso-­‐albumin	  which	   is	   the	  predominant	  S-­‐
nitrosothiol	  in	  the	  plasma	  (Stamler	  et	  al.,	  1992))	  or	  NO-­‐haem	  compounds.	  Although,	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pertinent	  to	  this	  possibility	  of	  a	  role	  for	  S-­‐nitrosothiols,	  a	  study	  in	  healthy	  subjects	  
supplemented	   with	   oral	   NO3
-­‐	   has	   shown	   that	   whilst	   plasma	   NO2
-­‐	   levels	   were	  
elevated	   4-­‐5	   fold	   there	   were	   no	   measureable	   changes	   in	   S-­‐nitrosothiol	   levels	  
(Lundberg	  and	  Govoni,	  2004).	  
	  
The	   potential	   clinical	   importance	   of	   these	   findings	   demonstrating	   the	   sequential	  
reduction	  of	  NO3
-­‐	   to	  NO2
-­‐	   and	   thence	   to	  NO	   in	  humans	   is	   considerable.	  The	  main	  
source	   of	   endogenous	   NO	  within	   the	   cardiovascular	   system	   is	   eNOS-­‐derived	   NO.	  
However,	   an	   important	   feature	   of	   hypertension,	   as	   well	   as	  most	   CVDs	   for	   which	  
hypertension	   is	   a	   risk	   factor,	   is	   ‘endothelial	   dysfunction’.	   This	   is	   a	   phenomenon	  
characterized	   by	   decreased	   bioavailability	   of	   eNOS-­‐derived	   NO	   (for	   review	   see	  
Brunner	   et	   al.,	   2005).	   In	   hypertensive	   subjects,	   total	   NOx	   levels	   in	   the	   circulation	  
and	   urine	   have	   been	   used	   as	   an	   index	   to	   reflect	   endothelial	   dysfunction	   and	  
reduced	  eNOS-­‐derived	  NO	  synthesis	  (Forte	  et	  al.,	  1997).	  Observations	  described	  in	  
this	   thesis	   with	   dietary	   and	   inorganic	   NO3
-­‐,	   suggest	   that	   NO	   synthesis	   via	   the	  
alternative	  NO3
-­‐-­‐NO2
-­‐-­‐NO	  generating	  pathway	   remains	   intact	   in	  hypertension	  and,	  
as	  such,	  may	  be	  a	  useful	  strategy	  that	  could	  be	  employed	  to	  elevate	  systemic	  NO	  
generation.	   Indeed,	   a	   recent	   meta	   analysis	   of	   11	   RCTs	   of	   oral	   L-­‐arginine	  
supplementation	   (4-­‐24	   g/day,	   for	   2-­‐24	   weeks	   (median	   9	   g/day,	   4	   weeks))	   in	  
hypertensive	   subjects	   demonstrated	   BP	   reduction	   of	   ~5.4/2.7	   mmHg,	   suggesting	  
that	   a	   strategy	   based	   on	   increasing	   endogenous	   NO	   synthesis	   may	   be	   useful	   in	  
hypertension	  (Dong	  et	  al.,	  2011).	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6.3	  BP-­‐lowering	  effects	  of	  NO3
-­‐	  supplementation	  
In	   this	   thesis,	   I	  have	  shown	  that	   inorganic	  NO3
-­‐	  capsules	  or	  a	  dietary	  NO3
-­‐	   load,	   in	  
the	   form	   of	   beetroot	   juice,	   results	   in	   dose-­‐dependent	   increases	   in	   plasma	   NO2
-­‐	  
levels	   via	   bioconversion	   in	   vivo	   and	  my	   findings	   confirm	   that	   this	   bioactive	   NO2
-­‐,	  
following	   reduction	   to	   NO,	   causes	   dose-­‐dependent	   decreases	   in	   BP	   in	   healthy	  
subjects	  and	  robust	  BP	  decreases	  in	  drug-­‐naïve	  hypertensive	  subjects	  as	  well.	  
	  
6.3.1	  BP-­‐lowering	  effects	  of	  NO3
-­‐	  are	  dose-­‐dependent	  	  
KNO3	   capsule	   ingestion	   (24	  mmol)	   substantially	   lowered	   SBP	   and	   DBP	   over	   24	   h,	  
whilst	  a	  similar	  dose	  of	  KCl	  did	  not	  alter	  BP	  over	  the	  same	  time	  period.	  A	  dose	  of	  24	  
mmol	  was	  chosen	   in	   this	   sub-­‐study	   to	  closely	  approximate	   the	  NO3
-­‐	  dose	  given	   in	  
dietary	   form	  (~22.5	  mmol	  NO3
-­‐	  as	  beetroot	   juice)	  previously	   (Webb	  et	  al.,	  2008a).	  
The	   effects	   of	   inorganic	   NO3
-­‐	   supplementation	   at	   a	   similar	   dose	   to	   dietary	   NO3
-­‐	  
supplementation	   elicited	   similar	   changes	   in	   BP,	   with	   peak	   changes	   in	   BP	   of	  
~9.4/6mmHg	   (after	   24	   mmol	   inorganic	   NO3
-­‐	   ingestion)	   and	   ~10.4/8mmHg	   (after	  
~22.5	  mmol)	  (Webb	  et	  al.,	  2008a).	  
	  
Previous	   studies	   have	   demonstrated	   that	   NO2
-­‐	   vasodilates	   both	   the	   arterial	   and	  
venous	  sides	  of	  the	  forearm	  circulation	  of	  humans	  (Cosby	  et	  al.,	  2003;	  Maher	  et	  al.,	  
2008)	  and	   systemic	  NO2
-­‐	   application	  decreases	  BP	   in	  both	  primates	   (Dejam	   et	  al.,	  
2007)	  and	  humans	  (Cosby	  et	  al.,	  2003;	  Dejam	  et	  al.,	  2007;	  Pluta	  et	  al.,	  2011).	  The	  
studies	   described	   in	   chapter	   3	   further	   contribute	   to	   the	   evidence	   previously	  
accumulated	   (Larsen	   et	   al.,	   2006;	   Webb	   et	   al.,	   2008a)	   that	   inorganic	   NO3
-­‐	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supplementation	   can	   elevate	   plasma	   NO2
-­‐	   levels	   sufficiently	   to	   elicit	   robust	   BP	  
decreases	  over	  3-­‐24	  h	  in	  healthy	  subjects.	  
	  
The	   BP-­‐lowering	   effects	   of	   inorganic	   NO3	   were	   found	   to	   be	   dose-­‐dependent	   as	  
reflected	   by	   the	   decreasing	  magnitude	   of	   response	   in	   SBP	   to	   a	   24,	   12,	   5.5	   and	   4	  
mmol	  dose.	  Importantly,	  as	  with	  plasma	  NOx	  levels,	  this	  dose-­‐dependency	  appeared	  
to	  hold	  irrespective	  of	  whether	  the	  inorganic	  NO3
-­‐	   load	  was	  administered	  by	  KNO3	  
capsules	   or	   in	   dietary	   NO3
-­‐	   form,	   as	   beetroot	   juice.	   The	   ability	   to	   replicate	   the	  
effects	  of	   beetroot	   juice	  on	   the	   cardiovascular	   system	  with	   inorganic	  NO3
-­‐	   and	   to	  
show	   dose-­‐dependency	   by	   either	   a	   dietary	   or	   inorganic	   formulation	   provides	  
further	  support	  for	  the	  proposal	  that	  inorganic	  NO3
-­‐	  underlies	  the	  beneficial	  effects	  
of	  beetroot	  juice	  on	  the	  cardiovascular	  system.	  	  
	  
6.3.2	  BP-­‐lowering	  effects	  of	  NO3
-­‐	  are	  dependent	  upon	  NO2
-­‐	  
Post-­‐hoc	   analyses	   of	   the	   24	   mmol	   KNO3	   vs.	   KCl	   study	   data	   in	   healthy	   subjects	  
revealed	  that	  the	  changes	  in	  BP	  from	  baseline	  (following	  supplementation	  with	  24	  
mmol	  KNO3)	  inversely	  correlated	  only	  to	  changes	  in	  plasma	  NO2
-­‐	  levels,	  but	  not	  NO3
-­‐	  
levels,	   revealing	   that	   NO2
-­‐	   is	   the	   bioactive	   moiety,	   not	   NO3
-­‐.	   These	   data	   fit	   with	  
previous	  observations	  after	  dietary	  NO3
-­‐	  ingestion	  in	  healthy	  subjects	  (Webb	  et	  al.,	  
2008a)	  and	  also	  fit	  with	  the	  prevailing	  dogma	  that	  humans	  are	  unable	  to	  metabolize	  
NO3
-­‐	   directly	   (Lundberg	   et	   al.,	   2004).	   These	   results	   suggest	   that	   the	   measure	   of	  
plasma	  NO2
-­‐	  levels	  do	  reflect,	  at	  least	  in	  part,	  NO2
-­‐	  bioactivity,	  via	  bioconversion	  to	  
NO	  in	  vivo.	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Interestingly,	  in	  this	  cohort,	  baseline	  BP	  was	  closely	  inversely	  correlated	  to	  baseline	  
plasma	  NO2
-­‐	  but	  not	  NO3
-­‐	  levels.	  Baseline	  plasma	  NO2
-­‐	  levels	  have	  been	  proposed	  to	  
be	   an	   accurate	   reflection	   of	   endogenous	   NO	   generation	   via	   eNOS-­‐dependent	  
conversion	  of	  L-­‐arginine	  to	  NO	  (Lauer	  et	  al.,	  2001;	  Kleinbongard	  et	  al.,	  2003,	  2006b)	  
and	   these	   findings	   may	   simply	   be	   highlighting	   the	   known	   relationship	   between	  
classical	   eNOS-­‐derived	  NO	   and	  BP.	  However,	  with	   the	   appreciation	   that	  NO2
-­‐	   is	   a	  
bioactive	  molecule,	  these	  findings	  also	  support	  the	  possibility	  that	  the	  correlation	  of	  
baseline	   plasma	   NO2
-­‐	   with	   BP	   is	   actually	   a	   reflection	   of	   the	   functional	   activity	   of	  
physiological	   NO2
-­‐	   reduction	   as	   first	   proposed	   in	   2000	   by	   Cannon	   and	   colleagues	  
(Gladwin	  et	  al.,	  2000).	  This,	  in	  turn,	  raises	  the	  possibility	  that	  intrinsic	  plasma	  NO2
-­‐	  
levels	  may	  be	  involved	  in	  ‘setting’	  the	  BP	  of	  healthy	  subjects.	  These	  results	  suggest	  
that	  the	  measure	  of	  plasma	  NO2
-­‐	  levels	  do	  reflect,	  at	  least	  in	  part,	  NO2
-­‐	  bioactivity,	  
via	  bioconversion	  to	  NO	  in	  vivo.	  These	  data	  also	  appear	  to	  suggest	  some	  clustering	  
within	  healthy	   subjects	   of	   responsiveness	   to	  NO2
-­‐	   into	   two	   groups	   i.e.	   that	  whilst	  
small	  changes	  in	  NO2
-­‐	  (~<1	  µM)	  effected	  apparently	  substantial	  changes	  in	  BP	  that	  
where	   the	   changes	   in	   NO2
-­‐	   were	   >1µM	   little	   effect	   on	   BP	   was	   evident.	   Further	  
analyses	  of	  these	  healthy	  subject	  data	  suggested	  that	  indeed,	  two	  distinct	  groups	  of	  
individuals	   that	   could	   be	   separated	   by	   sex	   did	   exist	   within	   the	   cohort	   as	   will	   be	  
discussed	  in	  section	  6.5.	  
	  
Further	   post-­‐hoc	   analyses	   of	   the	   24	  mmol	   KNO3	   vs.	   KCl	   data	   in	   healthy	   subjects	  
demonstrate	  that	  the	  magnitude	  of	  the	  BP	  response	   is	  directly	  related	  to	  baseline	  
BP	  (i.e.	  the	  higher	  the	  baseline	  BP	  the	  greater	  the	  peak	  BP	  reduction	  achieved).	  This	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relationship	  is	  consistent	  with	  the	  observation	  that	  the	  effect	  of	  BP-­‐lowering	  drugs	  
is	  proportional	  to	  resting	  BP	  (Law	  et	  al.,	  2003).	  
	  
6.3.3	  NO3
-­‐	  is	  more	  potent	  in	  hypertension	  
Hypertensive	   subjects	   exhibited	   greater	   BP-­‐lowering	   in	   response	   to	   elevations	   in	  
NO2
-­‐	   levels	   compared	   to	   the	   healthy	   subjects	   studied	   herein	   and	   published	  
previously	   (Larsen	   et	   al.,	   2006;	  Webb	   et	   al.,	   2008a).	   The	   peak	   BP	   drop	   following	  
dietary	   NO3
-­‐	   ingestion	   (~3.3	   mmol	   NO3
-­‐)	   in	   the	   hypertensive	   study	   was	   11.2/9.6	  
mmHg.	   This	   compares	   to	   peak	   BP	   reductions	   in	   healthy	   subjects	   of	   only	   1.7/4.6	  
mmHg	  in	  response	  to	  a	  comparable	  4	  mmol	  dose	  of	  NO3
-­‐	  (KNO3	  capsules).	  Indeed,	  
similar	   BP	   decreases	   (~9.4/6mmHg)	   in	   healthy	   subjects,	   with	   inorganic	   NO3
-­‐	  
supplementation,	   were	   achieved	   with	   ~7x	   higher	   dose	   of	   KNO3	   (24	   mmol),	   or,	  
previously,	  as	  dietary	  NO3
-­‐	   (~10.4/8mmHg	  after	  ~22.5	  mmol,	  Webb	   et	  al.,	  2008a).	  
The	  BP-­‐lowering	  effects	  of	  NO3
-­‐,	  in	  inorganic	  salt	  or	  dietary	  form	  (as	  beetroot	  juice)	  
in	  healthy	  subjects	  demonstrated	  dose-­‐dependency	  with	  doses	  ranging	  between	  4-­‐
24	  mmol	  NO3
-­‐	  and	  fitted	  well	  with	  previous	  observations	   in	  healthy	  subjects	  given	  
~22.5	  mmol	  NO3
-­‐	  (500	  mL	  beetroot	  juice,	  Webb	  et	  al.,	  2008a)	  (Figure	  6.1).	  However,	  
the	   BP-­‐lowering	   after	   dietary	   NO3
-­‐	   in	   hypertensive	   subjects	   does	   not	   fit	   into	   the	  





Figure	   6.1	   BP-­‐lowering	   effects	   of	   inorganic	   or	   dietary	   NO3
-­‐	   in	   healthy	   and	   hypertensive	  
subjects.	   The	   effects	   of	   KNO3	   (4,	   12	   or	   24mmol)	   in	   healthy	   subjects	   and	   dietary	   NO3
-­‐	   as	  
beetroot	   juice	   (250	   mL,	   ~5.5	   mmol	   NO3
-­‐;	   500	   mL,	   ~22.5	   mmol)	   in	   healthy	   subjects;	   and	  
dietary	  NO3
-­‐	  as	  beetroot	  juice	  (250	  mL,	  ~3.3	  mmol)	  in	  hypertensive	  subjects)	  on	  SBP	  over	  3	  
h.	  (n=6-­‐20).	  Data	  are	  expressed	  as	  mean	  only.	  (Data	  for	  effects	  of	  ~22.5	  mmol	  dietary	  NO3
-­‐	  
adapted	  with	  permission	  from	  Webb	  et	  al.,	  2008a)	  (KNO3=potassium	  nitrate;	  NO3
-­‐=nitrate;	  
SBP=systolic	  blood	  pressure).	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As	  with	  healthy	   subjects,	  baseline	  BP	   inversely	  correlated	  only	   to	  baseline	  plasma	  
NO2
-­‐	   levels,	   and	   the	   change	   in	   BP	   inversely	   correlated	   only	   to	   changes	   in	   plasma	  
NO2
-­‐	   levels,	  but	  not	  NO3
-­‐	   levels,	  affirming	  the	  importance	  of	  the	  NO2
-­‐	  anion	  as	  the	  
mediator	  of	  the	  BP-­‐lowering	  effects	  of	  NO3
-­‐	   ingestion	  and	  suggesting	  that	  baseline	  
plasma	  NO2
-­‐	  levels	  may	  be	  involved	  in	  BP	  regulation.	  
	  
This	   enhanced	   sensitivity	   of	   BP	   responses	   in	   hypertensive	   subjects	   could	   simply	  
reflect	  the	  higher	  baseline	  BP	  evident	  in	  the	  hypertensive	  cohort,	  a	  view	  consistent	  
with	   the	   observation	   from	  meta	   analyses	   that	   the	   effect	   of	   BP-­‐lowering	   drugs	   in	  
patients	   is	   proportional	   to	   pre-­‐treatment	   BP	   (Law	   et	   al.,	   2003)	   and	   the	   peak	   BP	  
decrease	  was	  correlated	  to	  baseline	  BP,	  as	  was	  apparent	  in	  healthy	  subjects.	  
	  
An	  additional	  explanation	  for	  the	  greater	  BP	  reductions	  in	  hypertensive	  subjects	  is	  
sensitization	  of	  downstream	  pathways	   in	   the	  classical	  NO-­‐signalling	  paradigm.	  For	  
instance,	   it	   has	   been	   demonstrated	   that	   there	   is	   an	   enhanced	   vasorelaxant	  
response	   to	   NO	   donors	   at	   the	   level	   of	   soluble	   guanylyl	   cyclase	   in	  wild-­‐type	  mice	  
treated	   with	   NOS	   inhibitors	   (Moncada	   et	   al.;	   1991)	   and	   in	   eNOS	   knockout	   mice	  
(Brandes	   et	  al.,	   2000).	  However,	  whether	   this	   is	   similar	   in	  human	  hypertension,	  a	  
situation	  in	  which	  eNOS	  activity	  is	  similarly	  reduced	  (Linder	  et	  al.,	  1990;	  Panza	  et	  al.,	  
1993),	  has	  not	  been	  explored.	  	  
	  
In	  hypertensive	  subjects,	  SBP	  was	  still	  appreciably	  reduced	  at	  24	  h	  by	  ~8.5	  mmHg	  
compared	  to	  water	  control,	  which	  is	  very	  close	  to	  the	  expected	  BP-­‐lowering	  effects	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of	  any	  anti-­‐hypertensive	  drug	  at	  standard	  dose	  in	  grade	  1	  hypertension	  (9.1	  mmHg)	  
(Law	  et	  al.,	  2009)	  This	  observation	  suggests	  that	  a	  dietary	  NO3
-­‐	   intervention	  could	  
be	   considered	  as	  a	  once	  daily,	   effective	  anti-­‐hypertensive	  agent,	   especially	   as	   the	  
peak:trough	  ratio	  of	  BP-­‐lowering	  effect	  is	  ~60%	  for	  dietary	  NO3
-­‐	  in	  this	  study	  which	  
is	  consistent	  with	  an	  effect	  size	  necessary	  for	  once	  daily	  dosage	  of	  anti-­‐hypertensive	  
medications	  (Lipicky,	  1994).	  
	  
6.3.4	  NO3
-­‐	  reduces	  arterial	  stiffness	  
It	   is	   also	   very	   encouraging,	   if	   at	   first	   somewhat	   surprising,	   that	   dietary	   NO3
-­‐	  
ingestion	   reduced	   aortic	   PWV,	   considered	   to	   be	   the	   gold-­‐standard	   approach	   to	  
assessing	  arterial	   stiffness	   (Laurent	   et	  al.,	  2006).	  Arterial	   stiffness	   is	   considered	   to	  
be	  an	   important,	   independent	  predictive	  marker	  of	  cardiovascular	   risk	  and	   is	  best	  
measured	   by	   aortic	   PWV	   (Laurent	   et	   al.,	   2006).	   Previous	   studies	   has	   shown	   that	  
acute	   BP	   reduction	   (using	  organic	   nitrovasodilators)	   did	   not	   alter	   PWV	   in	   treated	  
hypertensive	  subjects,	  though	  pharmacological	  manipulation	  of	  BP	  did	  alter	  PWV	  in	  
drug-­‐naïve	   normotensive	   controls	   (Stewart	   et	   al.,	   2006).	   These	   findings	   suggest	  
that,	   although	   raised	   BP	   contributes	   to	   increased	   functional	   arterial	   stiffness	  
through	  increased	  distending	  pressure,	  it	  may	  also	  be	  related	  to	  structural	  changes	  
in	   the	   arterial	   wall	   after	   prolonged	   increases	   in	   arterial	   tension.	   However,	  
contrasting	  data	  suggest	  that	  acute	  inhibition	  of	  endogenously	  generated	  NO	  does	  
modulate	   elastic	   artery	   distensibility	   and	   hence	   stiffness	   in	   vivo	   (Wilkinson	   et	   al.,	  
2002;	  Schmitt	  et	  al.,	  2005;	  Bellien	  et	  al.,	  2010).	  Therefore,	  a	  stratagem	  to	  increase	  
bioavailable	   NO,	   through	   increases	   in	   systemic	   NO2
-­‐	   levels,	   in	   the	   situation	   of	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endothelial	   dysfunction	   and	   reduced	   endogenous	   NO	   production,	   could	   be	  
expected	  to	  have	  a	  favorable	  effect.	  Other	  studies	  have	  shown	  acute	  reductions	  in	  
PWV	   (within	   4	   h)	   after	   the	   administration	   of	   vasoactive	   compounds,	   more	   than	  
would	  be	  expected	  from	  BP-­‐lowering	  on	  its	  own,	  such	  as	  with	  endothelin	  receptor	  
antagonism	  (Dhaun	  et	  al.,	  2009).	  This	  suggests	  that,	  although	  the	  reduction	  in	  PWV	  
is	   likely	   to	  be	  due	   to	   reduced	  BP,	   further	  studies	   to	  elucidate	   the	  mechanism	  and	  
potentially	  using	  other	  BP-­‐lowering	  drugs	  to	  achieve	  equivalent	  BP	  reductions,	  are	  
needed.	  	  
	  
Indeed,	   since	   the	   inception	   of	   these	   studies	   described	   herein,	   further	   work	   in	  
healthy	  subjects	  that	  did	  not	  form	  part	  of	  this	  thesis,	  demonstrates	  that	   inorganic	  
NO3
-­‐	   supplementation	   reduces	   arterial	   stiffness,	   as	  measured	   by	   PWV,	   in	   healthy	  
subjects	  as	  well	  (Bahra	  et	  al.,	  2012).	  In	  this	  particular	  study,	  healthy	  subjects	  were	  
supplemented	   with	   8	   mmol	   of	   KNO3	   (and	  matched	   KCl	   control	   in	   a	   randomized,	  
double-­‐blind,	   cross-­‐over	   design).	   PWV	   was	   measured	   at	   baseline	   and	   3	   h	   post-­‐
intervention,	  when	  plasma	  NO2
-­‐	   levels	   peak	   post-­‐NO3
-­‐	   ingestion	   (see	   section	   6.2).	  
Although	   there	   was	   no	   effect	   of	   the	   placebo,	   NO3
-­‐	   supplementation	   resulted	   in	  
significant	   elevations	   in	   plasma	   NO2
-­‐	   and	   cGMP	   levels,	   reductions	   in	   BP	   and	  
reductions	  in	  PWV	  (Bahra	  et	  al.,	  2012).	  These	  results	  suggest	  that	  the	  effects	  of	  NO3
-­‐	  
supplementation	  observed	  in	  our	  hypertensive	  cohort	  are	  not	  simply	  a	  reflection	  of	  
elevated	  arterial	  tone	  and	  may	  indeed	  reflect	  modulation	  of	  elastic	  distensibility	  of	  




6.3.5	  Implications	  of	  the	  lack	  of	  effect	  of	  placebo	  
Finally,	  in	  all	  of	  the	  measures	  of	  bioactivity,	  no	  significant	  changes	  were	  observed	  in	  
the	  control	  limbs	  using	  KCl	  capsules	  or	  water.	  The	  significance	  of	  this	  finding	  is	  two-­‐
fold.	  Firstly,	  this	  suggests	  that	  the	  effects	  on	  BP	  were	  due	  specifically	  to	  the	  activity	  
of	   NO3
-­‐.	   Beetroot	   juice	   contains	   other	   potentially	   vasoactive	   components,	   most	  
important	  amongst	  these,	  as	  with	  many	  other	  vegetables,	  significant	  levels	  of	  K+	  (up	  
to	  93	  mM	  (Webb	  et	  al.,	  2008a)),	  that	  have	  previously	  been	  suggested	  as	  a	  putative	  
mechanism	   of	   the	   BP-­‐lowering	   effects	   of	   a	   vegetable-­‐rich	   diet	   (Adrogué	   and	  
Madias,	  2007).	   Thus,	  by	  using	  a	  matched	  KCl	  dose	  as	  a	   control,	   the	  K+	   content	  of	  
dietary	  forms	  of	  NO3
-­‐	  has	  been	  accounted	  for.	  Thus,	  these	  findings	  suggest	  that	  the	  
BP	   changes	   after	   inorganic,	   or	   dietary,	   NO3
-­‐	   ingestion	   were	   not	   due	   to	   the	   K+	  
content,	  as	  there	  was	  no	  decrease	  in	  BP	  after	  KCl	   ingestion.	  Moreover,	  the	  lack	  of	  
correlation	  between	  change	  in	  plasma	  K+	  levels	  and	  change	  in	  SBP	  after	  dietary	  NO3
-­‐	  
ingestion	   in	   the	   hypertensive	   study	   also	   supports	   the	   view	   that	   the	   BP-­‐lowering	  
effects	  of	  beetroot	  juice	  are	  not	  due	  to	  the	  activity	  of	  this	  particular	  cation,	  as	  had	  
been	   previously	   suggested	   for	   the	   DASH	   diet	   (Appel	   et	   al.,	   1997).	   In	   addition,	  
matched	   KNO3	   supplementation	   closely	   replicated	   the	   BP-­‐lowering	   effects	   of	  
dietary	   NO3
-­‐	   (Webb	   et	   al.,	   2008a)	   Hence,	   the	   BP-­‐lowering	   mechanism	   of	   NO3
-­‐	  
supplementation	  is	  likely	  to	  be	  due	  to	  the	  endogenous	  conversion	  of	  NO3
-­‐	  to	  NO2
-­‐,	  
and	   thence	   to	   NO,	   especially	   since	   the	   changes	   in	   plasma	   NO2
-­‐	   levels	   correlated	  
closely	  with	  reductions	  in	  BP.	  
	  
In	   the	  hypertensive	   study,	  water-­‐placebo	  produced	  a	   short-­‐lived	  pressor	   response	  
after	   ingestion.	   It	   is	  well	  recognized	  that	  water	  can	  elevate	  SBP	  in	  healthy	  middle-­‐
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aged	  subjects	  of	  up	  to	  ~12mmHg	  within	  1	  h	  (Jordan	  et	  al.,	  2000),	  and	  it	  is	  interesting	  
to	   note	   that	   there	   was	   no	   apparent	   pressor	   response	   to	   volume	   ingestion	   after	  
dietary	   NO3
-­‐.	   Nevertheless,	   dietary	   NO3
-­‐	   ingestion	   significantly	   reduced	   BP	  
compared	  to	  baseline	  in	  itself.	  	  
	  
6.3.6	  NO3
-­‐	  supplementation	  does	  not	  alter	  HR	  
There	  were	  no	  significant	  elevations	   in	  HR	  with	   the	  BP-­‐lowering	  effects	  of	  dietary	  
NO3
-­‐	   in	   healthy	   or	   hypertensive	   subjects,	   similar	   to	   the	   effects	   on	   HR	   in	   healthy	  
subject	  in	  previous	  investigations	  (Webb	  et	  al.,	  2008a).	  This	  is	  surprising,	  as	  it	  would	  
be	   expected	   that	   a	   vasodilator,	   through	   reductions	   in	   BP,	   would	   cause	   a	   reflex	  
increase	  in	  HR.	  It	  may	  be	  that	  NO3
-­‐	  or	  NO2
-­‐	  have	  negatively	  chronotropic	  cardiac	  or	  
sympatholytic	  effects;	  a	  possibility	  that	  deserves	  further,	  separate	  investigations.	  It	  
may	  be	  that	  the	  slow-­‐developing,	  smooth	  reduction	  in	  BP	  observed	  after	  inorganic	  
or	   dietary	   NO3
-­‐	   ingestion	   mitigates	   against	   the	   reflex	   increases	   in	   HR	   normally	  




-­‐	  reduction	  by	  oral	  bacteria	  contributes	  to	  BP	  regulation	  
The	  colonization	  by	  micro-­‐organisms	  of	  most	  surfaces	  of	  the	  human	  body,	  including	  
the	   GI	   tract,	   provides	   us	   with	   a	   number	   of	   beneficial	   functions	   that	   we	   do	   not	  
possess	  innately.	  For	  example	  the	  symbiotic	  relationship	  that	  humans	  have	  with	  GI	  
microflora	   endows	   the	   host	   with	   a	   number	   of	   qualities	   not	   least	   the	   capacity	   to	  
digest	  components	  of	  plants,	  host	  defense	  and	  the	  development	  of	  tolerance	  to	  a	  
number	   of	   pathogens	   (Bäckhed	   et	   al.,	   2005).	  Whilst	   a	   symbiotic	   relationship	   has	  
been	   demonstrated	   for	   a	   number	   of	   host-­‐microbial	   interactions	   in	   the	   lower	   GI	  
tract,	   the	  oral	  microflora,	  however,	   remains	  virtually	  unexplored	   in	   this	  aspect.	   In	  
fact,	   the	   general	   view	   is	   of	   an	   overall	   detrimental	   role	   for	   this	   microflora,	  
traditionally	   associated	   with	   negative	   health	   effects	   ranging	   from	   halitosis	   and	  
caries	   (Ratcliff	   and	   Johnson,	   1999)	   to	   CVDs	   (Desvarieux	   et	   al.,	   2003,	   2005,	   2010).	  
This	  negative	  view	  is	  clearly	  reflected	   in	  the	  widespread	  usage	  (e.g.	  30-­‐45%	  in	  the	  
USA	   and	   UK)	   of	   antiseptic	   mouthwashes	   in	   the	   general	   population	   (Elmore	   and	  
Horwitz,	  1995;	  Fedorowicz	  et	  al.,	  2008;	  Chadwick	  et	  al.,	  2011).	  	  
	  
The	   conversion	   of	   dietary-­‐derived	   NO3
-­‐	   to	   NO2
-­‐	   by	   oral	   bacteria	   is	   a	   classical	  
example	  of	   a	  proposed	  harmful	  process	   since	   salivary	  NO2
-­‐,	  when	   swallowed,	   can	  
give	  rise	  to	  N-­‐nitrosamines	  (Harada	  et	  al.,	  1974;	  Tannenbaum	  et	  al.,	  1974;	  Ishiwata	  
et	  al.,	  1975a,	  b,	  c,	  d;	  Ishiwata,	  1976a,	  b;	  Spiegelhalder	  et	  al.,	  1976;	  Tannenbaum	  et	  
al.,	  1976;	  Eisenbrand	  et	  al.,	  1980;	  Tannenbaum	  and	  Correa,	  1985),	  with	  potentially	  
carcinogenic	  effects	  (Bogovski	  and	  Bogovski,	  1981).	  This	  has	  led	  to	  strict	  regulations	  
of	   permissible	   levels	   of	   NO3
-­‐	   in	   food	   and	   drinking	   water.	   In	   contrast,	   the	   results	  
presented	  herein	  support	  the	  notion	  that	  oral	  NO3
-­‐-­‐reducing	  bacteria	  are	  beneficial	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to	  the	  host	  and	  participate	  in	  control	  of	  cardiovascular	  NO	  homeostasis	  to	  modulate	  
BP.	  	  
	  
As	  discussed	   in	  section	  1.6.4,	  oral	  bacteria	  are	  crucial	   in	   the	   initial	   step	  of	  a	  NO3
-­‐-­‐
NO2
-­‐-­‐NO	   pathway.	   Thus,	   it	   was	   important	   to	   clarify	   the	   role	   of	   oral	   bacteria	   in	  
physiological	   processes	   related	   to	   NO	   bioactivity.	   The	   oral	   NO3
-­‐	   reductase	   study	  
presented	  in	  chapter	  4	  investigated	  whether	  reduction	  of	  endogenously-­‐generated	  
NO3
-­‐	   to	   NO2
-­‐	   by	   oral	   bacteria	   under	   basal	   conditions	   (i.e.	   without	   exogenous	  
provision	  of	  inorganic	  NO3
-­‐),	  contributes	  to	  plasma	  NO2
-­‐	  levels	  and	  BP	  regulation	  in	  
healthy	  subjects.	  For	  this,	  an	  intervention	  with	  antiseptic	  mouthwash	  for	  7	  days	  to	  
disrupt	   oral	   NO3
-­‐	   reduction	   was	   provided	   and	   thence	   plasma	   NO2
-­‐	   levels	   and	   BP	  
were	   measured.	   Twice-­‐daily	   use	   of	   an	   antiseptic	   mouthwash	   for	   7	   days	   near	  
abolished	  oral	  conversion	  of	  NO3
-­‐	  to	  NO2
-­‐.	  More	  importantly,	  this	  was	  accompanied	  
by	   a	   decrease	   in	   plasma	   NO2
-­‐	   levels	   (~25%)	   and	   a	   concomitant	   increase	   in	   BP.	  
Furthermore,	  as	  evidenced	  by	  the	  home	  BP	  measurements,	  the	  persistence	  of	  the	  
effect	  of	  mouthwash	  on	  BP	  from	  the	  first	  day	  of	  instigation	  suggests	  that	  there	  is	  no	  
immediate	   tachyphylaxis,	   at	   least	   over	   a	   7	   day	   period,	   in	   response	   to	   the	  
mouthwash.	   The	   hypothesis	   is	   that	   the	   mechanism	   underlying	   the	   observed	  
increase	  in	  BP	  is	  a	  decrease	  in	  the	  amounts	  of	  NO	  or	  other	  bioactive	  nitrogen	  oxides	  
generated	   from	   NO2
-­‐	   via	   recently	   described	   reductive	   pathways	   (as	   discussed	   in	  
section	   1.8).	   Support	   for	   this	   hypothesis	   emanates	   from	   the	   robust	   correlation	  
evident	   between	   changes	   in	   plasma	   NO2
-­‐	   and	   changes	   in	   BP	   that	   were	   apparent	  
after	  7	  days	  used	  of	  the	  antiseptic	  mouthwash	  intervention.	  It	  is	  unlikely	  that	  these	  
effects	   relate	   to	  other	  mechanisms,	   such	  as	   increased	   stress	  due	   to	   instillation	  of	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mouthwash,	   since	   the	  effects	  on	  SBP	  were	  present	  on	  every	  occasion	   throughout	  
the	   7	   day	   home	   BP	   measurement	   protocol	   and	   also	   evident	   in	   the	   averaged	  
nighttime	  BP	  mean.	  	  
	  
All	  subjects	  were	  fasted	  on	  clinic	  visits,	  therefore	  the	  majority	  of	  the	  circulating	  NO3
-­‐	  
measured	  in	  their	  plasma	  likely	  originates	  from	  the	  endogenous	  source	  of	  the	  NOS	  
pathway.	  The	  NO3
-­‐	  levels	  that	  were	  apparent	  in	  the	  subjects	  at	  baseline	  are	  in	  good	  
agreement	  with	  previous	  estimates	  of	   the	   relative	   contributions	  of	   exogenous	   vs.	  
endogenous	  NO3
-­‐	  (Packer	  et	  al.,	  1989).	  In	  light	  of	  this,	  the	  present	  data	  suggest	  the	  
existence	  of	  a	   salvage	  pathway	   in	  which	  NO3
-­‐,	  derived	   from	  oxidized	  NO,	   is	  partly	  
recycled	  back	   to	  NO	  with	   the	  help	  of	  oral	  NO3
-­‐-­‐reducing	  bacteria.	   This	   represents	  





-­‐	   is	  a	  very	   stable	  molecule	  and,	  unlike	  bacteria,	  human	  cells	   cannot	  efficiently	  
metabolize	  this	  anion.	  This	  fact	  together	  with	  these	  observations	  suggests	  that	  the	  
process	   we	   describe	   herein	   fulfill	   the	   criteria	   for	   a	   true	   symbiotic	   relationship	  
whereby	   the	  host	  provides	   the	  oral	   bacteria	  with	  NO3
-­‐	   via	   active	   secretion	   to	   the	  
site	  where	  they	  reside.	  The	  bacteria	  then	  use	  this	  NO3
-­‐	  as	  a	  terminal	  e-­‐	  acceptor	  to	  
allow	  respiration	  in	  the	  absence	  of	  O2.	  In	  return,	  the	  bacteria	  provide	  the	  host	  with	  
NO2
-­‐,	   a	   substrate	   used	   for	   further	   generation	   of	   the	   biological	   messenger	   NO	  
(Moreno-­‐Vivian	  et	  al.,	  1999;	  Lundberg	  et	  al.,	  2004).	  That	  NO	  is	  the	  likely	  mediator	  of	  
the	  effects	  seen	   is	  supported	  by	  observations	  demonstrating	  that	   the	  BP-­‐reducing	  
effects	  of	  exogenously	  administered	   inorganic	  or	  dietary	  NO3
-­‐	   are	  associated	  with	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levels	   of	   the	   signalling	   nucleotide	   cGMP	   in	   healthy	   and	   hypertensive	   subjects,	  
measurement	  of	  which	  has	  been	  recently	  shown	  to	  provide	  a	  sensitive	  indicator	  of	  
NO	   bioactivity	   and	   to	   underlie	   many	   of	   the	   beneficial	   effects	   of	   NO	   (Hobbs	   and	  
Stasch,	  2010).	  
	  
It	  has	  been	  estimated	  that	  30-­‐45%	  of	  the	  adult	  population	  in	  the	  US	  and	  UK	  (Elmore	  
and	  Horwitz,	  1995;	  Fedorowicz	  et	  al.,	  2008;	  Chadwick	  et	  al.,	  2011)	  use	  some	  form	  of	  
antiseptic	   mouthwash	   on	   a	   regular	   basis.	   In	   the	   present	   study	   the	   mouthwash	  
contained	   chlorhexidine	   as	   the	   active	   ingredient.	   It	   remains	   to	   be	   determined	  
whether	   other	   antiseptic	   mouthwash	   products	   would	   affect	   NO2
-­‐	   and	   NO	  
homeostasis	   in	   a	   similar	   manner.	   Nevertheless,	   the	   present	   results	   clearly	  
demonstrate	   effects	   on	   BP	   that	   could	   be	   of	   clinical	   significance	   if	   sustained	   over	  
prolonged	  periods	  of	   time	  beyond	  the	  7	  days	  measured	   in	   the	  present	  study.	  The	  
increase	   in	   BP	   was	   reflected	   in	   all	   of	   the	   3	   methods	   employed	   to	   accurately	  
measure	   BP.	   Indeed,	   home	   BP	   and	   24h	   ABP	   are	   being	   increasingly	   recognized	   as	  
important	   BP	   measures	   that	   are	   independently	   predictive	   of	   cardiovascular	  
mortality	  (Mancia	  et	  al.,	  2007).	  
	  
Although	  the	  increases	  in	  BP	  may	  seem	  small	  (~ΔSBP	  2-­‐3.5mmHg),	  on	  a	  population	  
scale	  if	  these	  increases	  were	  applied	  to	  a	  pre-­‐hypertensive	  or	  hypertensive	  cohort,	  
then	   it	   could	   reasonably	   be	   estimated	   from	   previous	   analyses	   that	   oral	   NO3
-­‐	  
reduction	   likely	   plays	   an	   important	   role	   in	   decreasing	   both	   stroke	   and	  
cardiovascular	  morbidity	  and	  mortality,	  since	  every	  2	  mmHg	  increase	  in	  SBP	  results	  
in	  a	  7%	  increase	  in	  the	  risk	  of	  mortality	  due	  to	  ischaemic	  heart	  disease	  and	  a	  10%	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increase	   in	  the	  risk	  of	  mortality	  due	  to	  stroke	  (Lewington	  et	  al.,	  2002).	  Whether	  a	  
similar	   pathway	   operates	   in	   individuals	   with	   hypertension	   or	   in	   individuals	   with	  
increased	  risk	  of	  developing	  clinical	  hypertension	  (i.e.	  pre-­‐hypertension),	  or	  indeed	  
whether	   dysfunction	   of	   this	   pathway	   might	   contribute	   to	   CVD	   progression	   is	  
unknown,	   although	   recent	   evidence	   clearly	   demonstrates	   the	   presence	   of	   NO3
-­‐-­‐
reducing	   bacterial	   species,	   including	   Veilonella	   spp.	   and	   Pseudomonas	   luteola	  
(Koren	   et	   al.,	   2011)	   in	   the	   oral	   cavity	   of	   individuals	   with	   atherosclerotic	   disease.	  
However,	   this	   possibility	   has	   been	   addressed,	   at	   least	   in	   part	   in	   chapter	   5,	   as	  
inorganic	   dietary	   NO3
-­‐	   supplementation	   in	   hypertensive	   subjects	   elevated	   plasma	  
NO2
-­‐	   levels	   and	   lowered	   BP	   in	   a	   similar	   vein	   to	   that	   demonstrated	   to	   occur	   in	  
healthy	   individuals,	  demonstrating	  effective	  oral	  NO3




In	   conclusion,	   these	   studies	   provide	   evidence	   of	   a	   role	   for	   oral	   NO3
-­‐-­‐reducing	  
bacteria	   in	   modulation	   of	   vascular	   NO2
-­‐	   and	   NO	   homeostasis	   and	   thereby,	   a	  
physiological	   role	   of	   NO2
-­‐,	   derived	   from	   the	   oral	   reduction	   of	   endogenously	  
generated	  NO3
-­‐,	   in	   BP	   regulation.	   These	  data	   further	   suggest	   that	   disturbances	   in	  
NO2
-­‐	   homeostasis	   (herein	   achieved	   via	   interruption	   of	   NO3
-­‐-­‐reduction	   in	   the	   oral	  
cavity	   by	   commercial	   mouthwash	   use)	   have	   small,	   yet	   potentially	   important	  
implications	  for	  cardiovascular	  health.	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6.5	  Sex	  differences	  in	  handling	  and	  response	  to	  inorganic	  NO3
-­‐	  supplementation	  
The	   post-­‐hoc	   analyses	   of	   the	   24	  mmol	   KNO3	   vs.	   KCl	   study	   exposed	   apparent	   sex	  
differences	  in	  the	  response	  to	  inorganic	  NO3
-­‐	  supplement.	  Significant	  differences	  in	  
baseline	  plasma	  NO2
-­‐,	  but	  not	  plasma	  NO3
-­‐,	  levels	  associated	  with	  lower	  baseline	  BP	  
were	  evident	  in	  the	  female	  subjects	  compared	  to	  the	  male	  subjects.	  This	  finding	  is	  
supportive	  of	  the	  view	  that	  a	  close	  relationship	  between	  NO2
-­‐	  levels	  and	  BP	  exists	  in	  
humans.	   This	   correlation	   has	   been	   demonstrated	   previously,	   but	   attributed	   to	  
differences	   in	  vascular	  eNOS	  expression	  and	  activity	   (Forte	   et	  al.,	  1998),	  an	  effect	  
that,	   in	   addition	   to	   endothelium-­‐derived	   hyperpolarising	   factor	   (Scotland	   et	   al.,	  
2005),	  has	  been	  proposed	  to	  mediate	  the	  prevalence	  of	  lower	  BP	  in	  premenopausal	  
women	   compared	   to	   age-­‐matched	   men	   (Lerner	   and	   Kannel,	   1986).	   These	   data,	  
herein,	  also	  raises	  the	  further	  possibility	  that	  the	  association	  of	  plasma	  NO2
-­‐	  levels	  
with	   lower	   BP	   evident	   in	   pre-­‐menopausal	   women	   may	   relate,	   in	   part,	   to	   the	  
bioactivity	   of	   the	   elevated	   NO2
-­‐	   levels.	   This	   difference	   in	   basal	   NO2
-­‐	   levels	   may	  
underlie	   the	   apparent	   decreased	   sensitivity	   to	   further	   elevations	   in	   plasma	   NO2
-­‐	  
levels	   in	  females	  due	  to	  a	  possible	  saturation	  of	  the	  vasodilating	  effect	  of	  NO2
-­‐,	  as	  
proposed	   by	   Gladwin	   and	   colleagues	   (Dejam	   et	   al.,	   2007).	   In	   this	   study,	   it	   was	  
demonstrated	   that	   increases	   in	  plasma	  NO2
-­‐	   levels	   (low	  µM)	  produced	  substantial	  
increases	  in	  FBF	  but	  that	  a	  saturation	  of	  the	  vasodilatory	  effect	  was	  observed	  with	  
higher	  µM	  plasma	  NO2
-­‐	  levels	  (Dejam	  et	  al.,	  2007).	  
	  
In	  addition,	  these	  analyses	  intimate	  sex-­‐differences	  in	  the	  endogenous	  handling	  of	  
NO3
-­‐.	   Indeed,	   an	   identical	   inorganic	  NO3
-­‐	   load	   (24	  mmol	   KNO3)	  whilst	   resulting	   in	  
only	  subtle,	  but	  significant,	  differences	  in	  NO3
-­‐	  levels	  between	  the	  sexes,	  caused	  ~2-­‐
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fold	  higher	  plasma	  NO2
-­‐	  levels	  in	  females	  compared	  to	  males.	  It	  is	  possible	  that	  the	  
differences	  in	  plasma	  NO2
-­‐	  and	  NO3
-­‐	  levels	  after	  ingestion	  of	  24	  mmol	  KNO3	  reflects	  
the	   differences	   in	   body	   weight	   between	   the	   2	   sexes,	   which	   was	   greater	   in	   the	  
females	  compared	   to	   the	  males.	   	  However,	  normalization	  of	  plasma	  NOx	   levels	   to	  
body	  weight	  did	  not	  alter	  the	  shape	  of	  the	  profiles	  seen	  and	  significant	  differences	  
in	  plasma	  NO2
-­‐	  levels	  still	  persisted.	  	  
	  
Whilst	  differences	   in	  absorption	  and	  excretion	  of	  NOx	  may	  underlie	  some	  of	  these	  
differences,	  it	  is	  apparent	  that	  the	  differences	  in	  plasma	  NO2
-­‐	  levels	  reflect,	  in	  part,	  
sex-­‐differences	  in	  bacterial	  conversion	  of	  NO3
-­‐	  to	  NO2
-­‐	  in	  the	  oral	  cavity.	  There	  were	  
significantly	   higher	   rates	   of	   oral	   NO3
-­‐	   reduction	   in	   the	   oral	   cavity	   in	   females	   in	  
response	  to	  physiological,	  basal	  salivary	  NO3
-­‐	  concentrations	  (~0.8	  mM)	  and	  also	  in	  
response	  to	  NO3
-­‐	  levels	  that	  are	  apparent	  in	  the	  mouth	  after	  ingestion	  of	  8-­‐10	  mmol	  
inorganic	  NO3
-­‐	  (Lundberg	  and	  Govoni,	  2004;	  Bahra	  et	  al.,	  2012)	  that	  may	  be	  found	  
in	  ~300	  g	  meal	  of	  spinach	  or	  lettuce	  (Hord	  et	  al.,	  2009).	  	  
	  
There	   are	   several,	   potential	   explanations	   as	   to	   how	   there	   could	   be	   differences	   in	  
this	  part	  of	  the	  entero-­‐salivary	  circulation.	  There	  could	  be	  a	  difference	  in	  bacterial	  
load	  between	   the	   sexes.	   Additionally,	   there	   could	   be	   differences	   in	   the	   prevalent	  
species	  of	  bacteria,	  and	  there	  is	  evidence	  within	  the	  oral	  cavity	  that	  sex	  hormones	  
can	   alter	   the	   prevailing	  microbial	   flora	   (Klinger	   et	   al.,	   1998).	   It	   is	  well	   recognized	  
that	   for	   different	   bacterial	   species,	   the	  NO3
-­‐-­‐reductase	   enzymes	  have	   significantly	  
different	   Km	   (Betlach	   and	   Tiedje,	   1981)	   and	   different	   bacterial	   species	   also	   may	  
contain	   vastly	   different	   copy	   number	   (Smith	   et	   al.,	   2007)	   of	   the	   3	   distinct	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prokaryotic	   NO3
-­‐-­‐reductase	   genes	   (Moreno-­‐Vivian	   et	   al.,	   1999;	   Lundberg	   et	   al.,	  
2004).	   Hence,	   there	   is	   a	   potential	   for	   wide	   variation	   in	   NO2
-­‐	   production	   with	  
differences	  in	  either	  load	  or	  species	  of	  symbiotic	  bacteria,	  which	  may	  be	  altered	  by	  
sex	  hormones.	  	  
	  
Currently,	   it	   is	   thought	   that	   the	  predominant	   lingual	  bacteria	   responsible	   for	  NO3
-­‐	  
reduction	   in	   the	   oral	   cavity	   are	   gram-­‐negative	   Veillonella	   spp.	   and	   gram-­‐positive	  
Actinomyces	   spp.	   (Duncan	   et	   al.,	   1995;	  Doel	   et	   al.,	   2005).	   	  However,	  whether	   sex	  
differences	   exist	   in	   the	   colonization	   of	   the	   tongue	   or	   NO3
-­‐	   reductase	   activities	   of	  
these	  bacteria	  in	  humans	  is	  currently	  unknown.	  	  
	  
However,	   these	   studies	   cannot	   rule	   out	   sex-­‐differences	   in	   excretion	   as	   another	  
important	   factor.	   Urinary	   NO2
-­‐	   levels	   was	   similar	   in	   males	   and	   females,	   despite	  
significantly	   higher	   plasma	   NO2
-­‐	   levels	   in	   females,	   suggesting	   that	   there	   may	   be	  
more	   efficient	   reabsorption	   or	   different	   renal	   threshold	   for	   NO2
-­‐	   reabsorption	   in	  
females.	  	  
	  
One	  of	  the	  problems	  in	  investigating	  these	  possibilities	  is	  that	  the	  specific	  pathways	  
for	   NOx	   movement	   across	   renal	   tubular	   cell	   membranes	   have	   not	   been	   fully	  
elucidated.	  In	  erythrocytes,	  there	  may	  be	  a	  role	  for	  AE-­‐1	  (Vitturi	  et	  al.,	  2009;	  Jensen	  
and	   Rohde,	   2010)	   and	   the	   sodium-­‐dependent	   phosphate	   transporter	   (May	   et	   al.,	  
2000)	   but	   only	   recently	   have	   renal	   carbonic	   anhydrases	   been	   implicated	   in	   renal	  
NO2
-­‐	  handling	  in	  humans	  (Chobanyan-­‐Jürgens	  et	  al.,	  2012).	  Very	  recently,	  a	  pathway	  
for	  NO3
-­‐	  transport	  that	  may	  be	  important	  in	  the	  salivary	  glands	  has	  been	  identified	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as	   the	   sialic	   acid	   transporter,	   sialin,	   which	   can	   additionally	   facilitate	   intracellular	  
movement	  of	  NO3
-­‐	  in	  a	  2NO3
-­‐/H+	  electrogenic	  manner	  (Qin	  et	  al.,	  2012).	  Sialin	  is	  also	  
present	  in	  renal	  tissue	  (Reimer	  and	  Edwards,	  2004)	  and	  therefore	  may	  be	  important	  
for	  renal	  NO3
-­‐	  transport	  as	  well.	  	  
	  
These	  differences	  in	  oral	  NO3
-­‐	  reduction	  between	  females	  and	  males	  was	  reflected	  
in	   not	   only	   higher	   baseline	   plasma	  NO2
-­‐	   levels	   despite	   similar	   plasma	  NO3
-­‐	   levels,	  
but	   also	   disruption	   of	   the	   entero-­‐salivary	   circulation	   by	   use	   of	   antiseptic	  
mouthwash	   reduced	  plasma	  NO2
-­‐	   levels	   to	   a	   greater	   extent	   in	   females.	   Following	  
antiseptic	   mouthwash	   use,	   plasma	   NO2
-­‐	   levels	   were	   similar	   in	   both	   sexes.	   These	  
results	   possibly	   suggest	   that	   bacterial	   NO3
-­‐	   reduction	   may	   be	   an	   important	  
determinant	  in	  the	  sex-­‐differences	  in	  plasma	  NO2
-­‐	  levels	  seen.	  In	  addition,	  reduction	  
in	  plasma	  NO2
-­‐	  levels	  was	  associated	  with	  significant	  elevation	  in	  clinic	  BP	  and	  24	  h	  
ABP	  only	  in	  females,	  though	  the	  change	  in	  home	  BP	  was	  significant	  in	  both	  sexes.	  
	  
Taking	  all	  of	  the	  analyses	  together	  the	  data	  suggest	  that	  these	  apparent	  differences	  
in	   processing	   of	   NO3
-­‐	   may	   contribute	   to	   the	   prevalence	   of	   lower	   baseline	   BP	   in	  
women	  compared	  to	  men	  (Lerner	  and	  Kannel,	  1986).	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6.6	  Nutritional	  and	  toxicological	  aspects	  
Determining	   how	   vegetables	   confer	   protection	   against	   CVD	   and	   exploiting	   this	   to	  
therapeutic	   advantage	   is	   likely	   to	   have	   considerable	   health	   and	   economic	  
implications.	  Recently,	  it	  has	  been	  suggested	  that	  dietary	  NO3
-­‐	  found	  in	  high	  levels	  
in	  vegetables	  might	  underlie	  some	  of	   the	  beneficial	  effects	  of	  vegetable-­‐rich	  diets	  
(Lundberg	   et	   al.,	   2006;	   Webb	   et	   al.,	   2008a;	   Ralt,	   2009).	   It	   is	   ironic	   that	   NO3
-­‐,	   a	  
natural	   component	   of	   vegetables	   with	   a	   proposed	   harmful	   effect	   (via	   proposed	  
carcinogenic	   properties	   as	   discussed	   earlier),	   is	   now	   emerging	   as	   a	   possible	  
mediator	   of	   cardiovascular	   benefits.	   Indeed,	   it	   would	   be	   strange,	   in	   evolutionary	  
terms,	   if	  NO3
-­‐	  would	  be	  purposefully	  concentrated	  by	  the	  salivary	  glands	  and	  then	  
secreted	   into	   the	   oral	   cavity,	   followed	   by	   entero-­‐salivary	   recycling,	   if	   this	   was	  
actually	  harmful.	   It	  would	  make	  biological	  sense	  that	  such	  a	  sophisticated,	  precise	  
mechanism	  has	  evolved	  for	  a	  net	  beneficial	  reason.	  These	  studies	  described	  herein	  
suggest	   that	   the	   recycling	  of	  NO3
-­‐	   to	  NO2
-­‐	  may	  play	   an	   important	   role	   in	   vascular	  
homeostasis.	  
	  
6.6.1	  Pharmacodynamic	  advantages	  of	  NO3
-­‐-­‐based	  therapeutics	  
As	  has	  been	  alluded	  throughout,	  NO3
-­‐	  can	  be	  thought	  of	  as	  a	  ‘pro-­‐drug’	  for	  bioactive	  
NO2
-­‐,	  formed	  by	  the	  action	  of	  bacterial	  NO3
-­‐	  reductases.	  However,	  there	  are	  some	  
advantages	  to	  this	  dietary	  NO3
-­‐	  approach	  over	  NO2
-­‐.	  Inorganic	  and	  dietary	  NO3
-­‐	  has	  
a	  much	   longer	   t1/2	   in	  human	  plasma	   (~6	  h)	   (van	  Velzen	   et	  al.,	   2008)	   compared	   to	  
NO2
-­‐	  given	  either	  by	  oral	  or	  i.v.	  routes	  (~15-­‐45	  min)	  (Dejam	  et	  al.,	  2007;	  Hunault	  et	  
al.,	   2009)	   and,	   therefore,	   could	   be	   given	   as	   an	   once-­‐daily	   dosing	   regime.	   The	  
peak:trough	  ratio	  of	   the	  pharmacodynamic	  effects	  of	  dietary	  NO3
-­‐	   in	  hypertensive	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subject	   described	   above	   also	   suggest	   that	   this	   is	   a	   viable	   dosing	   strategy.	  
Importantly,	  the	  rise	  in	  plasma	  NO2
-­‐	  levels	  after	  NO3
-­‐	  ingestion	  is	  slow	  and	  sustained	  
to	   6	   h	   and	   remaining	   slightly	   elevated	   at	   24	   h	   after	   a	   single	   dose.	   One	   could	  
speculate	   that	   such	   a	   once-­‐a-­‐day	   approach	   is	   one	   that	   has	   the	   potential	   for	  
improved	   compliance	   in	   the	   clinical	   setting,	   although	   this	   warrants	   further	  
exploration.	   There	   is,	   of	   course,	   the	   added	   attraction	   that	   dietary	   approaches	   to	  
chronic	  disease	  may	  be	  more	  attractive	  since	  they	  offer	  a	  ‘natural’	  and	  potentially	  
low	  cost	  approach	  to	  CVD.	  However,	   there	  are	  some	   important	  aspects	  of	  dietary	  
NO3
-­‐	  and	  NO2
-­‐	  that	  require	  consideration	  before	  such	  an	  approach	  can	  be	  taken.	  
	  
6.6.2	  Agricultural	  issues	  with	  a	  NO3
-­‐-­‐based	  therapeutic	  approach	  
An	   important	   limitation	   of	   the	   dietary	   approach	   to	   NO3
-­‐	   supplementation	   is	   the	  
range	   of	   NO3
-­‐	   concentrations	   found	   naturally	   in	   batches	   of	   plants.	   Plants	  
accumulate	  NO3
-­‐	  through	  the	  roots	  and	  use	  it	  for	  novel	  synthesis	  of	  amino	  acids	  and	  
proteins	   (Vogtmann	   and	   Biedermann,	   1985).	   If	   the	   plant	   does	   not	   use	   the	   NO3-­‐	  
immediately,	  it	  is	  stored	  in	  vacuoles	  and	  it	  remains	  in	  the	  vacuoles	  if	  the	  plants	  are	  
supplied	   with	   more	   NO3
-­‐	   than	   they	   can	   use	   (Martinoia	   et	   al.,	   2007).	   NO3
-­‐	   will	  
therefore	   be	   stored	   more	   readily	   in	   vegetables	   with	   low	   rate	   of	   photosynthesis	  
(Martinoia	   et	   al.,	   2007).	   Hence,	   vegetables	   harvested	   in	   winter	   have	   higher	   NO3
-­‐	  
content	   than	  those	  harvested	   in	   the	  summer	  (Food	  Standards	  Agency,	  2004).	  This	  
produces	   a	   problem	   when	   trying	   to	   give	   a	   fixed	   dose	   of	   NO3
-­‐	   in	   the	   form	   of	   a	  
vegetable	   or	   vegetable-­‐based	   drink.	   In	   the	   studies	   reported	   herein,	   the	   [NO3
-­‐]	   of	  
beetroot	   juice	   used	   was	   13.2±0.94	   mM	   (n=15)	   and	   22.4±3.8	   mM	   (n=9),	   whilst	  
previous	  research	  from	  Prof	  Ahluwalia’s	  group	  used	  a	  beetroot	  juice	  with	  [NO3
-­‐]	  of	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45.0±2.6	  mM	  (Webb	  et	  al.,	  2008a).	  It	  is	  impractical	  to	  alter	  the	  volume	  ingested	  on	  
a	  batch-­‐by-­‐batch	  basis.	  In	  this	  regard,	  a	  commercial	  company	  has	  recently	  produced	  
a	   beetroot	   juice	   concentrate	   with	   a	   fixed	   amount	   of	   NO3
-­‐	   (~5mmol,	  
http://www.beet-­‐it.com/organic)	  that	  is	  currently	  aimed	  at	  use	  in	  elite	  athletes	  and	  
this	   approach	   to	  provide	  a	   fixed	  dose	   could	  be	  used,	   as	   clearly,	   could	  a	   inorganic	  
NO3
-­‐	  capsule	  formulation.	  
	  
6.6.3	  NO3
-­‐	  supplementation	  is	  unlikely	  to	  cause	  significant	  methaemoglobinaemia	  	  
The	   fruit	   and	   vegetable-­‐rich	   DASH	   diet	   (Appel	   et	   al.,	   1997)	   that	   lowers	   BP	   is	  
estimated	   to	   contain	   up	   to	   ~20	  mmol	   of	   NO3
-­‐	   (Hord	   et	   al.,	   2009),	   exceeding	   the	  
recommended	  ADI	   limit	  for	  NO3
-­‐,	  which	  currently	   is	  set	  at	  3.7mg/kg	  daily	  (Speijers	  
and	  van	  den	  Brandt,	  2003)	  which	  would	  be	  ~4.2	  mmol	  in	  a	  70	  kg	  person.	  However,	  
most	   of	   the	   doses	   of	   NO3
-­‐	   given	   that	   show	   beneficial	   effects	   clearly	   exceed	   this	  
advised	  limit.	  	  
	  
The	   levels	   of	   NO3
-­‐	   consumption	   advised	   and	   concentration	   in	   drinking	   water	   is	  
strictly	  controlled	  in	  many	  countries	  and	  is	  based	  upon	  two	  main	  concerns.	  Firstly,	  
NO3
-­‐	   in	  drinking	  water	  has	  long	  been	  thought	  to	  cause	  methaemoglobinaemia	  and	  
on	  the	  basis	  of	  observational	  data	  (Comly,	  1945;	  Walton,	  1951)	  a	  maximum	  limit	  of	  
50	   mg/L	   (=0.8	   mM	   [NO3
-­‐])	   has	   been	   implemented	   in	   Europe	   and	   USA.	  
Methaemoglobinaemia	  caused	  by	  NO3
-­‐	  is	  a	  consequence	  of	  the	  interaction	  of	  NO2
-­‐,	  
formed	  as	  an	  intermediate,	  with	  erythrocytes,	  resulting	  in	  the	  oxidation	  of	  the	  Fe2+	  
(ferrous	  state)	  in	  Hb	  to	  the	  Fe3+	  (ferrous)	  state,	  forming	  stable	  metHb	  (Doyle	  et	  al.,	  
1981),	  which	  is	  incapable	  of	  O2	  transport.	  
 252	  
However	   more	   recently,	   there	   has	   been	   a	   reappraisal	   of	   these	   concerns	   and	   a	  
reevaluation	   of	   those	   early	   data	   (Fewtrell,	   2004).	   Most	   of	   the	   cases	   of	  
methaemoglobinaemia	   reported	   in	   the	   1940’s	   were	   associated	   with	   high-­‐NO3
-­‐	  
containing	   well	   water	   in	   infants	   who	   developed	   co-­‐existent	   diarrhoea	   from	  
presumed	  infectious	  gastroenteritis	  (Comly,	  1945;	  Walton,	  1951).	  It	  has	  since	  been	  
suggested	  that	  bacterial	  contamination	  of	  the	  well-­‐water	  (Avery,	  1999),	  or	  bacterial	  
NO3
-­‐	  reduction	  in	  vivo	  during	  intestinal	  infection	  (Hanukoglu	  and	  Danon,	  1996)	  may	  
be	   responsible	   for	   apparent	   NO3
-­‐-­‐induced	   infantile	   methaemoglobinaemia,	  
especially	  as	  recent	  reports	  have	  demonstrated	  no	  consistent	  association	  between	  
either	  metHb	   levels	   or	   the	   risk	   of	   developing	   clinical	  methaemoglobinaemia	  with	  
drinking	  water	  NO3
-­‐	  levels	  (reviewed	  in	  Ward	  et	  al.,	  2005).	  
	  
Interestingly,	   in	   the	   measurements	   of	   commercially	   available	   beetroot	   juice,	   the	  
NO3
-­‐	  concentration	  ranged	  from	  13-­‐45	  mM,	  clearly	  above	  the	  set	  limits	  for	  drinking	  
water.	   However,	   post-­‐ingestion	   of	   dietary	   NO3
-­‐,	   maximal	   plasma	   NO2
-­‐	   levels	  
remained	  on	  average	  below	  1	  µM	  (a	  level	  within	  the	  normal	  physiological	  realm).	  It	  
is	   also	   noteworthy	   that	   after	   intra-­‐arterial	   infusion	   of	   NO2
-­‐	   in	   healthy	   subjects,	  
systemic	  NO2
-­‐	  levels	  of	  16	  µM	  were	  achieved	  (far	  higher	  levels	  than	  those	  needed	  to	  
see	  BP	   lowering)	   but	  with	  no	  evidence	  of	   substantial	  methaemoglobinaemia	  with	  
levels	   being	   measured	   at	   ~1%	   (Cosby	   et	   al.,	   2003).	   More	   recently,	   a	  
pharmacokinetic	  study	  was	  performed	  to	  determine	  dose-­‐limiting	  toxicity	  in	  healthy	  
subjects	  (Pluta	  et	  al.,	  2011).	  Doses	  of	  NaNO2	  between	  6.4-­‐7.7	  µmol/kg/h	  i.v.	  for	  3-­‐9	  
h	  produced	  large,	  symptomatic	  reductions	  in	  BP	  (~20	  mmHg	  decrease	  in	  MAP)	  but	  
only	   clinically	   insignificant,	   asymptomatic	   metHb	   levels	   of	   between	   2-­‐5%	   with	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plasma	   NO2
-­‐	   levels	   between	   1-­‐5	   µM	   (Pluta	   et	   al.,	   2011);	   methaemoglobinaemia	  
becoming	   symptomatic	   when	   levels	   >8%	   (Ash-­‐Bernal	   et	   al.,	   2004).	   Importantly,	  
there	   have	   been	   no	   cases	   of	   vegetable-­‐induced	   methaemoglobinaemia	   in	   adults	  
reported	   in	   the	   literature	   and	   cases	   in	   children	   have	   been	   related	   to	   improper	  
storage	   of	   cooked	   or	   salted	   vegetables	   that	   allowed	   bacterial	   contamination	   and	  
elevated	  NO2




-­‐	  is	  unlikely	  to	  increase	  risk	  of	  carcinogenesis	  
There	   has	   also	   been	   a	   concern	   for	   many	   years	   about	   the	   formation	   of	   N-­‐
nitrosamines	   after	   ingestion	   of	   both	   NO2
-­‐	   and	   NO3
-­‐	   and	   therefore,	   potential	  
carcinogenesis	  (Harada	  et	  al.,	  1974;	  Tannenbaum	  et	  al.,	  1974;	  Ishiwata	  et	  al.,	  1975a,	  
b,	   c,	   d;	   Ishiwata,	   1976a,	   b;	   Spiegelhalder	   et	   al.,	   1976;	   Tannenbaum	   et	   al.,	   1976;	  
Eisenbrand	  et	  al.,	  1980;	  Tannenbaum	  and	  Correa,	  1985),	  especially	  in	  the	  upper	  GI	  
tract	  (Iijima	  et	  al.,	  2003).	  However,	  a	  comprehensive	  review	  of	  the	  data	  in	  2003	  by	  
the	  World	  Health	  Organization	  Expert	  Committee	  on	  Food	  Additives	  concluded	  that	  
there	  was	  no	  evidence	  that	  NO3
-­‐	  was	  carcinogenic	  to	  humans	  (Speijers	  and	  van	  den	  
Brandt,	   2003).	   Reassuringly	   and	   importantly,	   in	   large	   cohorts	   (>100,000	   subjects)	  
followed	  for	  many	  years,	  a	  fruit	  and	  vegetable-­‐rich	  diet,	  where	  the	  ADI	  is	  exceeded	  
several	  fold,	  is	  not	  associated	  with	  any	  increase	  in	  cancer	  or	  mortality	  (Hung	  et	  al.,	  
2004),	  indeed	  the	  contrary	  is	  true	  (World	  Cancer	  Research	  Fund/American	  Institute	  




6.6.5	  Oral	  hygiene	  treatments	  may	  have	  adverse	  cardiovascular	  effects	  
The	   studies	   in	   this	   thesis	   also	   intimate	   possible	   adverse	   cardiovascular	   effects	   of	  
excessive	  antiseptic	  mouthwash	  use	   in	  healthy	   individuals.	  This	  view	   is	   in	  contrast	  
with	  the	  clear	  association	  of	  oral	  bacterial	  periodontal	   infection	  with	  hypertension	  
and	   vascular	   dysfunction	   (Tonetti	   et	   al.,	   2007;	   Desvarieux	   et	   al.,	   2010)	   but	   this	  
difference	  may	  reflect	  health	  status,	  possible	  translocation	  of	  bacteria	  and	  bacterial	  
species	   prevalent.	   However,	   considering	   the	   wide-­‐scale	   use	   of	   over-­‐the-­‐counter	  
mouthwash	   within	   the	   general	   population	   (estimates	   suggest	   30-­‐45%	   of	   the	   US	  
population	   use	   daily	   mouthwash	   (Elmore	   and	   Horwitz,	   1995;	   Fedorowicz	   et	   al.,	  




6.7.1	  Sample	  size	  
These	   studies	   in	   healthy	   and	   hypertensive	   subjects	   represent	   phase	   I/IIa-­‐type	  
studies	   that	   would	   be	   performed	   if	   dietary	   or	   inorganic	   NO3
-­‐	   were	   novel	   small	  
chemical	   entities.	  Although	   the	   sample	   sizes	  were	  not	   large	   in	   all	   studies	   (n=6-­‐20	  
completed),	   they	   were	   adequately	   powered	   by	   prospective	   power	   analyses	   to	  
detect	  differences	  in	  total	  cohorts	  for	  changes	  in	  NO2
-­‐	  levels	  and	  BP.	  The	  oral	  NO3
-­‐	  
reductase	   study,	   described	   in	   chapter	   4,	   recruited	   n=19	   subjects	   to	   completion,	  
rather	   than	   the	   prescribed	   n=21	   by	   the	   initial	   power	   calculation.	   However,	   even	  
with	   this	   n	   number,	   the	   achieved	   1-­‐β	   of	   the	   study	   was	   0.86.	   This	   power	   level	   is	  
above	   the	   conventionally	   accepted	   level	   of	   0.80	   that	   is	   expected	   for	   medical	  
research	   (Bacchetti,	   2010;	   Norman	   et	   al.,	   2012).	   Post-­‐hoc	   analyses	   in	   healthy	  
subjects	   and	   stratification	   of	   results	   by	   sex	   (the	   latter	   due	   to	   dropouts)	   were	  
underpowered	   to	   robustly	   detect	   statistical	   sex-­‐differences	   in	   BP.	   However,	   sex-­‐
differences	   in	   baseline	   plasma	  NO2
-­‐	   levels	   were	   detected	   in	   both	   healthy	   subject	  
cohorts	  and	  the	  large	  sex-­‐dependent	  differences	  in	  oral	  NO3
-­‐	  reduction	  are	  likely	  to	  
be	  significant.	  An	   important	   limitation	  of	   the	   findings	   is	   that	   the	  studies	  were	  not	  
controlled	  for	  the	  stage	  of	  the	  menstrual	  cycle	  in	  female	  subjects	  and	  this	  may	  have	  
some	  relevance	  since	  resting	  BP	  is	  different	  throughout	  the	  menstrual	  cycle	  (Dunne	  
et	   al.,	   1991).	   However,	   this	   is	   likely	   to	   have	   increased	   the	   heterogeneity	   of	   the	  
female	  results	  and	  reduced	  the	  likelihood	  of	  determining	  significant	  differences.	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6.7.2	  Study	  design	  
The	  gold-­‐standard	  design	  for	  clinical	  intervention	  studies	  is	  the	  randomized,	  double-­‐
blind,	  placebo-­‐controlled	   study.	  However	   the	   taste	  and	  colour	  of	   the	  dietary	  NO3
-­‐	  
used	  (beetroot	  juice)	  is	  hard	  to	  blind	  and	  so	  water	  was	  used	  in	  an	  open-­‐label	  design.	  
Other	   researchers	   have	   used	   fruit	   juice	   cordials	   as	   a	   placebo	   (Bailey	   et	   al.,	   2009;	  
Vanhatalo	   et	   al.,	   2010),	   though	   this	   design	   introduces	   other	   chemicals	   in	   the	  
placebo	  that	  may	  have	  vascular	  effects.	  More	  recently,	  Prof	  N	  Benjamin	  (University	  
of	  Exeter)	  has	  developed	  a	  beetroot	  juice	  ‘placebo’	  made	  by	  passing	  beetroot	  juice	  
through	   a	   commercially	   available	   anion-­‐exchange	   resin,	   Purolite	   a520E,	   (Purolite,	  
Ltd.,	  Bala	  Cynwyd,	  USA)	  as	  used	  to	  control	  NO3
-­‐	  in	  water	  supplies.	  This	  has	  recently	  
been	  used	  as	  placebo	  in	  ethically-­‐approved	  research	  studies	  (Lansley	  et	  al.,	  2011a,	  
b;	  Vanhatalo	  et	  al.,	  2011)	  and	  contains	  only	  0.008	  μM	  [NO3-­‐]	  and	  is	  indistinguishable	  
by	  taste	  or	  appearance	  from	  NO3
-­‐-­‐rich	  beetroot	  juice	  (Vanhatalo	  et	  al.,	  2011).	  
	  
Similarly,	  there	  was	  no	  adequate	  placebo	  for	  the	  oral	  mouthwash.	  All	  commercially-­‐
available	   mouthwashes	   contain	   antiseptic	   ingredients	   and	   the	   taste	   of	   the	  
mouthwash	  precludes	  blinding	  with	  water	  or	  saline.	  When	  this	  study	  was	  designed,	  
it	  was	  not	  clear	  how	  long	  the	  effects	  of	  antiseptic	  mouthwash	  would	  last	  for	  after	  
termination	   of	   use	   (it	   has	   recently	   been	   demonstrated	   that	   oral	   NO3
-­‐	   reductase	  
activity	  returns	  to	  baseline	  levels	  48	  h	  following	  cessation	  of	  antiseptic	  mouthwash	  
use	   (Kanady	   et	   al.,	   2012)).	   Therefore,	   it	  was	  not	   possible	   to	   conduct	   a	   cross-­‐over	  
design	  in	  the	  oral	  NO3
-­‐	  reduction	  study	  and	  there	  is	  a	  potential	  problem	  with	  order	  
effect.	   These	   problems	   could	   have	   been	   solved	   using	   a	   parallel	   design	   if	   a	   useful	  
placebo	   could	   have	   been	   found.	   However,	   the	   required	   sample	   size	   would	   have	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been	  much	  larger	  and	  there	  were	  ongoing	  problems	  throughout	  these	  studies	  with	  
adequate	  recruitment.	  All	  participants	  in	  the	  oral	  NO3
-­‐	  reduction	  study	  had	  a	  control	  
period	   followed	   by	   an	   intervention	   period,	   so	   treatment	   effects	   could	   be	  
confounded	  with	  a	  change	  over	  time.	  However,	  efforts	  were	  made	  to	  minimize	  this	  
possibility	   by	   using	   3	   different	   measures	   of	   BP.	   In	   particular,	   home	   BP	   was	  
measured	   on	   a	   daily	   basis	   for	   7	   days	   prior	   to	   the	   intervention.	   This	   data	  
demonstrates	   the	   reproducibility	   of	   the	   BP	   measure	   on	   a	   day-­‐to-­‐day	   basis	   and	  
clearly	  demonstrates	  no	  change	  from	  one	  day	  to	  the	  next	  supporting	  the	  view	  that	  
instigation	  of	  the	  intervention	  did	  indeed	  affect	  BP.	  In	  spite	  of	  the	  lack	  of	  a	  placebo	  
mouthwash,	   the	   dramatic	   drop	   in	   salivary	   NO2
-­‐	   levels	   together	   with	   the	   strong	  
correlation	   between	   the	   change	   in	   plasma	  NO2
-­‐	   levels	   and	   change	   in	   BP,	   strongly	  
supports	  the	  view	  that	  disruption	  of	  oral	  bacterial	  conversion	  of	  NO3
-­‐	  to	  NO2
-­‐	  is	  the	  
cause	  of	  the	  observed	  effects.	  Saliently,	  none	  of	  the	  participants	  in	  the	  dietary	  NO3
-­‐	  
or	  oral	  NO3
-­‐	  reduction	  studies	  were	  aware	  of	  the	  hypotheses	  and	  statistical	  analyses	  
were	   performed	   blind	   to	   the	   treatment	   groups,	  making	   bias	   from	   the	   open-­‐label	  
designs	  less	  likely.	  
	  
6.7.3	  Time-­‐course	  
The	   studies	   that	   involved	  NO3
-­‐	   supplementation	  were	   conducted	   over	   a	   range	   of	  
times	  between	  3-­‐24	  h.	  The	  initial	  study	  described	  in	  this	  thesis	  (24	  mmol	  KNO3	  vs.	  
KCl	  study)	  was	  so	  designed	  to	  investigate	  whether	  inorganic	  NO3
-­‐	  supplementation	  
would	  replicate	  the	  effects	  of	  dietary	  NO3
-­‐	  ingestion,	  thus	  providing	  evidence	  that	  it	  
was	   the	  NO3
-­‐	   content	  of	   the	  beetroot	   juice	   (as	  a	   source	  of	  dietary	  NO3
-­‐)	   that	  was	  
responsible	   for	   the	  BP-­‐lowering	  effects	  noted	  previously	   (Webb	  et	  al.,	  2008a)	  and	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thus	   the	  study	  design	  was	  replicated.	   In	  addition,	   this	  study	  design	  over	  24	  h	  was	  
used	   in	  hypertensive	  subjects,	  as	   the	  time-­‐course	  of	  changes	   in	  plasma	  NOx	   levels	  
and	  BP	  response	  following	  NO3
-­‐	  ingestion	  in	  hypertensives	  were	  not	  known.	  It	  was	  
elucidated	   from	   these	   healthy	   subject	   studies	   that	   the	   time	   to	   peak	   plasma	  NO2
-­‐	  
levels	   and	   BP-­‐lowering	   after	   NO3
-­‐	   ingestion	   was	   consistent	   at	   ~3	   h.	   Thus,	   in	   the	  
further	  dose-­‐response	  and	  dietary	  NO3
-­‐	  studies	   in	  healthy	  subjects,	   it	  was	  decided	  
that	   the	   design	   would	   last	   only	   up	   to	   3	   h	   post-­‐NO3
-­‐	   ingestion	   to	   maximize	   the	  
recruitment	  for	  the	  studies.	  Throughout	  these	  studies,	  recruitment	  was	  a	  significant	  
hurdle	  and	  recruitment	  was	  improved	  by	  limiting	  the	  length	  of	  the	  study	  visits.	  
	  
6.7.4	  Interpretation	  of	  oral	  NO3
-­‐	  reductase	  activity	  
The	  biological	  nitrogen	  cycle	  in	  bacteria	  is	  complex	  and	  can	  take	  inorganic	  NO3
-­‐	  (+5	  
oxidation)	   all	   the	   way	   to	   ammonia	   (-­‐3	   oxidation)	   (Schreiber	   et	   al.,	   2010).	   NO3
-­‐	  
reduction	   is	   only	   the	   first	   of	   many	   steps	   and	   several	   enzymes	   are	   involved	   in	  
denitrification	   (Lundberg	   et	   al.,	   2004).	   Many	   of	   these	   enzyme	   systems	   are	   co-­‐
localized	   within	   bacterial	   membranes	   and	   many	   bacteria	   have	   the	   complete	  
denitrification	   pathway	   taking	   metabolites	   produced	   from	   one	   enzyme	   and	  
reducing	  it	  in	  a	  step-­‐wise	  fashion.	  Therefore,	  measuring	  NO2
-­‐	  accumulation	  may	  not	  
be	   precise	   enough	   to	   adequately	   determine	   and	   quantify	   oral	   NO3
-­‐	   reductase	  
activity.	  Any	  NO2
-­‐	   that	  may	  be	  produced	  may	  be	   further	   reduced	   to	  NO	  or	  all	   the	  
way	  down	  to	  ammonia.	  NO3
-­‐	  disappearance	  from	  solution	  is	  an	  alternative	  indicator	  
of	  NO3
-­‐	  reduction,	  but	  does	  not	  always	  mean	  that	   it	  ends	  up	  as	  NO2
-­‐	  and	   in	  these	  
studies	  the	  primary	  interest	  was	  the	  contribution	  of	  the	  entero-­‐salivary	  circulation	  
to	  salivary	  and	  plasma	  NO2
-­‐	  levels	  as	  this	  is	  the	  anion	  with	  reported	  bioactivity.	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6.8	  Future	  perspectives	  
Despite	  the	  substantial	  advances	  made	  in	  anti-­‐hypertensive	  pharmacotherapy,	  it	  is	  
estimated	   that	   by	   2025	   the	   world	   will	   have	   1.5	   billion	   hypertensive	   patients	  
(Kearney	  et	  al.,	  2005).	  Indeed,	  over	  the	  past	  3	  decades	  the	  numbers	  of	  patients	  with	  
uncontrolled	  essential	  hypertension	  has	  continued	  to	  rise	  year	  on	  year	  (Egan	  et	  al.,	  
2011).	   These	   are	   worrying	   statistics	   since	   raised	   BP	   is	   thought	   to	   underlie	  
approximately	   50%	   of	   all	   coronary	   events	   and	   greater	   than	   60%	   of	   all	   strokes	  
(Rodgers	  et	  al.,	  2002);	  an	  observation	  supported	  by	  recent	  a	  meta	  analysis	  (Law	  et	  
al.,	   2009).	   Such	   statistics	   clearly	   support	   the	   rationale	   for	   identification	   of	   novel	  
therapeutic	  approaches	  for	  hypertension.	  	  	  
	  
In	   addition	   to	   identification	   of	   novel	   pharmacological	   and	   surgical	   approaches	   to	  
treat	  hypertension	  (Paulis	  and	  Unger,	  2010),	  there	  has	  been	  the	  implementation	  of	  
large,	   relatively	   ‘low	   cost’	   public	   health	   initiatives	   to	   improve	   a	   number	   of	  
modifiable	  lifestyle	  factors,	  such	  as	  increasing	  vegetable	  consumption	  (Department	  
of	  Health,	  2003;	  Lichtenstein	  et	  al.,	  2006).	  Whilst	  the	  benefits	  of	  vegetable-­‐rich	  diet	  
in	   populations	   at	   risk	   of	   CVD	   are	   well	   recognized	   (Appel	   et	   al.,	   1997),	   the	  
constituent	   elements	   of	   such	   diets	   have	   not	   replicated	   the	   same	   beneficial	  
outcomes.	  For	  the	  first	  time	  it	  has	  been	  demonstrated	  in	  hypertensive	  subjects	  that	  
a	  dietary	  NO3
-­‐	  load	  (in	  the	  form	  of	  beetroot	  juice)	  significantly	  elevates	  plasma	  NO2
-­‐	  
levels	   with	   resulting	   reductions	   in	   BP.	   For	   any	   therapy	   to	   become	   part	   of	   the	  
established	   armamentarium	   for	   CVD	   typically	   requires	   large-­‐scale	   outcome	   trials.	  
The	   results	   presented	   in	   this	   thesis	   offer	   support	   for	   advocating	   a	   fruit	   and	  
vegetable-­‐rich	   dietary	   approach	   to	   tackling	   the	   growing	   global	   burden	   of	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hypertension	  and	  associated	  CVD,	  that	  is	  cheap,	  robust	  and	  a	  palatable	  alternative	  
to	  medications	   that	  could	  be	   form	  part	  of	  both	  public	  health	   initiatives	  as	  well	  as	  
treatment.	  	  
	  
Given	   that	   ~50%	   of	   treated	   hypertensive	   subjects	   fail	   to	   achieve	   their	   target	   BP	  
(Egan	   et	   al.,	   2010,	   2011),	   an	   additional	   strategy,	   based	   on	   intake	   of	   NO3
-­‐-­‐rich	  
vegetables,	  may	  prove	   to	  be	  both	   cost-­‐effective	  and	   favourable	   for	  public	  health.	  
Hence,	   determining	   the	   long	   term	   therapeutic	   potential	   of	   inorganic	   and	   dietary	  
NO3
-­‐	  is	  warranted	  and	  is	  currently	  underway	  and	  will	   inform	  as	  to	  whether	  a	  long-­‐
term	  elevation	  of	   dietary	  NO3
-­‐	   intake	   can	  provide	   sustained	  BP	  benefits.	   To	  date,	  
>50%	   of	   patients	   have	   been	   recruited	   to	   a	   double-­‐blind,	   randomized,	   parallel,	  
placebo-­‐controlled	  4-­‐week	   intervention	   in	  hypertensive	  subjects	  with	  dietary	  NO3
-­‐	  
as	   beetroot	   juice	   (250mL	   daily)	   or	   a	   matched	   NO3
-­‐-­‐depleted	   beetroot	   juice	  
(clinicaltrials.gov:	   NCT01405898).	   In	   this	   study,	   it	   will	   be	   determined	   whether	  
dietary	   NO3
-­‐	   lowers	   BP	   and,	   in	   addition,	   whether	   dietary	   NO3
-­‐	   can	   improve	  
endothelial	   function	   and	   arterial	   stiffness	   in	   hypertensive	   subjects.	   Some	   recently	  
published	  results	   that	  do	  not	  appear	   in	  my	  thesis	  have	  shown	  that	   inorganic	  NO3
-­‐	  
supplementation	   (8	   mmol	   KNO3)	   did	   not	   improve	   endothelial	   function	   per	   se	   in	  
healthy	  subjects	  with	  normal	  endothelial	  function	  (Bahra	  et	  al.,	  2012).	  However,	  our	  
group	  has	  previously	  demonstrated	  that	  ingestion	  of	  dietary	  NO3
-­‐	  protected	  against	  
IR-­‐induced	  endothelial	  dysfunction	  of	  conduit	  vessels	   in	  healthy	  subjects	  (Webb	  et	  
al.,	  2008a).	  In	  10	  healthy	  subjects,	  IR	  caused	  reductions	  in	  brachial	  artery	  FMD	  that	  
could	  be	  prevented	  by	  ingestion	  of	  a	  single	  dose	  of	  dietary	  NO3
-­‐	  (22.5	  mmol	  dose)	  2	  
h	  prior	  to	  the	  IR	  injury	  (Webb	  et	  al.,	  2008a),	  reflecting	  the	  time	  taken	  for	  systemic	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NO2
-­‐	   levels	   to	  elevate	  due	  to	  entero-­‐salivary	  circulation	  of	  NO3
-­‐	   to	  NO2
-­‐	   (Lundberg	  
and	   Govoni,	   2004;	   Webb	   et	   al.,	   2008a).	   Hypertensive	   subjects	   have	   endothelial	  
dysfunction	  (Linder	  et	  al.,	  1990;	  Panza	  et	  al.,	  1993)	  and	  it	  may	  be	  that	  elevation	  of	  
NO2
-­‐	   levels	  may	   improve	  endothelial	   function	   in	   this	  setting	  and	  this	  hypothesis	   is	  
currently	  being	  tested	  (clinicaltrials.gov:	  NCT01405898).	  	  
	  
In	   this	   regard,	   it	   has	   recently	   been	   suggested	   that	   provision	   of	   NO	   via	   the	  
alternative	   reductive	   pathway	   (i.e.	   from	  NO2
-­‐	   or	   NO3
-­‐)	  might	   also	   have	   beneficial	  
effects	  in	  the	  pathogenic	  processes	  associated	  with	  endothelial	  dysfunction	  (Stokes	  
et	   al.,	   2009).	   Tsuchiya	   and	   colleagues	   demonstrated	   that	   in	   a	   L-­‐NAME	   induced	  
model	  of	  hypertension,	  co-­‐administration	  of	  dietary	  NO2
-­‐	   (~20-­‐200	  μM	   in	  drinking	  
water)	  for	  8	  weeks	  prevented	  NOS-­‐inhibition	  induced	  hypertension	  (Tsuchiya	  et	  al.,	  
2005),	   elevated	   systemic	   NO	   production	   (as	   measured	   by	   circulating	   HbNO)	  
(Tsuchiya	   et	   al.,	   2005;	   Kanematsu	   et	   al.,	   2008)	   and	   prevented	   associated	   renal	  
damage	  assessed	  histologically	  and	  by	  urinary	  proteinuria	  (Kanematsu	  et	  al.,	  2008)	  
suggesting	   that	   dietary	  NO2
-­‐	   can	  play	   a	   role	   in	   compensating	   for	   the	  depletion	  of	  
eNOS-­‐derived	   NO	   in	   situations	   such	   as	   endothelial	   dysfunction	   (Tsuchiya	   et	   al.,	  
2010).	  	  
	  
More	  recently,	  eNOS	  knockout	  mice	  were	   fed	  1	  mM	  NO3
-­‐	  water	  or	  placebo	  water	  
for	  8-­‐10	  weeks.	  Surprisingly,	  weight	  in	  the	  obese	  mice	  was	  significantly	  reduced	  at	  
the	  end	  of	  the	  supplementation	  period	  (~4.3g	  different	  to	  control	  population)	  with	  
no	   significant	   difference	   in	   food	   or	   water	   intake	   (Carlström	   et	   al.,	   2010).	  
Triglycerides,	   visceral	   fat,	   blood	   glucose	   homeostasis	   after	   oral	   glucose	   tolerance	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testing	   and	   glycated	   Hb	   were	   all	   also	   significantly	   improved	   in	   the	   active	   group	  
(Carlström	  et	  al.,	  2010),	  suggesting	  that	  dietary	  NO3
-­‐	  could	  compensate	  for	  some	  of	  
the	  metabolic	  consequences	  of	  disturbances	  in	  eNOS-­‐derived	  NO	  production.	  
	  
Interestingly,	   raising	   plasma	   NO2
-­‐	   levels	   in	   a	   sustained	   manner	   by	   dietary	  
supplementation	   with	   either	   NO2
-­‐	   or	   NO3
-­‐	   in	   the	   drinking	   water	   also	   produced	  
similar	  protection	  against	  myocardial	   IR	   injury.	  Lefer	  and	  colleagues	  demonstrated	  
that	  pre-­‐treatment	  with	  dietary	  NO2
-­‐	  (~0.7	  μM)	  or	  NO3
-­‐	  (~12	  mM)	  in	  mice	  for	  7	  days	  
increased	  plasma	  and	  heart	  NO2
-­‐	   levels	  by	  ~2-­‐3	  fold	  for	  both	  treatments	  (Bryan	  et	  
al.,	  2007).	  These	  elevations	   in	  plasma	  and	   tissue	  NO2
-­‐	   levels	  were	  associated	  with	  
reduced	  infarct	  size	  in	  response	  to	  a	  myocardial	  injury	  (30	  min	  left	  coronary	  ligation	  
and	  then	  reperfusion)	  (Bryan	  et	  al.,	  2007).	  There	  was	  a	  48%	  reduction	  in	  infarct	  size	  
after	   dietary	   NO2
-­‐	   supplementation	   and	   33%	   reduction	   in	   infarct	   size	   after	   NO3
-­‐	  
supplementation	   in	   drinking	   water	   (Bryan	   et	   al.,	   2007).	   In	   addition,	   depletion	   of	  
basal	  plasma	  and	  myocardial	  NO2
-­‐	  stores,	  by	  putting	  mice	  on	  a	  low-­‐NO2
-­‐	  diet	  for	  7	  
days,	   caused	   larger	   infarct	   size	   than	   mice	   fed	   normal	   chow	   diet	   alone,	   and	   this	  
worsening	  of	  outcome	  was	  entirely	  ameliorated	  by	  provision	  of	  NO2
-­‐	  in	  the	  drinking	  
water,	  restoring	  plasma	  and	  tissue	  NO2
-­‐	  levels	  to	  normal	  physiological	  levels	  (Bryan	  
et	  al.,	  2007).	  These	   findings	  support	   the	  view	  that	  elevation	  of	  plasma	  NO2
-­‐	   levels	  
may	  be	  a	  useful	  preventative	  strategy	  for	  at	  risk	  individuals	  and	  that	  basal,	  systemic	  
NO2
-­‐	   levels	   afforded	   by	   the	   entero-­‐salivary	   circulation	   have	   important	   effects	   on	  
cardiovascular	  homeostasis	  (Bryan	  et	  al.,	  2007).	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Further	  translation	  of	  these	  results	  in	  a	  canine	  model	  of	  myocardial	  infarction	  (MI)	  
demonstrated	   that	   infusion	  of	  NO2
-­‐	   (0.2	  μmol/min)	   in	   just	   the	   last	  5	  min	  of	  a	  2	  h	  
period	  of	  ischaemia	  reduced	  infarct	  size	  by	  ~50%	  compared	  to	  control	  (Gonzalez	  et	  
al.,	   2008).	   Such	  observations	   suggest	   that	  NO2
-­‐	  may	  have	  use	   in	   the	   treatment	  of	  
acute	   MI	   in	   humans,	   in	   which	   NO2
-­‐	   could	   be	   delivered	   at	   the	   time	   of	   primary	  
coronary	   intervention.	   Indeed,	   our	   group	   is	   translating	   this	   to	   the	   clinical	   setting	  
currently,	   where	   NaNO2	   has	   entered	   phase	   II	   trials	   to	   determine	   whether	  
intracoronary	   NO2
-­‐	   infusion	   can	   reduce	   infarct	   size	   and	   improve	   left	   ventricular	  
function	  following	  acute	  MI	  (clinicaltrials.gov:	  NCT01584453).	  
	  
Another	   intriguing	   aspect	   of	   the	   findings	   in	   this	   thesis	   is	   the	   role	   of	   the	   oral	  
microflora	   in	   regulating	   NO-­‐dependent	  mechanisms,	   such	   as	   BP	   in	   these	   studies.	  
Apart	   from	   vasodilator	   actions,	   NO2
-­‐-­‐derived	   NO	   also	   has	   a	   number	   of	   other	  
potentially	   beneficial	   effects	   in	   humans,	   including	   cytoprotection	   after	   IR	   injury	  
(Lang	  et	  al.,	  2007),	  inhibition	  of	  platelet	  aggregation	  (Richardson	  et	  al.,	  2002;	  Webb	  
et	   al.,	   2008a;	   Srihirun	   et	   al.,	   2012)	   and	   improvement	   of	   mitochondrial	   efficiency	  
(Larsen	  et	  al.,	  2011).	  Future	  studies	  will	  reveal	  if	  the	  disturbances	  in	  circulating	  NO2
-­‐	  
homeostasis	   following	   the	   use	   of	   an	   antiseptic	   mouthwash	   or	   other	   similar	  
interventions,	  might	  affect	  these	  processes	  too.	  	  
	  
It	  is	  already	  apparent	  that	  the	  entero-­‐salivary	  circulation	  additionally	  has	  important	  
effects	  on	  gastric	  physiology,	  including	  protecting	  against	  stress	  and	  NSAID-­‐induced	  
ulcers	   and	   that	   disruption	   of	   this	   pathway	   is	   detrimental	   (Björne	   H	   et	   al.,	   2004;	  
Jansson	  et	  al.,	  2007;	  Petersson	  et	  al.,	  2007,	  2009;	  Jädert	  et	  al.,	  2012).	  The	  role	  and	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importance	  of	  this	  pathway	  in	  the	  prevention	  and	  treatment	  of	  disease	  in	  which	  NO	  
plays	   an	   important	   part	   including	   osteoporosis	   (Wimalawansa,	   2010)	   and	   pre-­‐
eclampsia	   (Savvidou	   et	   al.,	   2003)	   are	   clearly	   warranted.	   Similarly,	   further	  
investigation	  into	  the	  oral	  microflora	  may	  elucidate	  species	  differences	  between	  the	  
sexes	   that	   explain	   differences	   in	   oral	   NO3
-­‐	   reduction	   that	   appear	   to	   have	  
functionally	  important	  cardiovascular	  effects.	  	  
	  
Depending	   on	   the	   appropriate	   validation	   of	   these	   results	   in	   larger	   populations	   of	  
healthy	   subjects	  and	  patient	  populations,	  with	  hard	  end-­‐point	  data	   such	  as	  major	  
cardiovascular	  event	  and	  mortality	  outcomes	  and	  with	  the	  caveats	   listed	  above	   in	  
mind,	   finally	   I	   wish	   to	   speculate	   on	   how	   this	   research	   could	   possibly	   change	   the	  
medical	  and	  therapeutics	  landscape.	  
	  
There	  should	  be	  a	   further	  public	  health	  push	   to	   increase	   the	   intake	  of	   specifically	  
dietary	   NO3
-­‐-­‐rich	   green	   leafy	   vegetables,	   led	   by	   governments	   and	   inter-­‐
governmental	  agencies.	  There	   is	  the	  possibility	  that	  this	  focused	  approach	  may	  be	  
more	  successful	  in	  persuading	  the	  general	  public	  to	  increase	  vegetable	  intake,	  with	  
the	  backing	  of	  a	  definitive,	  scientifically-­‐robust	  mechanism	  behind	  the	  calls,	  with	  a	  
concurrent	  change	  in	  the	  ADI	  for	  NO3
-­‐	  to	  reflect	  this.	  
	  
One	  could	  envisage	  a	  situation	  where	  dietary	  NO3
-­‐,	  in	  the	  form	  of	  a	  vegetable	  drink,	  
could	  be	  recommended,	  or	  prescribed,	   long-­‐term	  to	  patients	  with	  high-­‐normal	  BP	  
to	  retard	  the	  progression	  to	  a	  clinical	  diagnosis	  of	  hypertension.	   In	  the	  same	  vein,	  
the	   same	  approach	  could	  be	  used	  as	   first-­‐line	   treatment,	   and	   in	   conjunction	  with	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established	   therapeutics,	   for	   hypertension	   and	   possibly	   other	   cardiovascular	   risk	  
factors	  and	  CVDs.	  	  
	  
In	  addition,	  there	  may	  an	  imperative	  to	  develop	  antibiotics,	  for	  common	  infections	  
and	   infectious	   agents	   that	   require	   systemic	   antibiotics,	   which	   do	   not	   target	   the	  
important	   oral-­‐NO3
-­‐	   reducing	   microflora.	   Similarly,	   over-­‐the-­‐counter	   antiseptic	  
mouthwashes	  should	  be	  developed	  that	  only	  target	  the	  pathogenic	  bacteria	  behind	  
medical	   problems	   such	   as	   halitosis	   and	   periodontitis,	   without	   targeting	   NO3
-­‐-­‐
reducing	  bacteria	  that	  inhabit	  the	  posterior,	  dorsal	  lingual	  surface.	  	  
	  
Lastly,	   for	   patients	   that	   do	   require	   systemic	   antibiotics	   that	   destroy	   the	   NO3
-­‐-­‐
reducing	  microflora	  in	  the	  oral	  cavity,	  one	  could	  envisage	  an	  oral	  suspension	  of	  the	  
important	  species	  that	  could	  be	   instilled	  after	  the	  end	  of	   the	  antibiotics	  course	  to	  
actively	   repopulate	   the	   oral	   cavity,	   in	   the	   same	   fashion	   as	   bio-­‐cultures	   currently	  
commercially	   available	   to	   replenish	   GI	   microflora.	   Other	   patients	   that	   have	  
disrupted	   entero-­‐salivary	   circulations,	   such	   as	   those	   intubated	   and	   ventilated	   on	  
intensive	   therapy	  units	   (Weitzberg	   et	  al.,	   2010)	  or	  with	   salivary	  gland	  dysfunction	  
(Chen	   et	   al.,	   2010a)	   may	   require	   systemic	   supplementation	   with	   NO2
-­‐	   itself	   to	  
elevate	   circulating	   and	   tissue	   NO2
-­‐	   levels	   to	   avoid	   the	   detrimental	   effect	   of	  
decreased	  NO2




In	   summary,	   inorganic	   NO3
-­‐	   administration	   either	   via	   the	   diet,	   in	   the	   form	   of	  
beetroot	  juice,	  or	  supplementation	  exerts	  dose-­‐dependent	  decreases	  in	  BP	  that	  are	  
due	   to	   its	   entero-­‐salivary	   processing	   to	   NO2
-­‐	   and	   then	   to	   NO	   in	   healthy	   and	  
hypertensive	   subjects.	   These	   findings	   suggest	   a	   role	   for	   NO3
-­‐	   in	   preventing	   and	  
treating	  hypertension,	  and	  supplementation	  either	  in	  water	  or	  by	  diet	  may	  provide	  
a	  cheap	  and	  effective	  health	  strategy	  to	  combat	  the	  prevalence	  of	  CVD.	  
	  
These	   observations	   also	   support	   the	   notion	   that	   oral	   NO3
-­‐-­‐reducing	   bacteria	  
participate	   in	   physiological	   control	   of	   cardiovascular	  NO2
-­‐	   and	  NO	  homeostasis	   to	  
modulate	   BP	   and	   suggest	   a	   potentially	   novel	   adverse	   cardiovascular	   effect	   of	  
antiseptic	  mouthwash	  in	  healthy	  individuals	  in	  terms	  of	  BP	  regulation.	  
	  
To	   conclude,	   this	   thesis	   challenges	   the	   current	   dogma	   that	   NO3
-­‐	   intake	   is	   only	  
detrimental,	   and	   on	   the	   contrary	   suggests	   that	   dietary	   NO3
-­‐	   is	   important	   for	  
cardiovascular	   health.	   It	   may	   be	   that	   sufficient	   supply	   of	   NO3
-­‐	   through	   the	   diet	  
together	  with	  the	  functioning,	  oral	  microflora	  is	  essential	  for	  normal	  cardiovascular	  
homeostasis.	  	  
	  
These	  concepts	  resurrect	  the	  prescience	  of	  the	  early	  pioneers	  in	  the	  NO2
-­‐	  field	  from	  
more	  than	  80	  years	  ago	  (Stieglitz	  and	  Palmer,	  1937):	  
 
“Because of the rapid disappearance of nitrite from blood and the relative constancy of 
the level found in freshly drawn blood, one may tentatively assume that there is a 
constant production and destruction of the nitrite going on in the body. 
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“The source of the nitrite of the blood may be from administration by any route, 
absorption of nitrites from the bacterial reduction of food or drug nitrates in the lower 
portion of the bowel or absorption of nitrates and a subsequent reduction in the blood 
stream itself or a reduction of nitrates in the tissues. Any of these sources may be foci of 
a more or less constant production of nitrite… 
 
“Nitrite… has profound effects in very small amounts on a great many functions of the 
body directly by its action of relaxing smooth muscle, especially arteriolar muscle, and 
indirectly by its effects on the blood flow in secretory organs. 
 
The exact physiological significance of the blood nitrite is uncertain, but it may be that 
normally it aids in maintaining those functions which are stimulated by the 
administration of therapeutic doses. Clinical application of nitrite analysis of the blood 
may reveal some correlation between a disturbed nitrite metabolism and abnormalities 
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